UserInput	GeneName	KnownADR	n_PMIDs	Note	Type	Cosmic
O00141/A342V	SGK1	-	1	A -> V (in dbSNP:rs55932330)	VARIANT	0
O00141/K127M	SGK1	loss	3	K->M: Abolishes enzymatic activity.	MUTAGEN	0
O00141/S422A	SGK1	decrease	4	S->A: Low activity.	MUTAGEN	0
O00141/S422D	SGK1	increase	4	S->D: 10-fold activation.	MUTAGEN	0
O00141/T256A	SGK1	decrease	1	T->A: Low activity.	MUTAGEN	0
O00141/T256D	SGK1	decrease	1	T->D: Low activity.	MUTAGEN	0
O00141/T256E	SGK1	decrease	1	T->E: Low activity.	MUTAGEN	0
O00141/V219I	SGK1	-	1	V -> I (in dbSNP:rs34133418)	VARIANT	0
O00141/Y298A	SGK1	decrease	1	Y->A: Abolishes interaction with NEDD4 and NEDD4L.	MUTAGEN	0
O00238/C53R	BMPR1B	loss	1	C -> R (in AMD3; mouse BMPR1B construct containing this mutation shows loss of GDF5-dependent receptor activation, chicken BMPR1B construct containing this mutation does not show reduced chondrocyte differentiation, mouse BMPR1B construct containing this mutation shows no loss of cell membrane localization; dbSNP:rs863225041)	VARIANT	0
O00238/D297N	BMPR1B	-	1	D -> N (in a metastatic melanoma sample; somatic mutation)	VARIANT	2
O00238/I200K	BMPR1B	loss	1	I -> K (in BDA2; in animal models loss of kinase activity and loss of positive regulation of chondrocyte differentiation; dbSNP:rs121434417)	VARIANT	0
O00238/K325N	BMPR1B	-	1	K -> N (in BDA1D; acts in a dominant-negative manner; dbSNP:rs869025614)	VARIANT	0
O00238/R149W	BMPR1B	-	1	R -> W (in dbSNP:rs34231464)	VARIANT	0
O00238/R224H	BMPR1B	-	1	R -> H (in dbSNP:rs35973133)	VARIANT	0
O00238/R31C	BMPR1B	decrease	1	R -> C (in AMD3; unknown pathological significance; mouse BMPR1B construct containing this mutation shows reduced GDF5-dependent receptor activation, mouse BMPR1B construct containing this mutation shows no loss of cell membrane localization; dbSNP:rs745854387)	VARIANT	0
O00238/R31H	BMPR1B	-	1	R -> H (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs200035802)	VARIANT	1
O00238/R371Q	BMPR1B	-	1	R -> Q (in dbSNP:rs34970181)	VARIANT	0
O00238/R486Q	BMPR1B	-	1	R -> Q (in brachydactyly type C and BDA2; with also additional features of symphalangism-1; dbSNP:rs121434419)	VARIANT	0
O00238/R486W	BMPR1B	-	1	R -> W (in BDA2; in animal models no effect on kinase activity but strongly decreased positive regulation of chondrocyte differentiation; dbSNP:rs121434418)	VARIANT	1
O00311/E209D	CDC7	-	1	E -> D (in dbSNP:rs56327502)	VARIANT	0
O00311/F162L	CDC7	neutral	1	F -> L (in dbSNP:rs13447503)	VARIANT	0
O00311/G112W	CDC7	-	0	G -> W (in dbSNP:rs13447493)	VARIANT	0
O00311/I208M	CDC7	-	1	I -> M (in dbSNP:rs34979509)	VARIANT	0
O00311/I99V	CDC7	-	0	I -> V (in dbSNP:rs13447492)	VARIANT	0
O00311/K441R	CDC7	neutral	1	K -> R (in dbSNP:rs13447539)	VARIANT	0
O00311/Q23P	CDC7	-	0	Q -> P (in dbSNP:rs13447459)	VARIANT	0
O00311/S498A	CDC7	-	1	S -> A (in dbSNP:rs35055915)	VARIANT	0
O00311/T472I	CDC7	-	1	T -> I (in dbSNP:rs56381770)	VARIANT	0
O00418/D609H	EEF2K	-	1	D -> H	VARIANT	0
O00418/H23R	EEF2K	neutral	2	H -> R (in dbSNP:rs9935059)	VARIANT	0
O00418/P75A	EEF2K	neutral	1	P -> A (in dbSNP:rs17841292)	VARIANT	0
O00418/Q361R	EEF2K	-	2	Q -> R (in dbSNP:rs4783453)	VARIANT	0
O00418/R433W	EEF2K	-	1	R -> W (in dbSNP:rs56137739)	VARIANT	0
O00418/S366A	EEF2K	decrease	2	S->A: Decreased kinase activity.	MUTAGEN	0
O00418/S78A	EEF2K	decrease	1	S->A: Decreased kinase activity.	MUTAGEN	0
O00418/T291M	EEF2K	-	1	T -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs147978363)	VARIANT	0
O00418/T348A	EEF2K	decrease	1	T->A: Decreased kinase activity.	MUTAGEN	0
O00444/A226T	PLK4	-	1	A -> T (in dbSNP:rs35448573)	VARIANT	0
O00444/D154A	PLK4	loss	1	D->A: Catalytically inactive mutant that causes some centrosome amplification above background levels when overexpressed.	MUTAGEN	0
O00444/E830D	PLK4	neutral	3	E -> D (in dbSNP:rs17012739)	VARIANT	1
O00444/I670P	PLK4	-	1	I->P: Decreases substantially the interaction with TENT5C. Does not affect localization to the centrosome. Loss of TENT5C recruitment to the centrosome.	MUTAGEN	0
O00444/K41M	PLK4	loss	2	K->M: Abolishes ability to phosphorylate CDC25C and CHEK2.	MUTAGEN	0
O00444/N449D	PLK4	-	1	N -> D (in dbSNP:rs34906574)	VARIANT	0
O00444/N669R	PLK4	-	1	N->R: Does not affect the interaction with TENT5C.	MUTAGEN	0
O00444/P317L	PLK4	-	1	P -> L (in dbSNP:rs35049837)	VARIANT	0
O00444/R146H	PLK4	-	1	R -> H (in dbSNP:rs35232579)	VARIANT	0
O00444/S232T	PLK4	neutral	3	S -> T (in dbSNP:rs3811740)	VARIANT	0
O00444/T170D	PLK4	activating	2	T->D: Activating mutant.	MUTAGEN	0
O00444/W519S	PLK4	neutral	1	W -> S (in dbSNP:rs56043017)	VARIANT	0
O00444/Y86C	PLK4	-	1	Y -> C (in dbSNP:rs34156294)	VARIANT	0
O00506/D158A	STK25	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
O00506/K49R	STK25	loss	1	K->R: Loss of kinase activity and autophosphorylation.	MUTAGEN	0
O00506/Q64H	STK25	-	0	Q -> H (in dbSNP:rs34341643)	VARIANT	0
O14578/D230V	CIT	decrease	1	D -> V (in MCPH17; impairs kinase activity; exhibits abnormal mitotic cytokinesis; exhibits multipolar spindles; increases the neurons apoptotic process; dbSNP:rs886037894)	VARIANT	0
O14578/G106V	CIT	decrease	1	G -> V (in MCPH17; impairs kinase activity; exhibits abnormal mitotic cytokinesis; exhibits multipolar spindles; increases the neurons apoptotic process; dbSNP:rs886037892)	VARIANT	0
O14578/G7E	CIT	neutral	1	G -> E (in dbSNP:rs36054900)	VARIANT	0
O14578/K126Q	CIT	decrease	1	K -> Q (in MCPH17; impairs kinase activity; exhibits abnormal mitotic cytokinesis; exhibits multipolar spindles; increases the neurons apoptotic process; dbSNP:rs886037893)	VARIANT	0
O14578/L183F	CIT	-	1	L -> F	VARIANT	0
O14578/R9Q	CIT	neutral	1	R -> Q (in dbSNP:rs56193743)	VARIANT	0
O14730/K290A	RIOK3	loss	2	K->A: Decreases autophosphorylation (in vitro); abolishes inhibition of TNF-alpha-induced NF-kappaB activation; no effect on interaction with IRF3; fails to activate IFN-beta promoter and IRF3 phosphorylation.	MUTAGEN	0
O14730/L336V	RIOK3	-	1	L -> V (in dbSNP:rs35401850)	VARIANT	0
O14730/R441Q	RIOK3	-	1	R -> Q (in dbSNP:rs33969048)	VARIANT	0
O14730/S447L	RIOK3	neutral	1	S -> L (in dbSNP:rs56282762)	VARIANT	0
O14733/A195T	MAP2K7	-	1	A -> T (in dbSNP:rs55800262)	VARIANT	0
O14733/L259F	MAP2K7	-	1	L -> F (in dbSNP:rs1053566)	VARIANT	0
O14733/N118S	MAP2K7	-	1	N -> S (in dbSNP:rs56316660)	VARIANT	0
O14733/R138C	MAP2K7	-	1	R -> C (in dbSNP:rs56106612)	VARIANT	0
O14733/R162C	MAP2K7	-	1	R -> C (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	1
O14733/R162H	MAP2K7	-	1	R -> H (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	1
O14757/D130A	CHEK1	loss	8	D->A: Abolishes kinase activity.	MUTAGEN	0
O14757/E223V	CHEK1	-	1	E -> V (in dbSNP:rs35817404)	VARIANT	0
O14757/F344A	CHEK1	increase	1	F->A: Impairs nuclear export.	MUTAGEN	0
O14757/I471V	CHEK1	neutral	6	I -> V (in dbSNP:rs506504)	VARIANT	0
O14757/K132R	CHEK1	decrease	1	K->R: Strong reduction of chromatin-associated CHK1 ubiquitination.	MUTAGEN	0
O14757/K38R	CHEK1	loss	2	K->R: Abolishes kinase activity.	MUTAGEN	0
O14757/K436R	CHEK1	-	1	K->R: Enhances stability of the protein, probably by preventing ubiquitination at this site.	MUTAGEN	0
O14757/M353A	CHEK1	increase	1	M->A: Impairs nuclear export.	MUTAGEN	0
O14757/R156Q	CHEK1	-	0	R -> Q (in dbSNP:rs3731410)	VARIANT	0
O14757/R372E	CHEK1	-	1	R->E: In 3RE mutant. Disrupts the folding and/or conformation, allowing increased accessibility to FBXO6 component of SCF-type E3 ubiquitin ligase complex; when associated with E-376 and E-379.	MUTAGEN	0
O14757/R376E	CHEK1	-	1	R->E: In 3RE mutant. Disrupts the folding and/or conformation, allowing increased accessibility to FBXO6 component of SCF-type E3 ubiquitin ligase complex; when associated with E-372 and E-379.	MUTAGEN	0
O14757/R379E	CHEK1	-	1	R->E: In 3RE mutant. Disrupts the folding and/or conformation, allowing increased accessibility to FBXO6 component of SCF-type E3 ubiquitin ligase complex; when associated with E-372 and E-376.	MUTAGEN	0
O14757/S317A	CHEK1	decrease	5	S->A: Abrogates interaction with RAD51; when associated with A-345. Reduces phosphorylation and impairs activation by hydroxyurea and ionizing radiation. Abrogates nuclear retention upon checkpoint activation. Impairs interaction with FBXO6.	MUTAGEN	0
O14757/S317E	CHEK1	increase	5	S->E: Enhances interaction with RAD51; when associated with E-345.	MUTAGEN	0
O14757/S345A	CHEK1	decrease	6	S->A: Abrogates interaction with RAD51; when associated with A-317. Reduces phosphorylation and impairs activation by hydroxyurea and ionizing radiation. Impairs interaction with YWHAZ which is required for nuclear retention after checkpoint activation.	MUTAGEN	0
O14757/S345E	CHEK1	increase	6	S->E: Enhances interaction with RAD51; when associated with E-317.	MUTAGEN	0
O14757/S357A	CHEK1	-	1	S->A: No effect on phosphorylation induced by hydroxyurea.	MUTAGEN	0
O14757/S366A	CHEK1	-	1	S->A: No effect on phosphorylation induced by hydroxyurea.	MUTAGEN	0
O14757/S468A	CHEK1	-	1	S->A: No effect on phosphorylation induced by hydroxyurea.	MUTAGEN	0
O14757/V312M	CHEK1	-	1	V -> M (in dbSNP:rs34097480)	VARIANT	0
O14874/L389P	BCKDK	loss	1	L -> P (in BCKDKD; complete loss of kinase activity)	VARIANT	0
O14874/R174G	BCKDK	decrease	1	R -> G (in BCKDKD; partial loss of kinase activity)	VARIANT	0
O14874/R224P	BCKDK	-	1	R -> P (in BCKDKD; dbSNP:rs147210405)	VARIANT	0
O14920/A360S	IKBKB	-	2	A -> S (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	VARIANT	2
O14920/A710T	IKBKB	-	1	A -> T (in dbSNP:rs34309584)	VARIANT	0
O14920/A736T	IKBKB	-	0	A -> T (in dbSNP:rs17611716)	VARIANT	0
O14920/D166A	IKBKB	loss	1	D->A: Loss of protein kinase activity.	MUTAGEN	0
O14920/F734L	IKBKB	-	1	F -> L (in dbSNP:rs56301637)	VARIANT	0
O14920/K163R	IKBKB	-	1	K->R: Monoubiquitinated; when associated with E-177 and E-181.	MUTAGEN	0
O14920/K171E	IKBKB	increase	1	K->E: Increased activation of NF-kappa-B signaling.	MUTAGEN	8
O14920/K44A	IKBKB	loss	2	K->A: Loss of kinase activity and no effect on binding to NIK.	MUTAGEN	0
O14920/P191A	IKBKB	-	1	P->A: Loss of hypoxic inducibility.	MUTAGEN	0
O14920/Q369R	IKBKB	-	1	Q -> R (in dbSNP:rs56411242)	VARIANT	0
O14920/R526Q	IKBKB	-	1	R -> Q (in dbSNP:rs2272736)	VARIANT	1
O14920/R554W	IKBKB	-	0	R -> W (in dbSNP:rs17875749)	VARIANT	0
O14920/S177A	IKBKB	decrease	2	S->A: Decrease of activity.	MUTAGEN	0
O14920/S177E	IKBKB	activating	2	S->E: Full activation. Interaction with TRIM21 is enhanced; when associated with E-181. Monoubiquitinated; when associated with R-163 and E-181. Strongly promoted NF-kappa-B gene expression; when associated with E-181.	MUTAGEN	0
O14920/S181A	IKBKB	decrease	2	S->A: Decrease of activity.	MUTAGEN	0
O14920/S181E	IKBKB	activating	2	S->E: Full activation. Interaction with TRIM21 is enhanced; when associated with E-177. Monoubiquitinated; when associated with R-163 and E-177. Strongly promoted NF-kappa-B gene expression; when associated with E-177.	MUTAGEN	0
O14920/V203I	IKBKB	increase	1	V -> I (in IMD15A; gain-of-function mutation resulting in increased activation of NF-kappa-B signaling pathway; dbSNP:rs1563340753)	VARIANT	6
O14936/D710G	CASK	-	1	D -> G (in MICPCH; dbSNP:rs137852818)	VARIANT	0
O14936/G96V	CASK	-	1	G -> V (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
O14936/P396S	CASK	-	1	P -> S (in MICPCH; dbSNP:rs137852820)	VARIANT	0
O14936/R28L	CASK	-	1	R -> L (in FGS4; does not reveal significant alterations induced by the mutation substitution; causes a partial skipping of exon 2 of the protein; dbSNP:rs137852816)	VARIANT	0
O14936/Y268H	CASK	-	1	Y -> H (in MICPCH; dbSNP:rs137852817)	VARIANT	0
O14965/C290A	AURKA	-	1	C->A: Enhances stability; when associated with A-393.	MUTAGEN	0
O14965/C393A	AURKA	-	1	C->A: Enhances stability; when associated with A-290.	MUTAGEN	0
O14965/D274N	AURKA	loss	2	D->N: Abolishes cilia disassembly and kinase activity.	MUTAGEN	1
O14965/F165A	AURKA	-	1	F->A: Decreases the interaction with phosphatase type 1 isoforms.	MUTAGEN	0
O14965/F31I	AURKA	neutral	5	F -> I (in dbSNP:rs2273535)	VARIANT	12
O14965/F346A	AURKA	-	1	F->A: Decreases the interaction with phosphatase type 1 isoforms.	MUTAGEN	0
O14965/G11R	AURKA	-	0	G -> R (in dbSNP:rs6069717)	VARIANT	1
O14965/G198N	AURKA	decrease	1	G->N: Reduces interaction with TPX2. Reduces kinase activity tenfold. Promotes interaction with the AURKB binding partners INCENP and BIRC5 that are normally not bound by AURKA.	MUTAGEN	0
O14965/I57V	AURKA	increase,neutral	7	I -> V (increased kinase activity; dbSNP:rs1047972)	VARIANT	0
O14965/K162R	AURKA	loss	1	K->R: Loss of kinase activity.	MUTAGEN	0
O14965/M373V	AURKA	neutral	1	M -> V (in dbSNP:rs33923703)	VARIANT	0
O14965/P50L	AURKA	neutral	1	P -> L (in dbSNP:rs34572020)	VARIANT	0
O14965/Q335A	AURKA	decrease	1	Q->A: Reduces binding to MYCN.	MUTAGEN	0
O14965/R205A	AURKA	-	1	R->A: Reduces ubiquitination and proteasomal degradation.	MUTAGEN	0
O14965/S104L	AURKA	-	0	S -> L (in dbSNP:rs2230743)	VARIANT	1
O14965/S155R	AURKA	decrease	2	S -> R (in a colorectal adenocarcinoma sample; somatic mutation; reduces interaction with TPX2)	VARIANT	1
O14965/T287A	AURKA	-	1	T->A: No direct effect on catalytic activity.	MUTAGEN	0
O14965/T287E	AURKA	activating	1	T->E: Enhances interaction with TPX2.	MUTAGEN	0
O14965/T288A	AURKA	decrease	1	T->A: Reduces cilia disassembly and kinase activity.	MUTAGEN	0
O14965/T288D	AURKA	increase	1	T->D: Mimics phosphorylation state and increases kinase activity.	MUTAGEN	0
O14965/V174M	AURKA	activating	2	V -> M (in a metastatic melanoma sample; somatic mutation; constitutively enhanced kinase activity)	VARIANT	1
O14965/Y334A	AURKA	decrease	1	Y->A: Reduces binding to MYCN.	MUTAGEN	0
O14976/D1297N	GAK	neutral	1	D -> N (in dbSNP:rs1134921)	VARIANT	0
O14976/D787Y	GAK	neutral	1	D -> Y (in dbSNP:rs34585705)	VARIANT	2
O14976/G962D	GAK	-	1	G -> D (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs773153935)	VARIANT	0
O14976/K1265R	GAK	neutral	1	K -> R (in dbSNP:rs2306242)	VARIANT	1
O14976/P1137L	GAK	-	1	P -> L (in dbSNP:rs56169884)	VARIANT	0
O14976/Q1120H	GAK	-	1	Q -> H (in dbSNP:rs55801437)	VARIANT	0
O14976/Q877R	GAK	neutral	1	Q -> R (in dbSNP:rs149842313)	VARIANT	0
O14976/S1168N	GAK	-	1	S -> N (in dbSNP:rs56326341)	VARIANT	0
O14976/S144L	GAK	-	1	S -> L (in dbSNP:rs768962219)	VARIANT	1
O14976/T1051M	GAK	-	1	T -> M (in dbSNP:rs35227944)	VARIANT	0
O14976/V580M	GAK	-	1	V -> M (in dbSNP:rs34255232)	VARIANT	0
O15075/G29C	DCLK1	-	1	G -> C (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	3
O15075/R292H	DCLK1	-	1	R -> H (in dbSNP:rs56185003)	VARIANT	1
O15075/R93Q	DCLK1	-	1	R -> Q (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1366698690)	VARIANT	6
O15075/S291F	DCLK1	-	1	S -> F (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	2
O15075/T46M	DCLK1	-	1	T -> M (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	2
O15111/K44A	CHUK	loss	2	K->A: Loss of kinase activity.	MUTAGEN	0
O15111/K44M	CHUK	loss	2	K->M: Loss of autophosphorylation.	MUTAGEN	0
O15111/S126C	CHUK	-	1	S -> C (in dbSNP:rs34427437)	VARIANT	0
O15111/S176A	CHUK	loss	2	S->A: Loss of phosphorylation and of activity.	MUTAGEN	0
O15111/S176E	CHUK	activating	2	S->E: Full activation.	MUTAGEN	0
O15111/S180A	CHUK	-	1	S->A: No change in phosphorylation.	MUTAGEN	0
O15111/T179A	CHUK	-	1	T->A: No change in phosphorylation.	MUTAGEN	0
O15111/T23A	CHUK	decrease	1	T->A: Loss of phosphorylation and decrease of kinase activity.	MUTAGEN	0
O15111/V155A	CHUK	neutral	1	V -> A (in dbSNP:rs2230803)	VARIANT	2
O15111/V268I	CHUK	neutral	6	V -> I (in dbSNP:rs2230804)	VARIANT	2
O15146/A27G	MUSK	-	1	A -> G (in dbSNP:rs56054734)	VARIANT	0
O15146/A727V	MUSK	decrease	1	A -> V (in CMS9; affects interaction with DOK7 and impairs MUSK phosphorylation; altered AChR clustering; dbSNP:rs397515450)	VARIANT	0
O15146/D38E	MUSK	-	1	D -> E (in CMS9; dbSNP:rs775587809)	VARIANT	0
O15146/D743N	MUSK	loss	1	D->N: Severe loss of kinase activity.	MUTAGEN	0
O15146/E782D	MUSK	-	1	E -> D (in dbSNP:rs34614566)	VARIANT	0
O15146/G107E	MUSK	-	1	G -> E (in dbSNP:rs55786136)	VARIANT	0
O15146/G584C	MUSK	decrease	1	G->C,D: Mild decrease in kinase activity.	MUTAGEN	0
O15146/G584D	MUSK	decrease	1	G->C,D: Mild decrease in kinase activity.	MUTAGEN	0
O15146/I575T	MUSK	decrease	1	I -> T (in FADS1; reduces agrin-dependent AChR aggregation and tyrosine kinase activity in developing neuromuscular junction; dbSNP:rs751889864)	VARIANT	0
O15146/K609R	MUSK	loss	1	K->R: Severe loss of kinase activity.	MUTAGEN	0
O15146/L629F	MUSK	-	1	L -> F (in dbSNP:rs34267283)	VARIANT	0
O15146/M413I	MUSK	neutral	1	M -> I (in dbSNP:rs2274419)	VARIANT	0
O15146/M605I	MUSK	decrease	1	M -> I (in CMS9; affects interaction with DOK7 and impairs MUSK phosphorylation; altered AChR clustering; dbSNP:rs766640370)	VARIANT	0
O15146/M835V	MUSK	-	1	M -> V (in CMS9; reduces AChR aggregation in developing neuromuscular junction)	VARIANT	0
O15146/N222S	MUSK	-	1	N -> S (in dbSNP:rs55826142)	VARIANT	0
O15146/N664S	MUSK	-	1	N -> S (in dbSNP:rs55963442)	VARIANT	0
O15146/N819S	MUSK	-	1	N -> S (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs757577755)	VARIANT	0
O15146/P344R	MUSK	-	1	P -> R (in CMS9; dbSNP:rs387906803)	VARIANT	0
O15146/P696L	MUSK	-	1	P -> L (in dbSNP:rs56126328)	VARIANT	0
O15146/R858H	MUSK	-	1	R -> H (in dbSNP:rs34115159)	VARIANT	3
O15146/S159G	MUSK	neutral	1	S -> G (in dbSNP:rs35176182)	VARIANT	1
O15146/T100M	MUSK	neutral	1	T -> M (in dbSNP:rs35142681)	VARIANT	0
O15146/V644A	MUSK	neutral	1	V -> A (in dbSNP:rs41279055)	VARIANT	0
O15146/V790M	MUSK	decrease	1	V -> M (in CMS9; does not affect catalytic kinase activity; reduces protein expression and stability; dbSNP:rs199476083)	VARIANT	1
O15146/V829L	MUSK	neutral	1	V -> L (in dbSNP:rs578430)	VARIANT	0
O15164/C840W	TRIM24	-	1	C->W: Abolishes interaction with histone H3.	MUTAGEN	0
O15164/D827A	TRIM24	-	1	D->A: Strongly reduced affinity for histone H3 that is not methylated at 'Lys-4' (H3K4me0).	MUTAGEN	0
O15164/I320T	TRIM24	-	1	I -> T (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
O15164/N796S	TRIM24	neutral	0	N -> S (in dbSNP:rs35356723)	VARIANT	0
O15164/R1009S	TRIM24	neutral	1	R -> S (in dbSNP:rs34585297)	VARIANT	0
O15164/S762N	TRIM24	-	1	S -> N	VARIANT	0
O15164/S768A	TRIM24	-	1	S->A: Ubiquitination is significantly lower than wild-type.	MUTAGEN	0
O15164/T403N	TRIM24	-	1	T -> N (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
O15197/A221V	EPHB6	-	1	A -> V	VARIANT	0
O15197/A603P	EPHB6	-	1	A -> P (in a colorectal cancer sample; somatic mutation)	VARIANT	0
O15197/A662V	EPHB6	-	1	A -> V (in dbSNP:rs35984674)	VARIANT	0
O15197/D360N	EPHB6	-	1	D -> N (in a colorectal cancer sample; somatic mutation)	VARIANT	0
O15197/D930G	EPHB6	-	1	D -> G (in a colorectal cancer sample; somatic mutation)	VARIANT	0
O15197/E875K	EPHB6	-	1	E -> K (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	0
O15197/G122S	EPHB6	neutral	1	G -> S (in dbSNP:rs8177173)	VARIANT	0
O15197/I993V	EPHB6	-	1	I -> V	VARIANT	0
O15197/P282H	EPHB6	-	1	P -> H	VARIANT	0
O15197/P282R	EPHB6	-	0	P -> R (in dbSNP:rs8177143)	VARIANT	0
O15197/P743S	EPHB6	-	1	P -> S (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
O15197/R309Q	EPHB6	-	1	R -> Q (in dbSNP:rs55728646)	VARIANT	0
O15197/R499Q	EPHB6	-	0	R -> Q (in dbSNP:rs8177175)	VARIANT	0
O15197/R719Q	EPHB6	-	1	R -> Q (in a colorectal cancer sample; somatic mutation)	VARIANT	0
O15197/R813H	EPHB6	-	1	R -> H	VARIANT	0
O15197/S170T	EPHB6	-	1	S -> T	VARIANT	0
O15197/S324A	EPHB6	neutral	1	S -> A (in dbSNP:rs8177146)	VARIANT	0
O15197/S332L	EPHB6	neutral	1	S -> L (in dbSNP:rs35189999)	VARIANT	0
O15264/A282V	MAPK13	-	1	A -> V (in dbSNP:rs55990045)	VARIANT	0
O15264/A300T	MAPK13	neutral	1	A -> T (in dbSNP:rs41270090)	VARIANT	1
O15264/S41L	MAPK13	-	1	S -> L (in dbSNP:rs55776345)	VARIANT	4
O15264/T180A	MAPK13	loss	1	T->A: Loss of kinase activity.	MUTAGEN	0
O15264/Y182A	MAPK13	loss	1	Y->A: Loss of kinase activity.	MUTAGEN	0
O15530/A277V	PDPK1	increase	1	A->V: 3-fold increase in kinase activity.	MUTAGEN	0
O15530/R474A	PDPK1	-	1	R->A: No PDGF-dependent translocation to the membrane.	MUTAGEN	0
O15530/S241A	PDPK1	loss	1	S->A: No activation.	MUTAGEN	0
O15530/S25A	PDPK1	-	1	S->A: No effect.	MUTAGEN	0
O15530/S393A	PDPK1	-	1	S->A: No effect.	MUTAGEN	0
O15530/S394A	PDPK1	-	1	S->A: Abolishes phosphorylation by MAP3K5; when associated with A-398.	MUTAGEN	0
O15530/S396A	PDPK1	-	1	S->A: No effect.	MUTAGEN	0
O15530/S398A	PDPK1	-	1	S->A: Abolishes phosphorylation by MAP3K5; when associated with A-394.	MUTAGEN	0
O15530/S410A	PDPK1	-	1	S->A: No effect.	MUTAGEN	0
O15530/T354A	PDPK1	increase	1	T->A: Abolishes phosphorylation by MELK.	MUTAGEN	0
O15530/T513E	PDPK1	increase	1	T->E: Enhanced kinase activity towards PKB.	MUTAGEN	0
O15530/Y373F	PDPK1	decrease	1	Y->F: Reduction in basal activity.	MUTAGEN	0
O15530/Y376F	PDPK1	decrease	1	Y->F: Reduction in basal activity.	MUTAGEN	0
O15530/Y9F	PDPK1	decrease	1	Y->F: Slight reduction in pervanadate-stimulated tyrosine phosphorylation.	MUTAGEN	0
O43187/D431E	IRAK2	neutral	2	D -> E (in dbSNP:rs708035)	VARIANT	2
O43187/D469N	IRAK2	-	1	D -> N (in dbSNP:rs56242986)	VARIANT	0
O43187/D574H	IRAK2	neutral	0	D -> H (in dbSNP:rs11465930)	VARIANT	0
O43187/I99V	IRAK2	neutral	1	I -> V (in dbSNP:rs55898544)	VARIANT	0
O43187/L392V	IRAK2	neutral	1	L -> V (in dbSNP:rs3844283)	VARIANT	2
O43187/L439V	IRAK2	neutral	1	L -> V (in dbSNP:rs11465927)	VARIANT	0
O43187/L503I	IRAK2	neutral	1	L -> I (in dbSNP:rs9854688)	VARIANT	0
O43187/P421T	IRAK2	-	1	P -> T (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	0
O43187/R147T	IRAK2	neutral	1	R -> T (in dbSNP:rs56053222)	VARIANT	0
O43187/R214G	IRAK2	-	1	R -> G (in dbSNP:rs35060588)	VARIANT	0
O43187/R43Q	IRAK2	-	1	R -> Q (in dbSNP:rs34945585)	VARIANT	0
O43187/R566W	IRAK2	neutral	1	R -> W (in dbSNP:rs55740652)	VARIANT	1
O43187/S249L	IRAK2	-	1	S -> L (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
O43187/S47Y	IRAK2	neutral	1	S -> Y (in dbSNP:rs11465864)	VARIANT	0
O43283/E44K	MAP3K13	-	0	E -> K (in dbSNP:rs35266179)	VARIANT	0
O43283/E712K	MAP3K13	-	1	E -> K (in dbSNP:rs56309231)	VARIANT	3
O43283/K195A	MAP3K13	loss	1	K->A: Kinase inactive. Fails to activate NF-kappa-B.	MUTAGEN	0
O43283/P746L	MAP3K13	-	1	P -> L (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
O43283/R517G	MAP3K13	-	1	R -> G (in dbSNP:rs56408536)	VARIANT	0
O43283/R915H	MAP3K13	-	0	R -> H (in dbSNP:rs3732576)	VARIANT	0
O43293/D161A	DAPK3	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
O43293/D161N	DAPK3	decrease	2	D -> N (in an ovarian mucinous carcinoma sample; somatic mutation; greatly reduces kinase activity, increases cell proliferation and cell survival)	VARIANT	0
O43293/K42A	DAPK3	loss	1	K->A: Loss of kinase activity at low concentrations of ATP.	MUTAGEN	0
O43293/L441A	DAPK3	-	1	L->A: Predominantly nuclear localization; when associated with A-427 and A-434.	MUTAGEN	0
O43293/P216S	DAPK3	decrease	2	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation; greatly reduces kinase activity, increases cell proliferation, cell adhesion and cell survival)	VARIANT	0
O43293/T112M	DAPK3	decrease	2	T -> M (in a colorectal adenocarcinoma sample; somatic mutation; greatly reduces kinase activity, increases cell proliferation and cell survival)	VARIANT	1
O43293/T180A	DAPK3	decrease	1	T->A: Greatly reduced kinase activity.	MUTAGEN	0
O43293/T225A	DAPK3	loss	1	T->A: Loss of kinase activity.	MUTAGEN	0
O43293/T265A	DAPK3	loss	1	T->A: Loss of phosphorylation by ROCK1, catalytically inactive.	MUTAGEN	0
O43293/T299A	DAPK3	loss	1	T->A: Loss of phosphorylation by ROCK1.	MUTAGEN	0
O43293/T299D	DAPK3	-	1	T->D: Predominantly cytoplasmic localization; phosphomimetic.	MUTAGEN	0
O43293/V427A	DAPK3	-	1	V->A: Predominantly nuclear localization; when associated with A-434 and A-441.	MUTAGEN	0
O43293/V434A	DAPK3	-	1	V->A: Predominantly nuclear localization; when associated with A-427 and A-441.	MUTAGEN	0
O43318/E70Q	MAP3K7	-	1	E -> Q (in FMD2; dbSNP:rs886039231)	VARIANT	0
O43318/G110C	MAP3K7	-	1	G -> C (in CSCF; dbSNP:rs886039235)	VARIANT	0
O43318/G168R	MAP3K7	-	1	G -> R (in FMD2; increases autophosphorylation; no effect on MAPK signaling; no effect on NF-kappa-B signaling; dbSNP:rs886039233)	VARIANT	0
O43318/K158R	MAP3K7	-	1	K->R: Abolishes ubiquitination.	MUTAGEN	0
O43318/K209R	MAP3K7	-	1	K->R: Strongly decreases ubiquitination.	MUTAGEN	0
O43318/K34R	MAP3K7	-	1	K->R: No effect on ubiquitination.	MUTAGEN	0
O43318/K63W	MAP3K7	loss	2	K->W: Loss of kinase activity. Loss of autophosphorylation.	MUTAGEN	0
O43318/P512A	MAP3K7	-	1	P->R,A: Enhances autophosphorylation; Alters MAPK signaling.	MUTAGEN	0
O43318/P512L	MAP3K7	increase	1	P -> L (in FMD2; does not affect interaction with TAB2; does not affect homodimerization; increases autophosphorylation; increases MAPK signaling; increases NF-kappa-B signaling; dbSNP:rs886039230)	VARIANT	0
O43318/P512R	MAP3K7	-	1	P->R,A: Enhances autophosphorylation; Alters MAPK signaling.	MUTAGEN	0
O43318/R410Q	MAP3K7	-	1	R -> Q (found in a consanguineous family with intellectual disability; unknown pathological significance; dbSNP:rs201721045)	VARIANT	0
O43318/V100E	MAP3K7	-	1	V -> E (in FMD2; dbSNP:rs886039232)	VARIANT	0
O43318/W241R	MAP3K7	-	1	W -> R (in CSCF; dbSNP:rs886039237)	VARIANT	0
O43353/D146N	RIPK2	loss	1	D->N: Abolishes kinase activity.	MUTAGEN	0
O43353/D467R	RIPK2	-	1	D->R: Decreased interaction with NGFR.	MUTAGEN	0
O43353/E500R	RIPK2	-	1	E->R: Decreased interaction with NGFR.	MUTAGEN	0
O43353/I259T	RIPK2	neutral	1	I -> T (in dbSNP:rs2230801)	VARIANT	0
O43353/I496A	RIPK2	-	1	I->A: Decreased interaction with NGFR.	MUTAGEN	0
O43353/K209R	RIPK2	decrease	1	K->R: Complete loss of polyubiquitination.	MUTAGEN	0
O43353/K313N	RIPK2	-	1	K -> N (in dbSNP:rs35395048)	VARIANT	0
O43353/K471E	RIPK2	-	1	K->E: Decreased interaction with NGFR.	MUTAGEN	0
O43353/K47A	RIPK2	loss	2	K->A: Abolishes kinase activity.	MUTAGEN	0
O43353/K47M	RIPK2	-	2	K->M: Reduces FAS-mediated apoptosis.	MUTAGEN	0
O43353/K503R	RIPK2	increase	1	K->R: Abolished ubiquitination by ZNRF4.	MUTAGEN	0
O43353/L268V	RIPK2	neutral	1	L -> V (in dbSNP:rs35004667)	VARIANT	0
O43353/Q437E	RIPK2	-	1	Q->E: Decreased interaction with NGFR.	MUTAGEN	0
O43353/R444E	RIPK2	-	1	R->E: Abolishes interaction with NOD1.	MUTAGEN	0
O43353/R483E	RIPK2	-	1	R->E: Abolishes interaction with NOD1.	MUTAGEN	0
O43353/R488E	RIPK2	-	1	R->E: Abolishes interaction with NOD1.	MUTAGEN	0
O43353/R528E	RIPK2	-	1	R->E: Decreased interaction with NGFR.	MUTAGEN	0
O43353/Y381A	RIPK2	decrease	1	Y->A: Prevents phosphorylation. Reduces serine and threonine phosphorylation of ARHGEF2.	MUTAGEN	0
O43353/Y474F	RIPK2	-	1	Y->F: Decreases interaction with NOD2.	MUTAGEN	0
O43683/A106D	BUB1	-	1	A->D,W: Loss of interaction with KNL1.	MUTAGEN	0
O43683/A106W	BUB1	-	1	A->D,W: Loss of interaction with KNL1.	MUTAGEN	0
O43683/A130S	BUB1	-	1	A->S: Partial rescue of the spindle-assembly checkpoint activity. Increased rate of chromosome congression errors. Impaired localization to kinetochores and loss of kinetochore binding of CENPF, SGO1 and BUBR1 but not of MCAK, MAD1L1 or MAD2L1.	MUTAGEN	0
O43683/E36D	BUB1	-	1	E -> D (in colorectal cancer; dbSNP:rs1801328)	VARIANT	1
O43683/E536A	BUB1	-	1	E->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-535 and A-537.	MUTAGEN	0
O43683/E626A	BUB1	-	1	E->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-625 and A-627.	MUTAGEN	0
O43683/G20D	BUB1	-	1	G -> D (in dbSNP:rs35890336)	VARIANT	0
O43683/H265N	BUB1	-	2	H -> N (in pancreatic cancer; associated with C-259; complete rescue of the spindle-assembly checkpoint activity; increased rate of chromosome congression errors)	VARIANT	0
O43683/K535A	BUB1	-	1	K->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-536 and A-537.	MUTAGEN	0
O43683/K625A	BUB1	-	1	K->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-626 and A-627.	MUTAGEN	0
O43683/K821A	BUB1	loss	1	K->A: Loss of activity.	MUTAGEN	0
O43683/L122G	BUB1	-	1	L->G: Loss of interaction with KNL1.	MUTAGEN	0
O43683/N534D	BUB1	-	1	N -> D (in dbSNP:rs36109304)	VARIANT	0
O43683/N537A	BUB1	-	1	N->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-535 and A-536.	MUTAGEN	0
O43683/N627A	BUB1	-	1	N->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-625 and A-626.	MUTAGEN	0
O43683/P648R	BUB1	-	1	P -> R (in colorectal cancer; dbSNP:rs376649190)	VARIANT	0
O43683/S492Y	BUB1	-	1	S -> Y (in colorectal cancer; dbSNP:rs121909055)	VARIANT	0
O43683/T609A	BUB1	-	1	T->A: Diminished interaction with PLK1.	MUTAGEN	0
O43683/Y259C	BUB1	-	2	Y -> C (in pancreatic cancer; associated with N-265; failure to rescue the spindle-assembly checkpoint activity as a result of a deficient recruitment of MAD2L1 and BUBR1 to kinetochores; efficient restoration of chromosome congression; reduced binding to BUB3; rescue of the ability of kinetochores to bind SGO1 and CENPF but not MCAK)	VARIANT	0
O43781/K238M	DYRK3	loss	3	K->M: Kinase dead; Induces formation of stress granules-like in absence of stress. Impaired dissolution of membraneless organelles during mitosis, such as stress granules, nuclear speckles and pericentriolar material.	MUTAGEN	0
O43781/M239L	DYRK3	-	1	M -> L	VARIANT	0
O43781/S350A	DYRK3	decrease	1	S->A: Decreased stability of the protein.	MUTAGEN	0
O43781/S350D	DYRK3	increase	1	S->E,D: Phosphomimetic mutant; increased stability of the protein.	MUTAGEN	0
O43781/S350E	DYRK3	increase	1	S->E,D: Phosphomimetic mutant; increased stability of the protein.	MUTAGEN	0
O60229/E1326D	KALRN	-	0	E -> D (in dbSNP:rs2289838)	VARIANT	0
O60229/R213W	KALRN	-	1	R -> W (in a colorectal cancer sample; somatic mutation; dbSNP:rs1187034389)	VARIANT	0
O60229/S196L	KALRN	-	1	S -> L	VARIANT	0
O60285/G419D	NUAK1	-	1	G -> D (in dbSNP:rs55774704)	VARIANT	0
O60285/K84A	NUAK1	loss	2	K->A: Abolishes kinase activity and ability to induce senescence.	MUTAGEN	0
O60285/P543R	NUAK1	-	1	P -> R (in dbSNP:rs3741883)	VARIANT	3
O60285/S600A	NUAK1	loss	2	S->A: Abrogates phosphorylation by PKB/AKT1. Does not affect ability to induce senescence.	MUTAGEN	0
O60285/T211A	NUAK1	loss	3	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex. Abolishes ability to induce senescence.	MUTAGEN	0
O60307/F655L	MAST3	-	1	F -> L (found in a patient with autism spectrum disorder without history of seizures; unknown pathological significance)	VARIANT	0
O60307/G510S	MAST3	-	1	G -> S (in DEE108)	VARIANT	0
O60307/G515S	MAST3	-	2	G -> S (in DEE108)	VARIANT	0
O60307/G861S	MAST3	neutral	0	G -> S (in dbSNP:rs8108738)	VARIANT	1
O60307/G883S	MAST3	-	1	G -> S (in dbSNP:rs369960905)	VARIANT	0
O60307/L516P	MAST3	-	2	L -> P (in DEE108)	VARIANT	0
O60307/R203Q	MAST3	-	0	R -> Q (in dbSNP:rs35945810)	VARIANT	2
O60307/R406P	MAST3	-	1	R -> P (in DEE108)	VARIANT	0
O60307/S101F	MAST3	-	1	S -> F (in DEE108; unknown pathological significance)	VARIANT	2
O60307/S104L	MAST3	-	1	S -> L (in DEE108)	VARIANT	1
O60307/V551L	MAST3	-	1	V -> L (in DEE108; unknown pathological significance)	VARIANT	0
O60566/A159W	BUB1B	-	1	A->W: Loss of interaction with KNL1.	MUTAGEN	0
O60566/D579E	BUB1B	increase	1	D->E: Abolishes the cleavage by caspase-3.	MUTAGEN	0
O60566/D610E	BUB1B	increase	1	D->E: Abolishes the cleavage by caspase-3.	MUTAGEN	0
O60566/E390D	BUB1B	neutral	1	E -> D (in dbSNP:rs1017842)	VARIANT	0
O60566/F175A	BUB1B	-	1	F->A: Loss of interaction with KNL1.	MUTAGEN	0
O60566/I909T	BUB1B	-	1	I -> T (in MVA1; heterozygous compound with nonsense mutation; dbSNP:rs28989184)	VARIANT	0
O60566/K795A	BUB1B	loss	2	K->A: Does not abolish the capacity to inhibit APC/CDC20.	MUTAGEN	0
O60566/K795R	BUB1B	loss	2	K->R: Inhibits kinase activity.	MUTAGEN	0
O60566/L1012P	BUB1B	-	1	L -> P (in MVA1; heterozygous compound with nonsense mutation; dbSNP:rs28989185)	VARIANT	0
O60566/L844F	BUB1B	-	1	L -> F (in MVA1; associated with H-921; heterozygous compound with nonsense mutation; dbSNP:rs28989181)	VARIANT	0
O60566/M15T	BUB1B	-	1	M -> T (in a colorectal cancer cell line; dbSNP:rs1392369693)	VARIANT	0
O60566/P378S	BUB1B	-	1	P -> S (in dbSNP:rs17851677)	VARIANT	0
O60566/Q921H	BUB1B	-	1	Q -> H (in MVA1; associated with F-844; heterozygous compound with nonsense mutation; dbSNP:rs28989183)	VARIANT	0
O60566/R349Q	BUB1B	neutral	8	R -> Q (in dbSNP:rs1801376)	VARIANT	0
O60566/R36Q	BUB1B	-	1	R -> Q (in PCS; dbSNP:rs534297115)	VARIANT	0
O60566/R550Q	BUB1B	-	1	R -> Q (in MVA1; heterozygous compound with nonsense mutation; dbSNP:rs28989187)	VARIANT	0
O60566/R814H	BUB1B	-	1	R -> H (in MVA1; heterozygous compound with nonsense mutation; dbSNP:rs28989182)	VARIANT	0
O60566/T40M	BUB1B	neutral	1	T -> M (in dbSNP:rs56079734)	VARIANT	0
O60566/T620A	BUB1B	-	1	T->A: Induces chromosome congression defects and mitotic delay.	MUTAGEN	0
O60566/V618A	BUB1B	neutral	2	V -> A (in dbSNP:rs1801528)	VARIANT	0
O60674/A377E	JAK2	-	1	A -> E (in dbSNP:rs55953208)	VARIANT	0
O60674/D584E	JAK2	-	0	D -> E (in dbSNP:rs17490221)	VARIANT	0
O60674/G127D	JAK2	-	1	G -> D (in dbSNP:rs56118985)	VARIANT	0
O60674/K191Q	JAK2	-	1	K -> Q (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
O60674/K346R	JAK2	-	1	K -> R (in dbSNP:rs55667734)	VARIANT	0
O60674/K539L	JAK2	-	1	K -> L (in myeloproliferative disorder with erythrocytosis; requires 2 nucleotide substitutions; dbSNP:rs121912473)	VARIANT	16
O60674/K607N	JAK2	-	1	K -> N (in AML; dbSNP:rs121912472)	VARIANT	1
O60674/L393V	JAK2	neutral	1	L -> V (in dbSNP:rs2230723)	VARIANT	0
O60674/R1063H	JAK2	neutral	1	R -> H (in dbSNP:rs41316003)	VARIANT	0
O60674/V617F	JAK2	activating	6	V -> F (in PV, THCYT3 and AML; associated with susceptibility to Budd-Chiari syndrome; somatic mutation in a high percentage of patients with essential thrombocythemia or myelofibrosis; leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity; dbSNP:rs77375493)	VARIANT	48691
O60674/V617I	JAK2	-	1	V -> I (in THCYT3; dbSNP:rs77375493)	VARIANT	0
O60885/A371G	BRD4	-	1	A -> G (in dbSNP:rs55805532)	VARIANT	0
O60885/N140A	BRD4	-	2	N->A: Abolishes binding to acetylated histones.	MUTAGEN	0
O60885/N433A	BRD4	-	1	N->A: Abolishes binding to acetylated histones.	MUTAGEN	0
O60885/P37S	BRD4	-	1	P -> S (in dbSNP:rs35177876)	VARIANT	0
O60885/R1097H	BRD4	neutral	0	R -> H (in dbSNP:rs35676845)	VARIANT	0
O60885/R669H	BRD4	-	1	R -> H (in dbSNP:rs35824241)	VARIANT	0
O60885/S503A	BRD4	decrease	1	S->A: Impaired phosphorylation by CK2 and binding to acetylated histones.	MUTAGEN	0
O60885/S563N	BRD4	-	1	S -> N (in dbSNP:rs55970906)	VARIANT	0
O60885/T598S	BRD4	-	1	T -> S (in dbSNP:rs34362023)	VARIANT	0
O75116/D1131A	ROCK2	decrease	1	D->A: Abolishes cleavage by granzyme B.	MUTAGEN	0
O75116/D601V	ROCK2	-	1	D -> V (in dbSNP:rs35768389)	VARIANT	0
O75116/K1083M	ROCK2	-	0	K -> M (in dbSNP:rs34945852)	VARIANT	0
O75116/S1194P	ROCK2	-	1	S -> P (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
O75116/T431N	ROCK2	neutral	3	T -> N (in dbSNP:rs2230774)	VARIANT	18
O75385/K46I	ULK1	loss	2	K->I: Abolished serine/threonine-protein kinase activity.	MUTAGEN	0
O75385/P478L	ULK1	neutral	1	P -> L (in dbSNP:rs12827141)	VARIANT	0
O75385/P714L	ULK1	neutral	1	P -> L (in dbSNP:rs11546871)	VARIANT	2
O75385/S298L	ULK1	-	1	S -> L (in dbSNP:rs56364352)	VARIANT	0
O75385/S665L	ULK1	neutral	1	S -> L (in dbSNP:rs55815560)	VARIANT	0
O75385/S784C	ULK1	-	1	S -> C (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
O75385/T503M	ULK1	-	1	T -> M (in dbSNP:rs55824543)	VARIANT	0
O75385/T816A	ULK1	neutral	2	T -> A (in dbSNP:rs11609348)	VARIANT	1
O75385/V290M	ULK1	-	1	V -> M (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs370624303)	VARIANT	0
O75460/C109S	ERN1	-	2	C->S: No effect on dimerization. No effect on interaction with P4HB; when associated with S-148 and S-332.	MUTAGEN	0
O75460/C148S	ERN1	-	3	C->S: No effect on dimerization. Weakens dimer; when associated with S-332. Abolishes interaction with PDIA6. Prolonged splicing of XBP1, probably due to prolonged activation of PDIA6. Inhibits formation of oxidized multimeric forms of ERN1 in response to ER stress. No effect on interaction with P4HB; when associated with S-109 and S-332.	MUTAGEN	0
O75460/C332S	ERN1	-	2	C->S: No effect on dimerization. Weakens dimer; when associated with S-148. No effect on interaction with P4HB; when associated with S-109 and S-148.	MUTAGEN	0
O75460/D123P	ERN1	loss	1	D->P: Abolishes ability to homodimerize.	MUTAGEN	0
O75460/K599A	ERN1	loss	2	K->A: Loss of autophosphorylation and of endoribonuclease activity. Inhibition of growth arrest.	MUTAGEN	0
O75460/L474R	ERN1	-	1	L -> R (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs186305118)	VARIANT	0
O75460/N244S	ERN1	-	1	N -> S (in a renal clear cell carcinoma sample; somatic mutation; dbSNP:rs1397145500)	VARIANT	1
O75460/N700S	ERN1	-	1	N -> S (in dbSNP:rs918253870)	VARIANT	0
O75460/P830L	ERN1	-	1	P -> L (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs1279653488)	VARIANT	0
O75460/Q105E	ERN1	decrease	1	Q->E: Impaired ability to homodimerize.	MUTAGEN	0
O75460/R635W	ERN1	-	1	R -> W (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs146710304)	VARIANT	0
O75460/S769F	ERN1	-	1	S -> F (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	0
O75460/V418M	ERN1	-	1	V -> M (in dbSNP:rs55869215)	VARIANT	1
O75460/W125A	ERN1	loss	1	W->A: Abolishes ability to homodimerize.	MUTAGEN	0
O75582/D195A	RPS6KA5	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
O75582/D554N	RPS6KA5	-	1	D -> N (in dbSNP:rs55911249)	VARIANT	0
O75582/D565A	RPS6KA5	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
O75582/H190R	RPS6KA5	-	0	H -> R (in dbSNP:rs34699345)	VARIANT	0
O75582/P574L	RPS6KA5	-	1	P -> L (in dbSNP:rs34604933)	VARIANT	0
O75582/S212A	RPS6KA5	loss	1	S->A: Inactivates the N-terminal kinase domain.	MUTAGEN	0
O75582/S360A	RPS6KA5	decrease	1	S->A: Decreases kinase activity by 60% in response to PMA and UV-C.	MUTAGEN	0
O75582/S376A	RPS6KA5	loss	1	S->A: Loss of kinase activity, and decreases the phosphorylation of S-360 and T-581.	MUTAGEN	0
O75582/T581A	RPS6KA5	loss	0	T->A: Loss of kinase activity, and blocks phosphorylation of S-212; S-376 and S-381 in response to 	MUTAGEN	0
O75582/T700A	RPS6KA5	decrease	1	T->A,D: Strongly reduces phosphorylation of T-581 in response to PMA and UV-C.	MUTAGEN	0
O75582/T700D	RPS6KA5	decrease	1	T->A,D: Strongly reduces phosphorylation of T-581 in response to PMA and UV-C.	MUTAGEN	0
O75582/Y599C	RPS6KA5	-	1	Y -> C (in dbSNP:rs55968863)	VARIANT	0
O75676/F709A	RPS6KA4	increase	1	F->A: Strongly elevates basal activity.	MUTAGEN	0
O75676/S236L	RPS6KA4	-	1	S -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs746466314)	VARIANT	3
O75676/S758A	RPS6KA4	neutral	1	S -> A (in dbSNP:rs17857342)	VARIANT	0
O75716/C6S	STK16	-	1	C->S: Loss of palmitoylation.	MUTAGEN	0
O75716/C8S	STK16	-	1	C->S: Loss of palmitoylation.	MUTAGEN	0
O75716/E55K	STK16	-	1	E -> K (in dbSNP:rs35947471)	VARIANT	0
O75716/H41R	STK16	-	1	H -> R (in dbSNP:rs34799131)	VARIANT	0
O75716/I77V	STK16	-	1	I -> V (in dbSNP:rs34282267)	VARIANT	0
O75716/P277L	STK16	-	1	P -> L (in dbSNP:rs35454203)	VARIANT	0
O75716/R266W	STK16	neutral	2	R -> W (in dbSNP:rs17849638)	VARIANT	1
O75914/A380E	PAK3	-	1	A -> E (in XLID30; dbSNP:rs121434613)	VARIANT	0
O75914/R67C	PAK3	-	1	R -> C (in XLID30; dbSNP:rs121434612)	VARIANT	0
O75914/T440S	PAK3	-	1	T -> S (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
O75962/D1368V	TRIO	-	1	D -> V (found in patient with severe intellectual disability; unknown pathological significance)	VARIANT	0
O75962/D348E	TRIO	-	0	D -> E (in dbSNP:rs16903367)	VARIANT	0
O75962/E1299A	TRIO	decrease	1	E->A: 50% decrease in nucleotide exchange activity.	MUTAGEN	0
O75962/E1299K	TRIO	decrease	1	E -> K (in MRD44; severely decreased activation of RAC1-mediated signaling; severely decreased neurite outgrowth)	VARIANT	0
O75962/N1080I	TRIO	increase	2	N -> I (in MRD63; slightly increased occipitofrontal circumference; increased activation of RAC1-mediated signaling; increased neurite outgrowth; dbSNP:rs879255628)	VARIANT	0
O75962/N1389A	TRIO	-	1	N->A: No change in nucleotide exchange activity.	MUTAGEN	0
O75962/R1078G	TRIO	increase	1	R -> G (in MRD63; increased activation of RAC1-mediated signaling; increased neurite outgrowth)	VARIANT	0
O75962/R1078Q	TRIO	increase	1	R -> Q (in MRD63; increased activation of RAC1-mediated signaling; increased neurite outgrowth)	VARIANT	0
O75962/R1078W	TRIO	increase	1	R -> W (in MRD63; increased activation of RAC1-mediated signaling; increased neurite outgrowth; dbSNP:rs1554065887)	VARIANT	0
O75962/R924S	TRIO	-	1	R -> S (in MRD44; unknown pathological significance; dbSNP:rs772072746)	VARIANT	0
O75962/S291T	TRIO	-	1	S -> T (in dbSNP:rs55772118)	VARIANT	0
O75962/T1075I	TRIO	increase	1	T -> I (in MRD63; slightly increased occipitofrontal circumference; increased activation of RAC1-mediated signaling; increased lamellipodia formation)	VARIANT	0
O75962/T1303A	TRIO	decrease	1	T->A: 40% decrease in nucleotide exchange activity.	MUTAGEN	0
O75962/Y1238H	TRIO	-	1	Y -> H (in MRD44; unknown pathological significance; dbSNP:rs756004023)	VARIANT	0
O76039/A374T	CDKL5	-	1	A -> T (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
O76039/A40V	CDKL5	decrease	2	A -> V (in DEE2; causes mislocalization of the protein in the cytoplasm; dbSNP:rs122460159)	VARIANT	2
O76039/C152F	CDKL5	decrease	2	C -> F (in DEE2; affect activity; causes mislocalization of the protein in the cytoplasm; dbSNP:rs122460157)	VARIANT	0
O76039/C291Y	CDKL5	-	1	C -> Y (in DEE2; dbSNP:rs267606714)	VARIANT	0
O76039/G207E	CDKL5	-	1	G -> E (in DEE2)	VARIANT	0
O76039/H127R	CDKL5	-	1	H -> R (in DEE2; dbSNP:rs267608468)	VARIANT	0
O76039/H145Y	CDKL5	-	1	H -> Y (in DEE2; unknown pathological significance)	VARIANT	0
O76039/H581Y	CDKL5	-	1	H -> Y (in DEE2; unknown pathological significance)	VARIANT	0
O76039/I72N	CDKL5	-	1	I -> N (in DEE2; dbSNP:rs62641235)	VARIANT	0
O76039/I72T	CDKL5	-	1	I -> T (in DEE2; dbSNP:rs62641235)	VARIANT	0
O76039/L182P	CDKL5	-	1	L -> P (in DEE2)	VARIANT	0
O76039/L220P	CDKL5	decrease	2	L -> P (in DEE2; causes mislocalization of the protein in the cytoplasm; dbSNP:rs267608511)	VARIANT	0
O76039/N368H	CDKL5	-	1	N -> H (in a colorectal cancer sample; somatic mutation)	VARIANT	0
O76039/N399T	CDKL5	-	1	N -> T (in DEE2; dbSNP:rs267608611)	VARIANT	0
O76039/P180L	CDKL5	-	1	P -> L (in DEE2; dbSNP:rs61749704)	VARIANT	0
O76039/P574Q	CDKL5	-	1	P -> Q (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs199897804)	VARIANT	0
O76039/P647L	CDKL5	-	1	P -> L (probable disease-associated variant found in a patient with autism spectrum disorder)	VARIANT	0
O76039/Q791P	CDKL5	neutral	4	Q -> P (in dbSNP:rs35478150)	VARIANT	0
O76039/R175S	CDKL5	-	2	R -> S (in DEE2; affect activity; does not affect the cellular distribution of the protein; dbSNP:rs61749700)	VARIANT	0
O76039/R178P	CDKL5	-	1	R -> P (in DEE2; dbSNP:rs267606715)	VARIANT	0
O76039/R178Q	CDKL5	-	3	R -> Q (in DEE2; dbSNP:rs267606715)	VARIANT	2
O76039/R178W	CDKL5	-	1	R -> W (in DEE2; dbSNP:rs267608493)	VARIANT	0
O76039/R444C	CDKL5	-	1	R -> C (in dbSNP:rs61753977)	VARIANT	0
O76039/R858C	CDKL5	-	1	R -> C (in DEE2; unknown pathological significance; dbSNP:rs773760466)	VARIANT	0
O76039/S196L	CDKL5	-	1	S -> L (in DEE2; dbSNP:rs267608501)	VARIANT	0
O76039/T288I	CDKL5	-	1	T -> I (in DEE2; dbSNP:rs267606713)	VARIANT	0
O76039/T734A	CDKL5	-	1	T -> A (in dbSNP:rs55803460)	VARIANT	1
O76039/V718M	CDKL5	-	2	V -> M (in DEE2; dbSNP:rs267608653)	VARIANT	0
O76039/V793A	CDKL5	-	1	V -> A (in DEE2; unknown pathological significance; dbSNP:rs62643617)	VARIANT	0
O94768/K62A	STK17B	loss	1	K->A: Loss of activity and of apoptotic function.	MUTAGEN	0
O94768/S320F	STK17B	neutral	1	S -> F (in dbSNP:rs34740616)	VARIANT	0
O94804/C947Y	STK10	-	1	C -> Y (in dbSNP:rs56355550)	VARIANT	0
O94804/K277E	STK10	-	2	K -> E (in TGCT; somatic mutation; dbSNP:rs757545210)	VARIANT	0
O94804/K65I	STK10	loss	1	K->I: Loss of kinase activity.	MUTAGEN	0
O94804/M710T	STK10	-	1	M -> T (in dbSNP:rs34936670)	VARIANT	0
O94804/N467S	STK10	-	1	N -> S (in dbSNP:rs56063773)	VARIANT	0
O94804/P480L	STK10	-	0	P -> L (in dbSNP:rs34505340)	VARIANT	0
O94804/P520L	STK10	neutral	0	P -> L (in dbSNP:rs17074311)	VARIANT	0
O94804/R268C	STK10	-	1	R -> C (in dbSNP:rs35826078)	VARIANT	0
O94804/R322W	STK10	-	1	R -> W (in dbSNP:rs56214442)	VARIANT	0
O94804/S853L	STK10	neutral	1	S -> L (in dbSNP:rs56066852)	VARIANT	0
O94804/S905T	STK10	-	1	S -> T (in dbSNP:rs55791916)	VARIANT	0
O94804/S942N	STK10	-	0	S -> N (in dbSNP:rs1128204)	VARIANT	0
O94804/T336I	STK10	-	1	T -> I (in dbSNP:rs55972616)	VARIANT	0
O94806/A128T	PRKD3	-	1	A -> T (in dbSNP:rs17852819)	VARIANT	0
O94806/I284V	PRKD3	-	0	I->V: Slight increase in ability to bind DAG, no effect on phorbol-ester binding.	MUTAGEN	0
O94806/K293W	PRKD3	-	1	K->W: Increased ability to bind DAG, no effect on phorbol-ester binding.	MUTAGEN	0
O94806/L445I	PRKD3	neutral	0	L -> I (in dbSNP:rs55912911)	VARIANT	0
O94806/N42D	PRKD3	neutral	0	N -> D (in dbSNP:rs11896614)	VARIANT	0
O94806/P165G	PRKD3	-	1	P->G: No effect on ability to bind phorbol ester, loss of ability to bind DAG, reduced DAG-induced membrane translocation.	MUTAGEN	0
O94806/P225S	PRKD3	neutral	0	P -> S (in dbSNP:rs34280934)	VARIANT	0
O94806/P282G	PRKD3	-	1	P->G: No effect on ability to bind phorbol ester, increase in ability to bind DAG.	MUTAGEN	0
O94806/Q546R	PRKD3	-	1	Q -> R (in dbSNP:rs17856887)	VARIANT	0
O94806/T156A	PRKD3	-	1	T->A: Slight loss in ability to bind DAG and phorbol-ester; when associated with F-158.	MUTAGEN	0
O94806/T166A	PRKD3	-	1	T->A: Slight loss in ability to bind DAG and phorbol-ester.	MUTAGEN	0
O94806/V716M	PRKD3	-	1	V -> M (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
O94806/Y158F	PRKD3	-	1	Y->F: Slight loss in ability to bind DAG and phorbol-ester; when associated with A-156.	MUTAGEN	0
O94806/Y170F	PRKD3	-	1	Y->F: Slight loss in ability to bind DAG and phorbol-ester.	MUTAGEN	0
O94921/K164R	CDK14	loss	2	K->R: Abolishes protein kinase activity.	MUTAGEN	0
O94921/M432I	CDK14	-	1	M -> I (in an ovarian mucinous carcinoma; somatic mutation; dbSNP:rs773301216)	VARIANT	0
O94921/S463R	CDK14	-	1	S -> R (in dbSNP:rs35643773)	VARIANT	0
O95382/A1061T	MAP3K6	-	1	A -> T (in dbSNP:rs55990440)	VARIANT	0
O95382/G1233A	MAP3K6	neutral	0	G -> A (in dbSNP:rs17162549)	VARIANT	0
O95382/N622K	MAP3K6	neutral	1	N -> K (in dbSNP:rs35659744)	VARIANT	10
O95382/P869T	MAP3K6	-	1	P -> T (in a breast cancer sample; somatic mutation)	VARIANT	1
O95382/R499C	MAP3K6	neutral	0	R -> C (in dbSNP:rs11247641)	VARIANT	0
O95382/R544W	MAP3K6	-	1	R -> W (in dbSNP:rs55671988)	VARIANT	0
O95382/R668G	MAP3K6	-	1	R -> G (in dbSNP:rs55869163)	VARIANT	0
O95382/R673L	MAP3K6	-	1	R -> L (in dbSNP:rs56359841)	VARIANT	0
O95382/S925L	MAP3K6	-	1	S -> L (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	0
O95382/S969N	MAP3K6	-	1	S -> N (in dbSNP:rs17856498)	VARIANT	0
O95382/T455I	MAP3K6	-	2	T -> I (in dbSNP:rs1138294)	VARIANT	2
O95382/T968I	MAP3K6	-	1	T -> I (in an ovarian endometrioid cancer sample; somatic mutation)	VARIANT	1
O95747/K46A	OXSR1	loss	2	K->A: Loss of autophosphorylation and kinase activity.	MUTAGEN	0
O95747/K46M	OXSR1	loss	2	K->M: Loss of RELT, RELL1 and RELL2 phosphorylation. Retention of some autophosphorylation activity may be due to complex formation with other endogenous kinases in the assay.	MUTAGEN	0
O95747/P433S	OXSR1	-	1	P -> S (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
O95747/S425T	OXSR1	-	0	S -> T (in dbSNP:rs35295772)	VARIANT	0
O95747/T304I	OXSR1	neutral	2	T -> I (in dbSNP:rs6599079)	VARIANT	1
O95819/S712T	MAP4K4	-	1	S -> T	VARIANT	0
O95835/F641L	LATS1	-	1	F -> L (in dbSNP:rs35163691)	VARIANT	1
O95835/G1000S	LATS1	-	1	G -> S (in dbSNP:rs56412005)	VARIANT	0
O95835/K734A	LATS1	loss	1	K->A: Loss of kinase activity, autophosphorylation, increased ploidy, prolonged duration of mitosis and lack of p53 expression.	MUTAGEN	0
O95835/M669I	LATS1	-	1	M -> I (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs1390558952)	VARIANT	1
O95835/P237Q	LATS1	-	1	P -> Q (in dbSNP:rs56149740)	VARIANT	0
O95835/P531S	LATS1	-	1	P -> S (in dbSNP:rs55874734)	VARIANT	0
O95835/R370W	LATS1	-	1	R -> W (in dbSNP:rs56348064)	VARIANT	2
O95835/R806P	LATS1	-	1	R -> P (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
O95835/R96W	LATS1	neutral	1	R -> W (in dbSNP:rs55945045)	VARIANT	2
O95835/S204G	LATS1	neutral	1	S -> G (in dbSNP:rs34793526)	VARIANT	0
O95835/S464A	LATS1	loss	1	S->A: Abolishes phosphorylation by NUAK1 and NUAK2.	MUTAGEN	0
O95835/Y559F	LATS1	decrease	1	Y->F: Loss of interaction with YAP1.	MUTAGEN	0
O96013/A139T	PAK4	-	1	A -> T (in dbSNP:rs35655056)	VARIANT	0
O96013/R135Q	PAK4	neutral	1	R -> Q (in dbSNP:rs56099436)	VARIANT	1
O96013/S445N	PAK4	activating	1	S->N: Approximately 30-fold increased autophosphorylation (constitutively active mutant).	MUTAGEN	0
O96017/A17S	CHEK2	-	1	A -> S (in an osteogenic sarcoma sample; somatic mutation; might influence susceptibility to breast cancer; does not cause protein abrogation in familial colorectal cancer; dbSNP:rs137853008)	VARIANT	1
O96017/D347A	CHEK2	loss	2	D->A: Loss of kinase activity and of the ability to phosphorylate CDC25A.	MUTAGEN	0
O96017/D347N	CHEK2	-	0	D -> N (in dbSNP:rs28909980)	VARIANT	0
O96017/D368N	CHEK2	loss	1	D->N: Loss of autophosphorylation activity.	MUTAGEN	0
O96017/E239K	CHEK2	-	1	E -> K (in prostate cancer; germline mutation; dbSNP:rs121908702)	VARIANT	2
O96017/E501K	CHEK2	-	0	E -> K (in dbSNP:rs17883172)	VARIANT	0
O96017/E64K	CHEK2	-	1	E -> K (in prostate cancer; somatic mutation; dbSNP:rs141568342)	VARIANT	0
O96017/F447I	CHEK2	-	0	F -> I (in dbSNP:rs17881473)	VARIANT	0
O96017/G167R	CHEK2	-	1	G -> R (in prostate cancer; somatic mutation; dbSNP:rs72552322)	VARIANT	0
O96017/H371Y	CHEK2	decrease	1	H -> Y (confers a moderate risk of breast cancer; partially reduces kinase activity; dbSNP:rs531398630)	VARIANT	1
O96017/I157T	CHEK2	decrease,neutral	13	I -> T (might influence susceptibility to different types of cancer; does not cause protein abrogation in familial colorectal cancer; loss of the ability to interact with and phosphorylate CDC25A and to promote CDC25A degradation in response to ionizing radiation; dbSNP:rs17879961)	VARIANT	4
O96017/I251F	CHEK2	-	1	I -> F (in prostate cancer; unknown pathological significance; dbSNP:rs587780189)	VARIANT	0
O96017/I448S	CHEK2	neutral	0	I -> S (in dbSNP:rs17886163)	VARIANT	0
O96017/L436M	CHEK2	-	0	L -> M (in dbSNP:rs17882922)	VARIANT	0
O96017/L512V	CHEK2	-	0	L -> V (in dbSNP:rs17882942)	VARIANT	0
O96017/N446K	CHEK2	-	0	N -> K (in dbSNP:rs17880867)	VARIANT	0
O96017/P85L	CHEK2	-	2	P -> L (in an osteogenic sarcoma sample; neutral allele among Ashkenazi Jewish women; dbSNP:rs17883862)	VARIANT	2
O96017/R117G	CHEK2	-	3	R -> G (in BC; dbSNP:rs28909982)	VARIANT	2
O96017/R137Q	CHEK2	-	2	R -> Q (might influence susceptibility to breast cancer; does not cause protein abrogation in familial colorectal cancer; dbSNP:rs368570187)	VARIANT	0
O96017/R145P	CHEK2	-	1	R -> P (in prostate cancer; somatic mutation; dbSNP:rs587781667)	VARIANT	0
O96017/R145W	CHEK2	decrease	6	R -> W (in colon cancer and LFS2; does not cause protein abrogation in familial colorectal cancer; loss of the ability to interact with and phosphorylate CDC25A and to promote CDC25A degradation in response to ionizing radiation; dbSNP:rs137853007)	VARIANT	2
O96017/R180C	CHEK2	-	2	R -> C (in prostate cancer; somatic mutation; dbSNP:rs77130927)	VARIANT	2
O96017/R180H	CHEK2	-	3	R -> H (in prostate cancer; somatic mutation; dbSNP:rs137853009)	VARIANT	2
O96017/R181C	CHEK2	-	1	R -> C (in prostate cancer; somatic mutation; dbSNP:rs137853010)	VARIANT	0
O96017/R181H	CHEK2	-	1	R -> H (in prostate cancer; somatic mutation; dbSNP:rs121908701)	VARIANT	2
O96017/R318H	CHEK2	-	1	R -> H (in prostate cancer; unknown pathological significance; somatic mutation; dbSNP:rs143611747)	VARIANT	0
O96017/R406H	CHEK2	-	0	R -> H (in dbSNP:rs200649225)	VARIANT	0
O96017/S379A	CHEK2	decrease	1	S->A: Abrogates autophosphorylation at Ser-379 and prevents ubiquitination.	MUTAGEN	0
O96017/S428F	CHEK2	-	1	S -> F (may increase breast cancer risk; dbSNP:rs137853011)	VARIANT	2
O96017/S456A	CHEK2	-	1	S->A: Increased ubiquitination and degradation by the proteasome.	MUTAGEN	0
O96017/S500C	CHEK2	-	0	S -> C (in dbSNP:rs28909981)	VARIANT	0
O96017/S73A	CHEK2	decrease	1	S->A: Impaired activation, phosphorylation by ATM and G2/M transition checkpoint.	MUTAGEN	0
O96017/T323P	CHEK2	-	1	T -> P (in prostate cancer; somatic mutation; dbSNP:rs750984976)	VARIANT	0
O96017/T383A	CHEK2	loss	1	T->A: Loss of phosphorylation in response to ionizing radiation.	MUTAGEN	0
O96017/T387A	CHEK2	loss	1	T->A: Loss of phosphorylation in response to ionizing radiation.	MUTAGEN	0
O96017/T476K	CHEK2	-	1	T -> K (in prostate cancer; somatic mutation)	VARIANT	0
O96017/T59K	CHEK2	-	1	T -> K (in multiple cancers; dbSNP:rs149991239)	VARIANT	0
O96017/T68A	CHEK2	loss	2	T->A: Loss of activation and phosphorylation.	MUTAGEN	0
O96017/Y327C	CHEK2	-	1	Y -> C (in prostate cancer; unknown pathological significance; somatic mutation; dbSNP:rs587780194)	VARIANT	1
O96017/Y390C	CHEK2	loss	1	Y -> C (in BC; does not phosphorylate p53/TP53; dbSNP:rs200928781)	VARIANT	39
P00519/A337T	ABL1	increase	1	A -> T (in CHDSKM; increases kinase activity; no effect on protein levels; dbSNP:rs1060499548)	VARIANT	0
P00519/G706V	ABL1	-	1	G -> V (in dbSNP:rs34634745)	VARIANT	0
P00519/K247R	ABL1	neutral	0	K -> R (in dbSNP:rs34549764)	VARIANT	0
P00519/L140P	ABL1	-	1	L -> P (in dbSNP:rs1064152)	VARIANT	0
P00519/P810L	ABL1	neutral	1	P -> L (in dbSNP:rs2229071)	VARIANT	3
P00519/P900S	ABL1	-	0	P -> S (in dbSNP:rs35266696)	VARIANT	0
P00519/R166K	ABL1	-	1	R -> K (in a melanoma sample; somatic mutation)	VARIANT	1
P00519/R47G	ABL1	-	1	R -> G (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
P00519/S968P	ABL1	-	0	S -> P (in dbSNP:rs1064165)	VARIANT	0
P00519/S972L	ABL1	neutral	1	S -> L (in dbSNP:rs2229067)	VARIANT	9
P00519/T735A	ABL1	-	0	T->A: Abolishes phosphorylation. Loss of binding 	MUTAGEN	0
P00519/T852P	ABL1	-	0	T -> P (in dbSNP:rs1588283506)	VARIANT	0
P00519/Y226C	ABL1	increase	1	Y -> C (in CHDSKM; increases kinase activity; no effect on protein levels; dbSNP:rs1060499547)	VARIANT	0
P00533/C1049A	EGFR	-	1	C->A: Decreased palmitoylation.	MUTAGEN	0
P00533/C1146A	EGFR	-	1	C->A: Decreased palmitoylation.	MUTAGEN	0
P00533/D587A	EGFR	-	1	D->A: Increased EGF binding; when associated with A-590 and A-609.	MUTAGEN	0
P00533/D974A	EGFR	decrease	0	D->A: Strongly reduced phosphorylation.	MUTAGEN	0
P00533/E690A	EGFR	decrease	2	E->A: Reduced phosphorylation.	MUTAGEN	0
P00533/E709A	EGFR	-	3	E -> A (found in a lung cancer sample; more sensitive to gefitinib than wild-type; dbSNP:rs397517085)	VARIANT	14
P00533/E709G	EGFR	activating	2	E -> G (found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild-type; dbSNP:rs397517085)	VARIANT	13
P00533/E709K	EGFR	-	1	E -> K (found in a lung cancer sample; dbSNP:rs727504256)	VARIANT	39
P00533/E734K	EGFR	-	1	E -> K (found in a lung cancer sample; dbSNP:rs121913420)	VARIANT	2
P00533/F287A	EGFR	-	1	F->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.	MUTAGEN	0
P00533/G428D	EGFR	loss	1	G -> D (in NISBD2; loss of function; the mutant does not localize to the cell membrane; has diffuse cytoplasmic localization; dbSNP:rs606231253)	VARIANT	0
P00533/G719A	EGFR	resistance	1	G -> A (found in a lung cancer sample; dbSNP:rs121913428)	VARIANT	143
P00533/G719C	EGFR	-	2	G -> C (found in a lung cancer sample; dbSNP:rs28929495)	VARIANT	61
P00533/G719D	EGFR	-	1	G -> D (found in a lung cancer sample; dbSNP:rs121913428)	VARIANT	12
P00533/G724S	EGFR	-	1	G -> S (found in a lung cancer sample; dbSNP:rs1051753269)	VARIANT	4
P00533/G873E	EGFR	-	1	G -> E (found in a lung cancer sample)	VARIANT	2
P00533/H590A	EGFR	-	1	H->A: Increased EGF binding; when associated with A-587; A-590 and A-609.	MUTAGEN	0
P00533/H835L	EGFR	-	2	H -> L (found in a lung cancer sample; more sensitive to gefitinib than wild-type; dbSNP:rs397517128)	VARIANT	5
P00533/H988P	EGFR	-	0	H -> P (in dbSNP:rs17290699)	VARIANT	0
P00533/I706A	EGFR	loss	1	I->A: Abolishes phosphorylation.	MUTAGEN	0
P00533/K609A	EGFR	-	2	K->A: Decreases intramolecular interactions and facilitates EGF binding. Increased EGF binding; when associated with A-587; A-590 and A-609.	MUTAGEN	0
P00533/K745A	EGFR	loss	1	K->A,M: Abolishes kinase activity.	MUTAGEN	0
P00533/K745M	EGFR	loss	1	K->A,M: Abolishes kinase activity.	MUTAGEN	0
P00533/L1034R	EGFR	-	1	L -> R (in dbSNP:rs34352568)	VARIANT	0
P00533/L688A	EGFR	decrease	2	L->A: Strongly reduced phosphorylation.	MUTAGEN	0
P00533/L692A	EGFR	decrease	2	L->A,P: Strongly reduced phosphorylation.	MUTAGEN	0
P00533/L692P	EGFR	-	2	L->A,P: Strongly reduced phosphorylation.	MUTAGEN	2
P00533/L704A	EGFR	loss	1	L->A: Abolishes phosphorylation.	MUTAGEN	0
P00533/L747F	EGFR	-	1	L -> F (found in a lung cancer sample)	VARIANT	1
P00533/L833V	EGFR	-	3	L -> V (found in a lung cancer sample; more sensitive to gefitinib than wild-type; dbSNP:rs397517126)	VARIANT	13
P00533/L838V	EGFR	-	2	L -> V (found in a lung cancer sample; more sensitive to gefitinib than wild-type; dbSNP:rs864621996)	VARIANT	1
P00533/L858M	EGFR	-	1	L -> M (found in a lung cancer sample; dbSNP:rs121913443)	VARIANT	5
P00533/L861Q	EGFR	activating	3	L -> Q (found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild-type; dbSNP:rs121913444)	VARIANT	275
P00533/N700A	EGFR	loss	1	N->A: Abolishes phosphorylation.	MUTAGEN	0
P00533/P266R	EGFR	-	0	P -> R (in dbSNP:rs17336639)	VARIANT	0
P00533/P694A	EGFR	decrease	1	P->A: Strongly reduced phosphorylation.	MUTAGEN	0
P00533/P699A	EGFR	decrease	1	P->A: Reduced phosphorylation.	MUTAGEN	0
P00533/Q1067G	EGFR	-	1	Q->G: No effect on interaction with CBLC.	MUTAGEN	0
P00533/Q787R	EGFR	-	1	Q -> R (found in a lung cancer sample)	VARIANT	1
P00533/R1068G	EGFR	increase	1	R->G: Strongly decreases interaction with CBLC.	MUTAGEN	0
P00533/R309S	EGFR	-	1	R->S: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-275. Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-287.	MUTAGEN	0
P00533/R429E	EGFR	loss	1	R->E: Abolishes autophosphorylation and activation of downstream kinases.	MUTAGEN	0
P00533/R521K	EGFR	neutral	1	R -> K (in dbSNP:rs2227983)	VARIANT	73
P00533/R705A	EGFR	loss	1	R->A: Abolishes phosphorylation.	MUTAGEN	0
P00533/R748P	EGFR	-	1	R -> P (found in a lung cancer sample)	VARIANT	0
P00533/R962G	EGFR	-	0	R -> G (in dbSNP:rs17337451)	VARIANT	0
P00533/R977A	EGFR	decrease	1	R->A: Reduced phosphorylation.	MUTAGEN	0
P00533/R98Q	EGFR	-	0	R -> Q (in dbSNP:rs17289589)	VARIANT	2
P00533/S768I	EGFR	activating	2	S -> I (found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild-type; dbSNP:rs121913465)	VARIANT	226
P00533/T693A	EGFR	-	1	T->A: Increased phosphorylation.	MUTAGEN	0
P00533/T693D	EGFR	decrease	1	T->D: Strongly reduced phosphorylation.	MUTAGEN	0
P00533/T790M	EGFR	increase,resistance	2	T -> M (found in a lung cancer sample; increased kinase activity; dbSNP:rs121434569)	VARIANT	973
P00533/V674I	EGFR	-	0	V -> I (in dbSNP:rs17337079)	VARIANT	1
P00533/V689A	EGFR	decrease	1	V->A: Reduced autophosphorylation.	MUTAGEN	0
P00533/V689M	EGFR	activating	1	V->M: Constitutively activated kinase.	MUTAGEN	3
P00533/V769M	EGFR	-	1	V -> M (found in a lung cancer sample; dbSNP:rs147149347)	VARIANT	1
P00533/V834L	EGFR	-	1	V -> L (found in a lung cancer sample; dbSNP:rs397517127)	VARIANT	8
P00533/Y1016F	EGFR	-	1	Y->F: 50% decrease in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1197. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1092.	MUTAGEN	0
P00533/Y1069F	EGFR	activating	1	Y->F: Abolishes interaction with CBLC.	MUTAGEN	0
P00533/Y1092F	EGFR	-	1	Y->F: No change in interaction with PIK3C2B. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1016.	MUTAGEN	0
P00533/Y1110F	EGFR	-	1	Y->F: No change in interaction with PIK3C2B.	MUTAGEN	0
P00533/Y1172F	EGFR	-	1	Y->F: No change in interaction with PIK3C2B.	MUTAGEN	0
P00533/Y1197F	EGFR	-	1	Y->F: No change in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1016. Abolishes interaction with PIK3C2B; when associated with F-1092 and F-1016.	MUTAGEN	0
P00533/Y275A	EGFR	-	1	Y->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.	MUTAGEN	0
P00540/A105S	MOS	-	2	A -> S (in dbSNP:rs35392772)	VARIANT	0
P00540/A123T	MOS	-	1	A -> T (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P00540/R96L	MOS	-	1	R -> L (in dbSNP:rs34532635)	VARIANT	0
P00540/S300P	MOS	-	1	S -> P (in dbSNP:rs56300224)	VARIANT	0
P04049/A237T	RAF1	increase	1	A -> T (in CMD1NN; shows a mild increase in kinase activity; dbSNP:rs587777588)	VARIANT	0
P04049/D486G	RAF1	-	1	D -> G (in NS5; dbSNP:rs397516815)	VARIANT	0
P04049/D486N	RAF1	loss	1	D -> N (in NS5; has reduced or absent kinase activity; dbSNP:rs80338798)	VARIANT	0
P04049/H626R	RAF1	increase	1	H -> R (in CMD1NN; shows a mild increase in kinase activity; dbSNP:rs1553609795)	VARIANT	0
P04049/K375W	RAF1	loss	1	K->W: Catalytically inactive.	MUTAGEN	0
P04049/L603P	RAF1	decrease	1	L -> P (in CMD1NN; shows impaired kinase activity and reduced MAPK3 activation with this mutation; dbSNP:rs587777586)	VARIANT	0
P04049/L613V	RAF1	increase	2	L -> V (in NS5 and LPRD2; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild-type; dbSNP:rs80338797)	VARIANT	2
P04049/P261A	RAF1	increase	1	P -> A (in NS5; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild-type; dbSNP:rs121434594)	VARIANT	0
P04049/P261L	RAF1	increase	1	P -> L (in NS5; shows greater kinase activity and enhanced MAPK1 activation than wild-type; dbSNP:rs397516828)	VARIANT	1
P04049/P261S	RAF1	increase	3	P -> S (in NS5; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild-type; dbSNP:rs121434594)	VARIANT	0
P04049/P308L	RAF1	-	1	P -> L (in dbSNP:rs5746220)	VARIANT	0
P04049/P332A	RAF1	increase	1	P -> A (in CMD1NN; shows a mild increase in kinase activity; dbSNP:rs1057403865)	VARIANT	0
P04049/Q335H	RAF1	-	1	Q -> H (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P04049/R256S	RAF1	-	1	R -> S (in NS5; dbSNP:rs397516826)	VARIANT	0
P04049/R563K	RAF1	increase	1	R->K: Loss of methylation. Increased stability and catalytic activity in response to EGF treatment.	MUTAGEN	0
P04049/S257L	RAF1	increase	2	S -> L (in NS5 and LPRD2; shows in vitro greater kinase activity and enhanced ERK activation than wild-type; dbSNP:rs80338796)	VARIANT	13
P04049/S259A	RAF1	increase	2	S -> A (in an ovarian serous carcinoma sample; somatic mutation; increased ERK activation; dbSNP:rs3730271)	VARIANT	0
P04049/S259F	RAF1	-	1	S -> F (in NS5; dbSNP:rs397516827)	VARIANT	7
P04049/S494D	RAF1	activating	1	S->D: Increased kinase activity but can still be inhibited by PPP5C; when associated with D-491.	MUTAGEN	0
P04049/S612T	RAF1	-	1	S -> T (in NS5; dbSNP:rs1448392469)	VARIANT	0
P04049/T260I	RAF1	-	1	T -> I (in hypertrophic cardiomyopathy; unknown pathological significance; dbSNP:rs869025501)	VARIANT	0
P04049/T260R	RAF1	-	1	T -> R (in NS5)	VARIANT	0
P04049/T310A	RAF1	increase	1	T -> A (in CMD1NN; shows a mild increase in kinase activity; dbSNP:rs778155315)	VARIANT	0
P04049/T491D	RAF1	activating	1	T->D: Increased kinase activity but can still be inhibited by PPP5C; when associated with D-494.	MUTAGEN	0
P04049/T491I	RAF1	loss	1	T -> I (in NS5; has reduced or absent kinase activity; dbSNP:rs80338799)	VARIANT	2
P04049/T491R	RAF1	-	1	T -> R (in NS5; dbSNP:rs80338799)	VARIANT	0
P04049/T641M	RAF1	increase	1	T -> M (in CMD1NN; shows a mild increase in kinase activity; dbSNP:rs587777587)	VARIANT	0
P04049/V263A	RAF1	increase	1	V -> A (in NS5; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild-type; dbSNP:rs397516830)	VARIANT	1
P04626/A1216D	ERBB2	neutral	1	A -> D (in dbSNP:rs55943169)	VARIANT	0
P04626/A710V	ERBB2	loss	1	A -> V (in VSCN2; almost complete loss of ERBB2 and ERBB3 phosphorylation in the presence or in the absence of NRG1 stimulation, suggesting alteration of downstream signaling; does not affect the subcellular localization at the cell membrane)	VARIANT	0
P04626/E914K	ERBB2	-	1	E -> K (in GLM; somatic mutation; unknown pathological significance; dbSNP:rs28933368)	VARIANT	1
P04626/G776S	ERBB2	-	2	G -> S (in GASC; somatic mutation; unknown pathological significance; dbSNP:rs28933369)	VARIANT	2
P04626/I654V	ERBB2	neutral	2	I -> V (in allele B3; dbSNP:rs1801201)	VARIANT	0
P04626/I655V	ERBB2	neutral	2	I -> V (in allele B2 and allele B3; dbSNP:rs1136201)	VARIANT	20
P04626/L755P	ERBB2	-	1	L -> P (in LNCR; somatic mutation; unknown pathological significance; dbSNP:rs121913469)	VARIANT	0
P04626/L768S	ERBB2	-	1	L -> S (in dbSNP:rs56366519)	VARIANT	0
P04626/M611A	ERBB2	-	1	M->A: Prevents synthesis of isoform 2.	MUTAGEN	0
P04626/M687A	ERBB2	-	1	M->A: Prevents synthesis of isoform 3.	MUTAGEN	0
P04626/M706A	ERBB2	-	1	M->A: No effect on isoform production.	MUTAGEN	0
P04626/M712A	ERBB2	-	1	M->A: No effect on isoform production.	MUTAGEN	0
P04626/N857S	ERBB2	-	2	N -> S (in OC; somatic mutation; unknown pathological significance; dbSNP:rs28933370)	VARIANT	0
P04626/P1170A	ERBB2	neutral	3	P -> A (in dbSNP:rs1058808)	VARIANT	6
P04626/W452C	ERBB2	neutral	0	W -> C (in dbSNP:rs4252633)	VARIANT	0
P04629/A107V	NTRK1	-	1	A -> V (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs540521894)	VARIANT	3
P04629/A110D	NTRK1	-	1	A -> D (in CIPA)	VARIANT	0
P04629/C752S	NTRK1	-	1	C -> S (in CIPA; unknown pathological significance; following transfection in neuroblastoma cells and NGF treatment, no effect on neurite outgrowth, nor neurite length; no effect on N-glycosylation, subcellular location, basal and NGF-induced autophosphorylation, nor on NGF-stimulated calcium flux)	VARIANT	0
P04629/C763S	NTRK1	decrease	1	C -> S (in CIPA; following transfection in neuroblastoma cells and NGF treatment, decreased percentage of cells differentiated into neuronal phenotype and reduced neurite length compared with wild-type; slightly decreased N-glycosylation; reduced expression at the plasma membrane; reduced basal and NGF-induced autophosphorylation; small reduction in NGF-stimulated calcium flux)	VARIANT	0
P04629/D596N	NTRK1	loss	1	D -> N (in CIPA; abolishes autophosphorylation)	VARIANT	1
P04629/D674Y	NTRK1	-	3	D -> Y (in CIPA; might impair the function of the enzyme without compromising autophosphorylation; dbSNP:rs80356677)	VARIANT	0
P04629/E492K	NTRK1	-	1	E -> K (in CIPA; dbSNP:rs144901788)	VARIANT	3
P04629/G18E	NTRK1	neutral	0	G -> E (in dbSNP:rs1007211)	VARIANT	0
P04629/G517E	NTRK1	-	1	G -> E (in CIPA; following transfection in neuroblastoma cells and NGF treatment, small decrease in the percentage of cells differentiated into neuronal phenotype, but in differentiated cells, the average neurite length is comparable to wild-type; no effect on N-glycosylation, subcellular location, nor on basal and NGF-induced autophosphorylation; loss of NGF-stimulated calcium flux; dbSNP:rs606231467)	VARIANT	0
P04629/G522E	NTRK1	decrease	1	G -> E (in CIPA; no effect on N-glycosylation, nor on subcellular location; reduced basal autophosphorylation and complete loss of NGF-induced autophosphorylation; loss of NGF-stimulated calcium flux)	VARIANT	0
P04629/G522R	NTRK1	decrease	2	G -> R (in CIPA; processed as wild-type but shows significantly diminished autophosphorylation in both neuronal and non-neuronal cells; dbSNP:rs1571699266)	VARIANT	0
P04629/G577R	NTRK1	loss	4	G -> R (in CIPA; loss of function; processed as wild-type but shows significantly diminished autophosphorylation in both neuronal and non-neuronal cells; dbSNP:rs121964866)	VARIANT	0
P04629/G613V	NTRK1	neutral	7	G -> V (in dbSNP:rs6339)	VARIANT	5
P04629/G714S	NTRK1	decrease	2	G -> S (in CIPA; processed as wild-type but shows significantly diminished autophosphorylation in both neuronal and non-neuronal cells; dbSNP:rs770727871)	VARIANT	1
P04629/H604Y	NTRK1	neutral	6	H -> Y (in dbSNP:rs6336)	VARIANT	0
P04629/I572S	NTRK1	-	1	I -> S (in CIPA)	VARIANT	0
P04629/I699T	NTRK1	decrease	1	I -> T (in CIPA; partially decreased N-glycosylation; reduced expression at the plasma membrane; reduced basal autophosphorylation and complete loss of NGF-induced autophosphorylation; loss of NGF-stimulated calcium flux)	VARIANT	0
P04629/K544A	NTRK1	-	1	K->A: No effect on interaction with GGA3.	MUTAGEN	0
P04629/K544N	NTRK1	loss	2	K->N: Loss of kinase activity.	MUTAGEN	0
P04629/L213P	NTRK1	decrease	2	L -> P (in CIPA; aberrantly processed; shows diminished autophosphorylation in neuronal cells; dbSNP:rs747711259)	VARIANT	0
P04629/L657P	NTRK1	decrease	1	L -> P (in CIPA; following transfection in neuroblastoma cells and NGF treatment, loss of differentiation into neuronal phenotype; partially decreased N-glycosylation; reduced expression at the plasma membrane; reduced basal autophosphorylation and complete loss of NGF-induced autophosphorylation; loss of NGF-stimulated calcium flux)	VARIANT	0
P04629/L700P	NTRK1	-	1	L -> P (in CIPA)	VARIANT	0
P04629/L717R	NTRK1	-	1	L -> R (in CIPA)	VARIANT	0
P04629/L93P	NTRK1	decrease	2	L -> P (in CIPA; aberrantly processed; shows diminished autophosphorylation in neuronal cells)	VARIANT	0
P04629/M566T	NTRK1	-	1	M -> T (in dbSNP:rs55892037)	VARIANT	0
P04629/M587V	NTRK1	-	1	M -> V (in CIPA; dbSNP:rs121964870)	VARIANT	0
P04629/P695L	NTRK1	-	1	P -> L (in CIPA; dbSNP:rs121964868)	VARIANT	1
P04629/Q80R	NTRK1	-	1	Q -> R (in dbSNP:rs55891455)	VARIANT	0
P04629/R260G	NTRK1	-	1	R -> G (in dbSNP:rs35116695)	VARIANT	0
P04629/R444Q	NTRK1	neutral	1	R -> Q (in dbSNP:rs56320207)	VARIANT	1
P04629/R452C	NTRK1	-	1	R -> C (in dbSNP:rs34900547)	VARIANT	0
P04629/R649Q	NTRK1	-	1	R -> Q (in CIPA; dbSNP:rs786205449)	VARIANT	0
P04629/R649W	NTRK1	decrease	2	R -> W (in CIPA; processed as wild-type but shows significantly diminished autophosphorylation in both neuronal and non-neuronal cells; dbSNP:rs369353892)	VARIANT	2
P04629/R654C	NTRK1	decrease	3	R -> C (in CIPA; processed as wild-type but shows significantly diminished autophosphorylation in both neuronal and non-neuronal cells; dbSNP:rs764992664)	VARIANT	0
P04629/R6W	NTRK1	-	1	R -> W (in dbSNP:rs201472270)	VARIANT	2
P04629/R771C	NTRK1	decrease	1	R -> C (in CIPA; partially decreased N-glycosylation; reduced expression at the plasma membrane; reduced basal autophosphorylation and complete loss of NGF-induced autophosphorylation; loss of NGF-stimulated calcium flux; dbSNP:rs1324983370)	VARIANT	1
P04629/R780P	NTRK1	loss	1	R -> P (in CIPA; loss of function; dbSNP:rs35669708)	VARIANT	0
P04629/R780Q	NTRK1	-	2	R -> Q (in dbSNP:rs35669708)	VARIANT	3
P04629/R85S	NTRK1	-	2	R -> S (in dbSNP:rs543320028)	VARIANT	0
P04629/T237M	NTRK1	neutral	1	T -> M (in dbSNP:rs55909005)	VARIANT	4
P04629/V238G	NTRK1	-	1	V -> G (in dbSNP:rs56000394)	VARIANT	0
P04629/V790I	NTRK1	-	1	V -> I (in dbSNP:rs55948542)	VARIANT	0
P04629/Y359C	NTRK1	-	1	Y -> C (in CIPA; dbSNP:rs121964869)	VARIANT	0
P04629/Y496F	NTRK1	-	1	Y->F: Loss of interaction with SHC1 and altered phosphorylation of SHC1. Altered neurite outgrowth and altered activation of the MAPK pathway; when associated with F-791.	MUTAGEN	0
P04629/Y791F	NTRK1	-	2	Y->F: Loss of interaction with PLCG1 and altered phosphorylation of PLCG1. Altered neurite outgrowth and altered activation of the MAPK pathway; when associated with F-496.	MUTAGEN	0
P05129/A523D	PRKCG	-	1	A -> D	VARIANT	0
P05129/G128D	PRKCG	-	1	G -> D (in SCA14; dbSNP:rs121918513)	VARIANT	0
P05129/G63R	PRKCG	-	1	G -> R (in SCA14)	VARIANT	0
P05129/G63V	PRKCG	-	1	G -> V (in SCA14; dbSNP:rs386134159)	VARIANT	0
P05129/H101Y	PRKCG	-	1	H -> Y (in SCA14; dbSNP:rs121918511)	VARIANT	0
P05129/H415Q	PRKCG	-	1	H -> Q	VARIANT	0
P05129/R141C	PRKCG	-	1	R -> C	VARIANT	0
P05129/R659S	PRKCG	-	1	R -> S (in dbSNP:rs752933837)	VARIANT	0
P05129/S119P	PRKCG	-	1	S -> P (in SCA14; dbSNP:rs121918512)	VARIANT	0
P05771/P588H	PRKCB	-	1	P -> H (in dbSNP:rs35631544)	VARIANT	0
P05771/V144M	PRKCB	-	1	V -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs764534677)	VARIANT	0
P05771/V496M	PRKCB	-	1	V -> M (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs1466858740)	VARIANT	1
P06213/A1002D	INSR	-	1	A->D: Reduces interaction with IRS1 but has no effect on interaction with SHC1.	MUTAGEN	0
P06213/A1055V	INSR	-	1	A -> V (in IRAN type A; dbSNP:rs1599874183)	VARIANT	1
P06213/A1075D	INSR	-	1	A -> D (in IRAN type A)	VARIANT	0
P06213/A1161T	INSR	-	1	A -> T (in IRAN type A; dbSNP:rs121913139)	VARIANT	0
P06213/A1162E	INSR	-	1	A -> E (in IRAN type A; impairs proteolytic processing; dbSNP:rs121913154)	VARIANT	0
P06213/A119V	INSR	decrease	1	A -> V (in LEPRCH; markedly impairs insulin binding; dbSNP:rs1347473020)	VARIANT	0
P06213/A842V	INSR	-	1	A -> V (in RMS; decreases post-translational processing; dbSNP:rs1135401738)	VARIANT	0
P06213/C228R	INSR	-	1	C -> R (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	1
P06213/C280Y	INSR	-	1	C -> Y (in IRAN type A)	VARIANT	0
P06213/C286Y	INSR	-	1	C -> Y (in LEPRCH; abolishes post-translational processing)	VARIANT	0
P06213/C301Y	INSR	-	1	C -> Y (in LEPRCH)	VARIANT	0
P06213/D1159N	INSR	loss	1	D->N: Loss of kinase activity.	MUTAGEN	0
P06213/D86G	INSR	-	1	D -> G (in IRAN type A)	VARIANT	0
P06213/E1206D	INSR	decrease	1	E -> D (in IRAN type A; accelerates degradation of the protein and impairs kinase activity)	VARIANT	0
P06213/E1206K	INSR	-	1	E -> K (in LEPRCH)	VARIANT	0
P06213/E998A	INSR	-	1	E->A: Does not affect interaction with IRS1, SHC1 or PIK3R1.	MUTAGEN	0
P06213/F409V	INSR	-	1	F -> V (in IRAN type A; dbSNP:rs121913142)	VARIANT	0
P06213/G1035V	INSR	-	1	G -> V (in IRAN type A; dbSNP:rs121913135)	VARIANT	0
P06213/G386S	INSR	-	1	G -> S (in RMS; may impair receptor processing; dbSNP:rs764221583)	VARIANT	0
P06213/G393R	INSR	-	1	G -> R (in LEPRCH; Verona-1; dbSNP:rs267607184)	VARIANT	0
P06213/G58R	INSR	decrease	1	G -> R (in LEPRCH; Helmond; inhibits processing and transport; dbSNP:rs52836744)	VARIANT	0
P06213/G811S	INSR	-	1	G -> S (in dbSNP:rs35045353)	VARIANT	0
P06213/H236R	INSR	-	2	H -> R (in RMS and LEPRCH; Winnipeg; may impair receptor processing; dbSNP:rs121913145)	VARIANT	0
P06213/I1023F	INSR	-	1	I -> F	VARIANT	0
P06213/I1143T	INSR	decrease	2	I -> T (in RMS; reduces insulin binding)	VARIANT	0
P06213/I146M	INSR	-	2	I -> M (in LEPRCH; mild; dbSNP:rs121913159)	VARIANT	0
P06213/I448T	INSR	-	1	I -> T (in dbSNP:rs1051691)	VARIANT	0
P06213/I56T	INSR	decrease	1	I -> T (in LEPRCH; abolishes post-translational processing; dbSNP:rs1555689937)	VARIANT	0
P06213/I925T	INSR	loss	2	I -> T (in LEPRCH; abolishes post-translational processing; abolishes insulin binding; dbSNP:rs1599881881)	VARIANT	0
P06213/K1057A	INSR	loss	3	K->A: Abolishes the kinase activity and abolishes interaction with IRS1, SHC1, GRB7 and PIK3R1.	MUTAGEN	0
P06213/K1057M	INSR	loss	3	K->M,R: Abolishes the kinase activity.	MUTAGEN	0
P06213/K1057R	INSR	loss	3	K->M,R: Abolishes the kinase activity.	MUTAGEN	0
P06213/K1095E	INSR	-	1	K -> E (in a subject with non-insulin dependent diabetes mellitus; dbSNP:rs909008899)	VARIANT	0
P06213/K487E	INSR	-	1	K -> E (in LEPRCH; ARK-1; dbSNP:rs121913136)	VARIANT	0
P06213/L1000A	INSR	-	1	L->A,R: Severely reduces interaction with SHC1. Has no effect on interaction with IRS1.	MUTAGEN	0
P06213/L1000R	INSR	-	1	L->A,R: Severely reduces interaction with SHC1. Has no effect on interaction with IRS1.	MUTAGEN	0
P06213/L1065V	INSR	-	1	L -> V (in dbSNP:rs56395521)	VARIANT	2
P06213/L120Q	INSR	decrease	1	L -> Q (in LEPRCH; inhibits receptor processing)	VARIANT	0
P06213/L260P	INSR	-	1	L -> P (in LEPRCH; Geldeimalsen; dbSNP:rs121913141)	VARIANT	0
P06213/L89P	INSR	-	1	L -> P (in IRAN type A)	VARIANT	0
P06213/L991A	INSR	-	1	L->A: Reduces interaction with IRS1 but has no effect on interaction with SHC1.	MUTAGEN	0
P06213/M1180I	INSR	-	1	M -> I (in a patient with insulin resistance; dbSNP:rs121913157)	VARIANT	0
P06213/N42K	INSR	-	2	N -> K (in RMS; impairs transport to the plasma membrane and reduces the affinity to bind insulin; dbSNP:rs121913143)	VARIANT	0
P06213/N458D	INSR	decrease	1	N -> D (in LEPRCH; partially inhibits receptor processing and autophosphorylation; strongly impairs ERK phosphorylation; induces wild-type levels of IRS-1 phosphorylation; dbSNP:rs121913160)	VARIANT	0
P06213/N489D	INSR	-	1	N -> D (in IRAN type A; unknown pathological significance; dbSNP:rs1135401742)	VARIANT	0
P06213/N489S	INSR	-	1	N -> S (in IRAN type A; dbSNP:rs121913147)	VARIANT	0
P06213/N878S	INSR	-	1	N -> S (in RMS; impairs post-translational processing; dbSNP:rs887190835)	VARIANT	0
P06213/N996A	INSR	-	2	N->A: Abolishes interaction with IRS1 and significantly reduces interaction with SHC1. Has no effect on interaction with PIK3R1.	MUTAGEN	0
P06213/P1205L	INSR	-	2	P -> L (in IRAN type A; moderate; dbSNP:rs1295645322)	VARIANT	0
P06213/P220L	INSR	-	1	P -> L (in Ins resistance; severe; dbSNP:rs749094324)	VARIANT	0
P06213/P830L	INSR	-	0	P -> L (in dbSNP:rs2162771)	VARIANT	0
P06213/P874L	INSR	-	1	P -> L (in RMS; impairs post-translational processing)	VARIANT	1
P06213/P997A	INSR	-	2	P->A: Abolishes interaction with IRS1 and significantly reduces interaction with SHC1. Has no effect on interaction with PIK3R1.	MUTAGEN	0
P06213/P997T	INSR	-	1	P -> T (in RMS; reduces insulin binding)	VARIANT	0
P06213/Q492K	INSR	-	1	Q -> K	VARIANT	0
P06213/Q695R	INSR	-	1	Q -> R (in dbSNP:rs55906835)	VARIANT	0
P06213/R1020Q	INSR	-	1	R -> Q (in IRAN type A; dbSNP:rs121913148)	VARIANT	1
P06213/R1119W	INSR	-	2	R -> W (in LEPRCH; dbSNP:rs1229730671)	VARIANT	1
P06213/R113P	INSR	loss	2	R -> P (in LEPRCH; Atlanta-1; abolishes insulin binding; dbSNP:rs121913153)	VARIANT	0
P06213/R1158Q	INSR	-	1	R -> Q (in T2D)	VARIANT	0
P06213/R1158W	INSR	loss	2	R -> W (in RMS; abolishes insulin binding; dbSNP:rs111993466)	VARIANT	0
P06213/R1163Q	INSR	loss	1	R->Q: Loss of kinase activity.	MUTAGEN	0
P06213/R1191Q	INSR	-	1	R -> Q (in T2D; dbSNP:rs121913150)	VARIANT	1
P06213/R1201Q	INSR	-	3	R -> Q (in HHF5 and IRAN type A; interferes with kinase activation by insulin; dbSNP:rs121913156)	VARIANT	1
P06213/R1201W	INSR	-	2	R -> W (in LEPRCH and RMS; reduces insulin binding possibly due to reduced receptor levels on the cell surface; dbSNP:rs1568426700)	VARIANT	0
P06213/R1378Q	INSR	-	1	R -> Q (in IRAN type A; dbSNP:rs52826008)	VARIANT	2
P06213/R256C	INSR	-	1	R -> C (in RMS; dbSNP:rs781007453)	VARIANT	0
P06213/R279C	INSR	-	1	R -> C (in IRAN type A; inhibits receptor internalization; dbSNP:rs1568470274)	VARIANT	1
P06213/R279H	INSR	-	1	R -> H (in IRAN type A; interferes with receptor processing; dbSNP:rs1329693158)	VARIANT	1
P06213/R762S	INSR	-	1	R -> S (in IRAN type A; dbSNP:rs121913138)	VARIANT	0
P06213/R926W	INSR	decrease	2	R -> W (in LEPRCH; markedly impairs insulin binding;impairs post-translational processing; dbSNP:rs911929963)	VARIANT	0
P06213/S350L	INSR	-	2	S -> L (in RMS and LEPRCH)	VARIANT	0
P06213/S635L	INSR	-	1	S -> L (in RMS; decreases post-translational processing)	VARIANT	0
P06213/S835I	INSR	-	1	S -> I (in RMS; impairs post-translational processing; dbSNP:rs1135401739)	VARIANT	0
P06213/T1282A	INSR	-	1	T -> A (in dbSNP:rs55875349)	VARIANT	0
P06213/T858A	INSR	-	1	T -> A (in T2D; dbSNP:rs182552223)	VARIANT	0
P06213/T937M	INSR	decrease	2	T -> M (in LEPRCH; impaired receptor processing; impairs post-translational processing)	VARIANT	1
P06213/V1012M	INSR	neutral	5	V -> M (in dbSNP:rs1799816)	VARIANT	1
P06213/V1054M	INSR	-	1	V -> M (in IRAN type A; unknown pathological significance; dbSNP:rs1135401741)	VARIANT	0
P06213/V167L	INSR	-	1	V -> L (in IRAN type A; dbSNP:rs938519025)	VARIANT	0
P06213/V55A	INSR	-	1	V -> A (in LEPRCH; Verona-1; dbSNP:rs121913152)	VARIANT	0
P06213/V657F	INSR	decrease	1	V -> F (in LEPRCH; impairs post-translational processing; dbSNP:rs1135401737)	VARIANT	0
P06213/W1220L	INSR	decrease	2	W -> L (in IRAN type A; accelerates degradation of the protein and impairs kinase activity; dbSNP:rs52800171)	VARIANT	0
P06213/W1227S	INSR	-	1	W -> S (in IRAN type A; dbSNP:rs121913140)	VARIANT	0
P06213/W439S	INSR	-	1	W -> S (in LEPRCH; impairs transport of the receptor to the cell surface; dbSNP:rs121913158)	VARIANT	0
P06213/W659R	INSR	decrease	1	W -> R (in LEPRCH; impairs post-translational processing)	VARIANT	0
P06213/Y1011A	INSR	increase	1	Y->A: Increases kinase activity.	MUTAGEN	0
P06213/Y1189F	INSR	-	1	Y->F: Reduced interaction with GRB7.	MUTAGEN	0
P06213/Y1190F	INSR	-	1	Y->F: Strongly reduced interaction with GRB7.	MUTAGEN	0
P06213/Y1361C	INSR	-	1	Y -> C (in dbSNP:rs13306449)	VARIANT	0
P06213/Y171H	INSR	-	1	Y -> H (in dbSNP:rs1051692)	VARIANT	0
P06213/Y818C	INSR	decrease	2	Y -> C (in LEPRCH; abolishes post-translational processing)	VARIANT	0
P06213/Y992A	INSR	-	1	Y->A: Reduces interaction with IRS1 but has no effect on interaction with SHC1.	MUTAGEN	0
P06213/Y999E	INSR	-	4	Y->E: Abolishes interaction with IRS1 and SHC1.	MUTAGEN	0
P06213/Y999F	INSR	loss	4	Y->F: Has no effect on insulin-stimulated autophosphorylation, but inhibits the biological activity of the receptor. Abolishes interaction with IRS1 and almost completely prevents interaction with SHC1. Has no effect on interaction with PIK3R1. Abolishes interaction with STAT5B.	MUTAGEN	0
P06239/A353V	LCK	-	1	A -> V (found in leukemia)	VARIANT	0
P06239/G201S	LCK	-	0	G -> S (in dbSNP:rs11567841)	VARIANT	0
P06239/L341P	LCK	-	1	L -> P (in IMD22; dbSNP:rs587777335)	VARIANT	0
P06239/P447L	LCK	-	1	P -> L (found in leukemia)	VARIANT	0
P06239/R154K	LCK	-	1	R->K: No effect on interaction with SQSTM1.	MUTAGEN	0
P06239/S59E	LCK	-	1	S->E: Allows interaction with SQSTM1.	MUTAGEN	0
P06239/V28L	LCK	-	1	V -> L (found in leukemia)	VARIANT	0
P06241/D506E	FYN	neutral	1	D -> E (in dbSNP:rs28763975)	VARIANT	2
P06241/G410R	FYN	-	1	G -> R (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
P06241/I445F	FYN	-	0	I -> F (in dbSNP:rs1801121)	VARIANT	0
P06241/V243L	FYN	-	1	V -> L (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
P06493/Y4D	CDK1	decrease	1	Y->D,E: Constitutive polyubiquitination.	MUTAGEN	0
P06493/Y4E	CDK1	decrease	1	Y->D,E: Constitutive polyubiquitination.	MUTAGEN	0
P07332/G463V	FES	loss	1	G->V: Abolishes kinase activity.	MUTAGEN	0
P07332/K590E	FES	loss	2	K->E: Abolishes kinase activity. Fails to inhibit proliferation of melanoma cells.	MUTAGEN	0
P07332/L145P	FES	activating	2	L->P: Constitutively activated kinase that can act as oncogene. Promotes myeloid cell survival and proliferation.	MUTAGEN	1
P07332/L334P	FES	loss	1	L->P: Abolishes autophosphorylation.	MUTAGEN	0
P07332/M323V	FES	neutral	1	M -> V (in dbSNP:rs56296062)	VARIANT	0
P07332/M704V	FES	decrease	2	M->V: Reduced autophosphorylation and strongly reduced kinase activity.	MUTAGEN	0
P07332/R246Q	FES	-	1	R -> Q (in dbSNP:rs34573430)	VARIANT	0
P07332/R483M	FES	decrease	2	R->M: Abolishes pTyr binding. Abolishes association with microtubules. Abolishes autophosphorylation. Reduced kinase activity.	MUTAGEN	0
P07332/R706Q	FES	-	2	R->Q: Negligible effect on autophosphorylation and kinase activity.	MUTAGEN	0
P07332/R85C	FES	-	1	R -> C (in dbSNP:rs56041861)	VARIANT	0
P07332/S759F	FES	decrease	2	S->F: Reduced autophosphorylation and strongly reduced kinase activity.	MUTAGEN	0
P07332/V743M	FES	decrease	2	V->M: Strongly reduced autophosphorylation and kinase activity.	MUTAGEN	0
P07332/Y713F	FES	decrease	1	Y->F: Reduces kinase activity by over 90%.	MUTAGEN	0
P07333/A245S	CSF1R	-	0	A -> S (in dbSNP:rs41338945)	VARIANT	0
P07333/A770P	CSF1R	-	1	A -> P (in HDLS1; dbSNP:rs281860271)	VARIANT	0
P07333/A781E	CSF1R	decrease	1	A -> E (in HDLS1; impairs autophosphorylation upon stimulation with CSF1; dbSNP:rs587777247)	VARIANT	0
P07333/C653R	CSF1R	-	1	C -> R (in HDLS1; dbSNP:rs690016559)	VARIANT	0
P07333/D802V	CSF1R	activating	2	D->V: Constitutive kinase activity. Loss of inhibition by imatinib.	MUTAGEN	0
P07333/D837Y	CSF1R	-	1	D -> Y (in HDLS1; dbSNP:rs387906662)	VARIANT	0
P07333/E633K	CSF1R	decrease	1	E -> K (in HDLS1; impairs autophosphorylation upon stimulation with CSF1; dbSNP:rs281860269)	VARIANT	1
P07333/E920D	CSF1R	-	2	E -> D (in dbSNP:rs34030164)	VARIANT	0
P07333/F849S	CSF1R	-	1	F -> S (in HDLS1; dbSNP:rs281860277)	VARIANT	0
P07333/G413S	CSF1R	neutral	1	G -> S (in dbSNP:rs34951517)	VARIANT	5
P07333/G589E	CSF1R	-	1	G -> E (in HDLS1; dbSNP:rs281860268)	VARIANT	0
P07333/G747R	CSF1R	-	1	G -> R (in dbSNP:rs41355444)	VARIANT	0
P07333/G765D	CSF1R	decrease	1	G -> D (in HDLS1; impairs autophosphorylation upon stimulation with CSF1; dbSNP:rs690016566)	VARIANT	0
P07333/H362R	CSF1R	-	1	H -> R (in dbSNP:rs10079250)	VARIANT	0
P07333/H643Q	CSF1R	-	1	H -> Q (in BANDDOS; dbSNP:rs184499252)	VARIANT	0
P07333/I775N	CSF1R	decrease	1	I -> N (in HDLS1; impairs autophosphorylation upon stimulation with CSF1; dbSNP:rs281860273)	VARIANT	0
P07333/I794T	CSF1R	decrease	2	I -> T (in HDLS1; impairs autophosphorylation upon stimulation with CSF1; dbSNP:rs281860274)	VARIANT	0
P07333/I843F	CSF1R	-	1	I -> F (in HDLS1; dbSNP:rs690016558)	VARIANT	0
P07333/I906T	CSF1R	-	1	I -> T (in HDLS1; dbSNP:rs690016560)	VARIANT	0
P07333/L301S	CSF1R	activating	1	L->S: Constitutive kinase activity.	MUTAGEN	4
P07333/L536V	CSF1R	-	1	L -> V (in dbSNP:rs55942044)	VARIANT	0
P07333/L868P	CSF1R	-	1	L -> P (in HDLS1; dbSNP:rs281860278)	VARIANT	0
P07333/M766T	CSF1R	decrease	2	M -> T (in HDLS1; impairs autophosphorylation upon stimulation with CSF1; dbSNP:rs281860270)	VARIANT	0
P07333/M875T	CSF1R	decrease	2	M -> T (in HDLS1; impairs autophosphorylation upon stimulation with CSF1; dbSNP:rs281860279)	VARIANT	0
P07333/P132L	CSF1R	decrease	1	P -> L (in BANDDOS; impairs phosphorylation of JNK kinases upon stimulation with CSF1; dbSNP:rs1351319114)	VARIANT	0
P07333/P693H	CSF1R	-	1	P -> H (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
P07333/P824S	CSF1R	decrease	1	P -> S (in HDLS1; impairs autophosphorylation upon stimulation with CSF1)	VARIANT	0
P07333/P878T	CSF1R	-	1	P -> T (in HDLS1; dbSNP:rs281860280)	VARIANT	0
P07333/R710H	CSF1R	-	1	R -> H (in dbSNP:rs201569135)	VARIANT	3
P07333/R782H	CSF1R	decrease	1	R -> H (in HDLS1; impairs autophosphorylation upon stimulation with CSF1; dbSNP:rs281860281)	VARIANT	0
P07333/R921Q	CSF1R	-	1	R -> Q (in dbSNP:rs56059682)	VARIANT	0
P07333/V279M	CSF1R	neutral	0	V -> M (in dbSNP:rs3829986)	VARIANT	1
P07333/V32G	CSF1R	neutral	1	V -> G (in dbSNP:rs56048668)	VARIANT	5
P07333/Y708F	CSF1R	increase	1	Y->F: Impairs degradation of activated CSF1R.	MUTAGEN	0
P07333/Y809F	CSF1R	decrease	1	Y->F: Reduced kinase activity. Reduced interaction with SRC, FYN and YES1.	MUTAGEN	0
P07333/Y969C	CSF1R	-	0	Y -> C (in dbSNP:rs1801271)	VARIANT	13
P07333/Y969F	CSF1R	loss	1	Y->F: Abolishes down-regulation of activated CSF1R.	MUTAGEN	0
P07947/I198V	YES1	neutral	1	I -> V (in dbSNP:rs34580680)	VARIANT	1
P07947/K282R	YES1	-	1	K -> R (in dbSNP:rs35126906)	VARIANT	0
P07947/Y426F	YES1	increase	1	Y->F: About 50% loss of CSK-mediated inhibition.	MUTAGEN	0
P07948/C3A	LYN	-	1	C->A: Loss of localization to the cell membrane; when associated with A-2.	MUTAGEN	0
P07948/D346A	LYN	-	1	D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-353; A-498 and A-499.	MUTAGEN	0
P07948/D385Y	LYN	-	1	D -> Y (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	1
P07948/D498A	LYN	-	1	D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-353 and A-499.	MUTAGEN	0
P07948/D499A	LYN	-	1	D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-353 and A-498.	MUTAGEN	0
P07948/E353A	LYN	-	1	E->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-498 and A-499.	MUTAGEN	0
P07948/K275A	LYN	loss	4	K->A: Loss of activity and no effect on localization to the cell membrane. Abundant localization in the nucleus; when associated with A-2 and A-3.	MUTAGEN	0
P07948/K275L	LYN	loss	4	K->L,R: Loss of kinase activity.	MUTAGEN	0
P07948/K275R	LYN	loss	4	K->L,R: Loss of kinase activity.	MUTAGEN	0
P07948/Y397F	LYN	decrease	1	Y->F: Strongly reduced kinase activity.	MUTAGEN	0
P07949/A432E	RET	-	1	A -> E (found in a patient with congenital central hypoventilation syndrome; unknown pathological significance; dbSNP:rs552057730)	VARIANT	0
P07949/A639G	RET	-	1	A -> G (in MTC; sporadic form)	VARIANT	0
P07949/A640G	RET	-	1	A -> G (in MEN2A; dbSNP:rs78935588)	VARIANT	0
P07949/A641G	RET	-	1	A -> G (in MTC; sporadic form)	VARIANT	0
P07949/A883F	RET	-	2	A -> F (in MEN2B; somatic mutation in sporadic medullary thyroid carcinoma; requires 2 nucleotide substitutions; dbSNP:rs377767429)	VARIANT	26
P07949/C142S	RET	-	0	C -> S (in HSCR1; sporadic form)	VARIANT	0
P07949/C157Y	RET	-	0	C -> Y (in HSCR1; unknown pathological significance)	VARIANT	0
P07949/C197Y	RET	-	1	C -> Y (in HSCR1; sporadic form)	VARIANT	1
P07949/C609G	RET	-	0	C -> G (in MEN2A; dbSNP:rs77558292)	VARIANT	0
P07949/C609R	RET	-	0	C -> R (in MEN2A; dbSNP:rs77558292)	VARIANT	0
P07949/C609W	RET	-	1	C -> W (in HSCR1; familial form; dbSNP:rs377767396)	VARIANT	0
P07949/C609Y	RET	-	3	C -> Y (in MTC, MEN2A and HSCR1; familial and sporadic forms; dbSNP:rs77939446)	VARIANT	0
P07949/C611G	RET	-	1	C -> G (in MTC; familial form; dbSNP:rs377767391)	VARIANT	0
P07949/C611R	RET	-	0	C -> R (in MEN2A; dbSNP:rs377767391)	VARIANT	3
P07949/C611S	RET	-	0	C -> S (in MEN2A; dbSNP:rs377767391)	VARIANT	1
P07949/C611W	RET	-	1	C -> W (in MEN2A and MTC; familial form; dbSNP:rs80069458)	VARIANT	0
P07949/C611Y	RET	-	0	C -> Y (in MEN2A; dbSNP:rs377767397)	VARIANT	2
P07949/C618F	RET	-	0	C -> F (in MEN2A and MTC; familial form; dbSNP:rs79781594)	VARIANT	0
P07949/C618G	RET	-	1	C -> G (in MEN2A; dbSNP:rs76262710)	VARIANT	0
P07949/C618R	RET	-	4	C -> R (in MEN2A, MTC and HSCR1; dbSNP:rs76262710)	VARIANT	6
P07949/C618S	RET	-	5	C -> S (in MEN2A, HSCR1 and MTC; familial and sporadic forms; dbSNP:rs79781594)	VARIANT	8
P07949/C618Y	RET	-	0	C -> Y (in MEN2A and MTC; familial form; dbSNP:rs79781594)	VARIANT	4
P07949/C620F	RET	-	1	C -> F (in MEN2A and MTC; familial form; dbSNP:rs77503355)	VARIANT	0
P07949/C620G	RET	-	0	C -> G (in MEN2A and MTC; familial and sporadic forms; dbSNP:rs77316810)	VARIANT	0
P07949/C620R	RET	-	6	C -> R (in MEN2A, MTC and HSCR1; familial and sporadic forms; dbSNP:rs77316810)	VARIANT	11
P07949/C620S	RET	-	2	C -> S (in MEN2A and MTC; familial form; dbSNP:rs77503355)	VARIANT	2
P07949/C620W	RET	-	1	C -> W (in MEN2A and HSCR1; dbSNP:rs79890926)	VARIANT	4
P07949/C620Y	RET	-	1	C -> Y (in MEN2A; dbSNP:rs77503355)	VARIANT	2
P07949/C630F	RET	-	0	C -> F (in MEN2A and MTC; familial form; dbSNP:rs377767405)	VARIANT	0
P07949/C630S	RET	-	0	C -> S (in MTC; sporadic form; dbSNP:rs377767405)	VARIANT	3
P07949/C630Y	RET	-	0	C -> Y (in MTC; familial and sporadic forms; dbSNP:rs377767405)	VARIANT	1
P07949/C634F	RET	-	3	C -> F (in MEN2A and pheochromocytoma; dbSNP:rs75996173)	VARIANT	3
P07949/C634G	RET	-	3	C -> G (in MEN2A and pheochromocytoma; dbSNP:rs75076352)	VARIANT	3
P07949/C634R	RET	-	3	C -> R (in MEN2A, pheochromocytoma and MTC; familial form; also found as somatic mutation in a sporadic thyroid carcinoma; dbSNP:rs75076352)	VARIANT	60
P07949/C634S	RET	-	2	C -> S (in MEN2A, pheochromocytoma and MTC; familial form; dbSNP:rs75076352)	VARIANT	7
P07949/C634W	RET	-	1	C -> W (in MEN2A, pheochromocytoma and MTC; familial form; dbSNP:rs77709286)	VARIANT	25
P07949/C634Y	RET	-	4	C -> Y (in MEN2A, pheochromocytoma and MTC; familial form; dbSNP:rs75996173)	VARIANT	24
P07949/D300N	RET	-	1	D -> N (in HSCR1)	VARIANT	1
P07949/D353Y	RET	-	1	D -> Y (in HSCR1; dbSNP:rs1837785429)	VARIANT	0
P07949/D489N	RET	neutral	2	D -> N (in dbSNP:rs9282834)	VARIANT	2
P07949/D631G	RET	-	0	D -> G (in thyroid carcinoma; somatic mutation; dbSNP:rs121913308)	VARIANT	1
P07949/D707N	RET	-	1	D->N: Impaired cleavage by caspase-3 and loss of induced cell death.	MUTAGEN	0
P07949/E251K	RET	-	0	E -> K (in HSCR1; familial form; dbSNP:rs562449603)	VARIANT	0
P07949/E480K	RET	-	1	E -> K (in HSCR1; dbSNP:rs537874538)	VARIANT	1
P07949/E595Q	RET	-	1	E -> Q (in HSCR1; dbSNP:rs1483605155)	VARIANT	0
P07949/E762Q	RET	-	1	E -> Q (in HSCR1; sporadic form)	VARIANT	0
P07949/E768D	RET	-	3	E -> D (in MTC; familial and sporadic forms; dbSNP:rs78014899)	VARIANT	0
P07949/E921K	RET	-	0	E -> K (in HSCR1; sporadic form)	VARIANT	1
P07949/F1112Y	RET	-	1	F -> Y (in a bladder transitional cell carcinoma sample; somatic mutation)	VARIANT	0
P07949/F174S	RET	-	1	F -> S (in HSCR1; sporadic form)	VARIANT	0
P07949/F393L	RET	-	1	F -> L (in HSCR1; familial form; dbSNP:rs78098482)	VARIANT	0
P07949/F893L	RET	-	0	F -> L (in HSCR1; sporadic form)	VARIANT	0
P07949/F961L	RET	-	1	F -> L (in HSCR1)	VARIANT	0
P07949/G423R	RET	-	1	G -> R (in HSCR1; dbSNP:rs767601598)	VARIANT	2
P07949/G593E	RET	-	1	G -> E (in a colorectal cancer sample; somatic mutation)	VARIANT	0
P07949/G691S	RET	neutral	4	G -> S (in dbSNP:rs1799939)	VARIANT	18
P07949/G830R	RET	-	1	G -> R (in HSCR1; dbSNP:rs200127630)	VARIANT	0
P07949/G894S	RET	activating	1	G -> S (in a patient with renal agenesis; unknown pathological significance; constitutively phosphorylated; expressed only the immature intracellular form)	VARIANT	2
P07949/G93S	RET	-	1	G -> S (in HSCR1; unknown pathological significance; dbSNP:rs1477699803)	VARIANT	0
P07949/K758R	RET	loss	2	K->R: Loss of kinase activity. No effect on interaction with and dissociation from CBLC and CD2AP.	MUTAGEN	0
P07949/K907E	RET	-	0	K -> E (in HSCR1; sporadic form; dbSNP:rs377767430)	VARIANT	0
P07949/K907T	RET	-	1	K -> T (in HSCR1)	VARIANT	1
P07949/L1052V	RET	-	1	L -> V (in HSCR1; dbSNP:rs1564501947)	VARIANT	0
P07949/L1061P	RET	-	1	L -> P (in HSCR1; dbSNP:rs536486113)	VARIANT	0
P07949/L40P	RET	-	2	L -> P (in HSCR1)	VARIANT	0
P07949/L790F	RET	-	1	L -> F (in MEN2A and MTC; familial form; dbSNP:rs75030001)	VARIANT	1
P07949/M1064T	RET	-	1	M -> T (in HSCR1; familial form; dbSNP:rs149513065)	VARIANT	0
P07949/M918T	RET	-	6	M -> T (in MEN2B and MTC; sporadic form; somatic mutation; also found in a patient with renal agenesis; dbSNP:rs74799832)	VARIANT	822
P07949/M980T	RET	-	0	M -> T (in HSCR1; sporadic form)	VARIANT	0
P07949/N359K	RET	-	0	N -> K (in HSCR1; unknown pathological significance)	VARIANT	0
P07949/N394H	RET	-	1	N -> H (in a patient with renal agenesis; unknown pathological significance; prevents phosphorylation in response to GDNF)	VARIANT	0
P07949/N394K	RET	-	1	N -> K (in HSCR1)	VARIANT	0
P07949/N783S	RET	-	1	N -> S (in HSCR1; dbSNP:rs587778656)	VARIANT	0
P07949/P1039L	RET	-	1	P -> L (in HSCR1; dbSNP:rs79853121)	VARIANT	0
P07949/P1039Q	RET	-	0	P -> Q (in dbSNP:rs79853121)	VARIANT	0
P07949/P1049L	RET	-	1	P -> L (in a patient with renal agenesis; unknown pathological significance; prevents phosphorylation in response to GDNF; dbSNP:rs1490712863)	VARIANT	0
P07949/P1067S	RET	-	1	P -> S (in a patient with renal agenesis; unknown pathological significance; prevents phosphorylation in response to GDNF; dbSNP:rs775583354)	VARIANT	0
P07949/P155L	RET	-	1	P -> L (in HSCR1)	VARIANT	0
P07949/P198T	RET	-	1	P -> T (in a patient with renal agenesis; unknown pathological significance; prevents phosphorylation in response to GDNF; dbSNP:rs76736111)	VARIANT	0
P07949/P20L	RET	-	1	P -> L (in HSCR1; sporadic form)	VARIANT	0
P07949/P399L	RET	-	1	P -> L (in HSCR1; sporadic form; dbSNP:rs1554818362)	VARIANT	0
P07949/P64L	RET	-	1	P -> L (in HSCR1; familial form; dbSNP:rs77596424)	VARIANT	0
P07949/P679L	RET	-	1	P -> L (in HSCR1)	VARIANT	0
P07949/P973L	RET	-	1	P -> L (in HSCR1; familial form)	VARIANT	0
P07949/Q626K	RET	-	1	Q -> K (in HSCR1; sporadic form; dbSNP:rs1255575160)	VARIANT	0
P07949/R114C	RET	-	1	R -> C (in HSCR1; unknown pathological significance; dbSNP:rs747483905)	VARIANT	2
P07949/R114H	RET	-	3	R -> H (in dbSNP:rs76397662)	VARIANT	3
P07949/R163Q	RET	-	1	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs149403911)	VARIANT	0
P07949/R175P	RET	-	1	R -> P (in HSCR1)	VARIANT	0
P07949/R180P	RET	-	1	R -> P (in HSCR1; sporadic form)	VARIANT	0
P07949/R231H	RET	-	0	R -> H (in HSCR1; familial form; dbSNP:rs79661516)	VARIANT	0
P07949/R287Q	RET	-	0	R -> Q (in HSCR1; sporadic form; dbSNP:rs1564491460)	VARIANT	0
P07949/R313Q	RET	-	2	R -> Q (in HSCR1; dbSNP:rs77702891)	VARIANT	0
P07949/R330Q	RET	-	2	R -> Q (in HSCR1; dbSNP:rs80236571)	VARIANT	2
P07949/R360Q	RET	-	1	R -> Q (in HSCR1; dbSNP:rs762472027)	VARIANT	0
P07949/R360W	RET	-	2	R -> W (in HSCR1)	VARIANT	1
P07949/R475Q	RET	-	0	R -> Q (in HSCR1; sporadic form; dbSNP:rs138624658)	VARIANT	0
P07949/R600Q	RET	-	1	R -> Q (in dbSNP:rs377767393)	VARIANT	1
P07949/R67H	RET	-	1	R -> H (in dbSNP:rs192489011)	VARIANT	1
P07949/R694Q	RET	-	1	R -> Q (in HSCR1; dbSNP:rs141185224)	VARIANT	0
P07949/R749T	RET	-	1	R -> T (in dbSNP:rs34288963)	VARIANT	0
P07949/R77C	RET	-	1	R -> C (in HSCR1)	VARIANT	1
P07949/R813Q	RET	-	1	R -> Q (in HSCR1; sporadic form; dbSNP:rs1318733775)	VARIANT	0
P07949/R844L	RET	-	2	R -> L (in MTC; familial form; dbSNP:rs55947360)	VARIANT	0
P07949/R873Q	RET	-	0	R -> Q (in HSCR1; sporadic form; dbSNP:rs1451004715)	VARIANT	0
P07949/R897Q	RET	-	2	R -> Q (in HSCR1; sporadic form; dbSNP:rs76087194)	VARIANT	1
P07949/R972G	RET	-	2	R -> G (in HSCR1; familial form; dbSNP:rs76534745)	VARIANT	0
P07949/R982C	RET	neutral	5	R -> C (in dbSNP:rs17158558)	VARIANT	16
P07949/S316I	RET	-	1	S -> I (in HSCR1; dbSNP:rs1060499894)	VARIANT	0
P07949/S32L	RET	-	2	S -> L (in HSCR1; familial form; dbSNP:rs76764689)	VARIANT	0
P07949/S339L	RET	-	1	S -> L (in HSCR1; dbSNP:rs774829203)	VARIANT	0
P07949/S690P	RET	-	0	S -> P (in HSCR1; sporadic form)	VARIANT	0
P07949/S765P	RET	-	3	S -> P (in HSCR1; dbSNP:rs75075748)	VARIANT	0
P07949/S767R	RET	-	0	S -> R (in HSCR1; sporadic form)	VARIANT	0
P07949/S891A	RET	-	1	S -> A (in MTC; familial form; dbSNP:rs75234356)	VARIANT	8
P07949/S922F	RET	-	1	S -> F (in MTC; sporadic form; dbSNP:rs377767432)	VARIANT	0
P07949/S922Y	RET	-	1	S -> Y (in dbSNP:rs377767432)	VARIANT	0
P07949/T278A	RET	-	1	T -> A (in HSCR1; dbSNP:rs541929171)	VARIANT	0
P07949/T278N	RET	-	2	T -> N (found in two patients with Hirschsprung disease; dbSNP:rs35118262)	VARIANT	3
P07949/T278P	RET	-	1	T -> P (in HSCR1)	VARIANT	0
P07949/T946M	RET	-	0	T -> M (in MEN2B and MTC; familial form)	VARIANT	0
P07949/V145G	RET	-	2	V -> G (in HSCR1; also in a colorectal cancer sample; somatic mutation; dbSNP:rs1588863999)	VARIANT	0
P07949/V292M	RET	-	2	V -> M (found in patients with Hirschsprung disease; unknown pathological significance; dbSNP:rs34682185)	VARIANT	2
P07949/V376A	RET	activating	1	V -> A (in a patient with renal agenesis; unknown pathological significance; constitutively phosphorylated; expressed only the immature intracellular form)	VARIANT	0
P07949/V397M	RET	-	1	V -> M (in HSCR1; dbSNP:rs183729115)	VARIANT	0
P07949/V412M	RET	-	1	V -> M (in HSCR1; dbSNP:rs746970700)	VARIANT	0
P07949/V778I	RET	activating	1	V -> I (in a patient with renal agenesis; unknown pathological significance; constitutively phosphorylated; dbSNP:rs75686697)	VARIANT	1
P07949/V804L	RET	-	1	V -> L (in MTC; familial form; dbSNP:rs79658334)	VARIANT	0
P07949/V804M	RET	-	2	V -> M (in MTC; familial form; dbSNP:rs79658334)	VARIANT	4
P07949/Y1062C	RET	-	1	Y -> C (in HSCR1; dbSNP:rs587778659)	VARIANT	0
P07949/Y1062F	RET	loss	1	Y->F: Abolishes GFRAL-mediated MAPK1/MAPK2 phosphorylation.	MUTAGEN	0
P07949/Y791F	RET	-	3	Y -> F (in HSCR1, pheochromocytoma, MTC and MEN2A; familial form; dbSNP:rs77724903)	VARIANT	3
P07949/Y826S	RET	-	1	Y -> S (in dbSNP:rs34617196)	VARIANT	0
P08069/A1338T	IGF1R	-	1	A -> T (in dbSNP:rs34102392)	VARIANT	1
P08069/A1347V	IGF1R	-	1	A -> V (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
P08069/A828T	IGF1R	-	0	A -> T (in dbSNP:rs35224135)	VARIANT	0
P08069/H808R	IGF1R	-	0	H -> R (in dbSNP:rs34061581)	VARIANT	0
P08069/K1033A	IGF1R	loss	1	K->A: Kinase inactive. Abolishes tyrosine phosphorylation and abolishes interaction with IRS1, SHC1 and PIK3R1.	MUTAGEN	0
P08069/K145N	IGF1R	decrease	1	K -> N (in IGF1RES; has decreased IGF1R function; dbSNP:rs121912427)	VARIANT	0
P08069/N359Y	IGF1R	decrease	1	N -> Y (in IGF1RES; significant decrease in IGF1-induced DNA synthesis and AKT1 phosphorylation in patient fibroblasts)	VARIANT	0
P08069/N857S	IGF1R	neutral	1	N -> S (in dbSNP:rs45611935)	VARIANT	0
P08069/R1256S	IGF1R	decrease	1	R -> S (in IGF1RES; significant decrease in IGF1-induced DNA synthesis and AKT1 phosphorylation in patient fibroblasts)	VARIANT	0
P08069/R1337C	IGF1R	-	1	R -> C (in IGF1RES; unknown pathological significance; significant decrease in IGF1-induced DNA synthesis; significant increase in IGF1-induced AKT1 phosphorylation in patient fibroblasts; dbSNP:rs141802822)	VARIANT	2
P08069/R138Q	IGF1R	decrease	1	R -> Q (in IGF1RES; has decreased IGF1R function; dbSNP:rs121912426)	VARIANT	0
P08069/R437H	IGF1R	neutral	1	R -> H (in dbSNP:rs34516635)	VARIANT	2
P08069/R511Q	IGF1R	-	0	R -> Q (in dbSNP:rs33958176)	VARIANT	0
P08069/R595H	IGF1R	-	1	R -> H (in dbSNP:rs56248469)	VARIANT	0
P08069/R605H	IGF1R	-	0	R -> H (in dbSNP:rs45553041)	VARIANT	0
P08069/R739Q	IGF1R	-	1	R -> Q (in IGF1RES; leads to failure of processing of the IGF1R proreceptor to mature IGF1R; dbSNP:rs121912429)	VARIANT	0
P08069/V105L	IGF1R	-	1	V -> L (in a renal chromophobe sample; somatic mutation)	VARIANT	0
P08069/V388M	IGF1R	-	0	V -> M (in dbSNP:rs45445894)	VARIANT	0
P08069/Y1280F	IGF1R	-	1	Y->F: No effect on GRB10-binding.	MUTAGEN	0
P08069/Y1281F	IGF1R	-	1	Y->F: No effect on GRB10-binding.	MUTAGEN	0
P08069/Y1346F	IGF1R	-	1	Y->F: Loss of GRB10-binding.	MUTAGEN	0
P08069/Y865C	IGF1R	decrease	1	Y -> C (in IGF1RES; significant decrease in IGF1-induced DNA synthesis and AKT1 phosphorylation in patient fibroblasts)	VARIANT	0
P08069/Y980F	IGF1R	decrease	2	Y->F: Reduces tyrosine phosphorylation. Abolishes interaction with IRS1 and SHC1. Does not abolish interaction with PIK3R1, nor with GRB10.	MUTAGEN	0
P08581/A320V	MET	-	1	A -> V (in dbSNP:rs35776110)	VARIANT	4
P08581/C385Y	MET	-	1	C -> Y (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs752055485)	VARIANT	1
P08581/D1228H	MET	resistance	1	D -> H (in RCCP; somatic mutation; dbSNP:rs121913671)	VARIANT	2
P08581/D1228N	MET	resistance	1	D -> N (in RCCP; germline mutation; dbSNP:rs121913671)	VARIANT	12
P08581/E168D	MET	neutral	2	E -> D (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs55985569)	VARIANT	31
P08581/F841V	MET	-	1	F -> V (in DFNB97; dbSNP:rs794728016)	VARIANT	0
P08581/H1094L	MET	activating	1	H -> L (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines)	VARIANT	0
P08581/H1094R	MET	-	2	H -> R (in RCCP; causes malignant transformation in cell lines; dbSNP:rs121913243)	VARIANT	0
P08581/H1094Y	MET	activating	1	H -> Y (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines; dbSNP:rs121913244)	VARIANT	3
P08581/H1106D	MET	activating	2	H -> D (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines)	VARIANT	0
P08581/H150Y	MET	-	1	H -> Y (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs1436957498)	VARIANT	1
P08581/I316M	MET	-	0	I -> M (in dbSNP:rs35225896)	VARIANT	0
P08581/K1244R	MET	-	1	K -> R (in HCC; dbSNP:rs121913677)	VARIANT	1
P08581/L1195V	MET	-	1	L -> V (in RCCP; somatic mutation; dbSNP:rs121913673)	VARIANT	2
P08581/L238S	MET	-	0	L -> S (in dbSNP:rs34349517)	VARIANT	0
P08581/M1131T	MET	-	2	M -> T (in RCCP; germline mutation; dbSNP:rs121913668)	VARIANT	0
P08581/M1250I	MET	-	1	M -> I (in HCC; dbSNP:rs121913676)	VARIANT	1
P08581/M1250T	MET	-	2	M -> T (in RCCP; somatic mutation; dbSNP:rs121913245)	VARIANT	0
P08581/N375K	MET	decrease	1	N -> K (found in lung cancer also including cases carrying EGFR mutations; unknown pathological significance; decreased hepatocyte growth factor-activated receptor activity; decreased interaction with HGF; dbSNP:rs776693512)	VARIANT	0
P08581/N375S	MET	neutral	1	N -> S (in dbSNP:rs33917957)	VARIANT	31
P08581/P773L	MET	-	1	P -> L (in gastric cancer; dbSNP:rs771333219)	VARIANT	0
P08581/P991S	MET	increase	1	P -> S (in gastric cancer; prolonged tyrosine phosphorylation in response to HGF/SF; transforming activity in athymic nude mice; dbSNP:rs768678989)	VARIANT	0
P08581/R143Q	MET	-	1	R -> Q (in dbSNP:rs35469582)	VARIANT	0
P08581/R970C	MET	neutral	2	R -> C (in dbSNP:rs34589476)	VARIANT	4
P08581/S156L	MET	-	1	S -> L (in dbSNP:rs56311081)	VARIANT	0
P08581/T1173I	MET	-	1	T -> I (in HCC; dbSNP:rs121913675)	VARIANT	1
P08581/T992I	MET	neutral	4	T -> I (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs56391007)	VARIANT	60
P08581/V1092I	MET	activating	3	V -> I (in RCCP; constitutive autophosphorylation; dbSNP:rs786202724)	VARIANT	0
P08581/V1188L	MET	-	2	V -> L (in RCCP; germline mutation; dbSNP:rs121913669)	VARIANT	1
P08581/V1220I	MET	-	1	V -> I (in RCCP; germline mutation; dbSNP:rs121913670)	VARIANT	0
P08581/V1294I	MET	-	1	V -> I (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs1263785859)	VARIANT	1
P08581/Y1003S	MET	-	1	Y -> S (probable disease-associated variant found in lesional sample from a patient with sporadically occurring, unilateral osteofibrous dysplasia; somatic mutation; complete loss of ligand-induced CBL-mediated ubiquitination, resulting in protein stabilization)	VARIANT	0
P08581/Y1230C	MET	resistance	2	Y -> C (in RCCP; germline mutation; dbSNP:rs121913246)	VARIANT	2
P08581/Y1230D	MET	activating	2	Y -> D (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines)	VARIANT	0
P08581/Y1230H	MET	resistance	1	Y -> H (in RCCP; somatic mutation; dbSNP:rs121913247)	VARIANT	8
P08581/Y1234C	MET	decrease	1	Y -> C (in DA11; not phosphorylated in reponse to HGF; severely decreased tyrosin kinase activity; dbSNP:rs1554400286)	VARIANT	0
P08581/Y1234F	MET	-	2	Y->F: Complete loss of kinase activity and of ligand-induced ubiquitination. Alters interaction with PTPN1 and PTPN2. Loss of interaction with PTPN1 and PTPN2; when associated with F-1235.	MUTAGEN	0
P08581/Y1235F	MET	-	2	Y->F: Complete loss of kinase activity. Alters interaction with PTPN1 and PTPN2. Loss of interaction with PTPN1 and PTPN2; when associated with F-1234.	MUTAGEN	0
P08581/Y1313F	MET	-	1	Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1349, F-1356 and F-1365.	MUTAGEN	0
P08581/Y1349F	MET	-	1	Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1356 and F-1365.	MUTAGEN	0
P08581/Y1356F	MET	-	1	Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1349 and F-1365.	MUTAGEN	0
P08581/Y1365F	MET	-	1	Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1349 and F-1356.	MUTAGEN	1
P08631/A44T	HCK	neutral	1	A -> T (in dbSNP:rs56029200)	VARIANT	0
P08631/C24S	HCK	-	1	C->S: Palmitoylation is abolished, some cytoplasmic and no calveolar localization; in isoform 2.	MUTAGEN	0
P08631/D381E	HCK	loss	1	D->E: Loss of kinase activity.	MUTAGEN	0
P08631/D399G	HCK	-	1	D -> G (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
P08631/E305A	HCK	loss	1	E->A: Loss of kinase activity.	MUTAGEN	0
P08631/G23A	HCK	-	1	G->A: Myristoylation and palmitoylation are abolished, leading to entirely cytoplasmic localization; in isoform 2.	MUTAGEN	0
P08631/G3C	HCK	-	2	G->C: Slight palmitoylation, cytoplasmic and caveolar localization; in isoform 1;.	MUTAGEN	0
P08631/G3S	HCK	-	2	G->S: Abolishes palmitoylation and localization at the cell membrane.	MUTAGEN	0
P08631/K290E	HCK	loss	1	K->E: Loss of kinase activity.	MUTAGEN	0
P08631/M105L	HCK	neutral	2	M -> L (in dbSNP:rs55722810)	VARIANT	0
P08631/P502Q	HCK	-	0	P -> Q (in dbSNP:rs17093828)	VARIANT	0
P08631/Y411A	HCK	decrease	1	Y->A: Reduced catalytic activity and higher affinity for target peptides.	MUTAGEN	0
P08631/Y522F	HCK	activating	2	Y->F: Constitutively activated kinase, leading to cellular transformation.	MUTAGEN	0
P08922/C1370R	ROS1	-	1	C -> R (in dbSNP:rs36106063)	VARIANT	0
P08922/D1776H	ROS1	neutral	1	D -> H (in dbSNP:rs12664076)	VARIANT	4
P08922/D2203N	ROS1	-	1	D -> N (in dbSNP:rs556427413)	VARIANT	0
P08922/D2213E	ROS1	-	1	D -> E (in dbSNP:rs75510639)	VARIANT	1
P08922/D2213N	ROS1	neutral	2	D -> N (in dbSNP:rs529038)	VARIANT	11
P08922/E1902K	ROS1	neutral	1	E -> K (in dbSNP:rs9489124)	VARIANT	8
P08922/F1439S	ROS1	-	0	F -> S (in dbSNP:rs17079086)	VARIANT	0
P08922/F2138S	ROS1	-	1	F -> S (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	1
P08922/G126V	ROS1	-	1	G -> V (in dbSNP:rs34245787)	VARIANT	0
P08922/H1999N	ROS1	-	1	H -> N (in dbSNP:rs45569132)	VARIANT	0
P08922/I537M	ROS1	neutral	1	I -> M (in dbSNP:rs28639589)	VARIANT	13
P08922/K1980M	ROS1	loss	1	K->M: Loss of kinase activity.	MUTAGEN	0
P08922/K2003R	ROS1	-	1	K -> R (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P08922/K2228Q	ROS1	neutral	2	K -> Q (in dbSNP:rs529156)	VARIANT	10
P08922/K2328R	ROS1	neutral	0	K -> R (in dbSNP:rs35932630)	VARIANT	0
P08922/N13S	ROS1	-	1	N -> S (in dbSNP:rs45606237)	VARIANT	0
P08922/N2240K	ROS1	neutral	1	N -> K (in dbSNP:rs210968)	VARIANT	0
P08922/N790S	ROS1	neutral	0	N -> S (in dbSNP:rs34582164)	VARIANT	0
P08922/P224S	ROS1	neutral	1	P -> S (in dbSNP:rs55959124)	VARIANT	0
P08922/Q865H	ROS1	-	1	Q -> H (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
P08922/R1506G	ROS1	neutral	1	R -> G (in dbSNP:rs35841892)	VARIANT	0
P08922/R167Q	ROS1	neutral	1	R -> Q (in dbSNP:rs2243380)	VARIANT	30
P08922/R2039H	ROS1	-	0	R -> H (in dbSNP:rs3752566)	VARIANT	1
P08922/S1109L	ROS1	neutral	1	S -> L (in dbSNP:rs2229079)	VARIANT	16
P08922/S2229C	ROS1	neutral	2	S -> C (in dbSNP:rs619203)	VARIANT	10
P08922/S370P	ROS1	-	1	S -> P (in dbSNP:rs56274823)	VARIANT	0
P08922/S653F	ROS1	neutral	1	S -> F (in dbSNP:rs34203286)	VARIANT	0
P08922/T145P	ROS1	neutral	1	T -> P (in dbSNP:rs1998206)	VARIANT	37
P08922/Y1239F	ROS1	-	1	Y -> F (in dbSNP:rs56192249)	VARIANT	0
P08922/Y1353S	ROS1	-	1	Y -> S (in dbSNP:rs35269727)	VARIANT	1
P08922/Y2274F	ROS1	decrease	1	Y->F: Loss of phosphorylation at Y-2274 and loss of interaction with PTPN11.	MUTAGEN	0
P08922/Y2334F	ROS1	decrease	1	Y->F: Loss of phosphorylation at Y-2334 and loss of interaction with PTPN11.	MUTAGEN	0
P08922/Y338C	ROS1	-	1	Y -> C (in dbSNP:rs55707658)	VARIANT	0
P08922/Y419H	ROS1	-	1	Y -> H (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1444274116)	VARIANT	3
P09619/E1071V	PDGFRB	-	2	E -> V (in IBGC4; no effect on protein abundance; no effect on receptor activity; decreased PDGF signaling pathway)	VARIANT	0
P09619/E282K	PDGFRB	-	1	E -> K (in dbSNP:rs34586048)	VARIANT	0
P09619/E485K	PDGFRB	neutral	1	E -> K (in dbSNP:rs41287110)	VARIANT	1
P09619/I29F	PDGFRB	neutral	1	I -> F (in dbSNP:rs17110944)	VARIANT	2
P09619/K634A	PDGFRB	loss	3	K->A,R: Loss of kinase activity. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.	MUTAGEN	0
P09619/K634R	PDGFRB	loss	3	K->A,R: Loss of kinase activity. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.	MUTAGEN	0
P09619/L658P	PDGFRB	loss	3	L -> P (in IBGC4; no effect on protein abundance; loss of PDGF beta receptor activity; dbSNP:rs397509381)	VARIANT	0
P09619/N718Y	PDGFRB	-	1	N -> Y (in dbSNP:rs35322465)	VARIANT	0
P09619/P345S	PDGFRB	neutral	0	P -> S (in dbSNP:rs2229558)	VARIANT	0
P09619/P584R	PDGFRB	-	1	P -> R (in KOGS; dbSNP:rs863224946)	VARIANT	0
P09619/P660T	PDGFRB	-	1	P -> T (in IMF1; dbSNP:rs144050370)	VARIANT	0
P09619/R561C	PDGFRB	-	1	R -> C (in IMF1; dbSNP:rs367543286)	VARIANT	0
P09619/R987W	PDGFRB	-	3	R -> W (in IBGC4; decreased protein abundance; no effect on receptor activity; decreased PDGF signaling pathway; dbSNP:rs397509382)	VARIANT	4
P09619/S180F	PDGFRB	-	1	S -> F (in dbSNP:rs17853027)	VARIANT	0
P09619/T882I	PDGFRB	-	1	T -> I (in a breast infiltrating ductal carcinoma sample; somatic mutation)	VARIANT	1
P09619/V665A	PDGFRB	activating	1	V -> A (in PENTT; gain of function in protein tyrosine kinase activity; shows ligand-independent constitutive signaling; dbSNP:rs1554108211)	VARIANT	1
P09619/Y1009F	PDGFRB	-	3	Y->F: No effect on interaction with GRB10. Abolishes interaction with PLCG1; when associated with F-1021.	MUTAGEN	0
P09619/Y1021F	PDGFRB	-	4	Y->F: Strongly reduces up-regulation of cell proliferation. Abolishes interaction with PLCG1; when associated with F-1009. No effect on interaction with GRB10.	MUTAGEN	0
P09619/Y579F	PDGFRB	decrease	2	Y->F: Loss of kinase activity; when associated with F-581. Strongly reduces interaction with SRC family kinases. No effect on interaction with GRB10.	MUTAGEN	0
P09619/Y581F	PDGFRB	decrease	2	Y->F: Loss of kinase activity; when associated with F-579. No effect on interaction with GRB10.	MUTAGEN	0
P09619/Y589H	PDGFRB	-	1	Y -> H (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	3
P09619/Y716F	PDGFRB	-	2	Y->F: No effect neither on interaction with GRB10 and RASA1 nor on phosphatidylinositol 3-kinase activity.	MUTAGEN	0
P09619/Y740F	PDGFRB	-	4	Y->F: Strongly reduces up-regulation of cell proliferation; when associated with F-751. Strongly decreases phosphatidylinositol 3-kinase activity. No effect on interaction with GRB10 and RASA1.	MUTAGEN	0
P09619/Y751F	PDGFRB	-	6	Y->F: Strongly reduces up-regulation of cell proliferation; when associated with F-740. Abolishes phosphatidylinositol 3-kinase activity and interaction with NCK1, and slightly reduces interaction with RASA1. No effect on interaction with GRB10.	MUTAGEN	0
P09619/Y763F	PDGFRB	-	1	Y->F: No effect on interaction with RASA1 and on phosphatidylinositol 3-kinase activity.	MUTAGEN	0
P09619/Y771F	PDGFRB	-	3	Y->F: Loss of interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.	MUTAGEN	0
P09619/Y775F	PDGFRB	-	1	Y->F: No effect on interaction with RASA1 and on phosphatidylinositol 3-kinase activity.	MUTAGEN	0
P09619/Y778F	PDGFRB	-	1	Y->F: Strongly reduces expression levels.	MUTAGEN	0
P09619/Y857F	PDGFRB	decrease	4	Y->F: Reduces kinase activity. No effect on interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.	MUTAGEN	0
P09769/S130R	FGR	-	1	S -> R (in dbSNP:rs35334091)	VARIANT	0
P09769/T110I	FGR	-	1	T -> I (in dbSNP:rs34597831)	VARIANT	0
P09769/Y523F	FGR	increase	1	Y->F: Strongly increased catalytic activity. Functions as oncogene.	MUTAGEN	0
P0C1S8/D234H	WEE2	decrease	1	D -> H (in OOMD5; decreased WEE2 phosphorylation at serine residues; decreased CDK1/CDC2 phosphorylation at 'Y-15'; dbSNP:rs1554415096)	VARIANT	0
P0C1S8/D470E	WEE2	-	1	D -> E (in dbSNP:rs55901099)	VARIANT	0
P0C1S8/K8T	WEE2	neutral	1	K -> T (in dbSNP:rs35672788)	VARIANT	0
P0C1S8/N332K	WEE2	-	1	N -> K (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	1
P0C1S8/R398H	WEE2	-	1	R -> H (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs200610853)	VARIANT	0
P0C1S8/Y526D	WEE2	neutral	1	Y -> D (in dbSNP:rs35683659)	VARIANT	0
P10398/E578D	ARAF	-	1	E -> D (in dbSNP:rs55852926)	VARIANT	0
P10398/G331C	ARAF	-	1	G -> C (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P10398/M98T	ARAF	-	1	M -> T (in dbSNP:rs56197559)	VARIANT	0
P10721/A533D	KIT	-	1	A -> D (in MASTC; unknown pathological significance; dbSNP:rs753212327)	VARIANT	4
P10721/A829P	KIT	resistance	2	A -> P (in a germ cell tumor of the testis; somatic mutation; dbSNP:rs1057519713)	VARIANT	23
P10721/C691S	KIT	-	1	C -> S (in dbSNP:rs35200131)	VARIANT	0
P10721/D737N	KIT	-	1	D -> N (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs751005114)	VARIANT	3
P10721/D816F	KIT	activating	1	D -> F (in MASTC; sporadic case; somatic mutation; requires 2 nucleotide substitutions; constitutively activated and is much more rapidly autophosphorylated than wild type)	VARIANT	6
P10721/D816H	KIT	activating,resistance	3	D -> H (in a testicular tumor; seminoma; somatic mutation; constitutively activated; dbSNP:rs121913506)	VARIANT	107
P10721/D816I	KIT	activating	1	D -> I (in MASTC; somatic mutation; constitutively activated; requires 2 nucleotide substitutions; dbSNP:rs1057519709)	VARIANT	2
P10721/D816Y	KIT	activating	5	D -> Y (in MASTSYS and MASTC; also found in acute myeloid leukemia and a germ cell tumor of the testis; somatic mutation; constitutively activated; dbSNP:rs121913506)	VARIANT	71
P10721/D820G	KIT	resistance	1	D -> G (in mast cell disease; systemic; dbSNP:rs121913682)	VARIANT	24
P10721/E386A	KIT	decrease	1	E->A: Reduces autophosphorylation in response to KITLG/SCF.	MUTAGEN	0
P10721/E583K	KIT	-	1	E -> K (in PBT; dbSNP:rs121913680)	VARIANT	0
P10721/E839K	KIT	loss	1	E -> K (in MASTC; sporadic case; somatic mutation; dominant negative mutation; loss of autophosphorylation; dbSNP:rs121913509)	VARIANT	0
P10721/F584C	KIT	-	1	F -> C (in PBT; dbSNP:rs28933371)	VARIANT	0
P10721/F584L	KIT	-	1	F -> L (in PBT; dbSNP:rs794726671)	VARIANT	0
P10721/G601R	KIT	-	1	G -> R (in PBT)	VARIANT	1
P10721/G664R	KIT	-	1	G -> R (in PBT; dbSNP:rs121913679)	VARIANT	1
P10721/G812V	KIT	-	1	G -> V (in PBT)	VARIANT	0
P10721/I571A	KIT	-	1	I->A: Reduction in SH2B2/APS binding. Abolishes SH2B2/APS binding; when associated with A-939.	MUTAGEN	0
P10721/K550I	KIT	-	1	K -> I (in GIST; somatic mutation)	VARIANT	1
P10721/K623M	KIT	-	1	K->M: Stronger interaction with MPDZ.	MUTAGEN	0
P10721/L656P	KIT	-	1	L -> P (in PBT)	VARIANT	0
P10721/L939A	KIT	-	1	L->A: Reduction in SH2B2/APS binding. Abolishes SH2B2/APS binding; when associated with A-571.	MUTAGEN	0
P10721/M541L	KIT	-	2	M -> L (in dbSNP:rs3822214)	VARIANT	45
P10721/M541V	KIT	-	0	M -> V (in dbSNP:rs3822214)	VARIANT	0
P10721/N822I	KIT	activating	1	N -> I (in MASTC; constitutively activated; dbSNP:rs993022333)	VARIANT	1
P10721/R381A	KIT	decrease	1	R->A: Reduces autophosphorylation in response to KITLG/SCF.	MUTAGEN	0
P10721/R791G	KIT	-	1	R -> G (in PBT; dbSNP:rs1722708855)	VARIANT	0
P10721/R796G	KIT	-	1	R -> G (in PBT; with sensorineural deafness; dbSNP:rs121913684)	VARIANT	2
P10721/R804W	KIT	-	1	R -> W (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs145602440)	VARIANT	3
P10721/S451C	KIT	-	1	S -> C (in MASTC; unknown pathological significance)	VARIANT	1
P10721/S715N	KIT	-	1	S -> N (in dbSNP:rs56094246)	VARIANT	0
P10721/S741A	KIT	-	1	S->A: Abolishes down-regulation of kinase activity by PKC/PRKCA-mediated phosphorylation; when associated with A-746.	MUTAGEN	0
P10721/S746A	KIT	-	1	S->A: Abolishes down-regulation of kinase activity by PKC/PRKCA-mediated phosphorylation; when associated with A-741.	MUTAGEN	0
P10721/T847P	KIT	-	1	T -> P (in PBT; dbSNP:rs121913687)	VARIANT	0
P10721/V532I	KIT	-	1	V -> I (in dbSNP:rs55792975)	VARIANT	0
P10721/V559A	KIT	-	1	V -> A (in GIST; dbSNP:rs121913517)	VARIANT	83
P10721/V559D	KIT	-	1	V -> D (in GIST; somatic mutation; dbSNP:rs121913517)	VARIANT	268
P10721/Y823F	KIT	activating	1	Y->F: No decrease in activity. Leads to autophosphorylation at Tyr-900.	MUTAGEN	0
P11274/A1104G	BCR	-	1	A -> G (in dbSNP:rs11558696)	VARIANT	0
P11274/A1149T	BCR	-	1	A -> T (in dbSNP:rs200099830)	VARIANT	0
P11274/A1204G	BCR	-	1	A -> G (in dbSNP:rs56265970)	VARIANT	0
P11274/D1106N	BCR	-	1	D -> N (in dbSNP:rs879255379)	VARIANT	0
P11274/D752E	BCR	neutral	1	D -> E (in dbSNP:rs12484731)	VARIANT	0
P11274/E1037K	BCR	-	1	E -> K (in dbSNP:rs776552570)	VARIANT	0
P11274/E1161K	BCR	-	1	E -> K	VARIANT	0
P11274/I413M	BCR	-	1	I -> M (in dbSNP:rs56321828)	VARIANT	0
P11274/K1187E	BCR	-	1	K -> E (in dbSNP:rs1195127922)	VARIANT	0
P11274/K558T	BCR	-	0	K -> T (in dbSNP:rs4437065)	VARIANT	0
P11274/N1202A	BCR	-	1	N->A: Loss of GAP activity; when associated with A-1090.	MUTAGEN	0
P11274/N796S	BCR	neutral	4	N -> S (in dbSNP:rs140504)	VARIANT	0
P11274/R1090A	BCR	-	1	R->A: Loss of GAP activity. Loss of GAP activity; when associated with A-1202.	MUTAGEN	0
P11274/S400P	BCR	-	1	S -> P (in a bladder transitional cell carcinoma sample; somatic mutation)	VARIANT	0
P11274/T1096A	BCR	-	1	T -> A (in dbSNP:rs745459086)	VARIANT	0
P11274/T1127M	BCR	-	0	T -> M (in dbSNP:rs35812689)	VARIANT	0
P11274/V1091M	BCR	-	1	V -> M (in dbSNP:rs778229520)	VARIANT	0
P11274/V1189M	BCR	-	1	V -> M (in dbSNP:rs55816482)	VARIANT	0
P11274/V949I	BCR	neutral	1	V -> I (in dbSNP:rs2229038)	VARIANT	0
P11274/W1235R	BCR	-	1	W -> R (in dbSNP:rs55719322)	VARIANT	0
P11274/Y177F	BCR	-	2	Y->F: Abolishes interaction with FES and GRB2.	MUTAGEN	0
P11274/Y910C	BCR	-	1	Y -> C (in dbSNP:rs35537221)	VARIANT	0
P11309/E124Q	PIM1	-	1	E -> Q (in dbSNP:rs35760989)	VARIANT	0
P11309/E135K	PIM1	-	1	E -> K (in dbSNP:rs200523275)	VARIANT	30
P11309/E142D	PIM1	-	1	E -> D (in dbSNP:rs33989191)	VARIANT	12
P11309/H68Y	PIM1	increase	1	H->Y: Increased kinase activity.	MUTAGEN	6
P11309/L193F	PIM1	decrease	1	L->F: Decreased kinase activity.	MUTAGEN	13
P11309/N82K	PIM1	decrease	1	N->K: Decreased kinase activity.	MUTAGEN	0
P11309/P81S	PIM1	decrease	1	P->S: Decreased kinase activity.	MUTAGEN	33
P11309/Y53H	PIM1	-	1	Y -> H (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P11362/A167S	FGFR1	-	1	A -> S (in HH2; with cleft palate, corpus callosum agenesis, unilateral deafness and fusion of fourth and fifth metacarpal bones; dbSNP:rs121909630)	VARIANT	0
P11362/A343V	FGFR1	-	1	A -> V (in HH2)	VARIANT	0
P11362/A520T	FGFR1	-	1	A -> T (in HH2; dbSNP:rs749758370)	VARIANT	1
P11362/A671P	FGFR1	-	1	A -> P (in HH2)	VARIANT	0
P11362/C101F	FGFR1	-	1	C -> F (in HH2)	VARIANT	0
P11362/C178S	FGFR1	-	1	C -> S (in HH2; with severe ear anomalies)	VARIANT	0
P11362/C277Y	FGFR1	-	1	C -> Y (in HH2)	VARIANT	0
P11362/C381R	FGFR1	-	2	C -> R (in OGD; dbSNP:rs121909634)	VARIANT	0
P11362/C725Y	FGFR1	-	1	C -> Y (in HRTFDS; dbSNP:rs398122945)	VARIANT	0
P11362/D129A	FGFR1	-	1	D -> A (in HH2; dbSNP:rs765615419)	VARIANT	0
P11362/D224H	FGFR1	-	1	D -> H (in HH2)	VARIANT	0
P11362/D623A	FGFR1	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
P11362/D623Y	FGFR1	-	1	D -> Y (in HRTFDS; dbSNP:rs398122946)	VARIANT	0
P11362/D755V	FGFR1	-	0	D->V: Abolishes interaction with PLCG1.	MUTAGEN	0
P11362/D768Y	FGFR1	-	1	D -> Y (in HH2; the patient also carries a rare variant in FGF8; dbSNP:rs121909644)	VARIANT	0
P11362/E274G	FGFR1	-	0	E -> G (in HH2; also found in a family member with isolated anosmia; dbSNP:rs727505369)	VARIANT	0
P11362/E670K	FGFR1	-	1	E -> K (in HH2; phenotype consistent with Kallmann syndrome; the patient also carries a rare variant in FLRT3; dbSNP:rs397515446)	VARIANT	0
P11362/E692G	FGFR1	-	1	E -> G (in HH2; phenotype consistent with Kallmann syndrome; the patient also carries a rare variant in DUSP6; dbSNP:rs397515445)	VARIANT	0
P11362/G237D	FGFR1	-	1	G -> D (in HH2)	VARIANT	0
P11362/G237S	FGFR1	-	1	G -> S (in HH2; with or without anosmia; also found in a family member with isolated anosmia; may impair proper folding; dbSNP:rs121909635)	VARIANT	0
P11362/G270D	FGFR1	-	1	G -> D (in HH2)	VARIANT	0
P11362/G348R	FGFR1	-	2	G -> R (in HH2; phenotype consistent with Kallmann syndrome; the patient also carries a mutation in IL17RD; dbSNP:rs886037634)	VARIANT	0
P11362/G48S	FGFR1	-	1	G -> S (in HH2; phenotype consistent with normosmic idiopathic hypogonadotropic hypogonadism; dbSNP:rs121909640)	VARIANT	0
P11362/G490R	FGFR1	-	1	G -> R (in HRTFDS; dbSNP:rs869025670)	VARIANT	1
P11362/G687R	FGFR1	-	2	G -> R (in HH2; dbSNP:rs727505376)	VARIANT	1
P11362/G703R	FGFR1	-	1	G -> R (in HH2)	VARIANT	0
P11362/G703S	FGFR1	-	1	G -> S (in HH2; dbSNP:rs768957161)	VARIANT	2
P11362/G70R	FGFR1	-	1	G -> R (in HH2; dbSNP:rs140254426)	VARIANT	1
P11362/G818R	FGFR1	-	0	G -> R (in dbSNP:rs17182456)	VARIANT	1
P11362/G97D	FGFR1	-	1	G -> D (in HH2)	VARIANT	0
P11362/H621R	FGFR1	-	1	H -> R (in HH2)	VARIANT	0
P11362/I239T	FGFR1	-	2	I -> T (in HH2; some patients also carry PROKR2 and GNRH1 mutations; impairs the tertiary folding resulting in incomplete glycosylation and reduced cell surface expression)	VARIANT	0
P11362/I300T	FGFR1	-	1	I -> T (in TRIGNO1; dbSNP:rs121909633)	VARIANT	0
P11362/I538V	FGFR1	-	1	I -> V (in HH2)	VARIANT	0
P11362/I693F	FGFR1	-	1	I -> F (in HH2)	VARIANT	0
P11362/K514A	FGFR1	loss	1	K->A: Loss of kinase activity.	MUTAGEN	0
P11362/K618N	FGFR1	decrease	2	K -> N (in HH2; some patients also carry GNRHR mutations; impairs tyrosine kinase activity)	VARIANT	1
P11362/L165S	FGFR1	-	1	L -> S (in HRTFDS; dbSNP:rs397515481)	VARIANT	0
P11362/L191S	FGFR1	-	1	L -> S (in HRTFDS; dbSNP:rs869025669)	VARIANT	0
P11362/L245P	FGFR1	-	1	L -> P (in HH2)	VARIANT	0
P11362/L342S	FGFR1	-	1	L -> S (in HH2; phenotype consistent with Kallmann syndrome; the patient also carries a splice site mutation in NSMF; dbSNP:rs121909638)	VARIANT	0
P11362/L769V	FGFR1	-	1	L -> V (in dbSNP:rs2956723)	VARIANT	0
P11362/M719R	FGFR1	-	1	M -> R (in HH2)	VARIANT	0
P11362/M719V	FGFR1	-	1	M -> V (in HH2; unknown pathological significance; dbSNP:rs1085307879)	VARIANT	0
P11362/N117S	FGFR1	-	2	N -> S (in HH2; some patients also carry GNRHR mutations; dbSNP:rs780765366)	VARIANT	0
P11362/N330I	FGFR1	-	2	N -> I (in OGD; dbSNP:rs121909632)	VARIANT	0
P11362/N546K	FGFR1	activating,resistance	2	N -> K (in ECCL; somatic mutation; activating mutation; strongly increased speed of the first autophosphorylation and loss of the normal sequential order of autophosphorylation; dbSNP:rs779707422)	VARIANT	34
P11362/N628K	FGFR1	-	1	N -> K (in HRTFDS; dbSNP:rs869025672)	VARIANT	0
P11362/N724K	FGFR1	-	2	N -> K (in HH2; associated with H-722; also found in a family member with isolated anosmia; reduced tyrosine kinase activity; dbSNP:rs267606806)	VARIANT	0
P11362/N77K	FGFR1	-	1	N -> K (in dbSNP:rs767195580)	VARIANT	0
P11362/P252R	FGFR1	-	2	P -> R (in PS and JWS; dbSNP:rs121909627)	VARIANT	0
P11362/P252T	FGFR1	-	1	P -> T (in a lung bronchoalveolar carcinoma sample; somatic mutation; dbSNP:rs121913472)	VARIANT	0
P11362/P283R	FGFR1	-	1	P -> R (in HH2)	VARIANT	0
P11362/P366L	FGFR1	-	1	P -> L (in HH2; with or without anosmia; dbSNP:rs121909641)	VARIANT	0
P11362/P483T	FGFR1	-	1	P -> T (in HH2; phenotype consistent with Kallmann syndrome; the patient also carries a rare variant in SPRY4; dbSNP:rs397515444)	VARIANT	0
P11362/P722H	FGFR1	-	2	P -> H (in HH2; associated with K-724; also found in a family member with isolated anosmia; reduced tyrosine kinase activity; dbSNP:rs267606805)	VARIANT	0
P11362/P722S	FGFR1	-	1	P -> S (in HH2; dbSNP:rs121909642)	VARIANT	0
P11362/P745S	FGFR1	-	2	P -> S (in HH2)	VARIANT	0
P11362/P772S	FGFR1	-	2	P -> S (in dbSNP:rs56234888)	VARIANT	2
P11362/R22S	FGFR1	-	0	R -> S (in dbSNP:rs17175750)	VARIANT	0
P11362/R250Q	FGFR1	-	4	R -> Q (in HH2; with or without anosmia; results in Kallmann syndrome in the presence of HS6ST1 mutation TRP-306; reduces receptor affinity for fibroblast growth factor; dbSNP:rs121909645)	VARIANT	1
P11362/R250W	FGFR1	-	2	R -> W (in HH2)	VARIANT	2
P11362/R254Q	FGFR1	-	1	R -> Q (in HH2)	VARIANT	0
P11362/R470L	FGFR1	-	2	R -> L (in HH2; some patients also carry GNRHR mutations; dbSNP:rs121909637)	VARIANT	0
P11362/R577E	FGFR1	decrease	1	R->E: Strongly reduced autophosphorylation in response to FGF signaling. No effect on in vitro kinase activity.	MUTAGEN	0
P11362/R609V	FGFR1	-	0	R->V: Abolishes interaction with PLCG1.	MUTAGEN	0
P11362/R622G	FGFR1	-	1	R -> G (in HH2; with severe ear anomalies; dbSNP:rs121909628)	VARIANT	0
P11362/R622Q	FGFR1	-	1	R -> Q (in HH2)	VARIANT	0
P11362/R627T	FGFR1	-	1	R -> T (in HRTFDS; dbSNP:rs869025671)	VARIANT	0
P11362/R78C	FGFR1	-	1	R -> C (in HH2; dbSNP:rs1554570706)	VARIANT	0
P11362/S125L	FGFR1	-	1	S -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs121913473)	VARIANT	2
P11362/S332C	FGFR1	-	1	S -> C (in HH2)	VARIANT	0
P11362/S346C	FGFR1	-	1	S -> C (in HH2; also found in a family member with isolated anosmia)	VARIANT	0
P11362/S685F	FGFR1	-	1	S -> F (in HH2)	VARIANT	0
P11362/S96C	FGFR1	-	1	S -> C (in HH2; unknown pathological significance)	VARIANT	0
P11362/V102I	FGFR1	-	2	V -> I (in HH2; dbSNP:rs55642501)	VARIANT	0
P11362/V116I	FGFR1	-	1	V -> I (in HH2; dbSNP:rs747842199)	VARIANT	0
P11362/V174A	FGFR1	-	1	V -> A (in HH2)	VARIANT	0
P11362/V273M	FGFR1	-	2	V -> M (in HH2; dbSNP:rs1131691929)	VARIANT	0
P11362/V561M	FGFR1	-	1	V -> M	VARIANT	0
P11362/V607M	FGFR1	-	1	V -> M (in HH2; with bimanual synkinesis; dbSNP:rs121909629)	VARIANT	0
P11362/V664L	FGFR1	-	1	V -> L (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
P11362/V795I	FGFR1	-	1	V -> I (in HH2; also found in a family member with isolated anosmia; dbSNP:rs781328162)	VARIANT	1
P11362/W213G	FGFR1	-	1	W -> G (in dbSNP:rs17851623)	VARIANT	0
P11362/W4C	FGFR1	-	1	W -> C (in HH2; unknown pathological significance; dbSNP:rs760884357)	VARIANT	1
P11362/W666R	FGFR1	-	1	W -> R (in HH2; with cleft palate; dbSNP:rs1563433902)	VARIANT	0
P11362/Y228D	FGFR1	-	2	Y -> D (in HH2; some patients also carry KISS1R mutations; impairs the tertiary folding resulting in incomplete glycosylation and reduced cell surface expression)	VARIANT	0
P11362/Y339C	FGFR1	-	1	Y -> C (in HH2)	VARIANT	0
P11362/Y374C	FGFR1	increase	1	Y -> C (in OGD; elevated basal activity and increased FGF2-mediated activity; dbSNP:rs121909631)	VARIANT	0
P11362/Y653F	FGFR1	-	1	Y->F: No effect on kinase activity. Loss of autophosphorylation and kinase activity; when associated with F-654.	MUTAGEN	0
P11362/Y654F	FGFR1	decrease	1	Y->F: Reduced kinase activity. Loss of autophosphorylation and kinase activity; when associated with F-653.	MUTAGEN	0
P11362/Y766F	FGFR1	decrease	0	Y->F: Abolishes interaction with PLCG1 and SHB. Decreases phosphorylation of FRS2, activation of RAS and 	MUTAGEN	0
P11362/Y99C	FGFR1	-	2	Y -> C (in HH2; impairs the tertiary folding resulting in incomplete glycosylation and reduced cell surface expression; dbSNP:rs727505373)	VARIANT	0
P11801/D218A	PSKH1	decrease	1	D->A: Loss of autophosphorylation.	MUTAGEN	0
P11801/N301S	PSKH1	-	1	N -> S (in dbSNP:rs35552721)	VARIANT	1
P11802/N41S	CDK4	-	1	N -> S (in CMM3; sporadic; dbSNP:rs144890720)	VARIANT	0
P11802/P173S	CDK4	decrease	1	P->S: No effect on in vitro phosphorylation by CDK7. Greatly reduced T-172 phosphorylation and enzyme activity.	MUTAGEN	0
P11802/R122H	CDK4	-	1	R -> H (in dbSNP:rs34386532)	VARIANT	0
P11802/R24H	CDK4	-	1	R -> H (in CMM3; dbSNP:rs104894340)	VARIANT	4
P11802/R82Q	CDK4	-	0	R -> Q (in dbSNP:rs3211612)	VARIANT	0
P11802/T172A	CDK4	decrease	1	T->A: Weak enzyme activity towards RB1, but no effect on binding of CCDN1 nor CCDN3.	MUTAGEN	0
P11802/T172E	CDK4	-	1	T->E: Retains moderate enzyme activity.	MUTAGEN	0
P12931/A237T	SRC	-	1	A -> T (in dbSNP:rs34881773)	VARIANT	0
P12931/K298M	SRC	loss	1	K->M: Kinase inactive. Abolishes ubiquitination promoted by CBLC.	MUTAGEN	0
P12931/L176F	SRC	-	0	L -> F (in dbSNP:rs6018260)	VARIANT	0
P12931/P302E	SRC	-	1	P->E: Kinase active. Interacts with PDLIM4; when associated with E-307 and F-419.	MUTAGEN	0
P12931/P307E	SRC	-	1	P->E: Kinase active. Interacts with PDLIM4; when associated with E-302 and F-419.	MUTAGEN	0
P12931/Y419F	SRC	loss	1	Y->F: Loss of kinase activity. Loss of interaction with PDLIM4.	MUTAGEN	0
P14616/A127E	INSRR	-	1	A -> E (in dbSNP:rs55757706)	VARIANT	0
P14616/A161V	INSRR	-	1	A -> V (in dbSNP:rs55971900)	VARIANT	0
P14616/C246R	INSRR	-	1	C -> R (in dbSNP:rs56377825)	VARIANT	0
P14616/E278Q	INSRR	-	1	E -> Q (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P14616/G1065E	INSRR	-	1	G -> E (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
P14616/P928L	INSRR	neutral	1	P -> L (in dbSNP:rs56252149)	VARIANT	8
P14616/R244H	INSRR	neutral	1	R -> H (in dbSNP:rs55951840)	VARIANT	0
P14616/R554C	INSRR	-	1	R -> C (in dbSNP:rs56068937)	VARIANT	0
P15056/A246P	BRAF	-	3	A -> P (in CFC1; dbSNP:rs180177034)	VARIANT	0
P15056/D594G	BRAF	-	1	D -> G (in NHL; dbSNP:rs121913338)	VARIANT	77
P15056/D638E	BRAF	-	1	D -> E (in CFC1; dbSNP:rs180177042)	VARIANT	1
P15056/E275K	BRAF	-	1	E -> K (in CFC1)	VARIANT	0
P15056/E501G	BRAF	-	2	E -> G (in CFC1; dbSNP:rs180177039)	VARIANT	0
P15056/E501K	BRAF	-	3	E -> K (in CFC1; dbSNP:rs180177038)	VARIANT	4
P15056/E586K	BRAF	-	1	E -> K (in ovarian cancer; dbSNP:rs121913340)	VARIANT	6
P15056/F468S	BRAF	-	2	F -> S (in CFC1; dbSNP:rs397507473)	VARIANT	1
P15056/F595L	BRAF	-	4	F -> L (in CFC1; also found in colon cancer; dbSNP:rs121913341)	VARIANT	4
P15056/G464E	BRAF	-	2	G -> E (in CRC; dbSNP:rs121913348)	VARIANT	9
P15056/G464V	BRAF	increase	1	G -> V (in a colorectal cancer cell line; elevated kinase activity; efficiently induces cell transformation; dbSNP:rs121913348)	VARIANT	11
P15056/G466A	BRAF	-	1	G -> A (in melanoma; dbSNP:rs121913351)	VARIANT	5
P15056/G466E	BRAF	-	1	G -> E (in melanoma; dbSNP:rs121913351)	VARIANT	31
P15056/G466V	BRAF	-	2	G -> V (in LNCR; dbSNP:rs121913351)	VARIANT	30
P15056/G469A	BRAF	increase	3	G -> A (in NHL; also in a lung adenocarcinoma sample; somatic mutation; elevated kinase activity; efficiently induces cell transformation; dbSNP:rs121913355)	VARIANT	96
P15056/G469E	BRAF	-	5	G -> E (in CFC1 and colon cancer; dbSNP:rs121913355)	VARIANT	22
P15056/G469R	BRAF	-	1	G -> R (in NHL; dbSNP:rs121913357)	VARIANT	26
P15056/G469V	BRAF	-	1	G -> V (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs121913355)	VARIANT	34
P15056/G596R	BRAF	-	2	G -> R (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs121913361)	VARIANT	6
P15056/G596V	BRAF	-	1	G -> V (in CFC1; dbSNP:rs397507483)	VARIANT	0
P15056/I463S	BRAF	-	1	I -> S (in CRC; dbSNP:rs180177033)	VARIANT	0
P15056/I666R	BRAF	decrease	1	I->R: No effect on MAP2K1-mediated-BRAF-KSR1 dimerization, however loss of BRAF-mediated phosphorylation of MAP2K1.	MUTAGEN	0
P15056/K483S	BRAF	decrease	1	K->S: Reduces kinase activity with MAP2K1.	MUTAGEN	0
P15056/K499E	BRAF	-	3	K -> E (in CFC1; dbSNP:rs180177037)	VARIANT	0
P15056/K499N	BRAF	-	2	K -> N (in CFC1; dbSNP:rs397507476)	VARIANT	1
P15056/K578R	BRAF	loss	1	K->R: Blocks EGF-induced ubiquitination and ERK activation.	MUTAGEN	0
P15056/K601E	BRAF	-	1	K -> E (in CRC; dbSNP:rs121913364)	VARIANT	221
P15056/K601Q	BRAF	-	1	K -> Q (in CFC1; dbSNP:rs121913364)	VARIANT	0
P15056/K88E	BRAF	decrease	1	K->E: Reduces interaction with KSR1 and MAP2K1 and thus phosphorylation of MAP2K1.	MUTAGEN	0
P15056/L245F	BRAF	-	1	L -> F (in CFC1; dbSNP:rs397507466)	VARIANT	1
P15056/L485F	BRAF	-	3	L -> F (in CFC1; dbSNP:rs180177036)	VARIANT	2
P15056/L525P	BRAF	-	1	L -> P (in CFC1; dbSNP:rs869025340)	VARIANT	0
P15056/L597R	BRAF	-	3	L -> R (in LNCR; also found in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs121913366)	VARIANT	28
P15056/L597V	BRAF	increase	3	L -> V (in NS7; also in a lung adenocarcinoma sample; somatic mutation; elevated kinase activity; efficiently induces cell transformation; dbSNP:rs121913369)	VARIANT	10
P15056/M53D	BRAF	decrease	1	M->D: Reduces interaction with KSR1 and MAP2K1 and thus phosphorylation of MAP2K1.	MUTAGEN	0
P15056/N580D	BRAF	-	1	N -> D (in CFC1)	VARIANT	0
P15056/N581D	BRAF	-	3	N -> D (in CFC1; dbSNP:rs180177040)	VARIANT	1
P15056/N581S	BRAF	-	1	N -> S (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs121913370)	VARIANT	21
P15056/P301S	BRAF	-	1	P -> S (in dbSNP:rs34776339)	VARIANT	0
P15056/Q257R	BRAF	-	4	Q -> R (in CFC1; dbSNP:rs180177035)	VARIANT	0
P15056/Q262K	BRAF	-	1	Q -> K (in CFC1; dbSNP:rs397507470)	VARIANT	0
P15056/Q709R	BRAF	-	1	Q -> R (in CFC1; dbSNP:rs397507486)	VARIANT	0
P15056/R462I	BRAF	-	1	R -> I (in CRC; dbSNP:rs180177032)	VARIANT	1
P15056/R509H	BRAF	loss	1	R->H: Loss of MAP2K1-mediated-BRAF-KSR1 dimerization.	MUTAGEN	0
P15056/R671K	BRAF	increase	1	R->K: Increased kinase activity and stability in response to EGF treatment.	MUTAGEN	0
P15056/S467A	BRAF	-	1	S -> A (in CFC1; dbSNP:rs869025606)	VARIANT	0
P15056/T241M	BRAF	-	1	T -> M (in NS7; dbSNP:rs387906660)	VARIANT	0
P15056/T241P	BRAF	-	2	T -> P (in CFC1 and LPRD3; dbSNP:rs387906661)	VARIANT	0
P15056/T241R	BRAF	-	1	T -> R (in NS7; dbSNP:rs387906660)	VARIANT	0
P15056/T244P	BRAF	-	1	T -> P (in CFC1; dbSNP:rs397507465)	VARIANT	0
P15056/T599R	BRAF	-	1	T -> R (in CFC1; dbSNP:rs121913375)	VARIANT	0
P15056/V600D	BRAF	-	1	V -> D (in a melanoma cell line; requires 2 nucleotide substitutions; dbSNP:rs121913377)	VARIANT	25
P15056/V600E	BRAF	activating,resistance	8	V -> E (in CRC; also found in sarcoma, metastatic melanoma, ovarian serous carcinoma, pilocytic astrocytoma; somatic mutation; most common mutation; constitutive and elevated kinase activity; efficiently induces cell transformation; suppression of mutation in melanoma causes growth arrest and promotes apoptosis; loss of regulation by PMRT5; dbSNP:rs113488022)	VARIANT	39181
P15056/W531C	BRAF	-	1	W -> C (in NS7; dbSNP:rs606231228)	VARIANT	0
P15735/A317T	PHKG2	-	1	A -> T (in dbSNP:rs759992249)	VARIANT	0
P15735/D215N	PHKG2	-	1	D -> N (in GSD9C; dbSNP:rs767427889)	VARIANT	0
P15735/E157K	PHKG2	-	1	E -> K (in GSD9C; dbSNP:rs752961445)	VARIANT	0
P15735/E247G	PHKG2	-	0	E -> G (in dbSNP:rs34006569)	VARIANT	0
P15735/G189E	PHKG2	-	1	G -> E (in GSD9C; dbSNP:rs137853588)	VARIANT	0
P15735/V106E	PHKG2	-	1	V -> E (in GSD9C; dbSNP:rs137853589)	VARIANT	0
P16066/A182V	NPR1	neutral	1	A -> V (in dbSNP:rs56019647)	VARIANT	0
P16066/E967K	NPR1	neutral	1	E -> K (in dbSNP:rs35479618)	VARIANT	0
P16066/F270C	NPR1	-	1	F -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	1
P16066/R939Q	NPR1	-	1	R -> Q (in dbSNP:rs35240348)	VARIANT	0
P16066/V755M	NPR1	-	1	V -> M (in dbSNP:rs55837780)	VARIANT	0
P16234/D1071N	PDGFRA	-	1	D -> N (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs376544204)	VARIANT	4
P16234/D842V	PDGFRA	activating,resistance	3	D -> V (in a GIST sample; imatinib resistant, constitutively activated kinase; dbSNP:rs121908585)	VARIANT	593
P16234/D842Y	PDGFRA	activating	1	D -> Y (in a GIST sample; imatinib sensitive, constitutively activated kinase; dbSNP:rs121913265)	VARIANT	4
P16234/D846Y	PDGFRA	-	1	D -> Y (in GISTPS; unknown pathological significance; dbSNP:rs121908588)	VARIANT	0
P16234/E996K	PDGFRA	-	1	E -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs779173667)	VARIANT	2
P16234/G426D	PDGFRA	-	1	G -> D (in dbSNP:rs55865821)	VARIANT	0
P16234/G79D	PDGFRA	neutral	1	G -> D (in dbSNP:rs36035373)	VARIANT	13
P16234/G829R	PDGFRA	-	1	G -> R (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	3
P16234/H570R	PDGFRA	-	1	H -> R (in a hypereosinophilic syndrome sample; does not lead to constitutive kinase activation)	VARIANT	0
P16234/H650Q	PDGFRA	activating	1	H -> Q (in a hypereosinophilic syndrome sample; constitutively activated kinase)	VARIANT	0
P16234/I562M	PDGFRA	-	1	I -> M (in a hypereosinophilic syndrome sample; does not lead to constitutive kinase activation)	VARIANT	0
P16234/L507P	PDGFRA	-	1	L -> P (in a hypereosinophilic syndrome sample; does not lead to constitutive kinase activation)	VARIANT	0
P16234/L705P	PDGFRA	-	1	L -> P (in a hypereosinophilic syndrome sample; does not lead to constitutive kinase activation)	VARIANT	0
P16234/N659K	PDGFRA	activating	1	N -> K (in GIST sample; constitutively activated kinase; dbSNP:rs1057519700)	VARIANT	22
P16234/N659S	PDGFRA	activating	1	N -> S (in a hypereosinophilic syndrome sample; constitutively activated kinase)	VARIANT	1
P16234/P653L	PDGFRA	-	1	P -> L (in GISTPS; unknown pathological significance)	VARIANT	1
P16234/R481G	PDGFRA	-	1	R -> G (in a hypereosinophilic syndrome sample; does not lead to constitutive kinase activation)	VARIANT	0
P16234/R748G	PDGFRA	activating	1	R -> G (in a hypereosinophilic syndrome sample; constitutively activated kinase)	VARIANT	0
P16234/R764C	PDGFRA	-	1	R -> C (in dbSNP:rs34392012)	VARIANT	1
P16234/S478P	PDGFRA	neutral	3	S -> P (in dbSNP:rs35597368)	VARIANT	7
P16234/V561D	PDGFRA	activating	2	V -> D (in a GIST sample; constitutively activated kinase; dbSNP:rs121908586)	VARIANT	28
P16234/Y555C	PDGFRA	activating	1	Y -> C (in GISTPS; increased platelet-derived growth factor alpha-receptor activity; constitutively activated kinase; dbSNP:rs121908589)	VARIANT	8
P16234/Y572F	PDGFRA	-	2	Y->F: Abolishes interaction with SRC-family members and impairs internalization of the activated receptor; when associated with F-574.	MUTAGEN	0
P16234/Y574F	PDGFRA	-	2	Y->F: Abolishes interaction with SRC-family members and impairs internalization of the activated receptor; when associated with F-572.	MUTAGEN	0
P16234/Y720F	PDGFRA	-	1	Y->F: Strongly reduced interaction with PTPN11 and GRB2.	MUTAGEN	0
P16234/Y731F	PDGFRA	decrease	1	Y->F: No effect on autophosphorylation and phosphorylation of PLCG1. Abolishes activation of phosphatidylinositol 3-kinase.	MUTAGEN	0
P16234/Y742F	PDGFRA	decrease	1	Y->F: No effect on autophosphorylation and phosphorylation of PLCG1. Abolishes activation of phosphatidylinositol 3-kinase.	MUTAGEN	0
P16234/Y762F	PDGFRA	-	1	Y->F: Abolishes interaction with CRK.	MUTAGEN	0
P16234/Y849C	PDGFRA	-	1	Y -> C (in GIST)	VARIANT	3
P16234/Y849S	PDGFRA	activating	1	Y -> S (in a hypereosinophilic syndrome sample; constitutively activated kinase)	VARIANT	0
P16591/A443P	FER	-	1	A -> P (in dbSNP:rs34259824)	VARIANT	0
P16591/E404Q	FER	-	1	E -> Q (in an ovarian Endometrioid carcinoma sample; somatic mutation)	VARIANT	1
P16591/E813Q	FER	-	1	E -> Q (in dbSNP:rs56097357)	VARIANT	0
P16591/I507T	FER	-	0	I -> T (in dbSNP:rs34204308)	VARIANT	0
P16591/K591R	FER	loss	1	K->R: Abolishes kinase activity.	MUTAGEN	0
P16591/L439V	FER	neutral	3	L -> V (in dbSNP:rs2229086)	VARIANT	0
P16591/M412V	FER	-	1	M -> V (in dbSNP:rs33940843)	VARIANT	0
P16591/R483Q	FER	loss	1	R->Q: Abolishes kinase activity. Abolishes location at microtubules.	MUTAGEN	0
P16591/V128F	FER	-	1	V -> F (in dbSNP:rs35150210)	VARIANT	0
P16591/W460C	FER	-	1	W -> C (in a lung small cell carcinoma sample; somatic mutation)	VARIANT	1
P17252/D467N	PRKCA	-	1	D -> N (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
P17252/M489V	PRKCA	-	1	M -> V (in dbSNP:rs34406842)	VARIANT	0
P17252/P98S	PRKCA	-	1	P -> S (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P17252/V568I	PRKCA	neutral	3	V -> I (in dbSNP:rs6504459)	VARIANT	0
P17612/G137R	PRKACA	-	1	G -> R (in CAFD1; decreased interaction with regulatory subunit PRKAR2B)	VARIANT	0
P17612/G201A	PRKACA	loss	1	G->A: No phosphorylation.	MUTAGEN	0
P17612/K48R	PRKACA	-	1	K->R: Enhanced basal kinase activity; when associated with Q-96, L-121, A-124, K-182 and A-184.	MUTAGEN	0
P17612/L41V	PRKACA	-	1	L -> V (in dbSNP:rs56029020)	VARIANT	0
P17612/L96Q	PRKACA	-	1	L->Q: Enhanced basal kinase activity; when associated with R-48, L-121, A-124, K-182 and A-184.	MUTAGEN	0
P17612/M121L	PRKACA	-	1	M->L: Enhanced basal kinase activity; when associated with R-48, Q-96, A-124, K-182 and A-184.	MUTAGEN	0
P17612/Q182K	PRKACA	-	1	Q->K: Enhanced basal kinase activity; when associated with R-48, Q-96, L-121, A-124 and A-184.	MUTAGEN	0
P17612/R195A	PRKACA	decrease	1	R->A: No phosphorylation.	MUTAGEN	0
P17612/R46Q	PRKACA	neutral	1	R -> Q (in dbSNP:rs56085217)	VARIANT	0
P17612/S264C	PRKACA	-	1	S -> C (in dbSNP:rs35635531)	VARIANT	0
P17612/T184A	PRKACA	-	1	T->A: Enhanced basal kinase activity; when associated with R-48, Q-96, L-121, A-124 and K-182.	MUTAGEN	0
P17612/T202A	PRKACA	loss	1	T->A: No phosphorylation.	MUTAGEN	0
P17612/V124A	PRKACA	-	1	V->A: Enhanced basal kinase activity; when associated with R-48, Q-96, L-121, K-182 and A-184.	MUTAGEN	0
P17612/Y205A	PRKACA	decrease	1	Y->A: Loss of allosteric regulation.	MUTAGEN	0
P17948/E144K	FLT1	-	1	E -> K (in dbSNP:rs55974987)	VARIANT	5
P17948/E982A	FLT1	neutral	1	E -> A (in dbSNP:rs35832528)	VARIANT	0
P17948/I128L	FLT1	-	0	I -> L (in dbSNP:rs35073261)	VARIANT	0
P17948/K60T	FLT1	-	1	K -> T (in dbSNP:rs56409818)	VARIANT	0
P17948/K861M	FLT1	loss	1	K->M: Abolishes enzyme activity. Abolishes interaction with PLCG.	MUTAGEN	0
P17948/L1061V	FLT1	-	1	L -> V (in a bladder transitional cell carcinoma sample; somatic mutation)	VARIANT	0
P17948/L422I	FLT1	-	1	L -> I (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P17948/M938V	FLT1	neutral	1	M -> V (in dbSNP:rs35549791)	VARIANT	1
P17948/N1050D	FLT1	increase	1	N->D: Strongly increases kinase activity. Increases activity in promoting proliferation of endothelial cells.	MUTAGEN	0
P17948/R281Q	FLT1	-	1	R -> Q (in dbSNP:rs55687105)	VARIANT	4
P17948/R781Q	FLT1	-	1	R -> Q (in a glioma low grade oligodendroglioma sample; somatic mutation; dbSNP:rs553261958)	VARIANT	10
P17948/V767A	FLT1	-	1	V->A: Abolishes proteolytic cleavage by PSEN1.	MUTAGEN	0
P17948/Y1169F	FLT1	-	1	Y->F: Loss of phosphorylation site. Abolishes interaction with PLCG.	MUTAGEN	0
P17948/Y1213F	FLT1	-	1	Y->F: Loss of phosphorylation site. Abolishes interaction with PIK3R1.	MUTAGEN	0
P17948/Y1242F	FLT1	loss	1	Y->F: Loss of phosphorylation site.	MUTAGEN	0
P17948/Y1327F	FLT1	loss	1	Y->F: Loss of phosphorylation site.	MUTAGEN	0
P17948/Y1333F	FLT1	-	2	Y->F: Loss of phosphorylation site. Abolishes interaction with CBL.	MUTAGEN	0
P17948/Y914F	FLT1	decrease	1	Y->F: Reduces phosphorylation at other tyrosine residues.	MUTAGEN	0
P19525/A109S	EIF2AK2	-	1	A -> S (in LEUDEN; unknown pathological significance)	VARIANT	0
P19525/A109V	EIF2AK2	-	1	A -> V (in LEUDEN; unknown pathological significance)	VARIANT	0
P19525/A67E	EIF2AK2	loss	1	A->E: Significant loss of activity; loss of dsRNA binding and dimerization.	MUTAGEN	0
P19525/G130R	EIF2AK2	increase	3	G -> R (in DYT33; gain-of-function variant resulting in increased levels of phosphorylated EIF2AK2 and EIF2A in patient cells compared to controls)	VARIANT	0
P19525/G138A	EIF2AK2	-	1	G -> A (in DYT33; unknown pathological significance)	VARIANT	0
P19525/G325S	EIF2AK2	-	1	G -> S (in LEUDEN; unknown pathological significance)	VARIANT	0
P19525/I506V	EIF2AK2	-	1	I -> V (in dbSNP:rs34821155)	VARIANT	0
P19525/K296R	EIF2AK2	loss	1	K->R: Loss of activity.	MUTAGEN	0
P19525/K60A	EIF2AK2	-	1	K->A: Impairs dsRNA binding but not dimerization or activity.	MUTAGEN	0
P19525/L114Q	EIF2AK2	-	1	L -> Q (found in a patient with dysmorphic facies, syndactyly, congenital microcephaly and global developmental delay; unknown pathological significance)	VARIANT	0
P19525/L439V	EIF2AK2	-	1	L -> V (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P19525/M11L	EIF2AK2	decrease	1	M -> L (in LEUDEN; unknown pathological significance; reduced phosphorylation of eukaryotic translation initiation factor 2-alpha in patient cells)	VARIANT	0
P19525/N32S	EIF2AK2	-	1	N -> S (in LEUDEN; unknown pathological significance)	VARIANT	0
P19525/N32T	EIF2AK2	increase	1	N -> T (in DYT33; unknown pathological significance; gain-of-function variant resulting in increased levels of phosphorylated EIF2AK2 and EIF2A in patient cells compared to controls)	VARIANT	0
P19525/S242A	EIF2AK2	-	1	S->A: Moderate loss of activity; when associated with A-255 and A-258.	MUTAGEN	0
P19525/S461C	EIF2AK2	decrease	1	S -> C (in LEUDEN; unknown pathological significance; reduced phosphorylation of eukaryotic translation initiation factor 2-alpha in patient cells)	VARIANT	0
P19525/S83A	EIF2AK2	-	1	S->A: No effect on enzymatic activity; when associated with A-88; A-89 and A-90.	MUTAGEN	0
P19525/S97F	EIF2AK2	-	1	S -> F (in LEUDEN; unknown pathological significance)	VARIANT	0
P19525/T255A	EIF2AK2	-	1	T->A: Moderate loss of activity; when associated with A-242 and A-255.	MUTAGEN	0
P19525/T258A	EIF2AK2	decrease	1	T->A: Moderate loss of activity.	MUTAGEN	0
P19525/T446A	EIF2AK2	decrease	1	T->A: Significant loss of activity and impairs autophosphorylation of T-451.	MUTAGEN	0
P19525/T451A	EIF2AK2	loss	1	T->A: Loss of activity.	MUTAGEN	0
P19525/T88A	EIF2AK2	-	1	T->A: No effect on enzymatic activity; when associated with A-83; A-89 and A-90.	MUTAGEN	0
P19525/T89A	EIF2AK2	-	1	T->A: No effect on enzymatic activity; when associated with A-83; A-88 and A-90.	MUTAGEN	0
P19525/T90A	EIF2AK2	-	1	T->A: No effect on enzymatic activity; when associated with A-83; A-88 and A-89.	MUTAGEN	0
P19525/V428E	EIF2AK2	-	1	V -> E (in dbSNP:rs56219559)	VARIANT	0
P19525/Y133F	EIF2AK2	decrease	1	Y -> F (in LEUDEN; unknown pathological significance; reduced phosphorylation of eukaryotic translation initiation factor 2-alpha in patient cells)	VARIANT	0
P19784/E188A	CSNK2A2	-	1	E -> A (in dbSNP:rs55911801)	VARIANT	0
P20594/A409T	NPR2	-	1	A -> T (in AMD1)	VARIANT	0
P20594/A488P	NPR2	-	1	A -> P (in ECDM; mutant and wild-type alleles have similar expression levels; the mutation results in increased guanylate cyclase activity; dbSNP:rs587777597)	VARIANT	0
P20594/D176E	NPR2	-	1	D -> E (in AMD1; dbSNP:rs28929479)	VARIANT	0
P20594/G413E	NPR2	decrease	1	G -> E (in AMD1; markedly deficient activity)	VARIANT	0
P20594/G959A	NPR2	-	2	G -> A (in AMD1; no effect on subcellular location; changed glycosylation; no effect on C-type natriuretic peptide binding; decreased guanylate cyclase activity)	VARIANT	0
P20594/L658F	NPR2	decrease	2	L -> F (in AMD1; no effect on subcellular location; changed glycosylation; no effect on C-type natriuretic peptide binding; decreased guanylate cyclase activity; loss of natriuretic peptide receptor activity; dominant negative effect; dbSNP:rs1314542724)	VARIANT	0
P20594/M232I	NPR2	-	1	M -> I (in dbSNP:rs55747238)	VARIANT	0
P20594/N24D	NPR2	-	1	N->D,Q: Decreased glycosylation. Decreased guanylate cyclase activity.	MUTAGEN	0
P20594/N24Q	NPR2	-	1	N->D,Q: Decreased glycosylation. Decreased guanylate cyclase activity.	MUTAGEN	0
P20594/P32T	NPR2	-	1	P -> T (in AMD1; dbSNP:rs28931581)	VARIANT	0
P20594/Q417E	NPR2	loss	1	Q -> E (in SNSK; loss of C-type natriuretic peptide-induced signaling; dominant negative effect; no effect on cell surface expression; dbSNP:rs796065356)	VARIANT	0
P20594/Q771E	NPR2	-	0	Q -> E (in dbSNP:rs5816)	VARIANT	0
P20594/R110C	NPR2	loss	1	R -> C (in SNSK; loss of C-type natriuretic peptide-induced signaling; dominant negative effect; retained in the endoplasmic reticulum; dbSNP:rs758478717)	VARIANT	0
P20594/R263P	NPR2	loss	1	R -> P (in SNSK; loss of C-type natriuretic peptide-induced signaling; dominant negative effect; loss of localization to the plasma membrane; dbSNP:rs139036657)	VARIANT	0
P20594/R655C	NPR2	-	1	R -> C (in ECDM; the mutation results in increased guanylate cyclase activity; dbSNP:rs587777596)	VARIANT	1
P20594/R776W	NPR2	-	2	R -> W (in AMD1; no effect on subcellular location; changed glycosylation; no effect on C-type natriuretic peptide binding; decreased guanylate cyclase activity; dbSNP:rs1303913631)	VARIANT	0
P20594/R819C	NPR2	decrease	1	R -> C (in SNSK; loss of C-type natriuretic peptide-induced signaling; dominant negative effect; no effect on cell surface expression; dbSNP:rs766256429)	VARIANT	0
P20594/R957C	NPR2	-	1	R -> C (in AMD1; dbSNP:rs370158184)	VARIANT	0
P20594/S76P	NPR2	loss	1	S -> P (in SNSK; loss of C-type natriuretic peptide-induced signaling; dominant negative effect; loss of localization to the plasma membrane; dbSNP:rs796065355)	VARIANT	0
P20594/T297M	NPR2	decrease	1	T -> M (in AMD1; markedly deficient activity; dbSNP:rs1313765432)	VARIANT	0
P20594/V187I	NPR2	-	1	V -> I (does not affect C-type natriuretic peptide-induced signaling; dbSNP:rs768423636)	VARIANT	0
P20594/V882I	NPR2	-	1	V -> I (in dbSNP:rs55700371)	VARIANT	0
P20594/V882M	NPR2	-	2	V -> M (in ECDM; the mutation results in higher guanylate cyclase activity; causes a 15-fold increase in basal Vmax; has higher affinity for GTP than wild-type in the presence of NPPC; might lead to a structural change that locks the enzyme in a conformation mimicking the ATP-bound state)	VARIANT	0
P20594/W115G	NPR2	decrease	1	W -> G (in AMD1; markedly deficient activity; dbSNP:rs28931582)	VARIANT	0
P20594/Y338C	NPR2	-	1	Y -> C (in AMD1; dbSNP:rs1828087195)	VARIANT	0
P20594/Y708C	NPR2	-	2	Y -> C (in AMD1; no effect on subcellular location; changed glycosylation; no effect on C-type natriuretic peptide binding; decreased guanylate cyclase activity; dbSNP:rs1305337032)	VARIANT	0
P20794/D329E	MAK	-	0	D -> E (in dbSNP:rs17579447)	VARIANT	0
P20794/F550L	MAK	-	1	F -> L (in dbSNP:rs56217305)	VARIANT	0
P20794/G13S	MAK	loss	1	G -> S (in RP62; results in a complete loss of kinase activity compared to wild-type; dbSNP:rs387906647)	VARIANT	0
P20794/G27R	MAK	-	1	G -> R (in RP62; dbSNP:rs754916169)	VARIANT	0
P20794/I181T	MAK	-	1	I -> T (in RP62; dbSNP:rs750559316)	VARIANT	0
P20794/I189V	MAK	-	1	I -> V (in dbSNP:rs56215624)	VARIANT	0
P20794/K33R	MAK	loss	1	K->R: Abolishes autophosphorylation.	MUTAGEN	0
P20794/N130H	MAK	loss	1	N -> H (in RP62; results in a complete loss of kinase activity compared to wild-type; dbSNP:rs387906646)	VARIANT	0
P20794/N384S	MAK	-	1	N -> S (in dbSNP:rs55773478)	VARIANT	0
P20794/P325L	MAK	-	1	P -> L (in dbSNP:rs371971492)	VARIANT	0
P20794/P520S	MAK	neutral	1	P -> S (in dbSNP:rs567083)	VARIANT	0
P20794/R166H	MAK	-	1	R -> H (in RP62; dbSNP:rs387906648)	VARIANT	0
P20794/R272P	MAK	-	1	R -> P (in a breast infiltrating ductal carcinoma sample; somatic mutation)	VARIANT	1
P20794/T157A	MAK	loss	1	T->A: Abolishes autophosphorylation and impairs kinase activity.	MUTAGEN	0
P20794/Y159F	MAK	loss	1	Y->F: Abolishes autophosphorylation and impairs kinase activity.	MUTAGEN	0
P21127/A670V	CDK11B	-	1	A -> V (in dbSNP:rs1059811)	VARIANT	6
P21127/G506S	CDK11B	-	1	G -> S	VARIANT	0
P21127/I463V	CDK11B	-	1	I -> V	VARIANT	0
P21127/K641N	CDK11B	-	1	K -> N (in dbSNP:rs1059815)	VARIANT	0
P21127/L601Q	CDK11B	-	2	L -> Q (in dbSNP:rs200190129)	VARIANT	0
P21127/R109C	CDK11B	-	0	R -> C (in dbSNP:rs1059830)	VARIANT	0
P21127/R201W	CDK11B	-	1	R -> W (in dbSNP:rs1557687207)	VARIANT	0
P21127/R57C	CDK11B	-	2	R -> C (in dbSNP:rs752740049)	VARIANT	1
P21127/R93W	CDK11B	-	0	R -> W (in dbSNP:rs1059831)	VARIANT	0
P21127/S414L	CDK11B	-	1	S -> L (in dbSNP:rs1241694892)	VARIANT	2
P21127/V452A	CDK11B	-	1	V -> A	VARIANT	0
P21675/A297G	TAF1	neutral	1	A -> G (in dbSNP:rs35317750)	VARIANT	0
P21675/C305A	TAF1	-	1	C->A: Reduces kinase activity; when associated with A-307; A-308; A-309 and A-310.	MUTAGEN	0
P21675/C786R	TAF1	-	1	C -> R (in MRXS33; dbSNP:rs864321628)	VARIANT	0
P21675/D145A	TAF1	-	1	D->A: Reduces kinase activity; when associated with A-147; A-149; A-150; A-152 and A-154.	MUTAGEN	0
P21675/D147A	TAF1	-	1	D->A: Reduces kinase activity; when associated with A-145; A-149; A-150; A-152 and A-154.	MUTAGEN	0
P21675/D150A	TAF1	-	1	D->A: Reduces kinase activity; when associated with A-145; A-147; A-149; A-152 and A-154.	MUTAGEN	0
P21675/D152A	TAF1	-	1	D->A: Reduces kinase activity; when associated with A-145; A-147; A-149; A-150 and A-154.	MUTAGEN	0
P21675/D308A	TAF1	-	1	D->A: Reduces kinase activity; when associated with A-305; A-307; A-309 and A-310.	MUTAGEN	0
P21675/D309A	TAF1	-	1	D->A: Reduces kinase activity; when associated with A-305; A-307; A-308 and A-310.	MUTAGEN	0
P21675/D955H	TAF1	-	1	D -> H (in MRXS33; dbSNP:rs864321631)	VARIANT	0
P21675/E149A	TAF1	-	1	E->A: Reduces kinase activity; when associated with A-145; A-147; A-150; A-152 and A-154.	MUTAGEN	0
P21675/E310A	TAF1	-	1	E->A: Reduces kinase activity; when associated with A-305; A-307; A-308 and A-309.	MUTAGEN	0
P21675/E651K	TAF1	-	1	E -> K (in a metastatic melanoma sample; somatic mutation)	VARIANT	0
P21675/E721Q	TAF1	decrease	1	E->Q: 25% decrease in histone acetylation.	MUTAGEN	0
P21675/G453D	TAF1	-	1	G -> D (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P21675/I1316T	TAF1	-	1	I -> T (in MRXS33; dbSNP:rs864321627)	VARIANT	0
P21675/K154A	TAF1	-	1	K->A: Reduces kinase activity; when associated with A-145; A-147; A-149; A-150 and A-152.	MUTAGEN	0
P21675/L269V	TAF1	neutral	1	L -> V (in dbSNP:rs28382158)	VARIANT	0
P21675/M691I	TAF1	-	1	M -> I (in a lung bronchoalveolar carcinoma sample; somatic mutation)	VARIANT	0
P21675/N1496H	TAF1	-	1	N -> H (in MRXS33; unknown pathological significance)	VARIANT	0
P21675/N472D	TAF1	-	1	N -> D (found in a patient with X-linked intellectual disability; unknown pathological significance; dbSNP:rs200177996)	VARIANT	0
P21675/P575S	TAF1	-	1	P -> S (in MRXS33; dbSNP:rs864321630)	VARIANT	0
P21675/R1169C	TAF1	-	1	R -> C (found in a patient with X-linked intellectual disability; unknown pathological significance; dbSNP:rs1569301036)	VARIANT	0
P21675/R1225W	TAF1	-	1	R -> W (in MRXS33; dbSNP:rs864321629)	VARIANT	0
P21675/R1431H	TAF1	-	1	R -> H (in MRXS33; unknown pathological significance)	VARIANT	0
P21675/S137A	TAF1	-	1	S->A: No decrease in kinase activity.	MUTAGEN	0
P21675/S307A	TAF1	-	1	S->A: Reduces kinase activity; when associated with A-305; A-308; A-309 and A-310.	MUTAGEN	0
P21675/V1383I	TAF1	-	0	V -> I (in dbSNP:rs7050748)	VARIANT	0
P21709/A585T	EPHA1	-	1	A -> T (in dbSNP:rs34178823)	VARIANT	1
P21709/E703K	EPHA1	-	1	E -> K (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	1
P21709/M900V	EPHA1	-	6	M -> V (in dbSNP:rs6967117)	VARIANT	0
P21709/P697L	EPHA1	neutral	1	P -> L (in dbSNP:rs34372369)	VARIANT	0
P21709/R351C	EPHA1	-	1	R -> C (in dbSNP:rs56006153)	VARIANT	0
P21709/R492Q	EPHA1	neutral	1	R -> Q (in dbSNP:rs11768549)	VARIANT	0
P21709/R575Q	EPHA1	-	1	R -> Q (in dbSNP:rs35719334)	VARIANT	0
P21709/S807R	EPHA1	-	1	S -> R (in dbSNP:rs56244405)	VARIANT	0
P21709/V160A	EPHA1	neutral	5	V -> A (in dbSNP:rs4725617)	VARIANT	1
P21802/A172F	FGFR2	-	1	A -> F (in PS; requires 2 nucleotide substitutions)	VARIANT	0
P21802/A314S	FGFR2	-	1	A -> S (in craniosynostosis; dbSNP:rs1358919643)	VARIANT	0
P21802/A315S	FGFR2	-	2	A -> S (in a non-syndromic craniosynostosis patient with abnormal intrauterine history; confers predisposition to craniosynostosis; dbSNP:rs121918504)	VARIANT	0
P21802/A337P	FGFR2	-	1	A -> P (in CS; dbSNP:rs387906676)	VARIANT	0
P21802/A344G	FGFR2	-	2	A -> G (in CS and JWS; dbSNP:rs121918492)	VARIANT	0
P21802/A344P	FGFR2	-	1	A -> P (in CS and PS)	VARIANT	0
P21802/A362S	FGFR2	-	1	A -> S (in CS)	VARIANT	0
P21802/A628T	FGFR2	decrease	1	A -> T (in LADD1; strongly reduced kinase activity; dbSNP:rs121918509)	VARIANT	0
P21802/A648T	FGFR2	-	1	A -> T (in LADD1; dbSNP:rs121918508)	VARIANT	1
P21802/C278F	FGFR2	activating	5	C -> F (in CS, JWS and PS; forms disulfide-linked dimers with constitutive kinase activity, is retained in an intracellular compartment and not detected at the cell surface; dbSNP:rs776587763)	VARIANT	0
P21802/C278Y	FGFR2	-	1	C -> Y (in CS; dbSNP:rs776587763)	VARIANT	0
P21802/C342F	FGFR2	-	3	C -> F (in CS; dbSNP:rs121918487)	VARIANT	0
P21802/C342G	FGFR2	-	1	C -> G (in PS; dbSNP:rs121918488)	VARIANT	0
P21802/C342R	FGFR2	-	9	C -> R (in CS, JWS, PS and ABS2; dbSNP:rs121918488)	VARIANT	0
P21802/C342S	FGFR2	-	7	C -> S (in CS, JWS, PS and ABS2; dbSNP:rs121918488)	VARIANT	0
P21802/C342W	FGFR2	-	3	C -> W (in CS; dbSNP:rs121918496)	VARIANT	0
P21802/D283N	FGFR2	-	1	D -> N (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
P21802/D321A	FGFR2	-	1	D -> A (in PS; dbSNP:rs121918510)	VARIANT	0
P21802/E565A	FGFR2	activating,resistance	1	E->A: Constitutive kinase activity.	MUTAGEN	0
P21802/E565G	FGFR2	activating	2	E -> G (in PS; constitutive kinase activity; dbSNP:rs121918506)	VARIANT	0
P21802/F276V	FGFR2	-	3	F -> V (in CS; dbSNP:rs1057519036)	VARIANT	0
P21802/G272V	FGFR2	-	1	G -> V (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
P21802/G338E	FGFR2	-	1	G -> E (in CS; dbSNP:rs1057519044)	VARIANT	0
P21802/G338R	FGFR2	-	3	G -> R (in CS; dbSNP:rs1057519043)	VARIANT	0
P21802/G384R	FGFR2	-	1	G -> R (in CS; dbSNP:rs1554927408)	VARIANT	1
P21802/G613R	FGFR2	-	2	G -> R	VARIANT	0
P21802/G663E	FGFR2	-	1	G -> E (in PS)	VARIANT	0
P21802/I288S	FGFR2	-	1	I -> S (in CS)	VARIANT	0
P21802/K292E	FGFR2	-	1	K -> E (in CS; dbSNP:rs121918500)	VARIANT	0
P21802/K526E	FGFR2	activating	2	K -> E (in FSPC; constitutive kinase activity; dbSNP:rs121918507)	VARIANT	0
P21802/K641R	FGFR2	activating,resistance	2	K -> R (in PS; constitutive kinase activity; dbSNP:rs1057519047)	VARIANT	0
P21802/K659N	FGFR2	activating	2	K -> N (in craniosynostosis; constitutive kinase activity; dbSNP:rs1589722765)	VARIANT	7
P21802/M186T	FGFR2	neutral	2	M -> T (in dbSNP:rs755793)	VARIANT	15
P21802/M391R	FGFR2	decrease	1	M -> R (in BBDS1; the mutation selectively reduces plasma-membrane levels of the protein and markedly diminishes the receptor's responsiveness to extracellular FGF; dbSNP:rs387906677)	VARIANT	1
P21802/N265Q	FGFR2	-	1	N->Q: Reduced N-glycosylation. Reduced expression at the cell surface.	MUTAGEN	0
P21802/N331I	FGFR2	-	1	N -> I (in CS)	VARIANT	0
P21802/N549H	FGFR2	activating,resistance	2	N -> H (in CS; constitutive kinase activity; dbSNP:rs1057519045)	VARIANT	0
P21802/N549T	FGFR2	activating,resistance	1	N->T: Constitutive kinase activity.	MUTAGEN	0
P21802/P253R	FGFR2	-	5	P -> R (in APRS; common mutation; dbSNP:rs77543610)	VARIANT	10
P21802/P263L	FGFR2	-	1	P -> L (in CS; dbSNP:rs779326224)	VARIANT	0
P21802/Q289P	FGFR2	-	5	Q -> P (in CS and JWS; dbSNP:rs121918497)	VARIANT	0
P21802/R203C	FGFR2	-	2	R -> C (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	VARIANT	2
P21802/R612T	FGFR2	-	1	R -> T (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P21802/R678G	FGFR2	-	1	R -> G (in CS; dbSNP:rs1845559552)	VARIANT	1
P21802/R6P	FGFR2	-	0	R -> P (in dbSNP:rs3750819)	VARIANT	0
P21802/S252F	FGFR2	-	1	S -> F (in APRS; requires 2 nucleotide substitutions; dbSNP:rs121918498)	VARIANT	0
P21802/S252L	FGFR2	-	1	S -> L (in dbSNP:rs79184941)	VARIANT	3
P21802/S252W	FGFR2	-	7	S -> W (in APRS and PS; common mutation; dbSNP:rs79184941)	VARIANT	85
P21802/S267P	FGFR2	-	1	S -> P (in CS; dbSNP:rs121918505)	VARIANT	1
P21802/S347C	FGFR2	-	2	S -> C (in CS; dbSNP:rs121918494)	VARIANT	0
P21802/S351C	FGFR2	-	3	S -> C (in CS, PS and ABS2; dbSNP:rs121918502)	VARIANT	0
P21802/S354C	FGFR2	-	5	S -> C (in CS; dbSNP:rs121918490)	VARIANT	0
P21802/S354Y	FGFR2	-	1	S -> Y (in CS)	VARIANT	0
P21802/S372C	FGFR2	-	1	S -> C (in BSTVS; dbSNP:rs121913477)	VARIANT	1
P21802/S57L	FGFR2	neutral	2	S -> L (in dbSNP:rs56226109)	VARIANT	0
P21802/T341P	FGFR2	-	3	T -> P (in PS and CS; dbSNP:rs121918495)	VARIANT	0
P21802/V359F	FGFR2	-	2	V -> F (in CS and PS)	VARIANT	0
P21802/W290C	FGFR2	-	3	W -> C (in PS; severe; also in a lung squamous cell carcinoma sample; somatic mutation; dbSNP:rs121918499)	VARIANT	2
P21802/W290G	FGFR2	-	1	W -> G (in CS; dbSNP:rs121918501)	VARIANT	0
P21802/W290R	FGFR2	-	0	W -> R (in CS; dbSNP:rs121918501)	VARIANT	0
P21802/Y105C	FGFR2	-	2	Y -> C (in CS; dbSNP:rs1434545235)	VARIANT	0
P21802/Y281C	FGFR2	-	2	Y -> C (in CS; dbSNP:rs1057519038)	VARIANT	0
P21802/Y301C	FGFR2	-	1	Y -> C (in CS; dbSNP:rs1554930684)	VARIANT	0
P21802/Y328C	FGFR2	-	1	Y -> C (in CS; dbSNP:rs121918493)	VARIANT	0
P21802/Y340C	FGFR2	-	2	Y -> C (in PS; dbSNP:rs1554928884)	VARIANT	0
P21802/Y340H	FGFR2	-	2	Y -> H (in CS; dbSNP:rs121918489)	VARIANT	0
P21802/Y375C	FGFR2	-	3	Y -> C (in PS and BSTVS; dbSNP:rs121913478)	VARIANT	7
P21802/Y381D	FGFR2	-	1	Y -> D (in BBDS1; dbSNP:rs387906678)	VARIANT	0
P21802/Y769F	FGFR2	decrease	0	Y->F: Increases fibroblast proliferation. Decreases phosphorylation of PLCG1 and FRS2. Decreases activation of 	MUTAGEN	0
P21860/A1337T	ERBB3	increase	1	A -> T (in FERLK; risk factor for erythroleukemia; results in increased ERBB-mediated signaling; results in a block of erythroid differentiation and increased cell proliferation; dbSNP:rs755855285)	VARIANT	0
P21860/G1271S	ERBB3	-	0	G -> S (in dbSNP:rs11171743)	VARIANT	0
P21860/I744T	ERBB3	-	1	I -> T (in dbSNP:rs55787439)	VARIANT	0
P21860/K742M	ERBB3	decrease	1	K->M: Strongly reduced autophosphorylation.	MUTAGEN	0
P21860/K998R	ERBB3	-	1	K -> R (in dbSNP:rs56259600)	VARIANT	0
P21860/L1177I	ERBB3	-	1	L -> I (in dbSNP:rs55699040)	VARIANT	5
P21860/N385S	ERBB3	-	0	N -> S (in dbSNP:rs12320176)	VARIANT	0
P21860/P30L	ERBB3	-	1	P -> L (in dbSNP:rs56017157)	VARIANT	0
P21860/Q932R	ERBB3	decrease	1	Q -> R (in VSCN1; unknown pathological significance; some decrease in ERBB2 phosphorylation upon NG1 treatment, compared to wild-type; does not affect the subcellular localization at the cell membrane)	VARIANT	0
P21860/R1127H	ERBB3	-	1	R -> H (in dbSNP:rs2271188)	VARIANT	1
P21860/R683W	ERBB3	-	1	R -> W (in dbSNP:rs56387488)	VARIANT	0
P21860/S1119C	ERBB3	neutral	1	S -> C (in dbSNP:rs773123)	VARIANT	11
P21860/S20Y	ERBB3	-	1	S -> Y (in dbSNP:rs34379766)	VARIANT	0
P21860/S717L	ERBB3	-	1	S -> L (in dbSNP:rs35961836)	VARIANT	0
P21860/T1254K	ERBB3	-	1	T -> K (in dbSNP:rs55709407)	VARIANT	0
P21860/T204I	ERBB3	-	1	T -> I (in dbSNP:rs56107455)	VARIANT	0
P21860/T787P	ERBB3	loss	1	T -> P (in VSCN1; almost complete loss of ERBB2 and ERBB3 phosphorylation in the presence or in the absence of NRG1 stimulation, suggesting alteration of downstream signaling; does not affect the subcellular localization at the cell membrane)	VARIANT	0
P21860/T873S	ERBB3	decrease	1	T -> S (in VSCN1; unknown pathological significance; some decrease in ERBB2 phosphorylation upon NG1 treatment, compared to wild-type; does not affect the subcellular localization at the cell membrane)	VARIANT	0
P21860/V104M	ERBB3	-	1	V -> M (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs1057519893)	VARIANT	39
P21860/V899M	ERBB3	loss	1	V -> M (in VSCN1; almost complete loss of ERBB2 and ERBB3 phosphorylation in the presence or in the absence of NRG1 stimulation, suggesting alteration of downstream signaling; does not affect the subcellular localization at the cell membrane)	VARIANT	1
P21860/Y868E	ERBB3	decrease	1	Y->E: Strongly reduced tyrosine phosphorylation.	MUTAGEN	0
P22455/D516N	FGFR4	-	1	D -> N (in dbSNP:rs34158682)	VARIANT	0
P22455/G388R	FGFR4	increase	6	G -> R (in cancer cells, may be associated with accelerated disease progression and increased tumor cell motility, possibly due to increased stability of the protease MMP14; leads to phosphorylation at residue Y-390, resulting in prolonged FGFR4 activity; increases interaction with STAT3, resulting in STAT3 phosphorylation and signaling activation.; dbSNP:rs351855)	VARIANT	28
P22455/G426S	FGFR4	-	1	G -> S (in dbSNP:rs55879131)	VARIANT	0
P22455/K503R	FGFR4	loss	2	K->R: Loss of kinase activity.	MUTAGEN	0
P22455/P136L	FGFR4	neutral	3	P -> L (in dbSNP:rs376618)	VARIANT	0
P22455/P712T	FGFR4	-	1	P -> T (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	3
P22455/R529Q	FGFR4	-	0	R -> Q (in dbSNP:rs34284947)	VARIANT	0
P22455/S772N	FGFR4	-	1	S -> N (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
P22455/T179A	FGFR4	neutral	1	T -> A (in dbSNP:rs55675160)	VARIANT	4
P22455/V10I	FGFR4	-	2	V -> I (in dbSNP:rs1966265)	VARIANT	9
P22455/V550M	FGFR4	resistance	1	V -> M (in breast pleomorphic lobular sample; somatic mutation; dbSNP:rs774571806)	VARIANT	11
P22455/Y754F	FGFR4	decrease	1	Y->F: Loss of interaction with PLCG1.	MUTAGEN	0
P22607/A441T	FGFR3	-	0	A -> T (in dbSNP:rs17884368)	VARIANT	2
P22607/A717T	FGFR3	-	0	A -> T (in dbSNP:rs17882190)	VARIANT	1
P22607/C228R	FGFR3	-	1	C -> R (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P22607/D513N	FGFR3	-	1	D -> N (in LADD2; unknown pathological significance; dbSNP:rs121913112)	VARIANT	1
P22607/D646N	FGFR3	-	1	D -> N	VARIANT	0
P22607/E322K	FGFR3	-	1	E -> K (in colorectal cancer; dbSNP:rs121913111)	VARIANT	0
P22607/F384L	FGFR3	neutral	1	F -> L (in dbSNP:rs17881656)	VARIANT	0
P22607/G370C	FGFR3	-	5	G -> C (in KERSEB, BLC, keratinocytic non-epidermolytic nevus and TD1; dbSNP:rs121913479)	VARIANT	0
P22607/G380R	FGFR3	activating	7	G -> R (in keratinocytic non-epidermolytic nevus and ACH; very common mutation; constitutively activated kinase with impaired internalization and degradation, resulting in prolonged FGFR3 signaling; dbSNP:rs28931614)	VARIANT	0
P22607/G65R	FGFR3	-	0	G -> R (in dbSNP:rs2305178)	VARIANT	1
P22607/I538V	FGFR3	-	1	I -> V (in hypochondroplasia; dbSNP:rs80053154)	VARIANT	0
P22607/I726F	FGFR3	-	0	I -> F (in dbSNP:rs17880763)	VARIANT	0
P22607/K508A	FGFR3	loss	2	K->A: Loss of kinase activity. Abolishes ubiquitination.	MUTAGEN	0
P22607/K650D	FGFR3	activating	0	K->D: Constitutively activated kinase.	MUTAGEN	0
P22607/K650E	FGFR3	activating	12	K -> E (in KERSEB, TD2, TGCT and BLC; bladder transitional cell carcinoma; somatic mutation; constitutively activated kinase with impaired internalization and degradation, resulting in prolonged FGFR3 signaling; dbSNP:rs78311289)	VARIANT	28
P22607/K650L	FGFR3	activating	0	K->L: Constitutively activated kinase.	MUTAGEN	0
P22607/K650M	FGFR3	activating	6	K -> M (in KERSEB, ACH, TD1 and SADDAN; constitutively activated kinase with impaired internalization and degradation, resulting in prolonged FGFR3 signaling; dbSNP:rs121913105)	VARIANT	32
P22607/K650Q	FGFR3	activating	3	K -> Q (in hypochondroplasia and BLC; in hypochondroplasia the form is milder than that seen in individuals with the K-540 or M-650 mutations; constitutively activated kinase; dbSNP:rs78311289)	VARIANT	0
P22607/N540K	FGFR3	-	1	N -> K (in hypochondroplasia; dbSNP:rs28933068)	VARIANT	0
P22607/N540S	FGFR3	-	2	N -> S (in hypochondroplasia; mild; dbSNP:rs77722678)	VARIANT	0
P22607/N540T	FGFR3	-	1	N -> T (in hypochondroplasia; dbSNP:rs77722678)	VARIANT	0
P22607/P250R	FGFR3	-	4	P -> R (in MNKS; also some individuals with autosomal dominant congenital sensorineural deafness without craniosynostosis; dbSNP:rs4647924)	VARIANT	0
P22607/R248C	FGFR3	activating	8	R -> C (in KERSEB, BLC, keratinocytic non-epidermolytic nevus and TD1; severe and lethal; also found as somatic mutation in one patient with multiple myeloma; constitutive dimerization and kinase activation; dbSNP:rs121913482)	VARIANT	56
P22607/R621H	FGFR3	-	1	R -> H (in CATSHLS; dbSNP:rs121913113)	VARIANT	2
P22607/S249C	FGFR3	-	5	S -> C (in KERSEB, BLC, cervical cancer and TD1; dbSNP:rs121913483)	VARIANT	28
P22607/S371C	FGFR3	-	2	S -> C (in KERSEB and TD1; dbSNP:rs121913484)	VARIANT	17
P22607/T338M	FGFR3	-	1	T -> M	VARIANT	0
P22607/T79S	FGFR3	-	1	T -> S (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P22607/Y373C	FGFR3	activating	5	Y -> C (in KERSEB and TD1; disulfide-linked dimer with constitutive kinase activation; dbSNP:rs121913485)	VARIANT	26
P22607/Y577F	FGFR3	increase	1	Y->F: Minor effect on kinase activity.	MUTAGEN	0
P22607/Y724F	FGFR3	decrease	1	Y->F: Strongly reduced kinase activity. Strongly reduced mitogen activity.	MUTAGEN	0
P22607/Y760F	FGFR3	increase	1	Y->F: Minor effect on kinase activity.	MUTAGEN	0
P22607/Y770F	FGFR3	increase	1	Y->F: Minor effect on kinase activity. Increased mitogen activity.	MUTAGEN	0
P22612/H268D	PRKACG	neutral	2	H -> D (in dbSNP:rs3730386)	VARIANT	3
P22612/I251N	PRKACG	-	1	I -> N (in dbSNP:rs56287972)	VARIANT	0
P22612/I74M	PRKACG	decrease	1	I -> M (in BDPLT19; patient platelets show impaired activation; dbSNP:rs724159972)	VARIANT	0
P22694/G235R	PRKACB	increase	1	G -> R (in CAFD2; increased sensitivity to cAMP activation; decreased interaction with regulatory subunits PRKAR1A and PRKAR2B)	VARIANT	0
P22694/H88N	PRKACB	-	1	H -> N (in CAFD2)	VARIANT	0
P22694/H88R	PRKACB	increase	1	H -> R (in CAFD2; increased sensitivity to cAMP activation; dbSNP:rs768056300)	VARIANT	0
P22694/R106Q	PRKACB	-	1	R -> Q (in dbSNP:rs36117118)	VARIANT	0
P22694/S54L	PRKACB	-	1	S -> L (in CAFD2; dbSNP:rs1663748771)	VARIANT	0
P23443/G289E	RPS6KB1	-	1	G -> E (in a colorectal cancer sample; somatic mutation)	VARIANT	0
P23443/K167N	RPS6KB1	decrease	1	K->N: Greatly reduces activity. Greatly reduces phosphorylation at T-412 and moderately reduces phosphorylation at T-252.	MUTAGEN	0
P23443/M225I	RPS6KB1	-	1	M -> I	VARIANT	0
P23443/R272C	RPS6KB1	-	1	R -> C (in dbSNP:rs766645749)	VARIANT	0
P23443/S394A	RPS6KB1	loss	1	S->A: Loss of activity. Loss of phosphorylation at T-412.	MUTAGEN	0
P23443/S398A	RPS6KB1	-	1	S -> A	VARIANT	0
P23443/S434E	RPS6KB1	-	1	S->E: Facilitates phosphorylation of T-252 by PDPK1; when associated with E-412; E-441; E-444 and E-447.	MUTAGEN	0
P23443/S441E	RPS6KB1	-	1	S->E: Facilitates phosphorylation of T-252 by PDPK1; when associated with E-412; E-434; E-444 and E-447.	MUTAGEN	0
P23443/S447E	RPS6KB1	-	1	S->E: Facilitates phosphorylation of T-252 by PDPK1; when associated with E-412; E-434; E-441 and E-444.	MUTAGEN	0
P23443/T412E	RPS6KB1	increase	3	T->E: Mimics phosphorylation. Facilitates phosphorylation of T-252 by PDPK1; when associated with E-434; E-441; E-444 and E-447. Mimics phosphorylation. No effect on interaction with PDPK1 and phosphorylation of T-252. Impairs association with the eIF3 complex.	MUTAGEN	0
P23443/T444E	RPS6KB1	-	1	T->E: Facilitates phosphorylation of T-252 by PDPK1; when associated with E-412; E-434; E-441 and E-447.	MUTAGEN	0
P23443/W276C	RPS6KB1	-	1	W -> C	VARIANT	0
P23458/A634D	JAK1	activating	1	A -> D (in AIIDE; constitutive gain of function resulting in increased receptor signaling pathway via JAK-STAT; no effect on protein abundance)	VARIANT	0
P23458/K908A	JAK1	loss	1	K->A: Loss of protein tyrosine kinase activity.	MUTAGEN	0
P23458/N973K	JAK1	-	1	N -> K (in dbSNP:rs34680086)	VARIANT	0
P23458/S703I	JAK1	increase	1	S -> I (in AIIDE; increased activation of protein kinase activity; constitutive gain of function through the transactivation of associated JAK kinases; increased receptor signaling pathway via JAK-STAT)	VARIANT	15
P24723/A19V	PRKCH	neutral	1	A -> V (in dbSNP:rs55645551)	VARIANT	0
P24723/D497Y	PRKCH	-	0	D -> Y (in dbSNP:rs11846991)	VARIANT	0
P24723/D645V	PRKCH	-	0	D -> V (in dbSNP:rs35561533)	VARIANT	0
P24723/K65R	PRKCH	-	1	K -> R (in dbSNP:rs55737090)	VARIANT	0
P24723/P612S	PRKCH	-	1	P -> S (in dbSNP:rs34159231)	VARIANT	0
P24723/R149Q	PRKCH	-	1	R -> Q (in dbSNP:rs55848048)	VARIANT	0
P24723/R359Q	PRKCH	-	1	R -> Q (in dbSNP:rs55818778)	VARIANT	1
P24723/T575A	PRKCH	-	1	T -> A (in a aLLTEL/AML1+ sample; somatic mutation; dbSNP:rs1378993559)	VARIANT	1
P24723/T594I	PRKCH	-	1	T -> I (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P24723/V374I	PRKCH	increase,neutral	2	V -> I (associated with susceptibility to ischemic stroke; increases autophosphorylation and kinase activity; dbSNP:rs2230500)	VARIANT	0
P24941/K9F	CDK2	decrease	1	K->F: Reduced phosphorylation by CAK.	MUTAGEN	0
P24941/L166R	CDK2	decrease	1	L->R: Reduced phosphorylation by CAK and reduced kinase activity.	MUTAGEN	0
P24941/P45L	CDK2	-	1	P -> L (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
P24941/T14A	CDK2	increase	1	T->A: 2-fold increase in activity.	MUTAGEN	0
P24941/T160A	CDK2	loss	1	T->A: Abolishes activity.	MUTAGEN	0
P24941/T290S	CDK2	neutral	1	T -> S (in dbSNP:rs2069413)	VARIANT	0
P24941/V18L	CDK2	-	0	V -> L (in dbSNP:rs11554376)	VARIANT	0
P24941/Y15F	CDK2	increase	1	Y->F: 2-fold increase in activity.	MUTAGEN	0
P24941/Y15S	CDK2	-	0	Y -> S (in dbSNP:rs3087335)	VARIANT	0
P25092/C30R	GUCY2C	-	1	C -> R (in dbSNP:rs56142849)	VARIANT	0
P25092/D387G	GUCY2C	decrease	1	D -> G (in MECIL; activation of guanylate cyclase activity is 60% lower than in wild-type; dbSNP:rs587776905)	VARIANT	0
P25092/E610K	GUCY2C	-	1	E -> K (in dbSNP:rs55897626)	VARIANT	0
P25092/F281L	GUCY2C	-	4	F -> L (in dbSNP:rs1420635)	VARIANT	0
P25092/G61R	GUCY2C	-	1	G -> R (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
P25092/I859V	GUCY2C	-	1	I -> V (in dbSNP:rs34890806)	VARIANT	0
P25092/Q1045R	GUCY2C	-	1	Q -> R (in dbSNP:rs35617837)	VARIANT	1
P25092/R114Q	GUCY2C	neutral	1	R -> Q (in dbSNP:rs56275235)	VARIANT	0
P25092/R464L	GUCY2C	-	1	R -> L (in dbSNP:rs55684775)	VARIANT	0
P25092/S840I	GUCY2C	increase	1	S -> I (in DIAR6; activating mutation; exposure of the mutant receptor to its ligands results in markedly increased production of cyclic guanosine monophosphate; dbSNP:rs587776871)	VARIANT	0
P25098/D10A	GRK2	decrease	1	D->A: 95% reduction in phosphorylation of G-protein coupled receptor rhodopsin and beta-2 adrenergic receptor ADRB2. Does not affect binding to ADRB2. Not activated by receptor binding. No effect on phosphorylation of the non-receptor substrate tubulin.	MUTAGEN	0
P25098/D3A	GRK2	decrease	1	D->A: 85% reduction in phosphorylation of G-protein coupled receptor rhodopsin.	MUTAGEN	0
P25098/D3K	GRK2	decrease	1	D->K: 95% reduction in phosphorylation of G-protein coupled receptor rhodopsin. 60% reduction in phosphorylation of beta-2 adrenergic receptor ADRB2. Does not affect binding to ADRB2. Not activated by receptor binding. No effect on phosphorylation of the non-receptor substrate tubulin.	MUTAGEN	0
P25098/D3N	GRK2	decrease	1	D->N: 60% reduction in phosphorylation of G-protein coupled receptor rhodopsin.	MUTAGEN	0
P25098/E5A	GRK2	decrease	1	E->A: 50% reduction in phosphorylation of G-protein coupled receptor rhodopsin.	MUTAGEN	0
P25098/I184T	GRK2	-	1	I -> T (in dbSNP:rs55696045)	VARIANT	0
P25098/L4A	GRK2	decrease	1	L->A: 95% reduction in phosphorylation of G-protein coupled receptor rhodopsin. 90% reduction in phosphorylation of beta-2 adrenergic receptor ADRB2. Does not affect binding to ADRB2. Not activated by receptor binding. No effect on phosphorylation of the non-receptor substrate tubulin.	MUTAGEN	0
P25098/L4K	GRK2	decrease	1	L->K: 95% reduction in phosphorylation of G-protein coupled receptor rhodopsin.	MUTAGEN	0
P25098/R578Q	GRK2	-	1	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P25440/A212P	BRD2	-	1	A -> P (in dbSNP:rs35952031)	VARIANT	0
P25440/A474V	BRD2	neutral	1	A -> V (in dbSNP:rs3918143)	VARIANT	0
P25440/A49G	BRD2	-	1	A -> G (in dbSNP:rs3918144)	VARIANT	0
P25440/A49S	BRD2	neutral	1	A -> S (in dbSNP:rs55669504)	VARIANT	0
P25440/A569T	BRD2	neutral	1	A -> T (in dbSNP:rs34530779)	VARIANT	0
P25440/A599P	BRD2	neutral	1	A -> P (in dbSNP:rs55952113)	VARIANT	0
P25440/E170A	BRD2	loss	1	E->A: Loss of homodimerization.	MUTAGEN	0
P25440/G30E	BRD2	-	1	G -> E (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	0
P25440/I154A	BRD2	-	1	I->A: Partial loss of homodimerization; when associated with A-182.	MUTAGEN	0
P25440/L174E	BRD2	loss	1	L->E: Loss of homodimerization.	MUTAGEN	0
P25440/L238F	BRD2	neutral	2	L -> F (in dbSNP:rs176250)	VARIANT	0
P25440/P260Q	BRD2	-	1	P -> Q (in dbSNP:rs35294809)	VARIANT	0
P25440/P714L	BRD2	-	1	P -> L (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	0
P25440/Q182A	BRD2	-	1	Q->A: Partial loss of homodimerization; when associated with A-154.	MUTAGEN	0
P25440/Q78A	BRD2	loss	1	Q->A: Loss of homodimerization.	MUTAGEN	0
P25440/R547K	BRD2	-	0	R -> K (in dbSNP:rs1049369)	VARIANT	0
P25440/R558G	BRD2	-	1	R -> G (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	0
P25440/V177E	BRD2	loss	1	V->E: Loss of homodimerization.	MUTAGEN	0
P25440/Y153K	BRD2	loss	1	Y->K: Loss of homodimerization.	MUTAGEN	0
P27037/A367T	ACVR2A	-	1	A -> T (found in a clear cell renal carcinoma case; somatic mutation)	VARIANT	0
P27037/D306N	ACVR2A	-	1	D -> N (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs764255410)	VARIANT	1
P27037/S258R	ACVR2A	-	1	S -> R (in dbSNP:rs34917571)	VARIANT	0
P27361/E323K	MAPK3	-	1	E -> K (in dbSNP:rs55859133)	VARIANT	0
P27361/K168R	MAPK3	-	1	K->R: Complete loss of ubiquitination by TRIM15; when associated with R-302.	MUTAGEN	0
P27361/K302R	MAPK3	-	1	K->R: Complete loss of ubiquitination by TRIM15; when associated with R-168.	MUTAGEN	0
P27448/R570G	MARK3	-	1	R -> G (in VIPB; dbSNP:rs376395495)	VARIANT	0
P27448/S410F	MARK3	-	0	S -> F (in dbSNP:rs10137161)	VARIANT	0
P27448/S443G	MARK3	neutral	2	S -> G (in dbSNP:rs56305318)	VARIANT	0
P27448/T211A	MARK3	loss	1	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
P27448/V429A	MARK3	-	1	V -> A	VARIANT	0
P28482/A174V	MAPK1	increase	1	A -> V (in NS13; results in increased MAPK signaling; increased translocation to the nucleus; reduced interaction wth DUSP6; no effect on interaction with MAP2K1)	VARIANT	0
P28482/D318A	MAPK1	increase	2	D->A: Loss of dephosphorylation by PTPRJ.	MUTAGEN	0
P28482/D318G	MAPK1	increase	1	D -> G (in NS13; results in increased MAPK signaling; increased translocation to the nucleus; reduced interaction wth DUSP6; no effect on interaction with MAP2K1)	VARIANT	0
P28482/D318N	MAPK1	-	2	D->N: Inhibits interaction with MAP2K1 but not with TPR; when associated with N-321.	VARIANT	0
P28482/D321N	MAPK1	-	1	D->N: Inhibits interaction with MAP2K1 but not with TPR; when associated with N-318.	MUTAGEN	1
P28482/E322Q	MAPK1	-	1	E -> Q (in NS13)	VARIANT	0
P28482/H80Y	MAPK1	increase	1	H -> Y (in NS13; results in increased MAPK signaling; reduced interaction wth DUSP6; no effect on interaction with MAP2K1)	VARIANT	0
P28482/I74N	MAPK1	increase	1	I -> N (in NS13; results in increased MAPK signaling; reduced interaction wth DUSP6; no effect on interaction with MAP2K1)	VARIANT	0
P28482/K54R	MAPK1	-	1	K->R: Does not inhibit interaction with MAP2K1.	MUTAGEN	0
P28482/L234A	MAPK1	-	1	L->A: Inhibits interaction with TPR.	MUTAGEN	0
P28482/P323R	MAPK1	increase	1	P -> R (in NS13; results in increased MAPK signaling; increased translocation to the nucleus; reduced interaction wth DUSP6; no effect on interaction with MAP2K1)	VARIANT	0
P28482/T185A	MAPK1	-	1	T->A: Inhibits interaction with TPR; when associated with A-187.	MUTAGEN	0
P28482/Y187A	MAPK1	-	1	Y->A: Inhibits interaction with TPR; when associated with A-185.	MUTAGEN	0
P29317/D739N	EPHA2	increase	1	D->N: Increases serum-induced chemotaxis. Loss of EFNA1-dependent regulation of cell migration.	MUTAGEN	0
P29317/G391R	EPHA2	neutral	1	G -> R (in dbSNP:rs34192549)	VARIANT	0
P29317/G777S	EPHA2	-	1	G -> S (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs922655349)	VARIANT	1
P29317/G948W	EPHA2	-	2	G -> W (in CTRCT6; reduced protein stability and reduced ability to stimulate cell migration in absence of its ephrin ligand; dbSNP:rs137853199)	VARIANT	0
P29317/K646M	EPHA2	loss	1	K->M: Loss of kinase activity.	MUTAGEN	0
P29317/K99N	EPHA2	-	0	K -> N (in dbSNP:rs1058372)	VARIANT	0
P29317/M631T	EPHA2	neutral	0	M -> T (in dbSNP:rs34021505)	VARIANT	0
P29317/R103E	EPHA2	decrease	1	R->E: Significantly reduced response to EFNA1.	MUTAGEN	0
P29317/R568H	EPHA2	-	1	R -> H (in dbSNP:rs56198600)	VARIANT	1
P29317/R721Q	EPHA2	activating	1	R -> Q (in CTRCT6; retained in the cytoplasm and constitutively active it alters EPHA2 signaling; dbSNP:rs116506614)	VARIANT	1
P29317/R876H	EPHA2	neutral	1	R -> H (in dbSNP:rs35903225)	VARIANT	0
P29317/S897A	EPHA2	-	1	S->A,D: Loss of serum-induced phosphorylation by PKB. Loss of serum-induced chemotaxis.	MUTAGEN	0
P29317/S897D	EPHA2	loss	1	S->A,D: Loss of serum-induced phosphorylation by PKB. Loss of serum-induced chemotaxis.	MUTAGEN	0
P29317/T511M	EPHA2	neutral	1	T -> M (in dbSNP:rs55747232)	VARIANT	3
P29317/T940I	EPHA2	-	2	T -> I (in CTRCT6; reduced protein stability and reduced ability to stimulate cell migration in absence of its ephrin ligand; dbSNP:rs137853200)	VARIANT	0
P29320/A777G	EPHA3	-	1	A -> G (in dbSNP:rs34437982)	VARIANT	0
P29320/C568S	EPHA3	-	1	C -> S (in dbSNP:rs56077781)	VARIANT	1
P29320/D806N	EPHA3	-	1	D -> N (in a colorectal cancer sample; somatic mutation)	VARIANT	1
P29320/F152L	EPHA3	loss	1	F->L: Loss of EFNA5-binding ability and function.	MUTAGEN	0
P29320/G518L	EPHA3	-	1	G -> L (in a lung squamous cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions)	VARIANT	0
P29320/G766E	EPHA3	-	1	G -> E (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P29320/I564V	EPHA3	neutral	1	I -> V (in dbSNP:rs55712516)	VARIANT	0
P29320/I621L	EPHA3	-	1	I -> L (in a colorectal cancer sample; somatic mutation; dbSNP:rs1414714315)	VARIANT	0
P29320/K207N	EPHA3	-	1	K -> N (in a pancreatic ductal adenocarcinoma sample; somatic mutation; dbSNP:rs200567888)	VARIANT	1
P29320/L590P	EPHA3	-	1	L -> P (in dbSNP:rs56081642)	VARIANT	1
P29320/N85S	EPHA3	-	1	N -> S (in a colorectal cancer sample; somatic mutation)	VARIANT	0
P29320/R914H	EPHA3	-	1	R -> H (in dbSNP:rs17801309)	VARIANT	1
P29320/S229Y	EPHA3	-	1	S -> Y (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
P29320/S449F	EPHA3	-	1	S -> F (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
P29320/S768A	EPHA3	-	1	S->A: Full kinase activity; when associated with F-596 and F-602.	MUTAGEN	0
P29320/T37K	EPHA3	-	1	T -> K (in a colorectal cancer sample; somatic mutation)	VARIANT	0
P29320/T660K	EPHA3	-	1	T -> K (in a lung carcinoma sample; somatic mutation)	VARIANT	0
P29320/T933M	EPHA3	-	1	T -> M (in a lung carcinoma sample; somatic mutation; dbSNP:rs372594677)	VARIANT	2
P29320/V133E	EPHA3	loss	1	V->E: Loss of EFNA5-binding ability and function.	MUTAGEN	0
P29320/W924R	EPHA3	neutral	2	W -> R (in dbSNP:rs35124509)	VARIANT	0
P29320/Y596F	EPHA3	-	1	Y->F: 10-fold suppression of kinase activity; when associated with F-602. Full kinase activity; when associated with F-602 and F-742. Full kinase activity; when associated with F-602 and A-768.	MUTAGEN	0
P29320/Y602F	EPHA3	-	1	Y->F: 10-fold suppression of kinase activity; when associated with F-596. Full kinase activity; when associated with F-596 and F-742. Full kinase activity; when associated with F-596 and A-768.	MUTAGEN	0
P29320/Y742F	EPHA3	-	1	Y->F: Full kinase activity; when associated with F-596 and F-602.	MUTAGEN	0
P29322/E612Q	EPHA8	neutral	1	E -> Q (in dbSNP:rs999765)	VARIANT	7
P29322/G45S	EPHA8	neutral	1	G -> S (in dbSNP:rs45498698)	VARIANT	0
P29322/N123K	EPHA8	-	1	N -> K (in a breast infiltrating ductal carcinoma sample; somatic mutation)	VARIANT	1
P29322/P321L	EPHA8	neutral	0	P -> L (in dbSNP:rs56656925)	VARIANT	0
P29322/P860L	EPHA8	-	1	P -> L (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
P29322/R179C	EPHA8	-	1	R -> C (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1557556639)	VARIANT	3
P29322/R198L	EPHA8	-	1	R -> L (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P29322/V444M	EPHA8	-	0	V -> M (in dbSNP:rs2295021)	VARIANT	0
P29322/V60L	EPHA8	-	1	V -> L (in dbSNP:rs56402644)	VARIANT	0
P29323/A279S	EPHB2	-	3	A -> S (in prostate cancer; dbSNP:rs35882952)	VARIANT	0
P29323/C289G	EPHB2	-	1	C -> G	VARIANT	0
P29323/D678N	EPHB2	-	1	D -> N (in dbSNP:rs28936395)	VARIANT	0
P29323/H679N	EPHB2	-	1	H -> N (in prostate cancer)	VARIANT	0
P29323/I361V	EPHB2	-	1	I -> V (in dbSNP:rs56180036)	VARIANT	0
P29323/I909M	EPHB2	-	1	I -> M (in prostate cancer)	VARIANT	0
P29323/K787R	EPHB2	-	1	K->R: No loss of ubiquitination by RNF186.	MUTAGEN	0
P29323/K891R	EPHB2	-	1	K->R: Complete loss of ubiquitination by RNF186.	MUTAGEN	0
P29323/M883V	EPHB2	-	1	M -> V (in prostate cancer; dbSNP:rs372653137)	VARIANT	0
P29323/R199H	EPHB2	-	1	R -> H (in prostate cancer; dbSNP:rs201754821)	VARIANT	0
P29323/R745C	EPHB2	-	1	R -> C (in BDPLT22; dbSNP:rs761749948)	VARIANT	0
P29323/R844W	EPHB2	-	1	R -> W (in dbSNP:rs55826626)	VARIANT	2
P29323/V650A	EPHB2	-	1	V -> A (in prostate cancer; dbSNP:rs142173175)	VARIANT	0
P29376/C384R	LTK	-	1	C -> R (in dbSNP:rs55683312)	VARIANT	1
P29376/D535N	LTK	neutral	1	D -> N (in dbSNP:rs35932273)	VARIANT	0
P29376/E763K	LTK	increase	1	E -> K (may possibly contribute to susceptibility to systemic lupus erythematosus; increases autophosphorylation and interaction with PI3-kinase subunit p85; dbSNP:rs76282169)	VARIANT	1
P29376/G750E	LTK	increase	1	G->E: Increases autophosphorylation and interaction with PI3-kinase subunit p85 (demonstrated with chimeric EGFR-LTK).	MUTAGEN	0
P29376/K544M	LTK	loss	1	K->M: Loss of interaction with PLCG1, PI3-kinase subunit p85, Ras GTPase-activating protein and RAF1.	MUTAGEN	0
P29376/P745S	LTK	-	1	P -> S (in dbSNP:rs55900837)	VARIANT	0
P29376/P838S	LTK	-	1	P -> S (in dbSNP:rs56367146)	VARIANT	0
P29376/R241A	LTK	loss	1	R->A: Abolished homodimerization following interaction with ALKAL1.	MUTAGEN	0
P29376/R42Q	LTK	neutral	2	R -> Q (in dbSNP:rs2305030)	VARIANT	0
P29376/R569S	LTK	neutral	1	R -> S (in dbSNP:rs148513655)	VARIANT	0
P29376/R673Q	LTK	-	1	R -> Q (in dbSNP:rs55876255)	VARIANT	0
P29376/Y753F	LTK	loss	1	Y->F: Abolishes interaction with PI3-kinase subunit p85, impairs PI3 kinase activity and leads to apoptosis (demonstrated with chimeric EGFR-LTK).	MUTAGEN	0
P29376/Y862F	LTK	decrease	1	Y->F: Impairs phosphorylation of CBLC (demonstrated with chimeric EGFR-LTK).	MUTAGEN	0
P29597/A81V	TYK2	-	0	A -> V (in dbSNP:rs1049619)	VARIANT	0
P29597/A928V	TYK2	neutral	1	A -> V (in dbSNP:rs35018800)	VARIANT	0
P29597/D1023N	TYK2	loss	1	D->N: Complete loss of catalytic activity.	MUTAGEN	0
P29597/E1163G	TYK2	neutral	1	E -> G (in dbSNP:rs55886939)	VARIANT	0
P29597/G363S	TYK2	neutral	1	G -> S (in dbSNP:rs2304255)	VARIANT	0
P29597/H732R	TYK2	-	1	H -> R (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P29597/I684S	TYK2	-	2	I -> S (in dbSNP:rs12720356)	VARIANT	4
P29597/K930R	TYK2	loss	1	K->R: Complete loss of catalytic activity.	MUTAGEN	0
P29597/P1104A	TYK2	neutral	1	P -> A (in dbSNP:rs34536443)	VARIANT	0
P29597/P820H	TYK2	neutral	0	P -> H (in dbSNP:rs34046749)	VARIANT	0
P29597/R197H	TYK2	neutral	0	R -> H (in dbSNP:rs12720263)	VARIANT	0
P29597/R442Q	TYK2	-	0	R -> Q (in dbSNP:rs2304254)	VARIANT	0
P29597/R4H	TYK2	-	0	R -> H (in dbSNP:rs12720343)	VARIANT	0
P29597/R703W	TYK2	-	1	R -> W (in dbSNP:rs55882956)	VARIANT	0
P29597/V362F	TYK2	neutral	2	V -> F (in dbSNP:rs2304256)	VARIANT	15
P29597/V386M	TYK2	-	1	V -> M (in dbSNP:rs55956017)	VARIANT	0
P29597/Y1054F	TYK2	decrease	1	Y->F: Reduces basal catalytic activity and abolishes IFN-dependent activation.	MUTAGEN	0
P29597/Y1055F	TYK2	decrease	1	Y->F: Reduces basal catalytic activity and abolishes IFN-dependent activation.	MUTAGEN	0
P29597/Y1145F	TYK2	-	1	Y->F: Does not affect phosphorylation state and enzymatic activity.	MUTAGEN	0
P29597/Y1176F	TYK2	-	1	Y->F: Does not affect phosphorylation state and enzymatic activity.	MUTAGEN	0
P30291/G210C	WEE1	neutral	1	G -> C (in dbSNP:rs34412975)	VARIANT	2
P30291/K328R	WEE1	loss	1	K->R: Abolishes activity.	MUTAGEN	0
P30291/S123A	WEE1	-	1	S->A: Abolishes phosphorylation by PLK1 and CDK1 and binding of the SCF(BTRC) complex, leading to stabilization of the protein; when associated with A-53.	MUTAGEN	0
P30291/S472I	WEE1	-	1	S -> I (in dbSNP:rs56411856)	VARIANT	0
P30291/S53A	WEE1	-	1	S->A: Abolishes phosphorylation by PLK1 and CDK1 and binding of the SCF(BTRC) complex, leading to stabilization of the protein; when associated with A-123.	MUTAGEN	0
P30291/S642A	WEE1	loss	1	S->A: Abolishes phosphorylation by BRSK1 and BRSK2.	MUTAGEN	0
P30530/D266N	AXL	-	0	D -> N (in dbSNP:rs7249222)	VARIANT	0
P30530/E63R	AXL	decrease	1	E->R: Slightly reduced affinity for GAS6.	MUTAGEN	0
P30530/E66R	AXL	decrease	1	E->R: Reduced affinity for GAS6.	MUTAGEN	0
P30530/K567M	AXL	loss	1	K->M: Catalytically inactive mutant.	MUTAGEN	0
P30530/R295W	AXL	-	1	R -> W (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs751738506)	VARIANT	3
P30530/R499C	AXL	-	1	R -> C (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs747576071)	VARIANT	0
P30530/S515G	AXL	-	1	S -> G (in dbSNP:rs1240393707)	VARIANT	0
P30530/T112M	AXL	-	1	T -> M (in dbSNP:rs35202236)	VARIANT	0
P30530/T84R	AXL	decrease	1	T->R: Reduced affinity for GAS6.	MUTAGEN	0
P31152/R371P	MAPK4	-	1	R -> P (in dbSNP:rs3752089)	VARIANT	0
P31152/V38M	MAPK4	neutral	2	V -> M (in dbSNP:rs3752087)	VARIANT	0
P31749/K14A	AKT1	decrease	3	K->A: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.	MUTAGEN	0
P31749/K14Q	AKT1	decrease	3	K->Q: Substantial reduction of phosphorylation at T-308 and S-473, loss of AKT activation, and loss of binding to PIP3 as well as IGF1-induced membrane recruitment.	MUTAGEN	0
P31749/K14R	AKT1	decrease	3	K->R: Substantial reduction of ubiquitination, phosphorylation at T-308 and S-473, AKT activation, loss of binding to PIP3 as well as IGF1-induced membrane recruitment.	MUTAGEN	0
P31749/K179M	AKT1	loss	1	K->M: Abolished serine/threonine-protein kinase activity.	MUTAGEN	0
P31749/K20Q	AKT1	-	1	K->Q: Substantial reduction of phosphorylation at T-308 and S-473, reduced AKT activation, and reduced binding to PIP3 as well as IGF1-induced membrane recruitment. Loss of membrane localization; when associated with K-17.	MUTAGEN	0
P31749/K20R	AKT1	increase	1	K->R: Slight increase of phosphorylation at T-308 and S-473.	MUTAGEN	0
P31749/K8R	AKT1	-	1	K->R: Substantial reduction of ubiquitination, phosphorylation at T-308 and S-473, AKT activation as well as IGF1-induced membrane recruitment. Decrease in ubiquitination and phosphorylation at T-308 as well as impaired association with the membrane; when associated with K-17.	MUTAGEN	0
P31749/R25A	AKT1	decrease	1	R->A,C: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.	MUTAGEN	0
P31749/R25C	AKT1	decrease	1	R->A,C: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.	VARIANT	0
P31749/R86A	AKT1	decrease	1	R->A: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.	MUTAGEN	0
P31749/T305A	AKT1	increase	1	T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc levels even more; when associated with A-312.	MUTAGEN	0
P31749/T305Y	AKT1	loss	1	T->Y: Abolishes phosphorylation at Thr-308.	MUTAGEN	0
P31749/T312A	AKT1	increase	1	T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc levels even more; when associated with A-305.	MUTAGEN	0
P31749/T312Y	AKT1	loss	1	T->Y: Abolishes phosphorylation at Thr-308.	MUTAGEN	0
P31749/T435P	AKT1	-	1	T -> P (in CWS6; dbSNP:rs397514645)	VARIANT	0
P31749/V167A	AKT1	-	0	V -> A (in dbSNP:rs11555433)	VARIANT	0
P31749/Y176F	AKT1	decrease	1	Y->F: Significant loss of interaction with TNK2. Loss of membrane localization. Significant reduction in phosphorylation on Ser-473.	MUTAGEN	0
P31749/Y474F	AKT1	decrease	1	Y->F: 55% inhibition of activation.	MUTAGEN	0
P31751/E17K	AKT2	activating	1	E -> K (in HIHGHH; exhibits plasma membrane localization in serum-starved cells and produced inappropriate tonic nuclear exclusion of FOXO1 in preadipocytes; dbSNP:rs387906659)	VARIANT	13
P31751/I188V	AKT2	-	1	I -> V (in dbSNP:rs55859611)	VARIANT	0
P31751/R208K	AKT2	-	1	R -> K (in dbSNP:rs35817154)	VARIANT	0
P31751/R274H	AKT2	increase	2	R -> H (in T2D; associated with typical metabolic dyslipidemia with elevated fastin triglyceride, high VLDL triglyceride/cholesterol ratios, low HDL cholesterol levels and high small dense LDL levels; de novo lipogenesis and liver fat are also significantly elevated in this subject; dbSNP:rs121434593)	VARIANT	0
P31751/S474A	AKT2	-	2	S->A: Impairs interaction with TTC3; when associated with A-309.	MUTAGEN	0
P31751/S474D	AKT2	-	2	S->D: Constitutively active; when associated with E-309.	MUTAGEN	0
P31751/T309A	AKT2	-	2	T->A: Impairs interaction with TTC3; when associated with A-474.	MUTAGEN	0
P31751/T309E	AKT2	-	2	T->E: Constitutively active; when associated with D-474.	MUTAGEN	0
P32298/A116T	GRK4	neutral	1	A -> T (in dbSNP:rs34857805)	VARIANT	0
P32298/A142V	GRK4	neutral	1	A -> V (in dbSNP:rs1024323)	VARIANT	0
P32298/A440V	GRK4	-	0	A -> V (in dbSNP:rs747003103)	VARIANT	1
P32298/A495T	GRK4	-	1	A -> T (in dbSNP:rs35463176)	VARIANT	0
P32298/D95H	GRK4	-	0	D -> H (in dbSNP:rs13305979)	VARIANT	0
P32298/H383Q	GRK4	-	1	H -> Q (in dbSNP:rs55852353)	VARIANT	0
P32298/L425P	GRK4	-	1	L -> P	VARIANT	0
P32298/R65L	GRK4	neutral	1	R -> L (in dbSNP:rs2960306)	VARIANT	0
P32298/T183R	GRK4	-	0	T -> R (in dbSNP:rs45538934)	VARIANT	0
P32298/V247I	GRK4	-	1	V -> I (in dbSNP:rs1140085)	VARIANT	0
P32298/V473I	GRK4	-	1	V -> I (in dbSNP:rs35024854)	VARIANT	0
P32298/V486A	GRK4	neutral	6	V -> A (in dbSNP:rs1801058)	VARIANT	0
P33981/A97V	TTK	neutral	0	A -> V (in dbSNP:rs2230513)	VARIANT	0
P33981/D664A	TTK	loss	2	D->A: Loss of kinase activity.	MUTAGEN	0
P33981/D758N	TTK	-	0	D -> N (in dbSNP:rs2230512)	VARIANT	0
P33981/T686A	TTK	loss	1	T->A: Loss of kinase activity.	MUTAGEN	0
P34925/A485G	RYK	increase	1	A->G: Gain of an autophosphorylation activity. Gain of an autophosphorylation activity; when associated with G-334 and F-481.	MUTAGEN	0
P34925/K364A	RYK	-	1	K->A: No induction of the MAPK pathway.	MUTAGEN	0
P34925/N484F	RYK	increase	1	N->F: Gain of an autophosphorylation activity. Gain of an autophosphorylation activity; when associated with A-359. Gain of an autophosphorylation activity; when associated with G-334 and G-482.	MUTAGEN	0
P34925/R227C	RYK	-	1	R -> C (in dbSNP:rs55740278)	VARIANT	2
P34925/S99N	RYK	neutral	4	S -> N (in dbSNP:rs1131262)	VARIANT	1
P34925/V243I	RYK	-	1	V -> I (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs746238409)	VARIANT	0
P34947/A119V	GRK5	neutral	1	A -> V (in dbSNP:rs55980792)	VARIANT	0
P34947/D163E	GRK5	-	1	D -> E (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
P34947/F555A	GRK5	-	1	F->A: No detectable plasma membrane localization; when associated with A-550; A-551; and A-554.	MUTAGEN	0
P34947/G122S	GRK5	-	1	G -> S (in dbSNP:rs55902633)	VARIANT	0
P34947/K215R	GRK5	decrease	1	K->R: Failed to phosphorylate p53/TP53.	MUTAGEN	0
P34947/K389A	GRK5	-	1	K->A: Nuclear exclusion; when associated with A-388; A-391; A-393 and A-394.	MUTAGEN	0
P34947/K391A	GRK5	-	1	K->A: Nuclear exclusion; when associated with A-388; A-389; A-393 and A-394.	MUTAGEN	0
P34947/K393A	GRK5	-	1	K->A: Nuclear exclusion; when associated with A-388; A-389; A-391 and A-394.	MUTAGEN	0
P34947/L141I	GRK5	neutral	1	L -> I (in dbSNP:rs56254855)	VARIANT	0
P34947/L550A	GRK5	-	1	L->A: No detectable plasma membrane localization; when associated with A-551; A-554; and A-555.	MUTAGEN	0
P34947/L551A	GRK5	-	1	L->A: No detectable plasma membrane localization; when associated with A-550; A-554; and A-555.	MUTAGEN	0
P34947/L554A	GRK5	-	1	L->A: No detectable plasma membrane localization; when associated with A-550; A-551; and A-555.	MUTAGEN	0
P34947/Q41L	GRK5	neutral	2	Q -> L (exerts a protective effect in heart failure and ischemia; dbSNP:rs2230345)	VARIANT	0
P34947/R304H	GRK5	neutral	1	R -> H (in dbSNP:rs2230349)	VARIANT	2
P34947/R388A	GRK5	-	1	R->A: Nuclear exclusion; when associated with A-389; A-391; A-393 and A-394.	MUTAGEN	0
P34947/R394A	GRK5	-	1	R->A: Nuclear exclusion; when associated with A-388; A-389; A-391 and A-393.	MUTAGEN	0
P34947/S484A	GRK5	-	1	S->A: 15-20 fold defects in kinase activity; when associated with A-485.	MUTAGEN	0
P34947/T129M	GRK5	-	1	T -> M (in dbSNP:rs34679178)	VARIANT	1
P34947/T485A	GRK5	-	1	T->A: 15-20 fold defects in kinase activity; when associated with A-484.	MUTAGEN	0
P35590/A1104V	TIE1	-	1	A -> V (in dbSNP:rs35573981)	VARIANT	0
P35590/E1061K	TIE1	-	1	E -> K (in LMPHM11; unknown pathological significance; dbSNP:rs760492428)	VARIANT	0
P35590/R1109H	TIE1	-	2	R -> H (in LMPHM11; unknown pathological significance; dbSNP:rs34993202)	VARIANT	0
P35590/R481C	TIE1	-	1	R -> C (in LMPHM11; unknown pathological significance; dbSNP:rs139244400)	VARIANT	0
P35590/V448M	TIE1	-	1	V -> M (in dbSNP:rs56302794)	VARIANT	0
P35626/N60S	GRK3	-	1	N -> S (in dbSNP:rs55740593)	VARIANT	0
P35626/R104K	GRK3	-	1	R -> K (in a lung bronchoalveolar carcinoma sample; somatic mutation)	VARIANT	0
P35626/R50S	GRK3	-	1	R -> S (in dbSNP:rs55700971)	VARIANT	0
P35626/V409M	GRK3	-	0	V -> M (in dbSNP:rs2272859)	VARIANT	0
P35916/A855T	FLT4	decrease	1	A -> T (in LMPHM1; recessive form; results in reduced autophosphorylation; results in impaired ligand-induced receptor internalization and downstream signaling; dbSNP:rs121909657)	VARIANT	0
P35916/D1049N	FLT4	-	1	D -> N (in dbSNP:rs56310180)	VARIANT	1
P35916/E1106K	FLT4	-	1	E -> K (in LMPHM1; dbSNP:rs121909656)	VARIANT	0
P35916/G857R	FLT4	loss	2	G -> R (in LMPHM1; loss of kinase activity; dbSNP:rs267606818)	VARIANT	0
P35916/H1035Q	FLT4	-	1	H -> Q (probable disease-associated variant found in sporadic congenital lymphedema; de novo mutation)	VARIANT	0
P35916/H1035R	FLT4	loss	1	H -> R (in LMPHM1; loss of kinase activity; dbSNP:rs121909653)	VARIANT	0
P35916/H868Y	FLT4	-	1	H -> Y (in dbSNP:rs35171798)	VARIANT	1
P35916/H890Q	FLT4	neutral	3	H -> Q (in dbSNP:rs448012)	VARIANT	2
P35916/I1086T	FLT4	-	1	I -> T (in LMPHM1; dbSNP:rs121909655)	VARIANT	0
P35916/K516A	FLT4	-	1	K->A: Decreases autophosphorylation on tyrosine residues upon ligand binding; when associated with E-446. Abolishes autophosphorylation on tyrosine residues upon ligand binding; when associated with E-446 and A-737.	MUTAGEN	0
P35916/K879G	FLT4	loss	1	K->G: Abolishes enzyme activity.	MUTAGEN	0
P35916/L1044P	FLT4	loss	1	L -> P (in LMPHM1; loss of kinase activity; dbSNP:rs121909651)	VARIANT	0
P35916/L1173V	FLT4	-	1	L -> V (in CHTD7; unknown pathological significance)	VARIANT	0
P35916/N149D	FLT4	neutral	1	N -> D (in dbSNP:rs34221241)	VARIANT	6
P35916/N527S	FLT4	neutral	1	N -> S (in dbSNP:rs35874891)	VARIANT	0
P35916/P1114L	FLT4	loss	2	P -> L (in LMPHM1; loss of kinase activity; dbSNP:rs121909652)	VARIANT	1
P35916/P1137S	FLT4	-	1	P -> S (in HCI)	VARIANT	0
P35916/P641S	FLT4	neutral	2	P -> S (in dbSNP:rs55667289)	VARIANT	2
P35916/P954S	FLT4	-	1	P -> S (in HCI; dbSNP:rs34255532)	VARIANT	4
P35916/Q1020L	FLT4	-	1	Q -> L (in LMPHM1)	VARIANT	0
P35916/R1031Q	FLT4	-	1	R -> Q (in dbSNP:rs56082504)	VARIANT	1
P35916/R1041P	FLT4	loss	2	R -> P (in LMPHM1; loss of kinase activity; dbSNP:rs121909650)	VARIANT	0
P35916/R1075Q	FLT4	-	1	R -> Q (in dbSNP:rs1400220848)	VARIANT	2
P35916/R1146H	FLT4	neutral	3	R -> H (in dbSNP:rs1130379)	VARIANT	5
P35916/R378C	FLT4	-	1	R -> C (in a renal clear cell carcinoma sample; somatic mutation; dbSNP:rs372947534)	VARIANT	2
P35916/R737A	FLT4	-	1	R->A: Decreases autophosphorylation on tyrosine residues upon ligand binding. Abolishes autophosphorylation on tyrosine residues upon ligand binding; when associated with E-446 and A-516.	MUTAGEN	0
P35916/S1235C	FLT4	-	1	S -> C (in LMPHM1; recessive form)	VARIANT	0
P35916/T1010I	FLT4	-	1	T -> I (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
P35916/T446E	FLT4	-	1	T->E: Decreases autophosphorylation on tyrosine residues upon ligand binding; when associated with A-516. Abolishes autophosphorylation on tyrosine residues upon ligand binding; when associated with A-516 and A-737.	MUTAGEN	0
P35916/T494A	FLT4	neutral	2	T -> A (in dbSNP:rs307826)	VARIANT	2
P35916/V878M	FLT4	-	1	V -> M (in LMPHM1; dbSNP:rs121909654)	VARIANT	0
P35916/Y1063F	FLT4	-	2	Y->F: Loss of phosphorylation site. No effect on stimulation of cell proliferation and cell migration.	MUTAGEN	0
P35916/Y1068F	FLT4	loss	2	Y->F: Global loss of autophosphorylation. Abolishes stimulation of cell proliferation and cell migration.	MUTAGEN	0
P35916/Y1230F	FLT4	decrease	2	Y->F: Loss of phosphorylation site. Strongly reduces stimulation of cell proliferation and cell migration.	MUTAGEN	0
P35916/Y1231F	FLT4	decrease	2	Y->F: Loss of phosphorylation site. Strongly reduces stimulation of cell proliferation and cell migration.	MUTAGEN	0
P35916/Y1265F	FLT4	-	1	Y->F: Loss of phosphorylation site. No effect on stimulation of cell proliferation and cell migration.	MUTAGEN	0
P35916/Y1333F	FLT4	decrease	2	Y->F: Loss of phosphorylation site. Reduced autophosphorylation.	MUTAGEN	0
P35916/Y1337F	FLT4	decrease	3	Y->F: Reduced autophosphorylation. Strongly reduces stimulation of cell proliferation and cell migration.	MUTAGEN	0
P35968/A1065T	KDR	-	1	A -> T (in dbSNP:rs56302315)	VARIANT	4
P35968/A248G	KDR	-	1	A -> G (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	0
P35968/C1045A	KDR	increase	1	C->A: Significantly higher kinase activity.	MUTAGEN	0
P35968/C482R	KDR	decrease	2	C -> R (in HCI; associated with disease susceptibility; expression of FLT1 in hemangioma endothelial cells is markedly reduced and KDR activity is increased compared to controls; low FLT1 expression in hemangioma cells is caused by reduced activity of a pathway involving ITGB1, ANTXR1, KDR and NFATC2IP; the mutation predicts to result in loss-of-function and disruption of the normal association of these molecules; dbSNP:rs34231037)	VARIANT	6
P35968/D731A	KDR	decrease	1	D->A: Strongly reduced autophosphorylation and activation of MAP kinases.	MUTAGEN	0
P35968/D814N	KDR	-	1	D -> N (in dbSNP:rs35603373)	VARIANT	0
P35968/G539R	KDR	-	1	G -> R (in dbSNP:rs55716939)	VARIANT	1
P35968/G873R	KDR	-	1	G -> R (in a colorectal cancer sample; somatic mutation)	VARIANT	0
P35968/K868M	KDR	loss	1	K->M: Loss of enzyme activity.	MUTAGEN	0
P35968/L462V	KDR	-	1	L -> V (in dbSNP:rs56286620)	VARIANT	0
P35968/P1147S	KDR	-	1	P -> S (in HCI; somatic mutation; dbSNP:rs121917766)	VARIANT	0
P35968/Q472H	KDR	neutral	2	Q -> H (in dbSNP:rs1870377)	VARIANT	67
P35968/R275L	KDR	-	1	R -> L (in a colorectal cancer sample; somatic mutation)	VARIANT	0
P35968/R726A	KDR	decrease	1	R->A: Strongly reduced autophosphorylation and activation of MAP kinases.	MUTAGEN	0
P35968/T689M	KDR	neutral	1	T -> M (in dbSNP:rs34038364)	VARIANT	3
P35968/V136M	KDR	-	1	V -> M (in dbSNP:rs35636987)	VARIANT	0
P35968/V297I	KDR	neutral	1	V -> I (in dbSNP:rs2305948)	VARIANT	19
P35968/V848E	KDR	decrease	2	V -> E (strongly reduced autophosphorylation and kinase activity; dbSNP:rs1139776)	VARIANT	0
P35968/V952I	KDR	-	0	V -> I (in dbSNP:rs13129474)	VARIANT	1
P35968/Y1054F	KDR	-	1	Y->F: Strongly reduced autophosphorylation. Abolishes phosphorylation of downstream signaling proteins; when associated with F-1059.	MUTAGEN	0
P35968/Y1059F	KDR	-	1	Y->F: Strongly reduced autophosphorylation. Abolishes phosphorylation of downstream signaling proteins; when associated with F-1054.	MUTAGEN	0
P35968/Y1175F	KDR	loss	1	Y->F: Abolishes phosphorylation of PLCG1 and MAP kinases in response to VEGFA.	MUTAGEN	0
P35968/Y1214F	KDR	loss	1	Y->F: Loss of phosphorylation site. Abolishes reorganization of the actin cytoskeleton in response to VEGFA.	MUTAGEN	0
P35968/Y801F	KDR	loss	1	Y->F: Abolishes stimulation of nitric oxide synthesis.	MUTAGEN	0
P35968/Y951F	KDR	loss	1	Y->F: Abolishes reorganization of the actin cytoskeleton and cell migration in response to VEGFA.	MUTAGEN	0
P35968/Y996F	KDR	decrease	1	Y->F: Strongly reduced autophosphorylation. Reduces phosphorylation of PLCG1.	MUTAGEN	0
P36507/F57C	MAP2K2	resistance	1	F -> C (in CFC4; dbSNP:rs121434497)	VARIANT	2
P36507/F57V	MAP2K2	-	1	F -> V (in CFC4; dbSNP:rs121434498)	VARIANT	2
P36507/P128Q	MAP2K2	increase	1	P -> Q (in CFC4; results in increased kinase activity; dbSNP:rs267607230)	VARIANT	0
P36507/Y134H	MAP2K2	-	1	Y -> H (in CFC4; dbSNP:rs121434499)	VARIANT	0
P36888/D324N	FLT3	neutral	1	D -> N (in dbSNP:rs35602083)	VARIANT	16
P36888/D358V	FLT3	-	1	D -> V (in dbSNP:rs34172843)	VARIANT	0
P36888/D7G	FLT3	neutral	0	D -> G (in dbSNP:rs12872889)	VARIANT	21
P36888/D835E	FLT3	activating	2	D -> E (in acute lymphoblastic leukemia patients and acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913487)	VARIANT	77
P36888/D835H	FLT3	activating,resistance	3	D -> H (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488)	VARIANT	73
P36888/D835N	FLT3	activating	1	D -> N (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488)	VARIANT	10
P36888/D835V	FLT3	activating,resistance	1	D -> V (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121909646)	VARIANT	103
P36888/D835Y	FLT3	activating,resistance	3	D -> Y (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488)	VARIANT	439
P36888/I417L	FLT3	neutral	0	I -> L (in dbSNP:rs56090538)	VARIANT	0
P36888/I836M	FLT3	-	1	I -> M (in acute lymphoblastic leukemia patients; somatic mutation; dbSNP:rs121913232)	VARIANT	5
P36888/K644A	FLT3	loss	1	K->A: Abolishes kinase activity.	MUTAGEN	0
P36888/T227M	FLT3	neutral	3	T -> M (in dbSNP:rs1933437)	VARIANT	29
P36888/V158A	FLT3	-	1	V -> A (in dbSNP:rs56321896)	VARIANT	0
P36888/V194M	FLT3	neutral	1	V -> M (in dbSNP:rs146030737)	VARIANT	4
P36888/V557I	FLT3	neutral	1	V -> I (in dbSNP:rs35958982)	VARIANT	4
P36888/Y589F	FLT3	decrease	3	Y->F: Reduced phosphorylation of the wild-type kinase in response to ligand binding. No effect on the phosphorylation of the constitutively activated mutant kinase variants. Abolishes activation of STAT5A.	MUTAGEN	0
P36888/Y591F	FLT3	decrease	2	Y->F: No significant effect on tyrosine phosphorylation. Abolishes activation of STAT5A.	MUTAGEN	0
P36888/Y599F	FLT3	decrease	1	Y->F: Abolishes interaction with PTPN11/SHP2 and phosphorylation of PTPN11/SHP2.	MUTAGEN	5
P36894/A338D	BMPR1A	-	1	A -> D (in JPS; dbSNP:rs199476086)	VARIANT	0
P36894/C124R	BMPR1A	-	1	C -> R (in JPS; dbSNP:rs199476087)	VARIANT	0
P36894/C130R	BMPR1A	-	1	C -> R (in JPS; dbSNP:rs1131691168)	VARIANT	0
P36894/C376Y	BMPR1A	-	1	C -> Y (in JPS; dbSNP:rs199476088)	VARIANT	0
P36894/C82Y	BMPR1A	-	1	C -> Y (in JPS)	VARIANT	0
P36894/F58Y	BMPR1A	-	1	F -> Y (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	0
P36894/M460T	BMPR1A	-	1	M -> T (found in a patient with tubular adenoma and rectal neuroendocrine tumor; unknown pathological significance; dbSNP:rs758309022)	VARIANT	0
P36894/M470T	BMPR1A	-	1	M -> T (in JPS; dbSNP:rs199476089)	VARIANT	0
P36894/R443C	BMPR1A	-	2	R -> C (in JPS; dbSNP:rs35619497)	VARIANT	0
P36894/R486Q	BMPR1A	-	1	R -> Q (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs752802257)	VARIANT	3
P36894/V450M	BMPR1A	-	1	V -> M (in dbSNP:rs55932635)	VARIANT	1
P36894/Y62D	BMPR1A	-	1	Y -> D (in JPS)	VARIANT	0
P36896/F146L	ACVR1B	-	1	F -> L (in dbSNP:rs34488074)	VARIANT	0
P36896/I70A	ACVR1B	decrease	1	I->A: Decreases binding to activin.	MUTAGEN	0
P36896/L408V	ACVR1B	-	0	L -> V (in dbSNP:rs928906)	VARIANT	0
P36896/L40A	ACVR1B	-	1	L->A: Increases binding to activin.	MUTAGEN	0
P36896/L75A	ACVR1B	decrease	1	L->A: Decreases binding to activin.	MUTAGEN	0
P36896/P77A	ACVR1B	decrease	1	P->A: Decreases binding to activin.	MUTAGEN	0
P36896/T206V	ACVR1B	activating	1	T->V: Leads to constitutive activation.	MUTAGEN	0
P36896/V73A	ACVR1B	-	1	V->A: Increases binding to activin.	MUTAGEN	0
P36897/C41Y	TGFBR1	-	1	C -> Y (in MSSE; hypomorphic variant)	VARIANT	0
P36897/D266Y	TGFBR1	-	1	D -> Y (in LDS1)	VARIANT	0
P36897/D351G	TGFBR1	-	1	D -> G (in LDS1)	VARIANT	0
P36897/D400G	TGFBR1	-	1	D -> G (in LDS1; dbSNP:rs121918711)	VARIANT	0
P36897/G52R	TGFBR1	-	1	G -> R (in MSSE; hypomorphic variant; dbSNP:rs587776865)	VARIANT	0
P36897/I139V	TGFBR1	-	1	I -> V (in dbSNP:rs148176750)	VARIANT	0
P36897/K232E	TGFBR1	-	1	K -> E (in LDS1)	VARIANT	0
P36897/L193G	TGFBR1	decrease	1	L->G: Loss of interaction with FKBP1A.	MUTAGEN	0
P36897/M318R	TGFBR1	-	1	M -> R (in LDS1; dbSNP:rs121918710)	VARIANT	0
P36897/N267H	TGFBR1	-	1	N -> H (in a patient with Marfan syndrome)	VARIANT	0
P36897/N45S	TGFBR1	-	1	N -> S (in MSSE; hypomorphic variant; dbSNP:rs387906696)	VARIANT	1
P36897/P194K	TGFBR1	decrease	1	P->K: Loss of interaction with FKBP1A.	MUTAGEN	0
P36897/P83L	TGFBR1	-	1	P -> L (in MSSE; hypomorphic variant; dbSNP:rs757374917)	VARIANT	1
P36897/R487P	TGFBR1	-	2	R -> P (in LDS1; dbSNP:rs113605875)	VARIANT	0
P36897/R487Q	TGFBR1	-	3	R -> Q (in LDS1; dbSNP:rs113605875)	VARIANT	4
P36897/R487W	TGFBR1	-	1	R -> W (in LDS1; dbSNP:rs111426349)	VARIANT	5
P36897/S187A	TGFBR1	-	1	S->A: Loss of threonine phosphorylation, reduced phosphorylation on serine residues and loss of response to TGF-beta; when associated with 185-VV-186; A-189 and A-191.	MUTAGEN	0
P36897/S189A	TGFBR1	-	1	S->A: Loss of threonine phosphorylation, reduced phosphorylation on serine residues and loss of response to TGF-beta; when associated with 185-VV-186; A-187 and A-191.	MUTAGEN	0
P36897/S191A	TGFBR1	-	1	S->A: Loss of threonine phosphorylation, reduced phosphorylation on serine residues and loss of response to TGF-beta; when associated with 185-VV-186; A-187 and A-189.	MUTAGEN	0
P36897/S241L	TGFBR1	-	2	S -> L (in LDS1; dbSNP:rs111854391)	VARIANT	3
P36897/T200D	TGFBR1	decrease	1	T->D: Loss of response to TGF-beta.	MUTAGEN	0
P36897/T200I	TGFBR1	-	1	T -> I (in LDS1; dbSNP:rs121918712)	VARIANT	0
P36897/T200V	TGFBR1	loss	1	T->V: Loss of phosphorylation. Loss of response to TGF-beta.	MUTAGEN	0
P36897/T204V	TGFBR1	decrease	1	T->V: Reduced phosphorylation. Reduced response to TGF-beta.	MUTAGEN	0
P36897/T375R	TGFBR1	-	1	T -> R (in LDS1; dbSNP:rs1827743139)	VARIANT	0
P36897/V153I	TGFBR1	-	1	V -> I (in dbSNP:rs56014374)	VARIANT	0
P36897/Y291C	TGFBR1	-	1	Y -> C (in dbSNP:rs35974499)	VARIANT	0
P37023/A306P	ACVRL1	loss	2	A -> P (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum; dbSNP:rs1940807179)	VARIANT	0
P37023/A347D	ACVRL1	-	1	A -> D (in HHT2)	VARIANT	0
P37023/A347P	ACVRL1	-	1	A -> P (in HHT2)	VARIANT	0
P37023/A400T	ACVRL1	-	1	A -> T (found in a patient with hereditary hemorrhagic talagiectasia; unknown pathological significance)	VARIANT	0
P37023/A482V	ACVRL1	-	1	A -> V (in HHT2; dbSNP:rs139142865)	VARIANT	0
P37023/C344R	ACVRL1	-	1	C -> R (in HHT2; dbSNP:rs1592224412)	VARIANT	0
P37023/C344Y	ACVRL1	-	2	C -> Y (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs28936688)	VARIANT	0
P37023/C34Y	ACVRL1	-	1	C -> Y (in HHT2)	VARIANT	0
P37023/C41G	ACVRL1	loss	1	C -> G (in HHT2; loss of receptor activity in response to BMP9; predominantly retained in the endoplasmic reticulum)	VARIANT	0
P37023/C41Y	ACVRL1	loss	1	C -> Y (in HHT2; loss of receptor activity in response to BMP9; predominantly retained in the endoplasmic reticulum; dbSNP:rs1184716348)	VARIANT	0
P37023/C443Y	ACVRL1	-	1	C -> Y (in HHT2; retained in the endoplasmic reticulum)	VARIANT	0
P37023/C46G	ACVRL1	loss	1	C -> G (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum)	VARIANT	0
P37023/C51Y	ACVRL1	-	1	C -> Y (in HHT2; dbSNP:rs863223409)	VARIANT	0
P37023/C69R	ACVRL1	-	1	C -> R (in HHT2)	VARIANT	2
P37023/C77F	ACVRL1	loss	1	C -> F (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum; dbSNP:rs1330837892)	VARIANT	0
P37023/C77W	ACVRL1	-	2	C -> W (in HHT2; retained in the endoplasmic reticulum)	VARIANT	0
P37023/D176Y	ACVRL1	-	1	D -> Y (in HHT2)	VARIANT	0
P37023/D179A	ACVRL1	-	1	D -> A (in HHT2; mutant protein is capable of targeting the cell surface appropriately; dbSNP:rs753792569)	VARIANT	0
P37023/D397G	ACVRL1	-	1	D -> G (in HHT2)	VARIANT	0
P37023/E111D	ACVRL1	-	1	E -> D (no loss of receptor activity in response to BMP9; mutant protein is capable of targeting the cell surface appropriately; dbSNP:rs1481094868)	VARIANT	0
P37023/E159V	ACVRL1	-	1	E -> V (found in a patient with pulmonary arterial hypertension; unknown pathological significance)	VARIANT	0
P37023/E215K	ACVRL1	-	1	E -> K (in HHT2; dbSNP:rs754283265)	VARIANT	0
P37023/E379D	ACVRL1	loss	1	E -> D (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum)	VARIANT	1
P37023/E379K	ACVRL1	loss	3	E -> K (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum; dbSNP:rs1131691686)	VARIANT	0
P37023/E407D	ACVRL1	-	2	E -> D (in HHT2; dbSNP:rs1565595129)	VARIANT	0
P37023/E59V	ACVRL1	-	1	E -> V (found in a patient with pulmonary arterial hypertension; unknown pathological significance; dbSNP:rs1466116430)	VARIANT	0
P37023/F425L	ACVRL1	-	1	F -> L (in HHT2)	VARIANT	0
P37023/F425V	ACVRL1	-	1	F -> V (in HHT2)	VARIANT	0
P37023/G211D	ACVRL1	loss	2	G -> D (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum; dbSNP:rs28936687)	VARIANT	0
P37023/G211S	ACVRL1	loss	1	G -> S (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum)	VARIANT	0
P37023/G219D	ACVRL1	-	1	G -> D (in HHT2)	VARIANT	0
P37023/G223R	ACVRL1	-	1	G -> R (in HHT2)	VARIANT	0
P37023/G416S	ACVRL1	-	1	G -> S (in HHT2)	VARIANT	0
P37023/G48R	ACVRL1	-	1	G -> R (in HHT2)	VARIANT	0
P37023/H280R	ACVRL1	-	1	H -> R (in HHT2)	VARIANT	0
P37023/H314Y	ACVRL1	loss	2	H -> Y (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum; dbSNP:rs1565594311)	VARIANT	0
P37023/H328Q	ACVRL1	-	1	H -> Q (in HHT2; dbSNP:rs1565594410)	VARIANT	0
P37023/H66P	ACVRL1	-	1	H -> P (in HHT2)	VARIANT	0
P37023/H66Y	ACVRL1	loss	1	H -> Y (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum; dbSNP:rs1480110873)	VARIANT	0
P37023/I245N	ACVRL1	-	0	I -> N (in dbSNP:rs1804508)	VARIANT	0
P37023/I245V	ACVRL1	-	1	I -> V (in HHT2; no loss of receptor activity in response to BMP9; mutant protein is capable of targeting the cell surface appropriately; affects splicing by inducing the creation of a new donor splice site and the loss of the 3' end of exon 6)	VARIANT	0
P37023/I260L	ACVRL1	-	1	I -> L (in HHT2)	VARIANT	0
P37023/I398N	ACVRL1	-	1	I -> N (in HHT2; dbSNP:rs121909286)	VARIANT	0
P37023/I417F	ACVRL1	-	1	I -> F (no loss of receptor activity in response to BMP9; mutant protein is capable of targeting the cell surface appropriately; dbSNP:rs141653630)	VARIANT	0
P37023/K229R	ACVRL1	-	1	K -> R (in HHT2)	VARIANT	0
P37023/K486E	ACVRL1	-	1	K -> E (found in a patient with hereditary hemorrhagic talagiectasia; unknown pathological significance; dbSNP:rs113700354)	VARIANT	0
P37023/K487T	ACVRL1	-	1	K -> T (in HHT2; mutant protein is capable of targeting the cell surface appropriately; dbSNP:rs1085307428)	VARIANT	0
P37023/K8N	ACVRL1	-	1	K -> N	VARIANT	0
P37023/L138P	ACVRL1	-	1	L -> P	VARIANT	0
P37023/L285F	ACVRL1	-	1	L -> F (in HHT2; dbSNP:rs1085307410)	VARIANT	0
P37023/L289P	ACVRL1	-	1	L -> P (in HHT2)	VARIANT	0
P37023/L294R	ACVRL1	-	1	L -> R (in HHT2)	VARIANT	0
P37023/L313V	ACVRL1	loss	1	L -> V (in HHT2; loss of receptor activity in response to BMP9; predominantly retained in the endoplasmic reticulum)	VARIANT	0
P37023/L337P	ACVRL1	-	1	L -> P (in HHT2; dbSNP:rs1592224349)	VARIANT	0
P37023/L342P	ACVRL1	-	1	L -> P (in dbSNP:rs762287966)	VARIANT	0
P37023/L403P	ACVRL1	-	1	L -> P (in HHT2)	VARIANT	0
P37023/M376R	ACVRL1	-	1	M -> R (in HHT2; dbSNP:rs28936399)	VARIANT	0
P37023/M376V	ACVRL1	-	1	M -> V (in HHT2; dbSNP:rs1555153277)	VARIANT	0
P37023/N335H	ACVRL1	-	1	N -> H (in HHT2)	VARIANT	0
P37023/N96D	ACVRL1	-	1	N -> D (in HHT2)	VARIANT	0
P37023/N96S	ACVRL1	-	1	N -> S (in HHT2)	VARIANT	0
P37023/P30S	ACVRL1	-	1	P -> S (found in a patient with hereditary hemorrhagic talagiectasia; unknown pathological significance; dbSNP:rs149664056)	VARIANT	1
P37023/P378L	ACVRL1	-	1	P -> L (in HHT2; retained in the endoplasmic reticulum)	VARIANT	0
P37023/P378S	ACVRL1	loss	2	P -> S (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum; dbSNP:rs959973779)	VARIANT	0
P37023/P424R	ACVRL1	-	1	P -> R (in HHT2; dbSNP:rs1940906429)	VARIANT	0
P37023/P424T	ACVRL1	-	1	P -> T (in HHT2; dbSNP:rs1085307419)	VARIANT	0
P37023/P433R	ACVRL1	-	1	P -> R (in HHT2)	VARIANT	0
P37023/P449S	ACVRL1	-	1	P -> S (in HHT2; dbSNP:rs1940908457)	VARIANT	0
P37023/Q237K	ACVRL1	-	1	Q -> K (in HHT2)	VARIANT	0
P37023/R374Q	ACVRL1	-	2	R -> Q (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs1060503248)	VARIANT	1
P37023/R374W	ACVRL1	-	4	R -> W (in HHT2; dbSNP:rs28936401)	VARIANT	2
P37023/R411P	ACVRL1	-	1	R -> P (in HHT2; dbSNP:rs121909284)	VARIANT	0
P37023/R411Q	ACVRL1	-	3	R -> Q (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs121909284)	VARIANT	2
P37023/R411W	ACVRL1	loss	4	R -> W (in HHT2; loss of receptor activity in response to BMP9; predominantly retained in the endoplasmic reticulum; dbSNP:rs121909287)	VARIANT	0
P37023/R479L	ACVRL1	-	1	R -> L (in HHT2)	VARIANT	0
P37023/R479P	ACVRL1	-	1	R -> P (in HHT2; dbSNP:rs1085307426)	VARIANT	0
P37023/R47P	ACVRL1	loss	1	R -> P (in HHT2; loss of receptor activity in response to BMP9; retained in the endoplasmic reticulum; dbSNP:rs774389618)	VARIANT	0
P37023/R484W	ACVRL1	-	2	R -> W (in HHT2; dbSNP:rs121909288)	VARIANT	0
P37023/R67Q	ACVRL1	-	2	R -> Q (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs863223414)	VARIANT	1
P37023/R67W	ACVRL1	-	1	R -> W (in HHT2; dbSNP:rs1085307405)	VARIANT	0
P37023/S225C	ACVRL1	-	1	S -> C (found in a patient with pulmonary arterial hypertension; unknown pathological significance)	VARIANT	0
P37023/S233L	ACVRL1	-	1	S -> L (in HHT2; dbSNP:rs762773076)	VARIANT	1
P37023/S333I	ACVRL1	-	3	S -> I (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs863223413)	VARIANT	0
P37023/S38C	ACVRL1	-	1	S -> C	VARIANT	0
P37023/T197I	ACVRL1	-	1	T -> I (in HHT2)	VARIANT	0
P37023/T265P	ACVRL1	-	1	T -> P (in HHT2; dbSNP:rs1592223978)	VARIANT	0
P37023/T277K	ACVRL1	-	1	T -> K (found in a patient with hereditary hemorrhagic talagiectasia; unknown pathological significance)	VARIANT	0
P37023/T396A	ACVRL1	-	1	T -> A (found in patients with pulmonary arterial hypertension; unknown pathological significance)	VARIANT	0
P37023/T52A	ACVRL1	-	1	T -> A (in HHT2; dbSNP:rs1131691346)	VARIANT	0
P37023/V226E	ACVRL1	-	1	V -> E (in HHT2; dbSNP:rs1565593639)	VARIANT	0
P37023/V404G	ACVRL1	loss	1	V -> G (in HHT2; loss of receptor activity in response to BMP9; predominantly retained in the endoplasmic reticulum)	VARIANT	0
P37023/V441M	ACVRL1	-	1	V -> M (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs1565596498)	VARIANT	1
P37023/W217G	ACVRL1	-	1	W -> G (in HHT2)	VARIANT	0
P37023/W399S	ACVRL1	-	1	W -> S (in HHT2; dbSNP:rs121909289)	VARIANT	0
P37023/W50C	ACVRL1	-	3	W -> C (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs121909285)	VARIANT	0
P37023/W50G	ACVRL1	-	1	W -> G (in HHT2)	VARIANT	0
P37023/Y426C	ACVRL1	-	1	Y -> C (in HHT2)	VARIANT	0
P37173/A355P	TGFBR2	-	1	A -> P (in LDS2; dbSNP:rs104893813)	VARIANT	0
P37173/C514R	TGFBR2	-	1	C -> R (in LDS2; dbSNP:rs193922664)	VARIANT	0
P37173/C61R	TGFBR2	-	1	C -> R (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	1
P37173/D247V	TGFBR2	-	1	D -> V (in LDS2; dbSNP:rs761231369)	VARIANT	0
P37173/D446N	TGFBR2	decrease	1	D -> N (in LDS2; dbSNP:rs886039551)	VARIANT	6
P37173/E526Q	TGFBR2	-	1	E -> Q (in esophageal cancer; dbSNP:rs121918714)	VARIANT	2
P37173/G357R	TGFBR2	-	1	G -> R (in LDS2)	VARIANT	0
P37173/G357W	TGFBR2	-	1	G -> W (in LDS2; dbSNP:rs104893814)	VARIANT	0
P37173/G509V	TGFBR2	-	1	G -> V (in LDS2; dbSNP:rs863223853)	VARIANT	0
P37173/H328Y	TGFBR2	-	1	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	1
P37173/H377R	TGFBR2	-	1	H -> R (in LDS2; dbSNP:rs1553630274)	VARIANT	0
P37173/I510F	TGFBR2	-	1	I -> F (in LDS2)	VARIANT	0
P37173/I510S	TGFBR2	-	1	I -> S (in LDS2)	VARIANT	0
P37173/I73V	TGFBR2	-	1	I -> V (in a colorectal cancer sample; somatic mutation)	VARIANT	0
P37173/K277R	TGFBR2	loss	1	K->R: Abolishes kinase activity, TGF-beta signaling and interaction with DAXX.	MUTAGEN	0
P37173/L308P	TGFBR2	decrease	2	L -> P (in LDS2; has a negative effect on TGF-beta signaling; dbSNP:rs28934568)	VARIANT	0
P37173/L452M	TGFBR2	decrease	1	L -> M (in a breast tumor; signaling of TGF-beta significantly inhibited)	VARIANT	1
P37173/M36V	TGFBR2	-	0	M -> V (in dbSNP:rs17025864)	VARIANT	0
P37173/M373I	TGFBR2	neutral	1	M -> I (in dbSNP:rs35719192)	VARIANT	0
P37173/M457K	TGFBR2	-	1	M -> K (in LDS2)	VARIANT	0
P37173/N435S	TGFBR2	decrease	1	N -> S (in a breast tumor; signaling of TGF-beta significantly inhibited)	VARIANT	3
P37173/N490S	TGFBR2	-	1	N -> S (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	1
P37173/R190H	TGFBR2	-	1	R -> H (in LDS2; dbSNP:rs780542125)	VARIANT	1
P37173/R460C	TGFBR2	-	1	R -> C (in LDS2; dbSNP:rs104893811)	VARIANT	1
P37173/R460H	TGFBR2	-	1	R -> H (in LDS2; dbSNP:rs104893816)	VARIANT	4
P37173/R528C	TGFBR2	-	1	R -> C (in LDS2; dbSNP:rs104893810)	VARIANT	4
P37173/R528H	TGFBR2	-	2	R -> H (in LDS2; dbSNP:rs104893815)	VARIANT	6
P37173/R537C	TGFBR2	decrease	1	R -> C (in LDS2; has a negative effect on TGF-beta signaling; dbSNP:rs104893809)	VARIANT	2
P37173/S449F	TGFBR2	decrease	2	S -> F (in LDS2; has a negative effect on TGF-beta signaling; dbSNP:rs104893807)	VARIANT	0
P37173/T315M	TGFBR2	-	2	T -> M (in HNPCC6; dbSNP:rs34833812)	VARIANT	0
P37173/T325P	TGFBR2	-	1	T -> P (in LDS2)	VARIANT	0
P37173/T530I	TGFBR2	-	1	T -> I (in LDS2)	VARIANT	0
P37173/V191I	TGFBR2	neutral	2	V -> I (in dbSNP:rs56105708)	VARIANT	0
P37173/V387M	TGFBR2	-	2	V -> M (in a breast tumor; dbSNP:rs35766612)	VARIANT	4
P37173/V439A	TGFBR2	-	4	V -> A (in dbSNP:rs1050833)	VARIANT	0
P37173/V447A	TGFBR2	decrease	1	V -> A (in a breast tumor; signaling of TGF-beta significantly inhibited)	VARIANT	2
P37173/W521R	TGFBR2	-	1	W -> R (in LDS2; dbSNP:rs1575166666)	VARIANT	0
P37173/Y336N	TGFBR2	-	1	Y -> N (in LDS2; dbSNP:rs104893812)	VARIANT	0
P41240/G287D	CSK	neutral	0	G -> D (in dbSNP:rs34866753)	VARIANT	0
P41240/H442R	CSK	-	0	H -> R (in dbSNP:rs35556162)	VARIANT	0
P41240/P45L	CSK	-	1	P -> L	VARIANT	0
P41240/R398Q	CSK	-	0	R -> Q (in dbSNP:rs34616395)	VARIANT	2
P41240/S364A	CSK	decrease	1	S->A: Strong decrease of phosphorylation by PRKACA (catalytic subunit of PKA).	MUTAGEN	0
P41240/Y184F	CSK	loss	1	Y->F: Abolishes phosphorylation.	MUTAGEN	0
P41240/Y304F	CSK	decrease	1	Y->F: Decreases activity by two-thirds and alters conformation.	MUTAGEN	0
P41279/S214F	MAP3K8	-	0	S -> F (in dbSNP:rs3087944)	VARIANT	0
P41279/T290A	MAP3K8	loss	1	T->A: Loss of MEK phosphorylation activity and almost abolished autophosphorylation activity. Loss of IL1-stimulated MEK phosphorylation activity but not of IL1-stimulated autophosphorylation activity. No effect on KSR2 binding.	MUTAGEN	0
P41279/T290D	MAP3K8	decrease	1	T->D: Impaired MEK phosphorylation and autophosphorylation activities. No effect on KSR2 binding.	MUTAGEN	0
P41279/T290E	MAP3K8	decrease	1	T->E: Loss of MEK phosphorylation activity and almost abolished autophosphorylation activity. No effect on KSR2 binding.	MUTAGEN	0
P41743/D72A	PRKCI	decrease	3	D->A: Loss of interaction with ECT2, PARD6A and with SQSTM1.	MUTAGEN	0
P41743/E85A	PRKCI	-	1	E->A: Slight decrease of interaction with PARD6A. Loss of interaction with PARD6A; when associated with A-91.	MUTAGEN	0
P41743/K274R	PRKCI	-	1	K->R: No effect on activity.	MUTAGEN	0
P41743/K274W	PRKCI	loss	1	K->W: Abolishes activity.	MUTAGEN	0
P41743/K29A	PRKCI	-	1	K->A: No effect on interaction with SQSTM1.	MUTAGEN	0
P41743/P118L	PRKCI	-	1	P -> L (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
P41743/R130C	PRKCI	-	1	R -> C (in dbSNP:rs56154494)	VARIANT	1
P41743/R91A	PRKCI	-	1	R->A: Slight decrease of interaction with PARD6A. Loss of interaction with PARD6A; when associated with A-85.	MUTAGEN	0
P41743/Y265F	PRKCI	-	2	Y->F: No effect on the SRC-mediated phosphorylation state. No effect on SRC-induced enzyme activity. Little effect on TRAF6-mediated activation of NF-kappa-B. Decreased binding to KPNB1/importin-beta.	MUTAGEN	0
P41743/Y280F	PRKCI	-	1	Y->F: No effect on the SRC-mediated phosphorylation state. No effect on SRC-induced enzyme activity. No effect on TRAF6-mediated activation of NF-kappa-B.	MUTAGEN	0
P41743/Y334F	PRKCI	-	1	Y->F: No effect on the SRC-mediated phosphorylation state. Significant reduction of SRC-induced enzyme activity. Greatly reduced TRAF6-mediated activation of NF-kappa-B. Reduces NGF-dependent cell survival.	MUTAGEN	0
P42679/A354T	MATK	-	1	A -> T (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
P42679/A496T	MATK	neutral	1	A -> T (in dbSNP:rs35351680)	VARIANT	0
P42679/R503Q	MATK	-	1	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs778726488)	VARIANT	0
P42680/R44Q	TEC	-	1	R -> Q (in dbSNP:rs35374286)	VARIANT	0
P42680/R563K	TEC	-	1	R -> K (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P42681/K299A	TXK	loss	1	K->A: Impairs kinase activity.	MUTAGEN	0
P42681/R336Q	TXK	neutral	1	R -> Q (in dbSNP:rs11724347)	VARIANT	0
P42681/R45H	TXK	neutral	2	R -> H (in dbSNP:rs7658300)	VARIANT	1
P42681/R63C	TXK	-	1	R -> C (in dbSNP:rs41265727)	VARIANT	0
P42681/Y91A	TXK	-	1	Y->A: Reduces expression levels if IFN-gamma.	MUTAGEN	0
P42684/E99Q	ABL2	-	1	E -> Q (somatic mutation in a breast cancer sample)	VARIANT	1
P42684/K930R	ABL2	neutral	1	K -> R (in dbSNP:rs17277288)	VARIANT	0
P42684/P996R	ABL2	neutral	1	P -> R (in dbSNP:rs28913890)	VARIANT	0
P42684/R519I	ABL2	-	1	R -> I (somatic mutation in a lung squamous cell carcinoma)	VARIANT	0
P42684/R78H	ABL2	-	1	R -> H (in dbSNP:rs55655202)	VARIANT	0
P42684/S1085N	ABL2	-	0	S -> N (in dbSNP:rs28913891)	VARIANT	0
P42684/T1101A	ABL2	-	0	T -> A (in dbSNP:rs28913892)	VARIANT	0
P42684/T769S	ABL2	neutral	1	T -> S (in dbSNP:rs55892721)	VARIANT	0
P42684/V946M	ABL2	-	0	V -> M (in dbSNP:rs28913889)	VARIANT	1
P42685/G122R	FRK	neutral	1	G -> R (in dbSNP:rs3756772)	VARIANT	1
P42685/I100V	FRK	-	1	I -> V (in dbSNP:rs34704018)	VARIANT	0
P42685/K262R	FRK	loss	1	K->R: Loss of ability to phosphorylate PTEN.	MUTAGEN	0
P42685/S133L	FRK	neutral	1	S -> L (in dbSNP:rs34064900)	VARIANT	0
P43250/C561S	GRK6	-	1	C->S: Abolishes palmitoylation; when associated with S-562 and S-565.	MUTAGEN	0
P43250/C562S	GRK6	-	1	C->S: Abolishes palmitoylation; when associated with S-561 and S-565.	MUTAGEN	0
P43250/C565S	GRK6	-	1	C->S: Abolishes palmitoylation; when associated with S-561 and S-562.	MUTAGEN	0
P43250/I275M	GRK6	-	1	I -> M (in a breast infiltrating ductal carcinoma sample; somatic mutation)	VARIANT	1
P43250/I6A	GRK6	-	1	I->A: 12-13 fold defects in kinase activity; 180-fold defects in kinase activity; when associated with A-7.	MUTAGEN	0
P43250/L12A	GRK6	loss	1	L->A: 1100-fold defects in kinase activity.	MUTAGEN	0
P43250/N9A	GRK6	loss	1	N->A: 140-fold defects in kinase activity.	MUTAGEN	0
P43250/R31Q	GRK6	-	1	R -> Q (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs141014084)	VARIANT	3
P43250/T73M	GRK6	-	1	T -> M (in dbSNP:rs56382815)	VARIANT	0
P43250/V7A	GRK6	-	1	V->A: 12-13 fold defects in kinase activity; 180-fold defects in kinase activity; when associated with A-6.	MUTAGEN	0
P43403/A141E	ZAP70	increase	1	A->E: Increased constitutive kinase activity.	MUTAGEN	0
P43403/A507V	ZAP70	-	1	A -> V (in IMD48)	VARIANT	0
P43403/C564R	ZAP70	-	1	C -> R (in IMD48)	VARIANT	0
P43403/D327P	ZAP70	increase	1	D->P: Increases constitutive kinase activity on LAT phosphorylation, strongly increases subcellular localization of CD69 at the cell surface and decreases autoinhibition conformation.	MUTAGEN	0
P43403/D461N	ZAP70	loss	1	D->N: Abolishes kinase activity.	MUTAGEN	0
P43403/D479N	ZAP70	loss	1	D->N: Abolishes kinase activity.	MUTAGEN	0
P43403/G448E	ZAP70	-	1	G -> E (in a head and neck squamous cell carcinoma sample; somatic mutation)	VARIANT	0
P43403/K304R	ZAP70	-	1	K->R: No effect on ubiquitination.	MUTAGEN	0
P43403/K362E	ZAP70	increase	1	K->E: Increases constitutive kinase activity on LAT phosphorylation, strongly increases subcellular localization of CD69 at the cell surface and decreases autoinhibition conformation.	MUTAGEN	0
P43403/K538R	ZAP70	-	1	K->R: No effect on ubiquitination.	MUTAGEN	0
P43403/K544R	ZAP70	-	1	K->R: Strongly decreased ubiquitination.	MUTAGEN	0
P43403/L133A	ZAP70	increase	1	L->A: Increased constitutive kinase activity.	MUTAGEN	0
P43403/L337R	ZAP70	-	1	L -> R (in IMD48; dbSNP:rs1254428002)	VARIANT	0
P43403/P147A	ZAP70	increase	1	P->A: Increased kinase activity after activation by LCK.	MUTAGEN	0
P43403/P191L	ZAP70	-	1	P -> L (in dbSNP:rs56403250)	VARIANT	1
P43403/Q145A	ZAP70	increase	1	Q->A: Increased kinase activity after activation by LCK.	MUTAGEN	0
P43403/R175L	ZAP70	-	1	R -> L (in dbSNP:rs55964305)	VARIANT	0
P43403/R190K	ZAP70	-	1	R->K: Decreases interaction with phosphorylated CD247; when associated with K-37.	MUTAGEN	0
P43403/R192W	ZAP70	decrease	1	R -> W (in ADMIO2; decreases interaction with phosphorylated CD247; decreases ZAP70 phosphorylation; no effect on subcellular localization of CD69 at the cell surface; dbSNP:rs199840952)	VARIANT	0
P43403/R360P	ZAP70	increase	1	R -> P (in ADMIO2; no effect on interaction with phosphorylated CD247; increases TCR-induced Y-319 and Y-493 phosphorylation of ZAP70 and phosphorylation of LAT and LCP2; increases subcellular localization of CD69 at the cell surface; weakly decreases autoinhibition conformation; dbSNP:rs869025224)	VARIANT	0
P43403/R37K	ZAP70	-	1	R->K: Decreases interaction with phosphorylated CD247; when associated with K-190.	MUTAGEN	0
P43403/R465C	ZAP70	-	1	R -> C (in IMD48; dbSNP:rs113994174)	VARIANT	0
P43403/R465H	ZAP70	-	1	R -> H (in IMD48; dbSNP:rs137853201)	VARIANT	2
P43403/S144A	ZAP70	increase	1	S->A: Increased kinase activity after activation by LCK.	MUTAGEN	0
P43403/S518R	ZAP70	-	1	S -> R (in IMD48; dbSNP:rs104893674)	VARIANT	0
P43403/V314A	ZAP70	increase	0	V->A: Increased constitutive kinase activity.	MUTAGEN	0
P43403/W131A	ZAP70	increase	1	W->A: Increased constitutive kinase activity.	MUTAGEN	0
P43403/W523L	ZAP70	-	1	W -> L (in dbSNP:rs56189815)	VARIANT	0
P43403/Y292F	ZAP70	increase	1	Y->F: Induces constitutive TCR stimulation-independent NFAT induction.	MUTAGEN	0
P43403/Y315A	ZAP70	-	4	Y->A: Increased constitutive kinase activity; when associated with F-319.	MUTAGEN	0
P43403/Y315F	ZAP70	-	4	Y->F: Increased constitutive kinase activity; when associated with F-319. About 75% loss of CD247/CD3Z-binding in stimulated TCR and complete loss of VAV1 interaction.	MUTAGEN	0
P43403/Y319A	ZAP70	-	2	Y->A: Increased constitutive kinase activity; when associated with F-315.	MUTAGEN	0
P43403/Y319F	ZAP70	-	2	Y->F: Increased constitutive kinase activity; when associated with F-315. About 80% loss of TCR-induced NFAT activation.	MUTAGEN	0
P43403/Y492F	ZAP70	increase	1	Y->F: Increases kinase activity.	MUTAGEN	0
P43403/Y493F	ZAP70	loss	1	Y->F: Impairs kinase activity.	MUTAGEN	0
P43403/Y597A	ZAP70	increase	1	Y->A: Increased kinase activity after activation by LCK.	MUTAGEN	0
P43403/Y598A	ZAP70	increase	1	Y->A: Increased kinase activity after activation by LCK.	MUTAGEN	0
P43405/A353T	SYK	activating	1	A -> T (in IMD82; constitutively active protein tyrosine kinase activity)	VARIANT	3
P43405/M450I	SYK	activating	1	M -> I (in IMD82; constitutively active protein tyrosine kinase activity)	VARIANT	0
P43405/P342T	SYK	activating	1	P -> T (in IMD82; constitutively active protein tyrosine kinase activity)	VARIANT	0
P43405/R45H	SYK	-	0	R -> H (in dbSNP:rs16906862)	VARIANT	1
P43405/S297A	SYK	decrease	1	S->A: Abolishes YWHAG binding.	MUTAGEN	0
P43405/S550F	SYK	activating	1	S -> F (in IMD82; constitutively active protein tyrosine kinase activity)	VARIANT	0
P43405/S550Y	SYK	activating	1	S -> Y (in IMD82; constitutively active protein tyrosine kinase activity)	VARIANT	0
P43405/Y630F	SYK	decrease	1	Y->F: Loss of interaction with BLNK.	MUTAGEN	0
P45983/E365K	MAPK8	-	0	E -> K (in dbSNP:rs45483593)	VARIANT	0
P45983/G171S	MAPK8	-	1	G -> S (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	2
P45983/G177R	MAPK8	-	1	G -> R (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
P45983/K55D	MAPK8	loss	2	K->D: Abolished protein kinase activity.	MUTAGEN	0
P45983/T183A	MAPK8	decrease	1	T->A: Phosphorylation blocked.	MUTAGEN	1
P45983/Y185F	MAPK8	decrease	1	Y->F: Phosphorylation blocked.	MUTAGEN	0
P45984/A246T	MAPK9	-	1	A -> T (in dbSNP:rs35421153)	VARIANT	0
P45984/G268A	MAPK9	-	0	G -> A (in dbSNP:rs35693958)	VARIANT	0
P45984/K56N	MAPK9	-	1	K -> N (in a head & Neck squamous cell carcinoma sample; somatic mutation)	VARIANT	0
P45984/R366I	MAPK9	-	1	R -> I (in dbSNP:rs55736180)	VARIANT	0
P45984/V13M	MAPK9	-	1	V -> M (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P45985/A279T	MAP2K4	-	1	A -> T (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs753665559)	VARIANT	6
P45985/N234I	MAP2K4	-	1	N -> I (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	1
P45985/Q142L	MAP2K4	-	1	Q -> L (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
P45985/R154W	MAP2K4	-	1	R -> W (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs1567657403)	VARIANT	1
P45985/S16R	MAP2K4	-	1	S -> R (in dbSNP:rs17855590)	VARIANT	0
P45985/S251N	MAP2K4	-	1	S -> N (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
P46734/A84T	MAP2K3	-	1	A -> T (in dbSNP:rs2305873)	VARIANT	6
P46734/L215V	MAP2K3	-	1	L -> V (in colon cancer; dbSNP:rs989026404)	VARIANT	0
P46734/M90I	MAP2K3	-	1	M -> I (in dbSNP:rs36076766)	VARIANT	0
P46734/P40T	MAP2K3	-	0	P -> T (in dbSNP:rs33911218)	VARIANT	0
P46734/R175W	MAP2K3	-	1	R -> W (in colon cancer; dbSNP:rs1339756947)	VARIANT	1
P46734/R26T	MAP2K3	-	1	R -> T	VARIANT	0
P46734/R293H	MAP2K3	-	1	R -> H (in dbSNP:rs35206134)	VARIANT	2
P46734/R55T	MAP2K3	-	0	R -> T (in dbSNP:rs36047035)	VARIANT	3
P46734/R94L	MAP2K3	-	1	R -> L (in dbSNP:rs56067280)	VARIANT	13
P46734/R96W	MAP2K3	-	1	R -> W (in dbSNP:rs56216806)	VARIANT	5
P46734/S218A	MAP2K3	loss	1	S->A: Inactivation.	MUTAGEN	0
P46734/S218E	MAP2K3	activating	1	S->E: Constitutive activation.	MUTAGEN	0
P46734/S68P	MAP2K3	-	1	S -> P (in dbSNP:rs34105301)	VARIANT	0
P46734/T222A	MAP2K3	loss	1	T->A: Inactivation.	MUTAGEN	0
P46734/T222E	MAP2K3	activating	1	T->E: Constitutive activation.	MUTAGEN	0
P46734/V339M	MAP2K3	-	1	V -> M (in dbSNP:rs2363198)	VARIANT	0
P48729/D297H	CSNK1A1	-	1	D -> H (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	0
P48730/H46R	CSNK1D	decrease	1	H -> R (in FASPS2; strongly reduces kinase activity; dbSNP:rs397514693)	VARIANT	0
P48730/K38M	CSNK1D	decrease	1	K->M: Impaired kinase activity and abnormal subcellular localization with exclusive accumulation to the nucleus.	MUTAGEN	0
P48730/P401A	CSNK1D	-	1	P -> A (in dbSNP:rs56124628)	VARIANT	0
P48730/S97C	CSNK1D	-	2	S -> C (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	VARIANT	2
P48730/T176I	CSNK1D	decrease	1	T->I: Impaired kinase activity and abnormal subcellular localization with exclusive accumulation to the nucleus.	MUTAGEN	0
P48730/T44A	CSNK1D	decrease	2	T -> A (in FASPS2; strongly reduces kinase activity; dbSNP:rs104894561)	VARIANT	0
P49137/A173G	MAPKAPK2	-	1	A -> G (in dbSNP:rs35671930)	VARIANT	0
P49137/A361S	MAPKAPK2	neutral	1	A -> S (in dbSNP:rs55894011)	VARIANT	0
P49137/D207A	MAPKAPK2	loss	1	D->A: Kinase defective mutant, abolishes activity.	MUTAGEN	0
P49137/K353R	MAPKAPK2	increase	1	K->R: Induces decreased sumoylation and increase in protein kinase activity.	MUTAGEN	0
P49137/K93R	MAPKAPK2	loss	1	K->R: Kinase defective mutant, abolishes activity.	MUTAGEN	0
P49137/S272A	MAPKAPK2	decrease	1	S->A: Strong decrease in kinase activity.	MUTAGEN	0
P49137/S272D	MAPKAPK2	increase	1	S->D: Mimicks phosphorylation state, leading to slight increase of basal kinase activity.	MUTAGEN	0
P49137/T222A	MAPKAPK2	decrease	3	T->A: Strong decrease in kinase activity.	MUTAGEN	0
P49137/T222D	MAPKAPK2	increase	3	T->D: Mimicks phosphorylation state, leading to slight increase of basal kinase activity.	MUTAGEN	0
P49137/T222E	MAPKAPK2	-	3	T->E: Mimicks phosphorylation state and constitutive protein kinase activity; when associated with E-334.	MUTAGEN	0
P49137/T334A	MAPKAPK2	decrease	3	T->A: Slight decrease in kinase activity.	MUTAGEN	0
P49137/T334D	MAPKAPK2	increase	3	T->D,E: Mimicks phosphorylation state, leading to elevated basal kinase activity.	MUTAGEN	0
P49137/T334E	MAPKAPK2	-	3	T->E: Mimicks phosphorylation state and constitutive protein kinase activity; when associated with E-222.	MUTAGEN	0
P49336/D173A	CDK8	loss	2	D->A: Abrogates kinase activity and TFIIH-dependent transcriptional repression.	MUTAGEN	0
P49336/D189N	CDK8	-	1	D -> N (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
P49336/F97L	CDK8	-	1	F -> L (in IDDHBA; unknown pathological significance)	VARIANT	0
P49336/G30S	CDK8	decrease	1	G -> S (in IDDHBA; decreased protein kinase activity; dbSNP:rs1593218890)	VARIANT	1
P49336/I223M	CDK8	decrease	1	I -> M (in IDDHBA; decreased protein kinase activity; dbSNP:rs1593310364)	VARIANT	0
P49336/R178Q	CDK8	decrease	1	R -> Q (in IDDHBA; decreased protein kinase activity; dbSNP:rs1418353379)	VARIANT	1
P49336/R29G	CDK8	decrease	1	R -> G (in IDDHBA; decreased protein kinase activity; dbSNP:rs1593218885)	VARIANT	0
P49336/R424C	CDK8	-	1	R -> C (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P49336/S62L	CDK8	decrease	1	S -> L (in IDDHBA; decreased protein kinase activity; dbSNP:rs1565977796)	VARIANT	2
P49336/V193G	CDK8	decrease	1	V -> G (in IDDHBA; decreased protein kinase activity; dbSNP:rs1875421510)	VARIANT	0
P49336/V27L	CDK8	decrease	1	V -> L (in IDDHBA; decreased protein kinase activity)	VARIANT	0
P49674/H413R	CSNK1E	-	1	H -> R (in dbSNP:rs35665927)	VARIANT	0
P49674/K38R	CSNK1E	loss	1	K->R: Loss of kinase activity.	MUTAGEN	0
P49674/R256L	CSNK1E	-	1	R -> L (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	3
P49759/E459G	CLK1	-	0	E -> G (in dbSNP:rs12709)	VARIANT	0
P49759/M440T	CLK1	-	1	M -> T (in dbSNP:rs35393352)	VARIANT	0
P49759/N99D	CLK1	neutral	0	N -> D (in dbSNP:rs6735666)	VARIANT	0
P49759/P307S	CLK1	-	1	P -> S (in dbSNP:rs35412475)	VARIANT	0
P49759/R118G	CLK1	-	1	R -> G (in dbSNP:rs56135616)	VARIANT	0
P49759/S61F	CLK1	-	1	S -> F (in dbSNP:rs55989135)	VARIANT	0
P49761/Q607R	CLK3	-	1	Q -> R (in dbSNP:rs910378995)	VARIANT	0
P49761/R486C	CLK3	-	1	R -> C (in dbSNP:rs975796055)	VARIANT	1
P49761/R628W	CLK3	-	1	R -> W (in dbSNP:rs920443187)	VARIANT	0
P49840/L461F	GSK3A	-	1	L -> F (in dbSNP:rs35454502)	VARIANT	0
P49840/Q109E	GSK3A	-	0	Q -> E (in dbSNP:rs35978177)	VARIANT	0
P49841/L128A	GSK3B	loss	1	L->A: Abolishes activity toward AXIN1.	MUTAGEN	0
P49841/R96A	GSK3B	loss	1	R->A: Prevents the phosphorylation of phosphate-primed glycogen synthase.	MUTAGEN	0
P49841/S9A	GSK3B	activating	3	S->A: Loss of phosphorylation; abolished inhibition of activity, leading to constitutively active.	MUTAGEN	0
P49842/A331V	STK19	-	1	A -> V (in dbSNP:rs7743647)	VARIANT	0
P49842/A39D	STK19	-	0	A -> D (in dbSNP:rs34843142)	VARIANT	0
P49842/D89N	STK19	increase	2	D -> N (recurrent gain-of-function variant found in metastatic melanoma; promotes NRAS signaling; somatic mutation; dbSNP:rs267600971)	VARIANT	0
P49842/K300P	STK19	decrease	1	K->P: Partial loss of activity.	MUTAGEN	0
P49842/K315P	STK19	decrease	1	K->P: Partial loss of activity.	MUTAGEN	0
P49842/K317P	STK19	loss	1	K->P: Complete loss of activity.	MUTAGEN	0
P49842/L139V	STK19	decrease	1	L->V: Prevents inhibition by ZT-12-037-01 (1a) without affecting much the serine/threonine-protein kinase activity.	MUTAGEN	0
P49842/S311G	STK19	neutral	2	S -> G (in dbSNP:rs616634)	VARIANT	0
P49842/V134Y	STK19	decrease	1	V->Y: Prevents inhibition by ZT-12-037-01 (1a) without affecting much the serine/threonine-protein kinase activity.	MUTAGEN	0
P50613/F91G	CDK7	-	1	F->G: Enhanced capacity to bind ATP analogs.	MUTAGEN	0
P50613/G163A	CDK7	-	0	G -> A	VARIANT	0
P50613/K41A	CDK7	loss	0	K->A: Total loss of activity.	MUTAGEN	0
P50613/K41M	CDK7	-	1	K->M: No effect on interaction with HINT1.	MUTAGEN	0
P50613/S164A	CDK7	-	1	S->A: No mitotic repression of transcriptional activity of the reconstituted TFIIH complex.	MUTAGEN	0
P50613/T170A	CDK7	loss	2	T->A: Total loss of activity. Total loss of transcriptional activity of the reconstituted TFIIH complex.	MUTAGEN	0
P50613/T170E	CDK7	-	1	T->E: No effect on interaction with HINT1.	MUTAGEN	0
P50613/T285M	CDK7	neutral	1	T -> M (in dbSNP:rs34584424)	VARIANT	1
P50750/D167N	CDK9	loss	2	D->N: Abrogates kinase activity.	MUTAGEN	0
P50750/F59L	CDK9	-	1	F -> L (in dbSNP:rs55640715)	VARIANT	0
P50750/G231A	CDK9	-	2	G -> A	VARIANT	0
P50750/K44R	CDK9	decrease	1	K->R: Impaired kinase and transcriptional elongation activities, but normal cyclin T1 and HEXIM1 binding.	MUTAGEN	0
P50750/K48Q	CDK9	decrease	1	K->Q: Mimics acetylation; leading to impaired protein kinase activity.	MUTAGEN	0
P50750/K48R	CDK9	activating	1	K->R: Decreased acetylation; leading to enhanced protein kinase activity.	MUTAGEN	0
P50750/R225C	CDK9	-	1	R -> C (found in patients with global developmental delay and epilepsy with history of choanal atresia; unknown pathological significance; dbSNP:rs767418586)	VARIANT	0
P50750/S175A	CDK9	activating	1	S->A: Constitutive kinase activity.	MUTAGEN	0
P50750/S175D	CDK9	loss	1	S->D: Mimics phosphorylation, constitutive loss of kinase activity.	MUTAGEN	0
P50750/T186A	CDK9	decrease	3	T->A: Abrogates autophosphorylation; no effect on kinase activity, but impaired CTD phosphorylation.	MUTAGEN	0
P50750/T186D	CDK9	activating	3	T->D: Mimics autophosphorylation; constitutive kinase activity, independently of calcium signaling.	MUTAGEN	0
P51451/A71T	BLK	decrease,neutral	2	A -> T (associated with MODY11; reduces the enhancing effect of BLK on insulin secretion; reduces the inducing effect of BLK on the expression of PDX1 and NKX6-1; found as somatic mutation in a colorectal adenocarcinoma sample; dbSNP:rs55758736)	VARIANT	0
P51451/T48I	BLK	-	1	T -> I (in dbSNP:rs35339715)	VARIANT	0
P51617/C203S	IRAK1	neutral	0	C -> S (in dbSNP:rs10127175)	VARIANT	0
P51617/D340N	IRAK1	loss	1	D->N: Loss of kinase activity.	MUTAGEN	0
P51617/F196S	IRAK1	neutral	1	F -> S (in dbSNP:rs1059702)	VARIANT	0
P51617/G619S	IRAK1	-	1	G -> S (in dbSNP:rs34112487)	VARIANT	0
P51617/K239S	IRAK1	loss	1	K->S: Loss of kinase activity.	MUTAGEN	0
P51617/Q421H	IRAK1	-	1	Q -> H (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	2
P51617/R194H	IRAK1	neutral	0	R -> H (in dbSNP:rs11465830)	VARIANT	0
P51617/R638W	IRAK1	-	1	R -> W (in dbSNP:rs56082801)	VARIANT	0
P51617/S532L	IRAK1	neutral	2	S -> L (in dbSNP:rs1059703)	VARIANT	3
P51617/S690G	IRAK1	-	1	S -> G (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	2
P51617/T209A	IRAK1	loss	1	T->A: Completely abolishes auto-phosphorylation in the kinase domain.	MUTAGEN	0
P51617/T387A	IRAK1	loss	1	T->A: Loss of kinase activity.	MUTAGEN	0
P51617/T398M	IRAK1	-	1	T -> M (in dbSNP:rs56340948)	VARIANT	0
P51617/T625M	IRAK1	-	1	T -> M (in dbSNP:rs35638718)	VARIANT	0
P51617/V412M	IRAK1	-	1	V -> M (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
P51812/A225V	RPS6KA3	-	1	A -> V (in CLS; dbSNP:rs879027948)	VARIANT	0
P51812/D154Y	RPS6KA3	-	1	D -> Y (in CLS)	VARIANT	0
P51812/F268S	RPS6KA3	-	1	F -> S (in CLS; dbSNP:rs122454131)	VARIANT	0
P51812/G431D	RPS6KA3	-	1	G -> D (in CLS)	VARIANT	0
P51812/G75V	RPS6KA3	-	1	G -> V (in CLS; dbSNP:rs122454124)	VARIANT	0
P51812/H127Q	RPS6KA3	-	1	H -> Q (in CLS)	VARIANT	0
P51812/I189K	RPS6KA3	-	1	I -> K (in CLS; dbSNP:rs122454130)	VARIANT	0
P51812/I38S	RPS6KA3	neutral	2	I -> S (in dbSNP:rs56218010)	VARIANT	0
P51812/I416V	RPS6KA3	-	1	I -> V (in a breast cancer sample; somatic mutation; dbSNP:rs148050184)	VARIANT	1
P51812/L608F	RPS6KA3	-	1	L -> F (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
P51812/R114W	RPS6KA3	-	1	R -> W (in CLS; dbSNP:rs122454127)	VARIANT	2
P51812/R383W	RPS6KA3	decrease	1	R -> W (in XLID19; kinase activity is decreased but not abolished; dbSNP:rs122454129)	VARIANT	1
P51812/R723C	RPS6KA3	-	1	R -> C (in dbSNP:rs35026425)	VARIANT	0
P51812/R729Q	RPS6KA3	-	1	R -> Q (in CLS; dbSNP:rs28935171)	VARIANT	0
P51812/S227A	RPS6KA3	-	1	S -> A (in CLS; dbSNP:rs122454125)	VARIANT	0
P51812/T115S	RPS6KA3	-	1	T -> S (in XLID19; dbSNP:rs387906703)	VARIANT	0
P51812/V82F	RPS6KA3	-	1	V -> F (in CLS; dbSNP:rs122454126)	VARIANT	0
P51812/Y483C	RPS6KA3	-	1	Y -> C (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1271090915)	VARIANT	3
P51813/R670W	BMX	-	1	R -> W (in a lung large cell carcinoma sample; somatic mutation; dbSNP:rs1029888196)	VARIANT	2
P51813/S284L	BMX	-	1	S -> L (in dbSNP:rs35353387)	VARIANT	0
P51813/Y566F	BMX	loss	1	Y->F: Abolishes almost completely the SRC-induced phosphorylation of BMX.	MUTAGEN	0
P51817/H93Q	PRKX	-	1	H->Q: Constitutive kinase activity; when associated with R-202.	MUTAGEN	0
P51817/K78R	PRKX	loss	1	K->R: Loss of function.	MUTAGEN	0
P51817/R283L	PRKX	increase	1	R->L: Increases the affinity for PRKAR2A and PRKAR2B.	MUTAGEN	0
P51817/V43A	PRKX	neutral	0	V -> A (in dbSNP:rs3752362)	VARIANT	1
P51817/W202R	PRKX	-	1	W->R: Constitutive kinase activity; when associated with Q-93.	MUTAGEN	0
P51841/A1010V	GUCY2F	-	1	A -> V (in dbSNP:rs55735218)	VARIANT	0
P51841/E1055D	GUCY2F	-	1	E -> D (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
P51841/E794K	GUCY2F	neutral	1	E -> K (in dbSNP:rs35726803)	VARIANT	0
P51841/G434R	GUCY2F	-	1	G -> R (in dbSNP:rs56293008)	VARIANT	0
P51841/G568D	GUCY2F	-	1	G -> D (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs779221554)	VARIANT	1
P51841/G872D	GUCY2F	-	1	G -> D (in dbSNP:rs148663380)	VARIANT	0
P51841/I160N	GUCY2F	neutral	1	I -> N (in dbSNP:rs33971675)	VARIANT	0
P51841/K1052R	GUCY2F	-	1	K -> R (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
P51841/L284P	GUCY2F	neutral	1	L -> P (in dbSNP:rs12008095)	VARIANT	1
P51841/Q380H	GUCY2F	neutral	1	Q -> H (in dbSNP:rs2272925)	VARIANT	0
P51841/R10P	GUCY2F	-	1	R -> P (in a breast cancer sample; somatic mutation; dbSNP:rs755991142)	VARIANT	2
P51841/R230W	GUCY2F	neutral	1	R -> W (in dbSNP:rs33973457)	VARIANT	0
P51841/R296Q	GUCY2F	neutral	1	R -> Q (in dbSNP:rs502209)	VARIANT	1
P51841/R305Q	GUCY2F	-	1	R -> Q (in dbSNP:rs55966326)	VARIANT	0
P51841/R628Q	GUCY2F	neutral	1	R -> Q (in dbSNP:rs7883913)	VARIANT	3
P51841/S40C	GUCY2F	neutral	1	S -> C (in dbSNP:rs34228145)	VARIANT	1
P51841/V677L	GUCY2F	neutral	1	V -> L (in dbSNP:rs35474112)	VARIANT	0
P51841/Y308C	GUCY2F	neutral	1	Y -> C (in dbSNP:rs16985750)	VARIANT	0
P51955/C410Y	NEK2	-	1	C -> Y (in dbSNP:rs56102977)	VARIANT	0
P51955/D141A	NEK2	loss	1	D->A: Loss of autophosphorylation.	MUTAGEN	0
P51955/K37R	NEK2	loss	3	K->R: Loss of kinase activity and of ability to activate NEK11. Loss of phosphorylation of CCDC102B.	MUTAGEN	0
P51955/N354S	NEK2	neutral	1	N -> S (in dbSNP:rs2230489)	VARIANT	0
P51955/S171A	NEK2	-	1	S->A: No effect on kinase activity.	MUTAGEN	0
P51955/S171D	NEK2	increase	1	S->D: Kinase activity increased by two fold.	MUTAGEN	0
P51955/S241A	NEK2	loss	1	S->A: Loss of kinase activity.	MUTAGEN	0
P51955/S241D	NEK2	loss	1	S->D: Loss of kinase activity.	MUTAGEN	0
P51955/T170A	NEK2	-	1	T->A: No effect on kinase activity.	MUTAGEN	0
P51955/T170E	NEK2	increase	1	T->E: Kinase activity increased by two fold.	MUTAGEN	0
P51955/T175A	NEK2	decrease	1	T->A: Kinase activity decreased by two fold.	MUTAGEN	0
P51955/T175E	NEK2	increase	1	T->E: Kinase activity increased by two fold.	MUTAGEN	0
P51955/T179A	NEK2	loss	1	T->A: Loss of kinase activity.	MUTAGEN	0
P51955/T179E	NEK2	loss	1	T->E: Loss of kinase activity.	MUTAGEN	0
P51956/D461N	NEK3	-	1	D -> N (in dbSNP:rs34076988)	VARIANT	0
P51956/E305D	NEK3	neutral	1	E -> D (in dbSNP:rs55969405)	VARIANT	0
P51956/E477K	NEK3	neutral	1	E -> K (in dbSNP:rs34488913)	VARIANT	0
P51956/H23L	NEK3	neutral	1	H -> L (in dbSNP:rs17482764)	VARIANT	0
P51956/P170L	NEK3	-	1	P -> L (in dbSNP:rs56021040)	VARIANT	0
P51956/P60R	NEK3	-	1	P -> R (in dbSNP:rs55946204)	VARIANT	0
P51956/R122H	NEK3	neutral	1	R -> H (in dbSNP:rs56190615)	VARIANT	0
P51956/R259G	NEK3	-	1	R -> G (in dbSNP:rs34077016)	VARIANT	0
P51957/F567L	NEK4	neutral	1	F -> L (in dbSNP:rs34986855)	VARIANT	0
P51957/P225A	NEK4	neutral	3	P -> A (in dbSNP:rs1029871)	VARIANT	0
P51957/P250L	NEK4	-	1	P -> L (in dbSNP:rs56408749)	VARIANT	0
P51957/Q456E	NEK4	-	1	Q -> E (in dbSNP:rs56019351)	VARIANT	0
P51957/R239G	NEK4	-	1	R -> G (in dbSNP:rs35778416)	VARIANT	0
P51957/R777K	NEK4	-	1	R -> K (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
P51957/T357I	NEK4	neutral	1	T -> I (in dbSNP:rs2230537)	VARIANT	0
P52333/C759R	JAK3	activating	1	C -> R (in T(-)B(+)NK(-) SCID; constitutive phosphorylation)	VARIANT	0
P52333/D169E	JAK3	-	1	D -> E (in T(-)B(+)NK(-) SCID; dbSNP:rs147181709)	VARIANT	0
P52333/E481G	JAK3	-	1	E -> G (in T(-)B(+)NK(-) SCID)	VARIANT	0
P52333/G589S	JAK3	-	1	G -> S (in T(-)B(+)NK(-) SCID; dbSNP:rs886039394)	VARIANT	0
P52333/I688F	JAK3	-	1	I -> F (in dbSNP:rs35785705)	VARIANT	0
P52333/K855A	JAK3	loss	1	K->A: More than 90% loss of STAT5a activation.	MUTAGEN	0
P52333/L521V	JAK3	-	1	L -> V (in dbSNP:rs55666418)	VARIANT	0
P52333/L527P	JAK3	-	1	L -> P (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	3
P52333/L910S	JAK3	-	1	L -> S (in T(-)B(+)NK(-) SCID)	VARIANT	0
P52333/P12L	JAK3	-	1	P -> L (in dbSNP:rs56061056)	VARIANT	0
P52333/P132T	JAK3	neutral	1	P -> T (in dbSNP:rs3212723)	VARIANT	0
P52333/P151R	JAK3	-	2	P -> R (in T(-)B(+)NK(-) SCID; likely benign variant; dbSNP:rs55778349)	VARIANT	0
P52333/R40H	JAK3	-	1	R -> H (in dbSNP:rs56384680)	VARIANT	3
P52333/R582W	JAK3	-	1	R -> W (in T(-)B(+)NK(-) SCID; dbSNP:rs193922361)	VARIANT	0
P52333/V722I	JAK3	neutral	3	V -> I (in dbSNP:rs3213409)	VARIANT	43
P52333/Y100C	JAK3	-	1	Y -> C (in T(-)B(+)NK(-) SCID; dbSNP:rs137852624)	VARIANT	0
P52333/Y785F	JAK3	decrease	1	Y->F: Strong decrease of JAK3 phosphorylation.	MUTAGEN	0
P52333/Y904F	JAK3	decrease	1	Y->F: About 40% loss of STAT5a activation.	MUTAGEN	0
P52333/Y939F	JAK3	loss	1	Y->F: About 80% loss of STAT5a activation.	MUTAGEN	0
P52564/S207A	MAP2K6	loss	0	S->A: Inactivation.	MUTAGEN	0
P52564/S207E	MAP2K6	activating	2	S->E: Constitutive activation according to PubMed:8622669, but not to PubMed:8621675.	MUTAGEN	0
P52564/T211A	MAP2K6	loss	0	T->A: Inactivation.	MUTAGEN	0
P52564/T211E	MAP2K6	activating	2	T->E: Constitutive activation according to PubMed:8622669, but not to PubMed:8621675.	MUTAGEN	0
P53004/A3T	BLVRA	neutral	2	A -> T (in dbSNP:rs699512)	VARIANT	0
P53004/L37V	BLVRA	-	0	L -> V (in dbSNP:rs17245918)	VARIANT	0
P53004/Q56R	BLVRA	neutral	0	Q -> R (in dbSNP:rs1050916)	VARIANT	0
P53350/C67V	PLK1	-	1	C->V: In analog-sensitive mutant; enlarged catalytic pocket to accommodate purine analogs; when associated with G-130.	MUTAGEN	0
P53350/D176N	PLK1	loss	1	D->N: Abolishes kinase activity.	MUTAGEN	0
P53350/D194A	PLK1	-	1	D->A: Does not interfere with FRY-binding.	MUTAGEN	0
P53350/H538A	PLK1	-	4	H->A: In pincer mutant; loss of centrosomal location and decreased interaction with phosphorylated CDC25C and BUB1; when associated with M-540.	MUTAGEN	0
P53350/K492R	PLK1	-	1	K->R: Severe mitotic defects leading to prometaphase delay. Increased localization at kinetochores leading to increased levels of phosphorylated BUBR1.	MUTAGEN	0
P53350/K540M	PLK1	-	4	K->M: In pincer mutant; loss of centrosomal location and decreased interaction with phosphorylated CDC25C and BUB1; when associated with A-538.	MUTAGEN	0
P53350/K82M	PLK1	loss	4	K->M: Loss of kinase activity. No effect on S-phase progression.	MUTAGEN	0
P53350/K82R	PLK1	loss	3	K->R: Loss of kinase activity. No effect on RIOK2-binding.	MUTAGEN	0
P53350/L130G	PLK1	-	1	L->G: In analog-sensitive mutant; enlarged catalytic pocket to accommodate purine analogs; when associated with V-67.	MUTAGEN	0
P53350/L261F	PLK1	neutral	1	L -> F (in dbSNP:rs35056440)	VARIANT	0
P53350/L332V	PLK1	-	1	L -> V (in dbSNP:rs45489499)	VARIANT	0
P53350/L340A	PLK1	-	2	L->A: Interferes with ubiquitination and subsequent proteasomal degradation in anaphase; when associated with A-337.	MUTAGEN	0
P53350/L427A	PLK1	-	1	L->A: No effect on centrosomal localization, nor on S-phase progression; when associated with A-414. Loss of centrosomal localization and of S-phase progression; when associated with A- 414 and A-415.	MUTAGEN	0
P53350/L463H	PLK1	neutral	1	L -> H (in dbSNP:rs45569335)	VARIANT	0
P53350/N297D	PLK1	-	0	N -> D (in dbSNP:rs16972799)	VARIANT	0
P53350/R12L	PLK1	-	1	R -> L (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
P53350/R337A	PLK1	-	2	R->A: Interferes with ubiquitination and subsequent proteasomal degradation in anaphase; when associated with A-340.	MUTAGEN	0
P53350/R518H	PLK1	-	1	R -> H (in dbSNP:rs56027600)	VARIANT	0
P53350/R599H	PLK1	-	0	R -> H (in dbSNP:rs34954545)	VARIANT	0
P53350/S137A	PLK1	-	2	S->A: No change in activity. Increases activity and restores recovery after DNA damage checkpoint; when associated with D-210.	MUTAGEN	0
P53350/S137D	PLK1	increase	2	S->D: Increases activity. Results in a block in G1/S.	MUTAGEN	0
P53350/S595L	PLK1	-	0	S -> L (in dbSNP:rs34001032)	VARIANT	0
P53350/T210A	PLK1	loss	5	T->A: Abolishes activity. Abolishes checkpoint recovery.	MUTAGEN	0
P53350/T210V	PLK1	decrease	5	T->V: Reduced catalytic activity, but no effect on affinity for ATP.	MUTAGEN	0
P53350/V415A	PLK1	-	1	V->A: Loss of centrosomal localization and of S-phase progression; when associated with A- 414 and A-427.	MUTAGEN	0
P53350/W414F	PLK1	-	1	W->F: No effect on centrosomal localization, nor on S-phase progression; when asscociated with A-427. Loss of centrosomal localization and of S-phase progression; when associated with A- 415 and A-427.	MUTAGEN	0
P53355/A461S	DAPK1	-	1	A -> S	VARIANT	0
P53355/C540Y	DAPK1	-	1	C -> Y (in dbSNP:rs56327474)	VARIANT	0
P53355/D1007Y	DAPK1	-	1	D -> Y	VARIANT	0
P53355/D994E	DAPK1	-	1	D -> E	VARIANT	0
P53355/E1005Q	DAPK1	-	1	E -> Q	VARIANT	0
P53355/G1405V	DAPK1	neutral	1	G -> V (in dbSNP:rs36220450)	VARIANT	0
P53355/I622M	DAPK1	neutral	0	I -> M (in dbSNP:rs36215047)	VARIANT	0
P53355/K42A	DAPK1	loss	2	K->A: Loss of activity, apoptotic function and of autophosphorylation.	MUTAGEN	0
P53355/K978N	DAPK1	-	1	K -> N	VARIANT	0
P53355/L1008P	DAPK1	-	1	L -> P	VARIANT	0
P53355/M1272I	DAPK1	neutral	1	M -> I (in dbSNP:rs56169226)	VARIANT	0
P53355/M941T	DAPK1	-	1	M -> T	VARIANT	0
P53355/P591L	DAPK1	-	0	P -> L (in dbSNP:rs36214022)	VARIANT	1
P53355/R1010C	DAPK1	-	1	R -> C (in dbSNP:rs371784492)	VARIANT	0
P53355/R977W	DAPK1	-	1	R -> W	VARIANT	0
P53355/S1346N	DAPK1	neutral	4	S -> N (in dbSNP:rs1056719)	VARIANT	3
P53355/S289A	DAPK1	activating	0	S->A: Loss of phosphorylation and significant increase in proapoptotic activity.	MUTAGEN	0
P53355/S289E	DAPK1	decrease	0	S->E: Reduction in proapoptotic activity.	MUTAGEN	0
P53355/S308A	DAPK1	increase	1	S->A: Elevated Ca(2+)-calmodulin binding and Ca(2+)-calmodulin-independent kinase activity. Increases apoptotic activity.	MUTAGEN	0
P53355/S308D	DAPK1	decrease	1	S->D: Reduced Ca(2+)-calmodulin binding and Ca(2+)-calmodulin-independent kinase activity. Decreases apoptotic activity.	MUTAGEN	0
P53355/S313A	DAPK1	-	1	S->A: Minimal effect on activity.	MUTAGEN	0
P53355/S519A	DAPK1	-	1	S -> A	VARIANT	0
P53355/T1018A	DAPK1	-	1	T -> A	VARIANT	0
P53355/V416I	DAPK1	neutral	1	V -> I (in dbSNP:rs12343465)	VARIANT	0
P53355/Y993C	DAPK1	-	1	Y -> C	VARIANT	0
P53667/C84S	LIMK1	increase	1	C->S: Enhances actin aggregation.	MUTAGEN	0
P53667/D460A	LIMK1	loss	2	D->N,A: Abrogates kinase activity.	MUTAGEN	0
P53667/D460N	LIMK1	loss	2	D->N,A: Abrogates kinase activity.	MUTAGEN	0
P53667/F580Y	LIMK1	-	2	F -> Y (in dbSNP:rs178412)	VARIANT	0
P53667/G190A	LIMK1	neutral	1	G -> A (in dbSNP:rs35827364)	VARIANT	0
P53667/R422Q	LIMK1	-	1	R -> Q (in dbSNP:rs55679316)	VARIANT	0
P53667/S247N	LIMK1	-	1	S -> N (in dbSNP:rs55661242)	VARIANT	0
P53667/T508A	LIMK1	loss	2	T->A: Abolishes activation by ROCK1.	MUTAGEN	0
P53667/T508E	LIMK1	increase	1	T->E: Phosphomimetic mutant; enhances kinase activity.	MUTAGEN	0
P53667/T508V	LIMK1	decrease	2	T->V: Reduces kinase activity.	MUTAGEN	0
P53671/D451A	LIMK2	loss	1	D->A: Abrogates kinase activity.	MUTAGEN	0
P53671/D45N	LIMK2	-	1	D -> N (in dbSNP:rs35923988)	VARIANT	0
P53671/G35S	LIMK2	neutral	1	G -> S (in dbSNP:rs5997917)	VARIANT	0
P53671/P296R	LIMK2	-	1	P -> R (in dbSNP:rs34875793)	VARIANT	0
P53671/R213C	LIMK2	neutral	1	R -> C (in dbSNP:rs34930775)	VARIANT	0
P53671/R381H	LIMK2	-	0	R -> H (in dbSNP:rs2229874)	VARIANT	0
P53671/R418C	LIMK2	-	1	R -> C (in dbSNP:rs35422808)	VARIANT	0
P53671/T505E	LIMK2	increase	2	T->E: Phosphomimetic mutant; enhances kinase activity.	MUTAGEN	0
P53671/T505V	LIMK2	loss	1	T->V: Abolishes cofilin phosphorylation and enhancement of stress fiber formation.	MUTAGEN	0
P53778/D179A	MAPK12	activating	1	D->A: Emulation of the active state.	MUTAGEN	0
P53778/D230N	MAPK12	-	1	D -> N (in dbSNP:rs35396905)	VARIANT	0
P53778/F330S	MAPK12	-	1	F->S: No effect.	MUTAGEN	0
P53778/T103M	MAPK12	-	2	T -> M (in dbSNP:rs34422484)	VARIANT	0
P53778/T244M	MAPK12	-	0	T -> M (in dbSNP:rs2066776)	VARIANT	0
P53778/Y185F	MAPK12	loss	1	Y->F: Loss of activity.	MUTAGEN	0
P53779/C462S	MAPK10	loss	1	C->S: Loss of palmitoylation.	MUTAGEN	0
P54646/P371T	PRKAA2	-	2	P -> T (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	VARIANT	3
P54646/R407Q	PRKAA2	-	1	R -> Q (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	3
P54646/S523G	PRKAA2	-	1	S -> G (in a breast cancer sample; somatic mutation)	VARIANT	2
P54646/T172D	PRKAA2	-	0	T->D: Phosphomimetic mutant.	MUTAGEN	0
P54753/I579V	EPHB3	-	1	I -> V (in dbSNP:rs56103851)	VARIANT	0
P54753/I601L	EPHB3	-	1	I -> L (in dbSNP:rs56129875)	VARIANT	0
P54753/K665R	EPHB3	loss	1	K->R: Kinase-dead. Loss of autophosphorylation.	MUTAGEN	0
P54753/R168L	EPHB3	-	1	R -> L (in a lung small cell carcinoma sample; somatic mutation)	VARIANT	1
P54753/R440C	EPHB3	-	1	R -> C (in dbSNP:rs56029711)	VARIANT	0
P54753/R724W	EPHB3	-	1	R -> W (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs371378866)	VARIANT	0
P54753/Y614F	EPHB3	-	1	Y->F: Partial loss of phosphorylation and loss of interaction with SH2-containing proteins.	MUTAGEN	0
P54756/A672T	EPHA5	neutral	1	A -> T (in dbSNP:rs36050417)	VARIANT	0
P54756/E330Q	EPHA5	-	1	E -> Q (in dbSNP:rs56205382)	VARIANT	0
P54756/E503K	EPHA5	-	1	E -> K (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
P54756/G582E	EPHA5	-	1	G -> E (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs1057520012)	VARIANT	0
P54756/H959R	EPHA5	-	1	H -> R (in dbSNP:rs56312931)	VARIANT	0
P54756/N1032S	EPHA5	-	1	N -> S (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
P54756/N81T	EPHA5	neutral	1	N -> T (in dbSNP:rs33932471)	VARIANT	0
P54756/R417Q	EPHA5	-	1	R -> Q (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs199614818)	VARIANT	2
P54756/S235A	EPHA5	-	1	S -> A (in dbSNP:rs55710198)	VARIANT	0
P54756/S673T	EPHA5	-	1	S -> T (in dbSNP:rs56359290)	VARIANT	0
P54756/T856I	EPHA5	-	1	T -> I (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
P54756/Y506C	EPHA5	-	1	Y -> C (in dbSNP:rs56074660)	VARIANT	0
P54760/A371V	EPHB4	neutral	1	A -> V (in dbSNP:rs55720981)	VARIANT	1
P54760/A509G	EPHB4	-	1	A -> G (does not affect tyrosine phosphorylation; does not affect interaction with RASA1; dbSNP:rs146937374)	VARIANT	0
P54760/A725T	EPHB4	-	1	A -> T (in CMAVM2; unknown pathological significance; dbSNP:rs1159930961)	VARIANT	0
P54760/A882T	EPHB4	neutral	1	A -> T (in dbSNP:rs34918225)	VARIANT	3
P54760/C107R	EPHB4	-	1	C -> R (in CMAVM2; unknown pathological significance; dbSNP:rs1562974383)	VARIANT	0
P54760/C268R	EPHB4	-	1	C -> R (in CMAVM2; unknown pathological significance; dbSNP:rs201816920)	VARIANT	0
P54760/C845R	EPHB4	loss	1	C -> R (in CMAVM2; the mutant protein is not detected by Western blot; loss of localization to cell membrane; dbSNP:rs1584653054)	VARIANT	0
P54760/C856Y	EPHB4	-	1	C -> Y (in CMAVM2; dbSNP:rs1584653005)	VARIANT	0
P54760/D576E	EPHB4	-	1	D -> E (in dbSNP:rs36050247)	VARIANT	0
P54760/D802G	EPHB4	-	1	D -> G (in CMAVM2; dbSNP:rs776410552)	VARIANT	0
P54760/E59K	EPHB4	-	1	E -> K (in CMAVM2; unknown pathological significance; dbSNP:rs1584667224)	VARIANT	0
P54760/E664K	EPHB4	loss	1	E -> K (in CMAVM2; the mutant protein is not detected by Western blot; loss of localization to cell membrane; dbSNP:rs1562969219)	VARIANT	0
P54760/E890D	EPHB4	neutral	1	E -> D (in dbSNP:rs35638378)	VARIANT	0
P54760/F867L	EPHB4	decrease	1	F -> L (in CMAVM2; loss of tyrosine phosphorylation; loss of interaction with RASA1; dbSNP:rs1584652949)	VARIANT	0
P54760/G516R	EPHB4	-	1	G -> R (in CMAVM2; unknown pathological significance; dbSNP:rs776305185)	VARIANT	0
P54760/G807R	EPHB4	-	1	G -> R (in CMAVM2; unknown pathological significance; dbSNP:rs1330628156)	VARIANT	0
P54760/I782S	EPHB4	loss	1	I -> S (in LMPHM7; loss of kinase activity; dbSNP:rs1057519264)	VARIANT	0
P54760/K162R	EPHB4	-	1	K -> R (in dbSNP:rs17854760)	VARIANT	0
P54760/K650N	EPHB4	decrease	1	K -> N (in CMAVM2; highly decreased tyrosine phosphorylation; highly decreased interaction with RASA1; dbSNP:rs1584658113)	VARIANT	0
P54760/L187P	EPHB4	-	1	L -> P (in CMAVM2; unknown pathological significance; dbSNP:rs1584666053)	VARIANT	0
P54760/L874P	EPHB4	-	1	L -> P (in CMAVM2; unknown pathological significance; dbSNP:rs1584652900)	VARIANT	0
P54760/L95R	EPHB4	decrease	1	L->R: Reduces binding affinity for EFNB2.	MUTAGEN	0
P54760/N745D	EPHB4	-	1	N -> D (in CMAVM2; dbSNP:rs1584654433)	VARIANT	0
P54760/P346L	EPHB4	-	1	P -> L (in a metastatic melanoma sample; somatic mutation; dbSNP:rs267601191)	VARIANT	1
P54760/P67L	EPHB4	-	1	P -> L (in dbSNP:rs34653459)	VARIANT	0
P54760/P789R	EPHB4	-	1	P -> R (in CMAVM2; unknown pathological significance; dbSNP:rs753075600)	VARIANT	0
P54760/P789S	EPHB4	-	1	P -> S (in CMAVM2; unknown pathological significance; dbSNP:rs1417508111)	VARIANT	0
P54760/P820L	EPHB4	-	1	P -> L (in CMAVM2; unknown pathological significance; dbSNP:rs1584653650)	VARIANT	0
P54760/P820T	EPHB4	-	1	P -> T (in CMAVM2; unknown pathological significance; dbSNP:rs1584653653)	VARIANT	0
P54760/R656W	EPHB4	-	1	R -> W (in CMAVM2; unknown pathological significance; dbSNP:rs745584371)	VARIANT	0
P54760/R678H	EPHB4	-	1	R -> H (in dbSNP:rs55692440)	VARIANT	0
P54760/R739Q	EPHB4	loss	1	R -> Q (in LMPHM7; loss of kinase activity; dbSNP:rs1057519263)	VARIANT	0
P54760/R74P	EPHB4	-	1	R -> P (in CMAVM2; unknown pathological significance; dbSNP:rs61735971)	VARIANT	0
P54760/R838W	EPHB4	loss	1	R -> W (in CMAVM2; the mutant protein is not detected by Western blot; loss of localization to cell membrane; dbSNP:rs764827256)	VARIANT	0
P54760/R864W	EPHB4	loss	1	R -> W (in CMAVM2; the mutant protein is not detected by Western blot; loss of localization to cell membrane; dbSNP:rs769965440)	VARIANT	0
P54760/R889W	EPHB4	-	1	R -> W (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs762016655)	VARIANT	4
P54760/V113I	EPHB4	-	1	V -> I (in dbSNP:rs55866373)	VARIANT	0
P54760/V469G	EPHB4	-	1	V -> G (in CMAVM2; unknown pathological significance; dbSNP:rs1584662591)	VARIANT	0
P54760/V870E	EPHB4	-	1	V -> E (in CMAVM2; unknown pathological significance; dbSNP:rs1584652920)	VARIANT	0
P54762/A912T	EPHB1	-	1	A -> T (in dbSNP:rs56345346)	VARIANT	0
P54762/G152R	EPHB1	-	0	G -> R (in dbSNP:rs1042793)	VARIANT	0
P54762/I719V	EPHB1	-	1	I -> V (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	2
P54762/K651R	EPHB1	loss	2	K->R: Kinase-dead mutant. Unable to autophosphorylate, to interact with SH2 domain-containing interactors, to activate the MAPK/ERK and JUN signaling cascades. Not ubiquitinated by CBL.	MUTAGEN	0
P54762/M18V	EPHB1	-	1	M -> V (in dbSNP:rs55650774)	VARIANT	0
P54762/M847T	EPHB1	-	0	M -> T (in dbSNP:rs1042785)	VARIANT	0
P54762/R367G	EPHB1	-	0	R -> G (in dbSNP:rs1042789)	VARIANT	0
P54762/R485S	EPHB1	-	0	R -> S (in dbSNP:rs1042788)	VARIANT	0
P54762/R743Q	EPHB1	-	1	R -> Q (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1338928289)	VARIANT	5
P54762/R973W	EPHB1	-	1	R -> W (in dbSNP:rs1042784)	VARIANT	0
P54762/S707T	EPHB1	-	1	S -> T (in an ovarian undifferentiated carcinoma sample; somatic mutation)	VARIANT	0
P54762/T387M	EPHB1	-	1	T -> M (in dbSNP:rs56396912)	VARIANT	4
P54762/T87S	EPHB1	-	0	T -> S (in dbSNP:rs1042794)	VARIANT	0
P54762/T981M	EPHB1	-	1	T -> M (in dbSNP:rs56186270)	VARIANT	0
P54762/Y594F	EPHB1	decrease	1	Y->F: Loss of interaction with NCK1.	MUTAGEN	0
P54762/Y600F	EPHB1	decrease	1	Y->F: Loss of interaction with SHC1 and SRC.	MUTAGEN	0
P54762/Y778F	EPHB1	decrease	1	Y->F: Loss of interaction with SHC1.	MUTAGEN	0
P54762/Y928F	EPHB1	decrease	3	Y->F: Disrupts binding with the GRB10 SH2 domain, providing evidence for phosphorylation. Disrupts interaction with GRB7 and ACP1.	MUTAGEN	0
P54764/E42A	EPHA4	-	1	E->A: 10-fold reduced affinity for EFNB2; when associated with A-40.	MUTAGEN	0
P54764/G370E	EPHA4	-	1	G -> E (in a bladder carcinoma NOS sample; somatic mutation; dbSNP:rs756952113)	VARIANT	0
P54764/Q40A	EPHA4	-	1	Q->A: 10-fold reduced affinity for EFNB2; when associated with A-42.	MUTAGEN	0
P54764/R269Q	EPHA4	-	1	R -> Q (in dbSNP:rs35084379)	VARIANT	0
P54764/R953K	EPHA4	-	0	R -> K (in dbSNP:rs35341687)	VARIANT	0
P54764/S399F	EPHA4	-	1	S -> F (in a metastatic melanoma sample; somatic mutation; dbSNP:rs868224085)	VARIANT	3
P57058/E625K	HUNK	-	1	E -> K (in dbSNP:rs56021554)	VARIANT	0
P57058/M648T	HUNK	-	1	M -> T (in dbSNP:rs56240027)	VARIANT	0
P57058/R157W	HUNK	-	1	R -> W (in dbSNP:rs35133981)	VARIANT	0
P57058/R591C	HUNK	neutral	1	R -> C (in dbSNP:rs10775648)	VARIANT	0
P57059/A615V	SIK1	neutral	3	A -> V (in dbSNP:rs430554)	VARIANT	1
P57059/A725V	SIK1	neutral	1	A -> V (in dbSNP:rs35596465)	VARIANT	0
P57059/D142N	SIK1	-	1	D -> N (in dbSNP:rs45491503)	VARIANT	2
P57059/G15S	SIK1	neutral	1	G -> S (in dbSNP:rs3746951)	VARIANT	3
P57059/G211S	SIK1	-	1	G -> S (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
P57059/G469D	SIK1	-	1	G -> D (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
P57059/G636S	SIK1	-	1	G -> S (in DEE30; no change in subcellular location; dbSNP:rs786205163)	VARIANT	0
P57059/K56M	SIK1	loss	2	K->M: Loss of kinase activity.	MUTAGEN	0
P57059/P287T	SIK1	-	1	P -> T (in DEE30; no change in subcellular location; dbSNP:rs786205159)	VARIANT	0
P57059/P696L	SIK1	neutral	1	P -> L (in dbSNP:rs56386767)	VARIANT	2
P57059/R430W	SIK1	-	0	R -> W (in dbSNP:rs34164089)	VARIANT	0
P57059/S135A	SIK1	decrease	1	S->A: Decreased kinase activity without affecting much autophosphorylation status.	MUTAGEN	0
P57059/S186A	SIK1	loss	1	S->A,D,C,G: Impaired autophosphorylation and kinase activity.	MUTAGEN	0
P57059/S186C	SIK1	-	1	S->A,D,C,G: Impaired autophosphorylation and kinase activity.	MUTAGEN	0
P57059/S186D	SIK1	-	1	S->A,D,C,G: Impaired autophosphorylation and kinase activity.	MUTAGEN	0
P57059/S186G	SIK1	-	1	S->A,D,C,G: Impaired autophosphorylation and kinase activity.	MUTAGEN	0
P57059/S186T	SIK1	decrease	1	S->T: Does not autophosphorylation and kinase activity.	MUTAGEN	0
P57059/S209A	SIK1	decrease	1	S->A: Decreased kinase activity without affecting much autophosphorylation status.	MUTAGEN	0
P57059/S248A	SIK1	decrease	1	S->A: Decreased kinase activity without affecting much autophosphorylation status.	MUTAGEN	0
P57059/S411C	SIK1	-	1	S -> C (in DEE30; no change in subcellular location)	VARIANT	0
P57059/S575A	SIK1	decrease	0	S->A: Loss of interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit 	MUTAGEN	0
P57059/S575E	SIK1	decrease	1	S->E: Strongly reduced but still present interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity.	MUTAGEN	0
P57059/T182A	SIK1	decrease	2	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex. Reduced inhibition of CRTC3-mediated transcriptional activity.	MUTAGEN	0
P57059/T473A	SIK1	-	1	T->A: Reduced but still present interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity. Resistant to inhibition by cAMP signaling and, thus, still able to inhibit TORC activity; when associated with A-575.	MUTAGEN	0
P57059/T473E	SIK1	decrease	1	T->E: Reduced but still present interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity.	MUTAGEN	0
P57078/A12G	RIPK4	neutral	0	A -> G (in dbSNP:rs6586239)	VARIANT	0
P57078/A496P	RIPK4	-	1	A -> P (in BPS; unknown pathological significance)	VARIANT	0
P57078/E284K	RIPK4	-	1	E -> K (in CHANDS; unknown pathological significance)	VARIANT	1
P57078/G163D	RIPK4	-	1	G -> D (in CHANDS; unknown pathological significance; dbSNP:rs764278537)	VARIANT	0
P57078/I121N	RIPK4	loss	1	I -> N (in BPS; loss of function; dbSNP:rs387906923)	VARIANT	0
P57078/I462N	RIPK4	-	1	I -> N (in dbSNP:rs55809511)	VARIANT	0
P57078/I81N	RIPK4	-	1	I -> N (in BPS; dbSNP:rs387906922)	VARIANT	0
P57078/N562Y	RIPK4	-	1	N -> Y (in dbSNP:rs55829311)	VARIANT	0
P57078/P189L	RIPK4	-	1	P -> L (in BPS; unknown pathological significance)	VARIANT	0
P57078/P749S	RIPK4	neutral	1	P -> S (in dbSNP:rs35537517)	VARIANT	0
P57078/R666H	RIPK4	-	1	R -> H (in BPS; unknown pathological significance; dbSNP:rs763794698)	VARIANT	2
P57078/R669H	RIPK4	-	1	R -> H (in dbSNP:rs56056485)	VARIANT	0
P57078/S177N	RIPK4	-	0	S -> N (in dbSNP:rs12482626)	VARIANT	0
P57078/T184I	RIPK4	loss	1	T -> I (in BPS; loss of function)	VARIANT	0
P57078/V463M	RIPK4	-	1	V -> M (in dbSNP:rs55645753)	VARIANT	0
P68400/D175G	CSNK2A1	-	1	D -> G (in OCNDS; dbSNP:rs869312848)	VARIANT	0
P68400/K198R	CSNK2A1	-	1	K -> R (in OCNDS; dbSNP:rs869312840)	VARIANT	0
P68400/R47Q	CSNK2A1	-	1	R -> Q (in OCNDS; dbSNP:rs869312845)	VARIANT	0
P68400/Y50S	CSNK2A1	-	1	Y -> S (in OCNDS; dbSNP:rs869312849)	VARIANT	0
P78362/G243D	SRPK2	-	1	G -> D (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
P78362/L615I	SRPK2	-	0	L -> I (in dbSNP:rs1050418)	VARIANT	0
P78362/P43L	SRPK2	-	1	P -> L (in dbSNP:rs34699980)	VARIANT	2
P78362/P515T	SRPK2	-	1	P -> T (in dbSNP:rs56017595)	VARIANT	0
P78362/S486F	SRPK2	-	1	S -> F (in dbSNP:rs56112661)	VARIANT	0
P78362/S608N	SRPK2	-	0	S -> N (in dbSNP:rs1050413)	VARIANT	0
P78362/T426P	SRPK2	-	1	T -> P (in dbSNP:rs55743527)	VARIANT	0
P78368/E194G	CSNK1G2	-	1	E -> G (in dbSNP:rs55780547)	VARIANT	0
P78368/E208Q	CSNK1G2	-	1	E -> Q (in dbSNP:rs55818316)	VARIANT	0
P78368/F189L	CSNK1G2	-	1	F -> L (in dbSNP:rs55702630)	VARIANT	0
P78368/I196T	CSNK1G2	-	1	I -> T (in dbSNP:rs55923222)	VARIANT	0
P78368/R207S	CSNK1G2	-	1	R -> S (in dbSNP:rs56340103)	VARIANT	0
P78368/R217C	CSNK1G2	-	1	R -> C (in dbSNP:rs55754218)	VARIANT	0
P78368/T223M	CSNK1G2	-	1	T -> M (in dbSNP:rs56038081)	VARIANT	0
P78368/Y206C	CSNK1G2	-	1	Y -> C (in dbSNP:rs56264133)	VARIANT	0
P78368/Y206H	CSNK1G2	-	1	Y -> H (in dbSNP:rs56108438)	VARIANT	0
P78527/A1237T	PRKDC	-	1	A -> T (in dbSNP:rs191531119)	VARIANT	0
P78527/A6S	PRKDC	-	1	A -> S (in dbSNP:rs8177999)	VARIANT	0
P78527/F649L	PRKDC	-	1	F -> L (in dbSNP:rs55811715)	VARIANT	0
P78527/G1314V	PRKDC	-	0	G -> V (in dbSNP:rs8178090)	VARIANT	0
P78527/G500S	PRKDC	-	1	G -> S (in a metastatic melanoma sample; somatic mutation)	VARIANT	0
P78527/I680M	PRKDC	neutral	0	I -> M (in dbSNP:rs8178040)	VARIANT	0
P78527/K263N	PRKDC	-	1	K -> N (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs758032015)	VARIANT	0
P78527/L1190V	PRKDC	-	1	L -> V (in dbSNP:rs34598508)	VARIANT	0
P78527/L1279F	PRKDC	-	1	L -> F	VARIANT	0
P78527/M333I	PRKDC	neutral	1	M -> I (in dbSNP:rs8178017)	VARIANT	0
P78527/N1071S	PRKDC	neutral	0	N -> S (in dbSNP:rs8178070)	VARIANT	0
P78527/P695S	PRKDC	-	1	P -> S (in dbSNP:rs8178046)	VARIANT	0
P78527/R1136H	PRKDC	-	1	R -> H (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs781401034)	VARIANT	0
P78527/T605S	PRKDC	neutral	1	T -> S (in dbSNP:rs8178033)	VARIANT	0
P78527/V420I	PRKDC	-	1	V -> I (in dbSNP:rs55925466)	VARIANT	0
P80192/A246V	MAP3K9	-	1	A -> V (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
P80192/K171A	MAP3K9	loss	1	K->A: Loss of kinase activity and threonine phosphorylation.	MUTAGEN	0
P80192/R467C	MAP3K9	-	1	R -> C (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs773256562)	VARIANT	3
P80192/R497Q	MAP3K9	-	1	R -> Q (in dbSNP:rs56196343)	VARIANT	0
P80192/S308A	MAP3K9	decrease	1	S->A: Impairs JNK activation.	MUTAGEN	0
P80192/T304A	MAP3K9	decrease	1	T->A: Reduces threonine phosphorylation. Impairs JNK activation.	MUTAGEN	0
P80192/T305A	MAP3K9	decrease	1	T->A: Little effect on threonine phosphorylation. Mildly impairs JNK activation.	MUTAGEN	0
P80192/T312A	MAP3K9	loss	1	T->A: Loss of threonine phosphorylation. Strongly impairs JNK activation.	MUTAGEN	0
P80192/Y646C	MAP3K9	neutral	1	Y -> C (in dbSNP:rs34322726)	VARIANT	0
Q00526/I124T	CDK3	-	1	I -> T (in dbSNP:rs34918446)	VARIANT	0
Q00526/M264T	CDK3	-	1	M -> T (in dbSNP:rs17884251)	VARIANT	0
Q00526/R214H	CDK3	-	1	R -> H (in dbSNP:rs34670267)	VARIANT	0
Q00526/S106N	CDK3	-	1	S -> N (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	0
Q00526/T226I	CDK3	neutral	0	T -> I (in dbSNP:rs2069532)	VARIANT	0
Q00532/K342N	CDKL1	-	0	K -> N (in dbSNP:rs770928060)	VARIANT	0
Q00532/L330V	CDKL1	neutral	1	L -> V (in dbSNP:rs9323183)	VARIANT	0
Q00532/L67P	CDKL1	-	0	L -> P (in dbSNP:rs11570814)	VARIANT	0
Q00532/Q275E	CDKL1	neutral	3	Q -> E (in dbSNP:rs7161563)	VARIANT	3
Q00534/A197T	CDK6	-	1	A -> T (in MCPH12; dbSNP:rs606231255)	VARIANT	0
Q00534/D110N	CDK6	neutral	1	D -> N (in dbSNP:rs35654944)	VARIANT	0
Q00534/P199L	CDK6	-	1	P -> L (in a metastatic melanoma sample; somatic mutation)	VARIANT	3
Q00535/E225D	CDK5	-	1	E -> D (in dbSNP:rs35186917)	VARIANT	0
Q00535/S159A	CDK5	-	1	S->A: No phenotype.	MUTAGEN	0
Q00535/S159T	CDK5	decrease	1	S->T: Impaired p35/p25 (CDK5R1) binding.	MUTAGEN	0
Q00536/K194A	CDK16	loss	2	K->A: Loss of kinase activity. Abolishes effect on insulin secretion.	MUTAGEN	0
Q00536/K194R	CDK16	loss	2	K->R: Loss of kinase activity.	MUTAGEN	0
Q00536/S119A	CDK16	decrease	1	S->A: Strongly reduces interaction with CCNY.	MUTAGEN	0
Q00536/S12A	CDK16	loss	1	S->A: Abolishes phosphorylation by BRSK2. Abolishes effect on insulin secretion.	MUTAGEN	0
Q00536/S153A	CDK16	activating	2	S->A: Constitutively activated, due to loss of an inhibitory phosphorylation site. Increases interaction with CCNY.	MUTAGEN	0
Q00536/S153D	CDK16	decrease	2	S->D: Abolishes interaction with CCNY.	MUTAGEN	0
Q00537/T214I	CDK17	-	1	T -> I (found in a renal cell carcinoma sample; somatic mutation; dbSNP:rs764448325)	VARIANT	0
Q01973/C482G	ROR1	-	1	C->G: No effect on kinase activity.	MUTAGEN	0
Q01973/E562D	ROR1	-	1	E -> D (in a breast cancer sample; somatic mutation; dbSNP:rs760789417)	VARIANT	1
Q01973/F150L	ROR1	-	1	F -> L (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
Q01973/G144E	ROR1	-	1	G -> E (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q01973/G624R	ROR1	-	1	G -> R (in dbSNP:rs55832740)	VARIANT	1
Q01973/I301V	ROR1	-	1	I -> V (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	0
Q01973/R567I	ROR1	-	1	R -> I (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q01973/R736T	ROR1	-	1	R -> T (in DFNB108; impairs plasma membrane location; abolishes downstream NFkB activation; dbSNP:rs1553163562)	VARIANT	0
Q01973/S776N	ROR1	-	1	S -> N (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q01973/T518M	ROR1	neutral	2	T -> M (in dbSNP:rs7527017)	VARIANT	1
Q01973/Y646C	ROR1	-	1	Y -> C (in dbSNP:rs34109134)	VARIANT	0
Q01974/C182Y	ROR2	-	1	C -> Y (in RRS1)	VARIANT	1
Q01974/D482G	ROR2	increase	1	D->G: Slight increase in kinase activity.	MUTAGEN	0
Q01974/D644N	ROR2	-	1	D -> N (in dbSNP:rs55798732)	VARIANT	0
Q01974/D672N	ROR2	-	1	D -> N (in dbSNP:rs55651110)	VARIANT	0
Q01974/D935E	ROR2	neutral	1	D -> E (in dbSNP:rs41277835)	VARIANT	0
Q01974/G490A	ROR2	-	1	G -> A (in dbSNP:rs56197744)	VARIANT	0
Q01974/G695R	ROR2	neutral	1	G -> R (in dbSNP:rs34431454)	VARIANT	1
Q01974/H349D	ROR2	neutral	1	H -> D (in dbSNP:rs55983376)	VARIANT	0
Q01974/N620K	ROR2	-	1	N -> K (in RRS1)	VARIANT	0
Q01974/P548S	ROR2	-	1	P -> S (in dbSNP:rs35764413)	VARIANT	0
Q01974/R184C	ROR2	-	1	R -> C (in RRS1; dbSNP:rs121909084)	VARIANT	0
Q01974/R189W	ROR2	-	1	R -> W (in RRS1; dbSNP:rs199975149)	VARIANT	0
Q01974/R244Q	ROR2	-	1	R -> Q (in dbSNP:rs55737262)	VARIANT	0
Q01974/R366W	ROR2	-	1	R -> W (in RRS1)	VARIANT	0
Q01974/R530Q	ROR2	neutral	1	R -> Q (in dbSNP:rs35852786)	VARIANT	0
Q01974/R738C	ROR2	-	1	R -> C (in dbSNP:rs56231927)	VARIANT	0
Q01974/S557L	ROR2	-	1	S -> L (in dbSNP:rs56099091)	VARIANT	2
Q01974/S762L	ROR2	-	1	S -> L (in dbSNP:rs34491822)	VARIANT	0
Q01974/T245A	ROR2	neutral	4	T -> A (in dbSNP:rs10820900)	VARIANT	5
Q01974/V542M	ROR2	-	1	V -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs140213020)	VARIANT	0
Q01974/V819I	ROR2	neutral	2	V -> I (in dbSNP:rs10761129)	VARIANT	0
Q02156/A333V	PRKCE	-	1	A -> V (in dbSNP:rs55989965)	VARIANT	0
Q02156/A654T	PRKCE	neutral	0	A -> T (in dbSNP:rs35777875)	VARIANT	0
Q02156/E143K	PRKCE	-	1	E -> K (in a colorectal cancer sample; somatic mutation; dbSNP:rs772834505)	VARIANT	0
Q02156/K437W	PRKCE	loss	1	K->W: Abolishes activity and S-729 phosphorylation.	MUTAGEN	0
Q02156/P389R	PRKCE	-	1	P -> R (in dbSNP:rs55767130)	VARIANT	0
Q02156/S729A	PRKCE	decrease	1	S->A: Enhances T-566 dephosphorylation.	MUTAGEN	0
Q02156/T563M	PRKCE	neutral	1	T -> M (in dbSNP:rs34077350)	VARIANT	0
Q02156/T566A	PRKCE	loss	1	T->A: Abolishes phosphorylation by PDK1, and S-729 phosphorylation.	MUTAGEN	0
Q02156/T566E	PRKCE	-	1	T->E: No effect on S-729 phosphorylation.	MUTAGEN	0
Q02156/T710E	PRKCE	-	1	T->E: No effect on activity; no effect on S-729 phosphorylation.	MUTAGEN	0
Q02750/A220L	MAP2K1	-	1	A->L: Increases interaction with KSR1 and BRAF; when associated with w-219.	MUTAGEN	0
Q02750/F311S	MAP2K1	decrease	1	F->S: Loss of interaction with BRAF and KSR1. Loss of BRAF-KSR1 dimerization.	MUTAGEN	0
Q02750/F53S	MAP2K1	-	1	F -> S (in CFC3; dbSNP:rs121908594)	VARIANT	0
Q02750/G128V	MAP2K1	resistance	1	G -> V (in CFC3; dbSNP:rs121908596)	VARIANT	7
Q02750/K57N	MAP2K1	increase,resistance	1	K -> N (in MEL; somatic mutation; results in increased MAPK signal transduction; dbSNP:rs869025608)	VARIANT	33
Q02750/K97A	MAP2K1	loss	1	K->A: Loss of catalytic activity. Strongly reduces phosphorylation upon UV irradiation.	MUTAGEN	0
Q02750/K97R	MAP2K1	loss	2	K->R: Loss of catalytic activity. No effect on BRAF-KSR1 or BRAF-KSR2 dimerization.	MUTAGEN	0
Q02750/M219V	MAP2K1	increase	1	M->V: Increases interaction with KSR1 and BRAF.	MUTAGEN	0
Q02750/M219W	MAP2K1	-	1	M->W: Increases interaction with KSR1 and BRAF; when associated with L-220.	MUTAGEN	0
Q02750/N221Y	MAP2K1	increase	1	N->Y: Increases interaction with KSR1 and BRAF.	MUTAGEN	0
Q02750/S150A	MAP2K1	-	1	S->A: No loss of activity.	MUTAGEN	0
Q02750/S212A	MAP2K1	-	1	S->A: No loss of activity.	MUTAGEN	0
Q02750/S218A	MAP2K1	-	2	S->A: Loss of catalytic activity. No effect on BRAF-KSR1 dimerization; when associated with A-222.	MUTAGEN	0
Q02750/S218D	MAP2K1	-	1	S->D: No effect on BRAF-KSR1 dimerization; when associated with D-222.	MUTAGEN	0
Q02750/S222A	MAP2K1	-	2	S->A: Loss of catalytic activity. No effect on BRAF-KSR1 dimerization; when associated with A-218.	MUTAGEN	0
Q02750/S222D	MAP2K1	-	1	S->D: No effect on BRAF-KSR1 dimerization; when associated with D-218.	MUTAGEN	0
Q02750/Y130C	MAP2K1	-	1	Y -> C (in CFC3; dbSNP:rs121908595)	VARIANT	1
Q02763/A226V	TEK	-	1	A -> V (in dbSNP:rs35814893)	VARIANT	0
Q02763/A724T	TEK	neutral	1	A -> T (in dbSNP:rs4631561)	VARIANT	0
Q02763/A925S	TEK	increase	1	A -> S (in VMCM; increased ligand-independent autophosphorylation and kinase activation)	VARIANT	0
Q02763/C224S	TEK	decrease	1	C->S: Reduces protein abundance.	MUTAGEN	0
Q02763/C233Y	TEK	-	1	C -> Y (in GLC3E; enhanced proteasomal degradation)	VARIANT	0
Q02763/I148T	TEK	neutral	1	I -> T (in dbSNP:rs35969327)	VARIANT	0
Q02763/K1100N	TEK	increase	1	K -> N (in VMCM; strongly increased ligand-independent autophosphorylation and kinase activation)	VARIANT	0
Q02763/K117N	TEK	-	2	K -> N (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	VARIANT	2
Q02763/K294N	TEK	-	1	K -> N (in GLC3E; unknown pathological significance; 10-fold decrease of Tyr-1102 phosphorylation; no effect on membrane location; dbSNP:rs146169480)	VARIANT	0
Q02763/K855R	TEK	loss	2	K->R: Loss of kinase activity.	MUTAGEN	0
Q02763/L634F	TEK	-	1	L -> F (in dbSNP:rs35378598)	VARIANT	0
Q02763/L914F	TEK	increase	1	L -> F (found in patients with solitary and multiple sporadic venous malformations; increased ligand-independent autophosphorylation; novel location at endoplasmic reticulum and Golgi apparatus; partially retained at endoplasmic reticulum and Golgi apparatus; dbSNP:rs1825682849)	VARIANT	0
Q02763/P883A	TEK	-	1	P -> A (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs1490428165)	VARIANT	0
Q02763/Q346P	TEK	-	3	Q -> P (in dbSNP:rs682632)	VARIANT	0
Q02763/R849W	TEK	increase	4	R -> W (in VMCM; increased ligand-independent autophosphorylation and kinase activation; no effect on location at membrane; dbSNP:rs80338908)	VARIANT	0
Q02763/R915C	TEK	increase	1	R -> C (found in a patient with solitary sporadic venous malformations; increased ligand-independent autophosphorylation; dbSNP:rs1825682922)	VARIANT	2
Q02763/R915H	TEK	increase	1	R -> H (in VMCM; strongly increased ligand-independent autophosphorylation and kinase activation; dbSNP:rs387906745)	VARIANT	0
Q02763/R915L	TEK	-	1	R -> L (found in a patient with multiple sporadic venous malformations; increased ligand-independent autophosphorylation; the autophosphorylation increases when associated with Phe-897)	VARIANT	0
Q02763/R918C	TEK	increase	1	R -> C (in VMCM; strongly increased ligand-independent autophosphorylation and kinase activation; dbSNP:rs1825683100)	VARIANT	1
Q02763/S917I	TEK	increase	1	S -> I (found in a patient with solitary sporadic venous malformations; increased ligand-independent autophosphorylation)	VARIANT	0
Q02763/T391I	TEK	neutral	0	T -> I (in dbSNP:rs34032300)	VARIANT	0
Q02763/V486I	TEK	neutral	1	V -> I (in dbSNP:rs1334811)	VARIANT	0
Q02763/V600L	TEK	neutral	1	V -> L (in dbSNP:rs35030851)	VARIANT	0
Q02763/V676I	TEK	-	1	V -> I (in dbSNP:rs56367117)	VARIANT	0
Q02763/V919L	TEK	increase	1	V -> L (in VMCM; increased ligand-independent autophosphorylation and kinase activation)	VARIANT	1
Q02763/Y1102F	TEK	decrease	1	Y->F: Abolishes interaction with SHC1.	MUTAGEN	0
Q02763/Y611C	TEK	loss	1	Y -> C (in GLC3E; reduced response to ligand; loss of ligand-induced phosphorylation; no effect on basal membrane location; dbSNP:rs1306527531)	VARIANT	0
Q02763/Y897C	TEK	increase	1	Y -> C (in VMCM; increased ligand-independent autophosphorylation and kinase activation; dbSNP:rs80338909)	VARIANT	0
Q02763/Y897F	TEK	-	1	Y -> F (found in a patient with multiple sporadic venous malformations; increased ligand-independent autophosphorylation; the hyperphosphorylation increases when associated with Leu-915)	VARIANT	0
Q02763/Y897H	TEK	increase	1	Y -> H (found in a patient with solitary sporadic venous malformations; increased ligand-independent autophosphorylation)	VARIANT	0
Q02763/Y897S	TEK	increase	3	Y -> S (in VMCM; also found in a patient with solitary sporadic venous malformations; increased ligand-independent autophosphorylation and kinase activation; dbSNP:rs80338909)	VARIANT	0
Q02779/G107E	MAP3K10	-	1	G -> E (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q02779/P168Q	MAP3K10	neutral	0	P -> Q (in dbSNP:rs36102209)	VARIANT	0
Q02846/A328V	GUCY2D	-	1	A -> V (in dbSNP:rs56280231)	VARIANT	0
Q02846/A362S	GUCY2D	-	0	A -> S (in LCA1; dbSNP:rs61749677)	VARIANT	0
Q02846/A52S	GUCY2D	-	2	A -> S (in LCA1; unknown pathological significance; dbSNP:rs61749665)	VARIANT	3
Q02846/A693E	GUCY2D	-	1	A -> E (in dbSNP:rs35146471)	VARIANT	0
Q02846/A710V	GUCY2D	loss	2	A -> V (in LCA1; loss of basal and GUCA1A-induced guanylate cyclase activity; does not affect endoplasmic reticulum membrane localization; dbSNP:rs781725943)	VARIANT	0
Q02846/C105Y	GUCY2D	-	2	C -> Y (in LCA1; does not affect basal guanylate cyclase activity; reduces GUCA1A-induced guanylate cyclase activity; dbSNP:rs61749669)	VARIANT	0
Q02846/C997D	GUCY2D	-	1	C->D: Changes the substrate specificity from GTP to ATP.	MUTAGEN	0
Q02846/D728H	GUCY2D	-	1	D -> H (in LCA1)	VARIANT	0
Q02846/E103V	GUCY2D	-	1	E -> V (in LCA1)	VARIANT	0
Q02846/E837D	GUCY2D	-	1	E -> D (in CORD6; dbSNP:rs28933695)	VARIANT	0
Q02846/E841K	GUCY2D	-	2	E -> K (in CORD6; decreases basal and GUCA1A-induced guanylate cyclase activity; inhibition by RD3 is less effective; does not affect endoplasmic reticulum membrane localization; dbSNP:rs1341592819)	VARIANT	0
Q02846/E925K	GUCY2D	-	1	E->K: Changes the substrate specificity from GTP to ATP.	MUTAGEN	0
Q02846/F565S	GUCY2D	loss	1	F -> S (in LCA1; loss of activity; dbSNP:rs61749755)	VARIANT	0
Q02846/G431D	GUCY2D	-	1	G -> D (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1451501407)	VARIANT	0
Q02846/I573V	GUCY2D	-	0	I -> V (in LCA1; dbSNP:rs61749756)	VARIANT	0
Q02846/I734A	GUCY2D	-	1	I -> A (in LCA1; requires 2 nucleotide substitutions)	VARIANT	0
Q02846/I949T	GUCY2D	-	1	I -> T (in CORD6; dbSNP:rs267606857)	VARIANT	0
Q02846/K846N	GUCY2D	-	2	K -> N (in CORD6; decreases basal and GUCA1A-induced guanylate cyclase activity; inhibition by RD3 is less effective; does not affect endoplasmic reticulum membrane localization; dbSNP:rs1598150539)	VARIANT	0
Q02846/L325P	GUCY2D	-	2	L -> P (in LCA1; does not affect basal guanylate cyclase activity; reduces GUCA1A-induced guanylate cyclase activity; dbSNP:rs61749675)	VARIANT	0
Q02846/L325R	GUCY2D	-	1	L -> R (found in a patient with LCA1)	VARIANT	0
Q02846/L782H	GUCY2D	neutral	1	L -> H (in dbSNP:rs8069344)	VARIANT	3
Q02846/L954P	GUCY2D	-	2	L -> P (in LCA1; severely impairs basal and GUCA1A induced guanylate cyclase; dbSNP:rs61750182)	VARIANT	0
Q02846/M784R	GUCY2D	-	1	M -> R (in LCA1; dbSNP:rs375010731)	VARIANT	0
Q02846/M823R	GUCY2D	decrease	1	M->R: Fails to become activated by GUCA1A and by GUCA1B. Does not affect the binding to RP3.	MUTAGEN	0
Q02846/P701S	GUCY2D	neutral	3	P -> S (at homozygosity may be associated with Leber congenital amaurosis in some populations; dbSNP:rs34598902)	VARIANT	1
Q02846/P858S	GUCY2D	-	2	P -> S (in LCA1; severely impairs basal and GUCA1A-induced guanylate cyclase activity; dbSNP:rs61750176)	VARIANT	0
Q02846/P873R	GUCY2D	loss	1	P -> R (in CORD6; loss basal and GUCA1A-induced guanylate cyclase activity; does not affect endoplasmic reticulum membrane localization; dbSNP:rs1567961680)	VARIANT	0
Q02846/R331S	GUCY2D	-	0	R -> S (in dbSNP:rs34596269)	VARIANT	0
Q02846/R438C	GUCY2D	-	1	R -> C (in LCA1; dbSNP:rs565948960)	VARIANT	0
Q02846/R602W	GUCY2D	-	0	R -> W (in dbSNP:rs770740012)	VARIANT	1
Q02846/R660Q	GUCY2D	-	1	R -> Q (in LCA1; dbSNP:rs61750162)	VARIANT	1
Q02846/R722W	GUCY2D	-	0	R -> W (in dbSNP:rs34331388)	VARIANT	0
Q02846/R768W	GUCY2D	-	3	R -> W (in LCA1 and CSNB1I; dbSNP:rs61750168)	VARIANT	0
Q02846/R795Q	GUCY2D	-	1	R -> Q (in LCA1; dbSNP:rs61750171)	VARIANT	1
Q02846/R822P	GUCY2D	decrease	1	R->P: Fails to become activated by GUCA1A and by GUCA1B. Does not affect the binding to RP3.	MUTAGEN	0
Q02846/R838C	GUCY2D	-	4	R -> C (in CORD6; dbSNP:rs61750172)	VARIANT	0
Q02846/R838G	GUCY2D	-	1	R -> G (in CORD6)	VARIANT	0
Q02846/R838H	GUCY2D	-	4	R -> H (in CORD6; dbSNP:rs61750173)	VARIANT	0
Q02846/R838P	GUCY2D	-	1	R -> P (in CORD6; dbSNP:rs61750173)	VARIANT	0
Q02846/S1007L	GUCY2D	-	1	S -> L (in LCA1)	VARIANT	0
Q02846/T312M	GUCY2D	-	1	T -> M (in LCA1; dbSNP:rs61749673)	VARIANT	0
Q02846/T55M	GUCY2D	-	1	T -> M (in LCA1; dbSNP:rs201414567)	VARIANT	0
Q02846/T849A	GUCY2D	-	1	T -> A (in CORD6)	VARIANT	0
Q02846/V507M	GUCY2D	-	1	V -> M (in dbSNP:rs746002871)	VARIANT	0
Q02846/V902L	GUCY2D	increase	1	V -> L (in LCA1; increases basal and GUCA1A-induced guanylate cyclase activity; inhibition by RD3 is less effective; does not affect endoplasmic reticulum membrane localization; dbSNP:rs1598150793)	VARIANT	0
Q02846/V933A	GUCY2D	-	1	V -> A (in CACD1; unknown pathological significance; dbSNP:rs1567961904)	VARIANT	0
Q02846/W21R	GUCY2D	neutral	1	W -> R (in dbSNP:rs9905402)	VARIANT	0
Q02846/W640L	GUCY2D	-	1	W -> L (in LCA1)	VARIANT	0
Q04759/A148E	PRKCQ	activating	1	A->E: Constitutively active form.	MUTAGEN	0
Q04759/D306V	PRKCQ	-	1	D -> V (in dbSNP:rs45590231)	VARIANT	0
Q04759/D354N	PRKCQ	-	1	D -> N (in dbSNP:rs34524148)	VARIANT	0
Q04759/K240N	PRKCQ	-	1	K -> N (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q04759/K409A	PRKCQ	loss	1	K->A,E: Loss of kinase activity.	MUTAGEN	0
Q04759/K409E	PRKCQ	loss	1	K->A,E: Loss of kinase activity.	MUTAGEN	0
Q04759/P330L	PRKCQ	neutral	2	P -> L (in dbSNP:rs2236379)	VARIANT	17
Q04759/S676A	PRKCQ	decrease	1	S->A: Reduction in kinase activity.	MUTAGEN	0
Q04759/S695A	PRKCQ	decrease	2	S->A: Reduction in kinase activity.	MUTAGEN	0
Q04759/T219A	PRKCQ	-	1	T->A: Loss of transactivation of the IL2 promoter and translocation to the plasma membrane. No effect on kinase activity.	MUTAGEN	0
Q04759/T538A	PRKCQ	loss	2	T->A: Loss of kinase activity.	MUTAGEN	0
Q04759/Y90F	PRKCQ	-	1	Y->F: Loss of function in T-cells proliferation. No effect on kinase activity.	MUTAGEN	0
Q04771/A15G	ACVR1	neutral	1	A -> G (in dbSNP:rs13406336)	VARIANT	0
Q04771/G325A	ACVR1	-	1	G->A: Almost complete loss of alcaline phosphatase induction; in association with V-203.	MUTAGEN	0
Q04771/G328E	ACVR1	-	2	G -> E (in FOP; variant phenotype; dbSNP:rs387906589)	VARIANT	13
Q04771/G328R	ACVR1	-	1	G -> R (in FOP; variant phenotype; dbSNP:rs387906588)	VARIANT	0
Q04771/G328W	ACVR1	-	1	G -> W (in FOP; variant phenotype; dbSNP:rs387906588)	VARIANT	4
Q04771/G356D	ACVR1	-	1	G -> D (in FOP; variant phenotype; dbSNP:rs121912679)	VARIANT	6
Q04771/H47Q	ACVR1	-	1	H -> Q (in dbSNP:rs34056189)	VARIANT	0
Q04771/P115S	ACVR1	-	1	P -> S (in a melanoma sample; somatic mutation)	VARIANT	1
Q04771/R202I	ACVR1	-	1	R -> I (in FOP; with some atypical features; dbSNP:rs387906591)	VARIANT	1
Q04771/R375P	ACVR1	-	1	R -> P (in FOP; variant phenotype; dbSNP:rs387906590)	VARIANT	0
Q04771/S41F	ACVR1	-	1	S -> F (in dbSNP:rs55957214)	VARIANT	0
Q04771/T203V	ACVR1	-	1	T->V: Almost complete loss of alcaline phosphatase induction; in association with A-325.	MUTAGEN	0
Q04912/A327T	MST1R	-	1	A -> T (in NPCA3; unknown pathological significance; dbSNP:rs200757776)	VARIANT	0
Q04912/A973T	MST1R	-	1	A -> T (in NPCA3; unknown pathological significance; dbSNP:rs773053723)	VARIANT	0
Q04912/G1195S	MST1R	-	0	G -> S (in dbSNP:rs7433231)	VARIANT	0
Q04912/G356D	MST1R	-	1	G -> D (in dbSNP:rs35924402)	VARIANT	0
Q04912/G465D	MST1R	-	1	G -> D (in dbSNP:rs34564898)	VARIANT	0
Q04912/N440S	MST1R	neutral	0	N -> S (in dbSNP:rs2230592)	VARIANT	0
Q04912/P95T	MST1R	-	1	P -> T (in dbSNP:rs55908300)	VARIANT	0
Q04912/Q523R	MST1R	neutral	2	Q -> R (in dbSNP:rs2230590)	VARIANT	1
Q04912/Q613P	MST1R	neutral	1	Q -> P (in dbSNP:rs35986685)	VARIANT	0
Q04912/R1304G	MST1R	-	1	R -> G (in dbSNP:rs528985327)	VARIANT	0
Q04912/R1335G	MST1R	neutral	1	R -> G (in dbSNP:rs1062633)	VARIANT	1
Q04912/R185C	MST1R	-	1	R -> C (in dbSNP:rs55633379)	VARIANT	0
Q04912/R306H	MST1R	-	1	R -> H (in NPCA3; dbSNP:rs200046052)	VARIANT	0
Q04912/R322Q	MST1R	neutral	2	R -> Q (in dbSNP:rs2230593)	VARIANT	0
Q04912/R504C	MST1R	-	1	R -> C (in dbSNP:rs34350470)	VARIANT	0
Q04912/R75S	MST1R	neutral	1	R -> S (in dbSNP:rs35887539)	VARIANT	0
Q04912/S434L	MST1R	neutral	1	S -> L (in dbSNP:rs2230591)	VARIANT	0
Q04912/V670G	MST1R	-	1	V -> G (in NPCA3; unknown pathological significance; dbSNP:rs201024956)	VARIANT	3
Q04912/V900M	MST1R	-	1	V -> M (in dbSNP:rs56091918)	VARIANT	0
Q04912/Y1360C	MST1R	-	1	Y -> C (in dbSNP:rs56330223)	VARIANT	0
Q05397/D1030E	PTK2	-	1	D -> E	VARIANT	0
Q05397/H292P	PTK2	-	1	H -> P	VARIANT	0
Q05397/H292Q	PTK2	-	1	H -> Q	VARIANT	0
Q05397/K1044E	PTK2	-	1	K -> E (in a metastatic melanoma sample; somatic mutation)	VARIANT	0
Q05397/L1034S	PTK2	decrease	1	L->S: Loss of interaction with TGFB1I1.	MUTAGEN	0
Q05397/V793A	PTK2	-	1	V -> A (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	0
Q05397/V928G	PTK2	decrease	1	V->G: Loss of interaction with TGFB1I1.	MUTAGEN	0
Q05397/Y397F	PTK2	decrease	2	Y->F: Abolishes autophosphorylation. Abolishes interaction with SRC and activation of BMX. Reduces phosphorylation of NEDD9.	MUTAGEN	0
Q05513/D62A	PRKCZ	decrease	1	D->A: Loss of interaction with SQSTM1 and PARD6B.	MUTAGEN	0
Q05513/D66A	PRKCZ	decrease	1	D->A: Loss of interaction with SQSTM1 and PARD6B.	MUTAGEN	0
Q05513/K19A	PRKCZ	-	1	K->A: No effect on interaction with SQSTM1 and PARD6B.	MUTAGEN	0
Q05513/R49H	PRKCZ	neutral	0	R -> H (in dbSNP:rs35271800)	VARIANT	0
Q05513/R519C	PRKCZ	-	1	R -> C (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs376894109)	VARIANT	0
Q05513/R84H	PRKCZ	-	1	R -> H (in dbSNP:rs56017162)	VARIANT	1
Q05513/S514F	PRKCZ	-	1	S -> F (in a colorectal cancer sample; somatic mutation)	VARIANT	0
Q05655/F375S	PRKCD	-	1	F -> S (in dbSNP:rs1056998)	VARIANT	0
Q05655/L410F	PRKCD	-	0	L -> F (in dbSNP:rs34502209)	VARIANT	0
Q05655/M494V	PRKCD	-	1	M -> V	VARIANT	1
Q05655/N348S	PRKCD	-	0	N -> S (in dbSNP:rs33911937)	VARIANT	0
Q05655/R483W	PRKCD	-	0	R -> W (in dbSNP:rs35891605)	VARIANT	0
Q05655/S299A	PRKCD	loss	1	S->A: Loss of phosphorylation.	MUTAGEN	0
Q05655/T507A	PRKCD	-	1	T->A: No effect on kinase activity.	MUTAGEN	0
Q05655/V593M	PRKCD	-	1	V -> M	VARIANT	0
Q05823/A289T	RNASEL	-	1	A -> T (in dbSNP:rs35553278)	VARIANT	0
Q05823/D541E	RNASEL	neutral	4	D -> E (no change in enzymatic activity; dbSNP:rs627928)	VARIANT	0
Q05823/D661A	RNASEL	loss	1	D->A: Complete loss of enzymatic activity.	MUTAGEN	0
Q05823/G59S	RNASEL	neutral	2	G -> S (in dbSNP:rs151296858)	VARIANT	0
Q05823/H583A	RNASEL	-	1	H->A: No change in enzymatic activity.	MUTAGEN	0
Q05823/H672A	RNASEL	loss	1	H->A: Complete loss of enzymatic activity. No change in 2-5A binding activity and enzyme dimerization.	MUTAGEN	0
Q05823/I97L	RNASEL	neutral	1	I -> L (in dbSNP:rs56250729)	VARIANT	0
Q05823/K240N	RNASEL	-	1	K->N: Reduced 2-5A binding activity; almost complete loss of 2-5A binding activity; when associated with N-274.	MUTAGEN	0
Q05823/K274N	RNASEL	-	1	K->N: Reduced 2-5A binding activity; almost complete loss of 2-5A binding activity; when associated with N-240.	MUTAGEN	0
Q05823/K392R	RNASEL	loss	1	K->R: Complete loss of enzymatic activity and enzyme dimerization. No change in binding to 2-5A and RNA.	MUTAGEN	0
Q05823/P584A	RNASEL	-	1	P->A: No change in enzymatic activity.	MUTAGEN	0
Q05823/R462Q	RNASEL	decrease,neutral	4	R -> Q (risk factor for prostate cancer; reduced enzymatic activity; dbSNP:rs486907)	VARIANT	0
Q05823/R592H	RNASEL	-	1	R -> H (in dbSNP:rs35896902)	VARIANT	0
Q05823/R667A	RNASEL	loss	1	R->A: Complete loss of enzymatic activity. No change in 2-5A binding and enzyme dimerization.	MUTAGEN	0
Q05823/S406F	RNASEL	-	1	S -> F (in dbSNP:rs145787003)	VARIANT	0
Q05823/W632A	RNASEL	-	1	W->A: No change in enzymatic activity.	MUTAGEN	0
Q06187/A508D	BTK	-	0	A -> D (in XLA)	VARIANT	1
Q06187/A523E	BTK	-	0	A -> E (in XLA)	VARIANT	0
Q06187/A582V	BTK	-	2	A -> V (in XLA)	VARIANT	0
Q06187/A607D	BTK	-	1	A -> D (in XLA; mild; dbSNP:rs128621208)	VARIANT	0
Q06187/A622P	BTK	-	1	A -> P (in XLA)	VARIANT	0
Q06187/C154S	BTK	-	1	C -> S (in XLA)	VARIANT	0
Q06187/C155G	BTK	-	0	C -> G (in XLA)	VARIANT	0
Q06187/C155R	BTK	-	2	C -> R (in XLA)	VARIANT	0
Q06187/C481S	BTK	resistance	3	C -> S (found in patients with chronic lymphocytic leukemia; unknown pathological significance; results in resistance to ibrutinib therapy; results in a protein that is reversibly inhibited by ibrutinib; disrupts the covalent binding between the enzyme and ibrutinib; dbSNP:rs1057519825 and dbSNP:rs1057519826)	VARIANT	49
Q06187/C502F	BTK	-	0	C -> F (in XLA)	VARIANT	0
Q06187/C502W	BTK	-	1	C -> W (in XLA; dbSNP:rs41310709)	VARIANT	0
Q06187/C506R	BTK	-	1	C -> R (in XLA; dbSNP:rs128621200)	VARIANT	0
Q06187/C506Y	BTK	-	1	C -> Y (in XLA)	VARIANT	0
Q06187/C633Y	BTK	-	1	C -> Y (in XLA)	VARIANT	0
Q06187/D308E	BTK	-	0	D -> E (in XLA)	VARIANT	0
Q06187/D521G	BTK	-	1	D -> G (in XLA)	VARIANT	0
Q06187/D521H	BTK	-	1	D -> H (in XLA; severe)	VARIANT	0
Q06187/D521N	BTK	-	0	D -> N (in XLA; severe)	VARIANT	0
Q06187/E445D	BTK	-	1	E -> D (in XLA)	VARIANT	0
Q06187/E567K	BTK	-	1	E -> K (in XLA; severe)	VARIANT	0
Q06187/E589D	BTK	-	0	E -> D (in XLA)	VARIANT	0
Q06187/E589G	BTK	decrease	2	E -> G (in XLA; moderate; interferes with substrate binding; dbSNP:rs128621206)	VARIANT	1
Q06187/E589K	BTK	-	1	E -> K (in XLA)	VARIANT	2
Q06187/F25S	BTK	-	1	F -> S (in XLA)	VARIANT	0
Q06187/F559S	BTK	-	1	F -> S (in XLA)	VARIANT	0
Q06187/F583S	BTK	-	0	F -> S (in XLA)	VARIANT	0
Q06187/F644L	BTK	-	0	F -> L (in XLA)	VARIANT	0
Q06187/F644S	BTK	-	1	F -> S (in XLA)	VARIANT	0
Q06187/G302E	BTK	-	2	G -> E (in XLA)	VARIANT	0
Q06187/G302R	BTK	-	0	G -> R (in XLA)	VARIANT	0
Q06187/G414R	BTK	-	1	G -> R (in XLA)	VARIANT	0
Q06187/G462D	BTK	-	0	G -> D (in XLA)	VARIANT	0
Q06187/G462V	BTK	-	0	G -> V (in XLA)	VARIANT	0
Q06187/G594E	BTK	decrease	2	G -> E (in XLA; mild; interferes with substrate binding)	VARIANT	0
Q06187/G594R	BTK	-	1	G -> R (in XLA; dbSNP:rs1555977339)	VARIANT	0
Q06187/G613D	BTK	decrease	2	G -> D (in XLA; mild; interferes with substrate binding and/or domain interactions; dbSNP:rs128621209)	VARIANT	0
Q06187/H362Q	BTK	-	0	H -> Q (in XLA)	VARIANT	0
Q06187/H364P	BTK	-	0	H -> P (in XLA)	VARIANT	0
Q06187/I370M	BTK	-	1	I -> M (in XLA)	VARIANT	0
Q06187/I429N	BTK	-	1	I -> N (in XLA)	VARIANT	0
Q06187/I61N	BTK	-	1	I -> N (in XLA)	VARIANT	0
Q06187/K12R	BTK	-	1	K -> R (in XLA)	VARIANT	0
Q06187/K19E	BTK	-	1	K -> E (in XLA)	VARIANT	0
Q06187/K27R	BTK	-	0	K -> R (in XLA)	VARIANT	0
Q06187/K430E	BTK	loss	1	K -> E (in XLA; loss of phosphorylation of GTF2I; dbSNP:rs128620184)	VARIANT	0
Q06187/K430R	BTK	-	1	K -> R (in XLA)	VARIANT	0
Q06187/L11P	BTK	-	0	L -> P (in XLA; dbSNP:rs1603020228)	VARIANT	0
Q06187/L295P	BTK	-	2	L -> P (in XLA)	VARIANT	0
Q06187/L358F	BTK	-	1	L -> F (in XLA)	VARIANT	0
Q06187/L369F	BTK	-	1	L -> F (in XLA)	VARIANT	0
Q06187/L408P	BTK	-	1	L -> P (in XLA; moderate; dbSNP:rs128621198)	VARIANT	0
Q06187/L512P	BTK	-	1	L -> P (in XLA)	VARIANT	0
Q06187/L512Q	BTK	-	1	L -> Q (in XLA)	VARIANT	0
Q06187/L518R	BTK	-	0	L -> R (in XLA)	VARIANT	0
Q06187/L542P	BTK	-	1	L -> P (in XLA; growth hormone deficiency; dbSNP:rs128621203)	VARIANT	0
Q06187/L647P	BTK	-	0	L -> P (in XLA)	VARIANT	0
Q06187/L652P	BTK	-	1	L -> P (in XLA; dbSNP:rs128622212)	VARIANT	0
Q06187/M477R	BTK	-	1	M -> R (in XLA)	VARIANT	0
Q06187/M509I	BTK	-	0	M -> I (in XLA)	VARIANT	0
Q06187/M509V	BTK	-	1	M -> V (in XLA)	VARIANT	0
Q06187/M587L	BTK	-	1	M -> L (in XLA; mild; dbSNP:rs1603001822)	VARIANT	0
Q06187/M630I	BTK	-	0	M -> I	VARIANT	0
Q06187/M630K	BTK	-	2	M -> K (in XLA; dbSNP:rs128621210)	VARIANT	0
Q06187/M630T	BTK	-	0	M -> T (in XLA)	VARIANT	0
Q06187/N365Y	BTK	-	0	N -> Y (in XLA)	VARIANT	0
Q06187/N526K	BTK	-	1	N -> K (in XLA; dbSNP:rs1569291237)	VARIANT	0
Q06187/P189A	BTK	-	1	P->A: No effect on phosphorylation of GTF2I.	MUTAGEN	0
Q06187/P190K	BTK	-	1	P -> K (in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions)	VARIANT	0
Q06187/P619A	BTK	-	0	P -> A (in XLA)	VARIANT	0
Q06187/P619S	BTK	-	0	P -> S (in XLA)	VARIANT	0
Q06187/P619T	BTK	-	1	P -> T (in XLA)	VARIANT	0
Q06187/Q127H	BTK	-	1	Q -> H (in XLA)	VARIANT	0
Q06187/R288Q	BTK	-	1	R -> Q (in XLA; dbSNP:rs1555978277)	VARIANT	0
Q06187/R288W	BTK	-	4	R -> W (in XLA; dbSNP:rs128621194)	VARIANT	0
Q06187/R28C	BTK	-	0	R -> C (in XLA; no effect on phosphorylation of GTF2I)	VARIANT	2
Q06187/R28H	BTK	-	3	R -> H (in XLA; moderate; dbSNP:rs128620185)	VARIANT	0
Q06187/R28P	BTK	-	1	R -> P (in XLA)	VARIANT	0
Q06187/R307G	BTK	loss	1	R -> G (in XLA; loss of activity; dbSNP:rs128621195)	VARIANT	0
Q06187/R307K	BTK	loss	1	R->K: Loss of phosphorylation of GTF2I.	MUTAGEN	0
Q06187/R307T	BTK	-	1	R -> T (in XLA)	VARIANT	0
Q06187/R372G	BTK	-	1	R -> G (in XLA)	VARIANT	0
Q06187/R520Q	BTK	loss	4	R -> Q (in XLA; severe; prevents activation due to absence of contact between the catalytic loop and the regulatory phosphorylated residue; dbSNP:rs128621202)	VARIANT	0
Q06187/R525G	BTK	-	1	R -> G (in XLA; dbSNP:rs886041149)	VARIANT	0
Q06187/R525P	BTK	-	1	R -> P (in XLA)	VARIANT	1
Q06187/R525Q	BTK	decrease	2	R -> Q (in XLA; severe; disturbs ATP-binding; dbSNP:rs128620183)	VARIANT	2
Q06187/R544G	BTK	-	1	R -> G (in XLA)	VARIANT	0
Q06187/R544K	BTK	-	1	R -> K (in XLA)	VARIANT	0
Q06187/R562P	BTK	-	2	R -> P (in XLA; dbSNP:rs104894770)	VARIANT	0
Q06187/R562W	BTK	-	4	R -> W (in XLA; dbSNP:rs128621204)	VARIANT	0
Q06187/R641C	BTK	-	1	R -> C (in XLA)	VARIANT	0
Q06187/R641H	BTK	-	2	R -> H (in XLA; severe)	VARIANT	2
Q06187/R82K	BTK	-	1	R -> K (in dbSNP:rs56035945)	VARIANT	0
Q06187/S115F	BTK	-	0	S -> F (in XLA)	VARIANT	0
Q06187/S14F	BTK	-	0	S -> F (in XLA; dbSNP:rs1057520682)	VARIANT	0
Q06187/S366F	BTK	-	0	S -> F (in XLA)	VARIANT	0
Q06187/S578Y	BTK	-	1	S -> Y (in XLA)	VARIANT	0
Q06187/S592P	BTK	-	1	S -> P (in XLA; dbSNP:rs1603001783)	VARIANT	0
Q06187/T117P	BTK	-	1	T -> P (in XLA)	VARIANT	0
Q06187/T184P	BTK	-	0	T -> P (in XLA)	VARIANT	0
Q06187/T33P	BTK	-	2	T -> P (in XLA; severe; dbSNP:rs128620189)	VARIANT	0
Q06187/V113D	BTK	-	1	V -> D (in XLA; dbSNP:rs128621190)	VARIANT	0
Q06187/V319A	BTK	-	0	V -> A (in XLA; moderate)	VARIANT	0
Q06187/V535F	BTK	-	1	V -> F (in XLA)	VARIANT	0
Q06187/V626G	BTK	-	1	V -> G (in XLA)	VARIANT	0
Q06187/V64D	BTK	-	0	V -> D (in XLA)	VARIANT	0
Q06187/V64F	BTK	-	1	V -> F (in XLA)	VARIANT	0
Q06187/W251L	BTK	-	1	W->L: No effect on phosphorylation of GTF2I.	MUTAGEN	0
Q06187/W563L	BTK	-	1	W -> L (in XLA; dbSNP:rs1555977474)	VARIANT	0
Q06187/W581R	BTK	-	0	W -> R (in XLA; dbSNP:rs128621205)	VARIANT	0
Q06187/Y223F	BTK	loss	2	Y->F: Loss of phosphorylation of GTF2I.	MUTAGEN	0
Q06187/Y334S	BTK	-	1	Y -> S (in XLA; dbSNP:rs128621196)	VARIANT	0
Q06187/Y361C	BTK	-	1	Y -> C (in XLA; mild; dbSNP:rs28935478)	VARIANT	0
Q06187/Y39S	BTK	-	1	Y -> S (in XLA)	VARIANT	0
Q06187/Y40C	BTK	-	0	Y -> C (in XLA; dbSNP:rs1555980875)	VARIANT	0
Q06187/Y40N	BTK	-	0	Y -> N (in XLA)	VARIANT	0
Q06187/Y418H	BTK	-	0	Y -> H (in XLA; dbSNP:rs144079566)	VARIANT	0
Q06187/Y476D	BTK	-	1	Y -> D (in XLA)	VARIANT	0
Q06187/Y551F	BTK	loss	1	Y->F: Loss of phosphorylation of GTF2I.	MUTAGEN	0
Q06187/Y598C	BTK	-	0	Y -> C (in XLA)	VARIANT	0
Q06187/Y617E	BTK	decrease	1	Y->E: Defective in mediating calcium response.	MUTAGEN	0
Q06418/A815V	TYRO3	-	1	A -> V (in dbSNP:rs1042057)	VARIANT	0
Q06418/A831T	TYRO3	-	1	A -> T	VARIANT	0
Q06418/G542S	TYRO3	-	1	G -> S (in dbSNP:rs17857363)	VARIANT	0
Q06418/I346N	TYRO3	neutral	0	I -> N (in dbSNP:rs12148316)	VARIANT	0
Q06418/I99R	TYRO3	loss	1	I->R: Abolishes dimerization.	MUTAGEN	0
Q06418/L819M	TYRO3	-	1	L -> M (in dbSNP:rs17854579)	VARIANT	0
Q06418/P21L	TYRO3	-	1	P -> L (in dbSNP:rs17854578)	VARIANT	0
Q06418/R824G	TYRO3	-	1	R -> G (in dbSNP:rs17857364)	VARIANT	0
Q07002/G48S	CDK18	-	1	G -> S (in dbSNP:rs35134237)	VARIANT	0
Q07002/G67R	CDK18	neutral	1	G -> R (in dbSNP:rs4623769)	VARIANT	0
Q07002/T166M	CDK18	neutral	2	T -> M (in dbSNP:rs17850752)	VARIANT	0
Q07912/E346K	TNK2	increase	3	E -> K (in an ovarian endometrioid cancer sample; somatic mutation; undergoes autoactivation and causes phosphorylation on Y-284 leading to activation of AKT1; increased autophosphorylation at Y-284; increased function in phosphorylation of peptide substrates and WASP; no effect on catalytic activity itself as the purified kinase domain has activity in vitro comparable to wild-type protein; no effect on subcellular localization to perinuclear region; dbSNP:rs970946035)	VARIANT	0
Q07912/K158R	TNK2	loss	2	K->R: Loss of autophosphorylation at Y-284.	MUTAGEN	0
Q07912/K71R	TNK2	-	1	K -> R (in dbSNP:rs56036945)	VARIANT	0
Q07912/L120Q	TNK2	-	1	L->Q: No effect on autophosphorylation at Y-284.	MUTAGEN	0
Q07912/L197Q	TNK2	-	1	L->Q: No effect on autophosphorylation at Y-284.	MUTAGEN	0
Q07912/L487F	TNK2	activating	1	L->F: Constantly active kinase.	MUTAGEN	0
Q07912/M409I	TNK2	increase	2	M -> I (in a gastric adenocarcinoma sample; somatic mutation; increased autophosphorylation at Y-284; increased function in phosphorylation of peptide substrates and WASP; no effect on subcellular localization to perinuclear region)	VARIANT	0
Q07912/P507S	TNK2	-	1	P -> S (in dbSNP:rs35759128)	VARIANT	0
Q07912/P725L	TNK2	neutral	2	P -> L (in dbSNP:rs56260729)	VARIANT	0
Q07912/P802L	TNK2	-	0	P -> L (in dbSNP:rs3749333)	VARIANT	0
Q07912/R34L	TNK2	increase	2	R -> L (in a lung adenocarcinoma sample; somatic mutation; increased autophosphorylation at Y-284; increased function in phosphorylation of peptide substrates; no effect on subcellular localization to perinuclear region)	VARIANT	0
Q07912/R748Q	TNK2	-	1	R -> Q (in dbSNP:rs57872314)	VARIANT	0
Q07912/R99Q	TNK2	increase	2	R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation; increased autophosphorylation at Y-284; increased function in phosphorylation of peptide substrates and WASP; no effect on subcellular localization to perinuclear region; dbSNP:rs113498671)	VARIANT	0
Q07912/R99W	TNK2	neutral	1	R -> W (in dbSNP:rs3747673)	VARIANT	0
Q07912/T152M	TNK2	-	1	T -> M (in dbSNP:rs56161912)	VARIANT	0
Q07912/V365R	TNK2	increase	1	V->R: Increased autophosphorylation at Y-284.	MUTAGEN	0
Q07912/V638M	TNK2	increase,neutral	1	V -> M (found in patients with childhood-onset epilepsy; unknown pathological significance; loss of interaction with NEDD4 and NEDD4L; increased protein abundance; dbSNP:rs201407161)	VARIANT	0
Q08345/A170D	DDR1	-	1	A -> D (in dbSNP:rs56231803)	VARIANT	0
Q08345/G707A	DDR1	increase	1	G->A: Confers over 20-fold resistance to the ability of an inhibitor to inhibit autophosphorylation.	MUTAGEN	0
Q08345/K655A	DDR1	-	1	K->A: Loss of kinase activity. Complete loss of the collagen-independent constitutive activation; when associated with Q-211.	MUTAGEN	0
Q08345/L833V	DDR1	-	2	L -> V (in dbSNP:rs2524235)	VARIANT	0
Q08345/N211A	DDR1	activating	1	N->A: Phosphorylates regardless of collagen presence, collagen addition does not alter significantly the levels of constitutive phosphorylation.	MUTAGEN	0
Q08345/N211Q	DDR1	-	1	N->Q: Sustained phosphorylation regardless of collagen presence, collagen addition does not alter significantly the levels of constitutive phosphorylation. Located intracellularly and at the cell surface. Displays a reduced rate of receptor internalization, which is not altered in the presence of collagen. Able to bind collagen as wild-type. Exhibits enhanced collagen-independent receptor dimerization. Complete loss of the collagen-independent constitutive activation; when associated with A-655.	MUTAGEN	0
Q08345/N260Q	DDR1	decrease	1	N->Q: Phosphorylates in response to collagen, but at lower levels compared to wild-type. No activation in the absence of collagen.	MUTAGEN	0
Q08345/N371Q	DDR1	decrease	1	N->Q: Phosphorylates in response to collagen, but at lower levels compared to wild-type. No activation in the absence of collagen.	MUTAGEN	0
Q08345/N394Q	DDR1	decrease	1	N->Q: Phosphorylates in response to collagen, but at lower levels compared to wild-type. No activation in the absence of collagen.	MUTAGEN	0
Q08345/R105A	DDR1	decrease	1	R->A: Inhibits collagen-induced phosphorylation.	MUTAGEN	0
Q08345/R169Q	DDR1	-	1	R -> Q (in dbSNP:rs55980643)	VARIANT	0
Q08345/R306W	DDR1	-	1	R -> W (in dbSNP:rs56024191)	VARIANT	0
Q08345/S17G	DDR1	-	1	S -> G (in dbSNP:rs55901302)	VARIANT	0
Q08345/S213A	DDR1	activating	1	S->A: Phosphorylates regardless of collagen presence, collagen addition does not alter significantly the levels of constitutive phosphorylation.	MUTAGEN	0
Q08345/S496A	DDR1	-	1	S -> A (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
Q08345/T379A	DDR1	-	1	T->A: Phosphorylates in response to collagen, but at lower levels compared to wild-type. Phosphorylates in response to collagen, but at lower levels compared to wild-type; when associated with A-393.	MUTAGEN	0
Q08345/T393A	DDR1	-	1	T->A: Phosphorylates in response to collagen, but at lower levels compared to wild-type. Phosphorylates in response to collagen, but at lower levels compared to wild-type; when associated with A-379.	MUTAGEN	0
Q08345/V100A	DDR1	-	1	V -> A (in dbSNP:rs34544756)	VARIANT	0
Q08345/Y740F	DDR1	decrease	1	Y->F: Abolishes interaction with PTPN11.	MUTAGEN	0
Q08881/P23L	ITK	-	1	P -> L (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q08881/P288G	ITK	decrease	1	P->G: Complete loss of interaction with PPIA/CYPA.	MUTAGEN	0
Q08881/R193Q	ITK	-	0	R -> Q (in dbSNP:rs17054374)	VARIANT	0
Q08881/R19K	ITK	-	1	R -> K (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q08881/R335W	ITK	-	0	R -> W (in LPFS1; shows nearly undetectable mutant 	VARIANT	0
Q08881/R451Q	ITK	-	1	R -> Q (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs779372373)	VARIANT	2
Q08881/R581W	ITK	-	1	R -> W (in dbSNP:rs34482255)	VARIANT	2
Q08881/V587I	ITK	neutral	1	V -> I (in dbSNP:rs56005928)	VARIANT	0
Q09013/K100A	DMPK	loss	1	K->A: Loss of kinase activity.	MUTAGEN	0
Q09013/L423V	DMPK	neutral	4	L -> V (in dbSNP:rs527221)	VARIANT	0
Q09013/L428V	DMPK	-	1	L -> V (in a lung small cell carcinoma sample; somatic mutation)	VARIANT	5
Q12852/E409K	MAP3K12	-	1	E -> K (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	0
Q12852/G628R	MAP3K12	-	1	G -> R (in dbSNP:rs34366500)	VARIANT	0
Q12852/G640S	MAP3K12	neutral	1	G -> S (in dbSNP:rs55794887)	VARIANT	0
Q12866/A282T	MERTK	-	2	A -> T (in dbSNP:rs7588635)	VARIANT	0
Q12866/A446G	MERTK	-	1	A -> G (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	1
Q12866/A708S	MERTK	-	1	A -> S (in a head & Neck squamous cell carcinoma sample; somatic mutation)	VARIANT	0
Q12866/E289K	MERTK	-	1	E -> K (in dbSNP:rs766215580)	VARIANT	1
Q12866/E540K	MERTK	-	1	E -> K (in RP38; dbSNP:rs113485015)	VARIANT	0
Q12866/E823Q	MERTK	-	1	E -> Q (in dbSNP:rs55924349)	VARIANT	0
Q12866/F214V	MERTK	-	1	F -> V (found in a patient with Leber congenital amaurosis; dbSNP:rs1475870132)	VARIANT	0
Q12866/I518V	MERTK	neutral	2	I -> V (in dbSNP:rs2230515)	VARIANT	2
Q12866/I871T	MERTK	-	1	I -> T (in RP38; dbSNP:rs377341255)	VARIANT	0
Q12866/I871V	MERTK	-	1	I -> V	VARIANT	0
Q12866/N329S	MERTK	-	0	N -> S (in dbSNP:rs34943572)	VARIANT	0
Q12866/N498S	MERTK	neutral	2	N -> S (in dbSNP:rs35858762)	VARIANT	0
Q12866/P958L	MERTK	-	1	P -> L (found in a patient with Leber congenital amaurosis; dbSNP:rs201460398)	VARIANT	0
Q12866/Q662E	MERTK	neutral	1	Q -> E (in dbSNP:rs56209758)	VARIANT	0
Q12866/R20S	MERTK	-	2	R -> S (in dbSNP:rs35898499)	VARIANT	0
Q12866/R293H	MERTK	neutral	2	R -> H (in dbSNP:rs34072093)	VARIANT	0
Q12866/R466K	MERTK	neutral	2	R -> K (in dbSNP:rs7604639)	VARIANT	1
Q12866/R865W	MERTK	neutral	1	R -> W (in dbSNP:rs2230516)	VARIANT	0
Q12866/S118N	MERTK	neutral	3	S -> N (in dbSNP:rs13027171)	VARIANT	0
Q12866/S661C	MERTK	-	1	S -> C (in RP38)	VARIANT	0
Q12866/V185M	MERTK	-	1	V -> M (in dbSNP:rs56205303)	VARIANT	0
Q12866/V452L	MERTK	-	1	V -> L (in dbSNP:rs34010621)	VARIANT	0
Q12866/V870I	MERTK	neutral	1	V -> I (in dbSNP:rs2230517)	VARIANT	0
Q12979/K517R	ABR	neutral	1	K -> R (in dbSNP:rs34169260)	VARIANT	0
Q12979/N795A	ABR	-	1	N->A: Loss of GAP activity; when associated with A-683.	MUTAGEN	0
Q12979/R683A	ABR	-	1	R->A: Reduces GAP activity. Loss of GAP activity; when associated with A-795.	MUTAGEN	0
Q13043/D326N	STK4	-	1	D->N: Resistant to proteolytic cleavage by caspase during apoptosis; when associated with N-349.	MUTAGEN	0
Q13043/D349N	STK4	-	1	D->N: Resistant to proteolytic cleavage by caspase during apoptosis; when associated with N-326.	MUTAGEN	0
Q13043/H162N	STK4	-	1	H -> N (in dbSNP:rs55850759)	VARIANT	0
Q13043/I355T	STK4	neutral	1	I -> T (in dbSNP:rs35944046)	VARIANT	3
Q13043/K59R	STK4	loss	2	K->R: Loss of activity.	MUTAGEN	0
Q13043/L444P	STK4	loss	1	L->P: Loss of homodimerization, activation, and autophosphorylation.	MUTAGEN	0
Q13043/P416L	STK4	neutral	1	P -> L (in dbSNP:rs33963346)	VARIANT	0
Q13043/R310Q	STK4	-	1	R -> Q (in dbSNP:rs35447878)	VARIANT	0
Q13043/T175A	STK4	-	1	T->A: No effect on activity.	MUTAGEN	0
Q13043/T177A	STK4	-	1	T->A: No effect on activity.	MUTAGEN	0
Q13043/T183A	STK4	loss	1	T->A: Loss of activity.	MUTAGEN	0
Q13043/V312M	STK4	neutral	2	V -> M (in dbSNP:rs17420378)	VARIANT	0
Q13131/M10L	PRKAA1	-	1	M -> L (in dbSNP:rs17855679)	VARIANT	0
Q13131/Q16R	PRKAA1	-	1	Q -> R (in a breast cancer sample; somatic mutation; dbSNP:rs928784854)	VARIANT	1
Q13131/V307G	PRKAA1	activating	1	V->G,Q: Activates the kinase activity.	MUTAGEN	0
Q13131/V307Q	PRKAA1	increase	1	V->G,Q: Activates the kinase activity.	MUTAGEN	0
Q13153/D389N	PAK1	-	1	D->N: Abolishes kinase activity; when associated with R-299.	MUTAGEN	0
Q13153/D393A	PAK1	loss	1	D->A: Abolishes autophosphorylation at Thr-423.	MUTAGEN	0
Q13153/H83L	PAK1	-	2	H->L: Abolishes interaction with CDC42, leading to strongly decreased activity; when associated with L-86.	MUTAGEN	0
Q13153/H86L	PAK1	-	2	H->L: Abolishes interaction with CDC42, leading to strongly decreased activity; when associated with L-83.	MUTAGEN	0
Q13153/K299R	PAK1	-	1	K->R: Strongly decreases activity. Abolishes kinase activity; when associated with N-389.	MUTAGEN	0
Q13153/L107F	PAK1	activating	1	L->F: Abolishes autoinhibition, leading to constitutive kinase activity.	MUTAGEN	1
Q13153/L515V	PAK1	-	0	L -> V (in dbSNP:rs35345144)	VARIANT	0
Q13153/T423A	PAK1	decrease	1	T->A: Decreases CDC42-stimulated activity and autophosphorylation.	MUTAGEN	0
Q13153/T423E	PAK1	activating	1	T->E: Constitutive kinase activity.	MUTAGEN	0
Q13153/Y131C	PAK1	increase	1	Y -> C (in IDDMSSD; gain of function; enhanced PAK1 kinase activity and significantly reduced homodimerization; dbSNP:rs1565638316)	VARIANT	0
Q13153/Y429C	PAK1	increase	1	Y -> C (in IDDMSSD; gain-of-function; enhanced PAK1 kinase activity and significantly reduced homodimerization; dbSNP:rs1565583382)	VARIANT	0
Q13163/A427V	MAP2K5	-	1	A -> V (in dbSNP:rs1226964455)	VARIANT	0
Q13163/A428T	MAP2K5	-	1	A -> T (in dbSNP:rs55811347)	VARIANT	0
Q13163/H118R	MAP2K5	-	1	H -> R (in dbSNP:rs56241934)	VARIANT	0
Q13163/K195M	MAP2K5	loss	1	K->M: Inactivation.	MUTAGEN	0
Q13163/S311A	MAP2K5	loss	1	S->A: Inactivation.	MUTAGEN	0
Q13163/T315A	MAP2K5	loss	1	T->A: Inactivation.	MUTAGEN	0
Q13164/G550A	MAPK7	-	1	G -> A (in dbSNP:rs56388327)	VARIANT	0
Q13164/R535H	MAPK7	-	1	R -> H	VARIANT	0
Q13177/D212N	PAK2	-	1	D->N: Inhibits caspase-mediated cleavage.	MUTAGEN	0
Q13177/E435K	PAK2	loss	1	E -> K (in KNO2; loss of protein serine/threonine kinase activity)	VARIANT	0
Q13177/G213A	PAK2	-	1	G->A: Abolishes myristoylation of PAK-2p34 and membrane location.	MUTAGEN	0
Q13177/K278R	PAK2	loss	1	K->R: Abolishes kinase activity and autophosphorylation.	MUTAGEN	0
Q13177/T402A	PAK2	loss	1	T->A: Abolishes kinase activity and greatly inhibits autophosphorylation of PAK-2p27 and PAK-2p34.	MUTAGEN	0
Q13188/D322N	STK3	-	1	D->N: Resistant to proteolytic cleavage.	MUTAGEN	0
Q13188/F418C	STK3	-	0	F -> C (in dbSNP:rs36047674)	VARIANT	0
Q13188/K56R	STK3	loss	1	K->R: Loss of activity.	MUTAGEN	0
Q13188/V60L	STK3	-	1	V -> L (in an ovarian clear cell carcinoma sample; somatic mutation)	VARIANT	0
Q13233/C443S	MAP3K1	-	1	C -> S	VARIANT	0
Q13233/D806N	MAP3K1	neutral	0	D -> N (in dbSNP:rs702689)	VARIANT	1
Q13233/G616R	MAP3K1	-	1	G -> R (in SRXY6; unknown pathological significance; dbSNP:rs143853590)	VARIANT	0
Q13233/L189P	MAP3K1	increase	1	L -> P (in SRXY6; increases phosphorylation of the downstream target MAPK3/MAPK1 compared to wild-type and enhances binding of RHOA to the mutant MAP3K1 complex; dbSNP:rs387906788)	VARIANT	0
Q13233/L189R	MAP3K1	increase	1	L -> R (in SRXY6; increases phosphorylation of the downstream targets MAPK14 and MAPK3/MAPK1 compared to wild-type and enhances binding of RHOA to the mutant MAP3K1 complex; dbSNP:rs387906788)	VARIANT	0
Q13233/S92N	MAP3K1	-	1	S -> N	VARIANT	0
Q13233/V906I	MAP3K1	neutral	0	V -> I (in dbSNP:rs832582)	VARIANT	2
Q13237/D412A	PRKG2	-	1	D->A: Reduces cGMP binding affinity; when associated with A-415.	MUTAGEN	0
Q13237/H106R	PRKG2	-	1	H -> R (in dbSNP:rs34616910)	VARIANT	0
Q13237/R415A	PRKG2	-	1	R->A: Reduces cGMP binding affinity; when associated with A-412.	MUTAGEN	0
Q13237/T22S	PRKG2	-	0	T -> S (in dbSNP:rs34956759)	VARIANT	0
Q13237/W716R	PRKG2	-	1	W -> R (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q13263/C651A	TRIM28	-	2	C->A: Complete loss of the PHD finger-mediated stimulatory effect on sumoylation. Loss of binding UBE2I.	MUTAGEN	0
Q13263/C65A	TRIM28	-	1	C->A: Reduces nuclear localization activity of ZNF268; when associated with A-68.	MUTAGEN	0
Q13263/C68A	TRIM28	-	1	C->A: Reduces nuclear localization activity of ZNF268; when associated with A-65.	MUTAGEN	0
Q13263/F370A	TRIM28	-	1	F->A: Some reduction in interaction with PPP1CA.	MUTAGEN	0
Q13263/F370G	TRIM28	-	1	F->G: Some reduction in interaction with PPP1CA.	MUTAGEN	0
Q13263/I368G	TRIM28	-	1	I->G: Increased interaction with PPP1CA. Greatly decreased phosphorylation on S-824.	MUTAGEN	0
Q13263/K366G	TRIM28	-	1	K->G: Greatly reduced interaction with PPP1CA.	MUTAGEN	0
Q13263/K554R	TRIM28	-	3	K->R: Moderately reduces sumoylation and repression. Abolishes both sumoylation and repression; when associated with R-575. Relieves the repressor activity on Dox-induced GADD45A transcription and 2-fold increase in phosphorylation at Ser-824; when associated with R-779 and R-804.	MUTAGEN	0
Q13263/K575R	TRIM28	-	2	K->R: Modestly reduced sumoylation and repression. Abolishes both sumoylation and repression; when associated with R-554.	MUTAGEN	0
Q13263/K676R	TRIM28	-	2	K->R: Modestly reduces sumoylation and repression.	MUTAGEN	0
Q13263/K750R	TRIM28	-	1	K->R: Some reduced sumoylation and repression.	MUTAGEN	0
Q13263/K779R	TRIM28	-	3	K->R: Abolishes both sumoylation and repression; when associated with R-804. Relieves the repressor activity on Dox-induced GADD45A transcription and 2-fold increase in phosphorylation at Ser-824; when associated with R-554 and R-804.	MUTAGEN	0
Q13263/K804R	TRIM28	-	3	K->R: Abolishes both sumoylation and repression; when associated with R-779. Relieves the repressor activity on Dox-induced GADD45A transcription and 2-fold increase in phosphorylation at Ser-824; when associated with R-554 and R-779.	MUTAGEN	0
Q13263/L306P	TRIM28	-	1	L->P: Disrupts the interaction with ZNF350 and amost completely relieves the transcription repressive effect of sumoylated TRIM28.	MUTAGEN	0
Q13263/L490E	TRIM28	-	1	L->E: Abolishes interaction with CBX5; when associated with E-488.	MUTAGEN	0
Q13263/L653A	TRIM28	-	1	L->A: Greatly reduced sumoylation. Little further effect on sumoylation; when associated with A-668 and/or A-709.	MUTAGEN	0
Q13263/L668A	TRIM28	-	1	L->A: Little effect on sumoylation. Little further effect on sumoylation; when associated with A-653 and/or A-709.	MUTAGEN	0
Q13263/L709A	TRIM28	-	1	L->A: Greatly reduced sumoylation. Little further effect on sumoylation; when associated with A-653 and/or A-668.	MUTAGEN	0
Q13263/S440A	TRIM28	-	1	S->A: No effect on interaction with PPP1CA nor on sumoylation levels. Decreased sumoylation levels; when associated with D-501 and D-824.	MUTAGEN	0
Q13263/S501A	TRIM28	-	1	S->A: No effect on interaction with PPP1CA nor on sumoylation levels. Decreased sumoylation levels; when associated with D-440 and D-824.	MUTAGEN	0
Q13263/S824A	TRIM28	-	2	S->A: Suppresses Dox-induced CDKN1A/p21 promoter activation. No effect on sumoylation levels. Decreased sumoylation levels; when associated with D-440 and D-501.	MUTAGEN	0
Q13263/S824D	TRIM28	-	2	S->D: Enhances Dox-induced CDKN1A/p21 promoter activation. Decreased sumoylation with or without Dox-treatment.	MUTAGEN	0
Q13263/T794M	TRIM28	-	1	T -> M (in dbSNP:rs56229738)	VARIANT	0
Q13263/V488E	TRIM28	-	1	V->E: Abolishes interaction with CBX5; when associated with E-490.	MUTAGEN	0
Q13308/A777V	PTK7	neutral	1	A -> V (in dbSNP:rs34764696)	VARIANT	0
Q13308/A933V	PTK7	-	1	A -> V (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	3
Q13308/E745D	PTK7	neutral	1	E -> D (in dbSNP:rs9472017)	VARIANT	0
Q13308/E766Q	PTK7	-	1	E -> Q (in dbSNP:rs56216742)	VARIANT	0
Q13308/H783R	PTK7	-	1	H -> R (in dbSNP:rs55820547)	VARIANT	0
Q13308/L622D	PTK7	-	1	L->D: Prevents proteolysis by MMP14.	MUTAGEN	0
Q13308/M641R	PTK7	-	1	M->R: No impact on proteolysis by MMP14.	MUTAGEN	0
Q13308/M701D	PTK7	-	1	M->D: No impact on proteolysis by MMP14.	MUTAGEN	0
Q13308/P1029T	PTK7	-	1	P -> T (in dbSNP:rs55755163)	VARIANT	0
Q13308/R1038Q	PTK7	neutral	1	R -> Q (in dbSNP:rs34865794)	VARIANT	1
Q13308/R276H	PTK7	-	1	R -> H (in dbSNP:rs56188167)	VARIANT	0
Q13308/T410S	PTK7	neutral	1	T -> S (in dbSNP:rs34021075)	VARIANT	4
Q13315/A350T	ATM	-	1	A -> T (in B-cell chronic lymphocytic leukemia; dbSNP:rs371713984)	VARIANT	0
Q13315/A869G	ATM	-	1	A -> G (found in a patient with familial pancreatic cancer; unknown pathological significance)	VARIANT	0
Q13315/C540Y	ATM	-	1	C -> Y (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q13315/D126E	ATM	neutral	2	D -> E (in dbSNP:rs2234997)	VARIANT	0
Q13315/D140H	ATM	-	1	D -> H (in dbSNP:rs55633650)	VARIANT	0
Q13315/D661A	ATM	-	1	D -> A (found in a patient with familial breast cancer; unknown pathological significance)	VARIANT	0
Q13315/D814E	ATM	neutral	0	D -> E (in dbSNP:rs3218695)	VARIANT	0
Q13315/E1091D	ATM	-	1	E -> D (in AT)	VARIANT	0
Q13315/E1313Q	ATM	-	0	E -> Q (in dbSNP:rs3092841)	VARIANT	0
Q13315/E699G	ATM	-	1	E -> G (found in a patient with familial pancreatic cancer; unknown pathological significance)	VARIANT	0
Q13315/E848Q	ATM	-	1	E -> Q (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs879254046)	VARIANT	0
Q13315/F570S	ATM	-	1	F -> S (in AT; dbSNP:rs777301065)	VARIANT	0
Q13315/F582L	ATM	-	1	F -> L (in dbSNP:rs2235006)	VARIANT	0
Q13315/F858L	ATM	neutral	8	F -> L (in dbSNP:rs1800056)	VARIANT	0
Q13315/F897I	ATM	-	1	F -> I (found in a patient with familial pancreatic cancer; unknown pathological significance)	VARIANT	0
Q13315/G514D	ATM	neutral	2	G -> D (in dbSNP:rs2235000)	VARIANT	0
Q13315/H1082L	ATM	-	1	H -> L (in AT; unknown pathological significance)	VARIANT	0
Q13315/H1380Y	ATM	neutral	1	H -> Y (in dbSNP:rs3092856)	VARIANT	0
Q13315/I323V	ATM	-	2	I -> V (in AT; loss of protein expression; dbSNP:rs587781511)	VARIANT	0
Q13315/I352T	ATM	-	1	I -> T (in B-cell chronic lymphocytic leukemia; dbSNP:rs369203092)	VARIANT	0
Q13315/I68V	ATM	-	1	I -> V (found in a patient with familial pancreatic cancer; unknown pathological significance)	VARIANT	0
Q13315/K224E	ATM	-	1	K -> E (in AT; unknown pathological significance; dbSNP:rs145053092)	VARIANT	0
Q13315/L1001Q	ATM	-	1	L -> Q (in AT; associated with T-cell acute lymphoblastic leukemia)	VARIANT	0
Q13315/L1046P	ATM	-	1	L -> P (in AT; loss of protein expression; dbSNP:rs568461905)	VARIANT	0
Q13315/L1255V	ATM	-	1	L -> V (found in a patient with early-onset breast cancer; unknown pathological significance)	VARIANT	0
Q13315/L1322I	ATM	-	1	L -> I (no effect on phosphorylation of target proteins; dbSNP:rs144535256)	VARIANT	0
Q13315/L546V	ATM	neutral	2	L -> V (no effect on phosphorylation of target proteins; dbSNP:rs2227924)	VARIANT	0
Q13315/L942F	ATM	-	0	L -> F (in dbSNP:rs3218688)	VARIANT	0
Q13315/L950R	ATM	-	0	L -> R (in AT; dbSNP:rs786203054)	VARIANT	0
Q13315/M1040V	ATM	neutral	1	M -> V (found in B-cell non-Hodgkin lymphoma; unknown pathological significance; dbSNP:rs3092857)	VARIANT	0
Q13315/M1321I	ATM	-	1	M -> I (in dbSNP:rs35184530)	VARIANT	0
Q13315/N504S	ATM	-	1	N -> S (in dbSNP:rs56365018)	VARIANT	0
Q13315/N768D	ATM	-	1	N -> D (in AT)	VARIANT	0
Q13315/N813S	ATM	-	1	N -> S (found in a patient with familial pancreatic cancer; unknown pathological significance)	VARIANT	0
Q13315/P1054R	ATM	-	11	P -> R (in AT, B-cell chronic lymphocytic leukemia, breast cancer patients and familial cancer patients; no effect on phosphorylation of target proteins; dbSNP:rs1800057)	VARIANT	0
Q13315/P1382S	ATM	-	1	P -> S (in dbSNP:rs55859590)	VARIANT	0
Q13315/P292L	ATM	-	3	P -> L (in AT; associated with lymphoma; decrease phosphorylation of target proteins; increases protein abundance; dbSNP:rs747727055)	VARIANT	0
Q13315/P597L	ATM	-	1	P -> L (found in a patient with familial pancreatic cancer; unknown pathological significance)	VARIANT	0
Q13315/P872S	ATM	neutral	1	P -> S (in dbSNP:rs3218673)	VARIANT	0
Q13315/R23Q	ATM	-	1	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs587779858)	VARIANT	0
Q13315/R250Q	ATM	-	1	R -> Q (in dbSNP:rs56123940)	VARIANT	0
Q13315/R337C	ATM	-	1	R -> C (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs138398778)	VARIANT	0
Q13315/R337H	ATM	-	1	R -> H (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs202160435)	VARIANT	0
Q13315/R45W	ATM	-	1	R -> W (found in a patient with breast cancer; unknown pathological significance; dbSNP:rs3218684)	VARIANT	0
Q13315/R785C	ATM	-	1	R -> C (in AT; dbSNP:rs587778065)	VARIANT	0
Q13315/R924W	ATM	-	2	R -> W (found in a patient with familial breast cancer; unknown pathological significance; dbSNP:rs55723361)	VARIANT	0
Q13315/S1179F	ATM	-	1	S -> F (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	0
Q13315/S333F	ATM	-	1	S -> F (in dbSNP:rs28904919)	VARIANT	0
Q13315/S367A	ATM	loss	1	S->A: Loss of IR-induced S-367 autophosphorylation. Reduced correction of cell cycle checkpoint defects and DNA-repair activity. No effect on S-1893 nor S-1981 autophosphorylation.	MUTAGEN	0
Q13315/S49C	ATM	-	9	S -> C (in AT; increases protein abundance; dbSNP:rs1800054)	VARIANT	0
Q13315/S707P	ATM	neutral	3	S -> P (in dbSNP:rs4986761)	VARIANT	0
Q13315/S759G	ATM	-	1	S -> G (found in a patient with familial pancreatic cancer; unknown pathological significance)	VARIANT	0
Q13315/S788R	ATM	-	0	S -> R (in dbSNP:rs641252)	VARIANT	0
Q13315/T761S	ATM	-	0	T -> S (in dbSNP:rs2235011)	VARIANT	0
Q13315/T935A	ATM	-	1	T -> A (in dbSNP:rs35813135)	VARIANT	0
Q13315/T935M	ATM	-	0	T -> M (in dbSNP:rs3218708)	VARIANT	0
Q13315/V182L	ATM	-	1	V -> L (in dbSNP:rs3218707)	VARIANT	0
Q13315/V341I	ATM	-	1	V -> I (found in a patient with familial pancreatic cancer; unknown pathological significance)	VARIANT	0
Q13315/V410A	ATM	neutral	1	V -> A (in dbSNP:rs56128736)	VARIANT	0
Q13315/Y332C	ATM	-	1	Y -> C (in B-cell chronic lymphocytic leukemia)	VARIANT	0
Q13418/A262V	ILK	-	1	A -> V (found in a patient with severe dilated cardiomyopathy; unknown pathological significance; dbSNP:rs387907366)	VARIANT	0
Q13418/E359K	ILK	loss	1	E->K: Inactivation of ILK.	MUTAGEN	0
Q13418/H99D	ILK	-	1	H->D: Alters interaction with LIMS1.	MUTAGEN	0
Q13464/C1264R	ROCK1	-	1	C -> R (in dbSNP:rs2663698)	VARIANT	0
Q13464/D1113A	ROCK1	-	1	D->A: Abolishes cleavage by caspase-3.	MUTAGEN	0
Q13464/P1193S	ROCK1	-	1	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs1057520015)	VARIANT	0
Q13464/Q1217E	ROCK1	-	1	Q -> E (in dbSNP:rs2847092)	VARIANT	11
Q13464/R1262Q	ROCK1	-	1	R -> Q (in dbSNP:rs1045142)	VARIANT	0
Q13464/S108N	ROCK1	-	1	S -> N (in dbSNP:rs55811609)	VARIANT	0
Q13464/T1112P	ROCK1	neutral	1	T -> P (in dbSNP:rs35881519)	VARIANT	0
Q13464/T773S	ROCK1	neutral	1	T -> S (in dbSNP:rs45562542)	VARIANT	0
Q13470/R339K	TNK1	-	1	R -> K (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q13470/R539C	TNK1	-	1	R -> C (in dbSNP:rs36046975)	VARIANT	0
Q13470/S546C	TNK1	neutral	1	S -> C (in dbSNP:rs56093628)	VARIANT	0
Q13470/T514K	TNK1	-	1	T -> K (in dbSNP:rs55641092)	VARIANT	0
Q13470/V278I	TNK1	neutral	1	V -> I (in dbSNP:rs55939858)	VARIANT	0
Q13470/V598M	TNK1	-	2	V -> M (in dbSNP:rs6503018)	VARIANT	1
Q13523/F658L	PRPF4B	-	2	F -> L (in a breast cancer sample; somatic mutation; dbSNP:rs1230491406)	VARIANT	0
Q13523/I584V	PRPF4B	-	1	I -> V (in dbSNP:rs56267049)	VARIANT	0
Q13523/I83V	PRPF4B	neutral	10	I -> V (in dbSNP:rs9503893)	VARIANT	0
Q13546/A220V	RIPK1	-	1	A -> V (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs759012409)	VARIANT	1
Q13546/A404S	RIPK1	-	1	A -> S (in dbSNP:rs34872409)	VARIANT	0
Q13546/A438V	RIPK1	-	3	A -> V (in dbSNP:rs3173519)	VARIANT	0
Q13546/A443V	RIPK1	-	1	A -> V (in dbSNP:rs35722193)	VARIANT	0
Q13546/A569V	RIPK1	neutral	1	A -> V (in dbSNP:rs55861377)	VARIANT	0
Q13546/A64V	RIPK1	-	1	A -> V (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs774996232)	VARIANT	0
Q13546/D324H	RIPK1	increase	2	D -> H (in AIEFL; prevents cleavage by CASP8; increased kinase activity; increased inflammatory response)	VARIANT	0
Q13546/D324K	RIPK1	-	1	D->K: Abolishes cleavage by caspase-8.	MUTAGEN	0
Q13546/D324N	RIPK1	-	1	D -> N (in AIEFL; prevents cleavage by CASP8; changed inflammatory response; dbSNP:rs1760720617)	VARIANT	0
Q13546/D324V	RIPK1	increase	1	D -> V (in AIEFL; prevents cleavage by CASP8; increased kinase activity; increased inflammatory response)	VARIANT	0
Q13546/D324Y	RIPK1	-	1	D -> Y (in AIEFL; prevents cleavage by CASP8; changed inflammatory response)	VARIANT	0
Q13546/E234K	RIPK1	-	0	E -> K (in dbSNP:rs17548383)	VARIANT	0
Q13546/K377R	RIPK1	-	1	K->R: Abolishes RIP-mediated NF-Kappa-B activation.	MUTAGEN	0
Q13546/K45A	RIPK1	loss	2	K->A: Abolishes kinase activity.	MUTAGEN	0
Q13546/K599R	RIPK1	-	1	K->R: Blocks homodimerization, necroptosis and apoptosis.	MUTAGEN	1
Q13546/R603A	RIPK1	-	1	R->A: Abolished GlcNAcylation by E.coli NleB1.	MUTAGEN	0
Q13546/S161A	RIPK1	decrease	1	S->A: Decreases RIPK1 kinase activity.	MUTAGEN	0
Q13546/S161E	RIPK1	-	1	S->E: No effect on RIPK1 autophosphorylation.	MUTAGEN	0
Q13546/S25D	RIPK1	loss	1	S->D: Phophomimetic mutant. Significant loss of kinase activity.	MUTAGEN	0
Q13546/S536C	RIPK1	-	1	S->C: Strongly reduced homodimerization and interaction with RIPK3.	MUTAGEN	0
Q13546/V81I	RIPK1	-	1	V -> I (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs758268804)	VARIANT	0
Q13554/E110K	CAMK2B	increase	1	E -> K (in MRD54; decreased protein abundance; increased autophosphorylation; decreased neuronal migration; dbSNP:rs1554402092)	VARIANT	0
Q13554/E237K	CAMK2B	increase	1	E -> K (in MRD54; no effect on protein abundance; increased autophosphorylation; decreased neuronal migration; dbSNP:rs1554386687)	VARIANT	1
Q13554/E510K	CAMK2B	neutral	1	E -> K (in dbSNP:rs35452727)	VARIANT	0
Q13554/K301E	CAMK2B	loss	1	K -> E (in MRD54; no effect on protein abundance; loss of autophosphorylation; changed function in neuronal migration; dbSNP:rs1554385111)	VARIANT	0
Q13554/P139L	CAMK2B	increase	1	P -> L (in MRD54; decreased protein abundance; increased autophosphorylation; decreased neuronal migration; dbSNP:rs1554389088)	VARIANT	0
Q13554/P213L	CAMK2B	-	1	P -> L (in MRD54; dbSNP:rs1554387293)	VARIANT	0
Q13554/P489L	CAMK2B	-	1	P -> L (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs555460132)	VARIANT	0
Q13554/R284S	CAMK2B	-	1	R -> S (in MRD54; dbSNP:rs1554385203)	VARIANT	0
Q13555/S36P	CAMK2G	-	1	S -> P (in dbSNP:rs17853266)	VARIANT	0
Q13557/D167E	CAMK2D	neutral	1	D -> E (in dbSNP:rs35367671)	VARIANT	0
Q13557/Q463E	CAMK2D	-	0	Q -> E (in dbSNP:rs1053668)	VARIANT	0
Q13557/T493I	CAMK2D	-	1	T -> I (in dbSNP:rs35765784)	VARIANT	0
Q13627/A679P	DYRK1A	-	2	A -> P (in dbSNP:rs55720916)	VARIANT	0
Q13627/K188R	DYRK1A	loss	2	K->R: Abolished protein kinase activity.	MUTAGEN	0
Q13627/Q681H	DYRK1A	-	1	Q -> H	VARIANT	0
Q13627/Y321F	DYRK1A	decrease	1	Y->F: Mildly reduces kinase activity. Does not abolish autophosphorylation on tyrosine residues.	MUTAGEN	0
Q13627/Y415F	DYRK1A	-	1	Y -> F	VARIANT	0
Q13705/E459D	ACVR2B	-	1	E -> D (in dbSNP:rs500611)	VARIANT	0
Q13705/P176R	ACVR2B	-	1	P -> R (in dbSNP:rs35882617)	VARIANT	0
Q13705/R40H	ACVR2B	-	1	R -> H (in HTX4; dbSNP:rs121434437)	VARIANT	0
Q13705/V494I	ACVR2B	-	1	V -> I (in HTX4; dbSNP:rs121434438)	VARIANT	1
Q13873/A162P	BMPR2	-	2	A -> P (in PPH1; unknown pathological significance; unchanged subcellular localization)	VARIANT	0
Q13873/C117Y	BMPR2	-	1	C -> Y (in PPH1; dbSNP:rs1085307215)	VARIANT	0
Q13873/C118W	BMPR2	-	1	C -> W (in PPH1; dbSNP:rs137852743)	VARIANT	0
Q13873/C123R	BMPR2	-	1	C -> R (in PPH1; dbSNP:rs137852750)	VARIANT	0
Q13873/C123S	BMPR2	-	1	C -> S (in PPH1; dbSNP:rs137852750)	VARIANT	0
Q13873/C347Y	BMPR2	-	1	C -> Y (in PPH1; dbSNP:rs137852744)	VARIANT	0
Q13873/C420R	BMPR2	-	1	C -> R (in PPH1; dbSNP:rs1085307324)	VARIANT	0
Q13873/C483R	BMPR2	-	2	C -> R (in PPH1; sporadic; dbSNP:rs1085307354)	VARIANT	0
Q13873/C60Y	BMPR2	-	1	C -> Y (in PPH1; dbSNP:rs1085307172)	VARIANT	0
Q13873/C84F	BMPR2	-	2	C -> F (in PPH1; alters alternative splicing of BMPR2; dbSNP:rs1085307197)	VARIANT	0
Q13873/D264N	BMPR2	-	2	D -> N (in PPH1; unknown pathological significance; unchanged subcellular localization)	VARIANT	0
Q13873/D485G	BMPR2	loss	2	D -> G (in PPH1; complete loss of function; dbSNP:rs137852745)	VARIANT	0
Q13873/E224D	BMPR2	-	1	E -> D (in dbSNP:rs754343081)	VARIANT	1
Q13873/G182D	BMPR2	-	1	G -> D (in PPH1; dbSNP:rs137852754)	VARIANT	0
Q13873/H87Y	BMPR2	-	2	H -> Y (in PPH1; unknown pathological significance; unchanged subcellular localization)	VARIANT	0
Q13873/I77L	BMPR2	-	2	I -> L (in PPH1; unknown pathological significance; unchanged subcellular localization)	VARIANT	0
Q13873/K467R	BMPR2	-	1	K -> R (in PPH1; unknown pathological significance; unchanged subcellular localization)	VARIANT	0
Q13873/K512T	BMPR2	-	1	K -> T (in PPH1; dbSNP:rs1085307364)	VARIANT	0
Q13873/N519K	BMPR2	-	0	N -> K (in PPH1; dbSNP:rs1085307365)	VARIANT	0
Q13873/P138A	BMPR2	-	1	P -> A (in PPH1; unknown pathological significance; unchanged subcellular localization)	VARIANT	0
Q13873/Q109H	BMPR2	-	1	Q -> H (in PPH1; unknown pathological significance; unchanged subcellular localization)	VARIANT	0
Q13873/Q82H	BMPR2	-	1	Q -> H (in PPH1; dbSNP:rs1085307185)	VARIANT	1
Q13873/Q92L	BMPR2	-	2	Q -> L (in PPH1; unknown pathological significance; unchanged subcellular localization)	VARIANT	0
Q13873/R248G	BMPR2	-	1	R -> G (in PPH1; unknown pathological significance; unchanged subcellular localization)	VARIANT	0
Q13873/R491Q	BMPR2	-	1	R -> Q (in PPH1; sporadic; dbSNP:rs137852749)	VARIANT	0
Q13873/R491W	BMPR2	-	1	R -> W (in PPH1; dbSNP:rs137852746)	VARIANT	1
Q13873/R899P	BMPR2	activating	1	R -> P (in PPH1; leads to constitutive activation of the MAPK14 pathway; dbSNP:rs137852752)	VARIANT	0
Q13873/S64R	BMPR2	-	1	S -> R (in PPH1; unknown pathological significance; unchanged subcellular localization)	VARIANT	0
Q13873/S775N	BMPR2	neutral	3	S -> N (unchanged subcellular localization; dbSNP:rs2228545)	VARIANT	0
Q13873/S863N	BMPR2	-	1	S -> N (in PPH1; abnormal subcellular localization; significant increase in apoptosis of endothelial cells; significant decrease in proliferation of endothelial cells; significant decrease in nitric oxide synthesis by endothelial cells; significant increase in endothelin 1 synthesis by endothelial cells; dbSNP:rs1006246556)	VARIANT	0
Q13873/V341M	BMPR2	-	2	V -> M (in PPH1; unknown pathological significance; unchanged subcellular localization; dbSNP:rs767882551)	VARIANT	0
Q13873/Y67C	BMPR2	-	1	Y -> C (in PPH1; significant decrease in nitric oxide synthesis by endothelial cells; dbSNP:rs1085307177)	VARIANT	0
Q13882/A436T	PTK6	-	1	A -> T (in dbSNP:rs56145017)	VARIANT	0
Q13882/K219M	PTK6	loss	3	K->M: Abolishes kinase activity and cell transformation, and phosphorylation of STAP2.	MUTAGEN	0
Q13882/K219R	PTK6	loss	1	K->R: Abolishes kinase activity.	MUTAGEN	0
Q13882/L16F	PTK6	-	1	L -> F (in a renal papillary sample; somatic mutation)	VARIANT	0
Q13882/R105L	PTK6	decrease	1	R->L: Decrease in STAP2 phosphorylation.	MUTAGEN	0
Q13882/W184A	PTK6	loss	1	W->A: Abrogates interaction between PTK6-domain kinase and PTK6-linker. Abrogates autophosphorylation and phosphorylation of KHDRBS1.	MUTAGEN	0
Q13882/W44A	PTK6	decrease	2	W->A: Strong decrease in STAP2 phosphorylation. Markedly decreased interaction between SH3 domain the linker region.	MUTAGEN	0
Q13882/Y342A	PTK6	decrease	1	Y->A: 3-fold lower specific kinase activity. Decreased, but still significant, autophosphorylation. Decreased, but still significant, autophosphorylation; when associated with A-447.	MUTAGEN	0
Q13882/Y447F	PTK6	increase	3	Y->F: Decrease in transforming potential and increase in the kinase activity level. Decreased, but still significant, autophosphorylation; when associated with A-342.	MUTAGEN	0
Q13882/Y66A	PTK6	decrease	1	Y->A: Decrease in STAP2 phosphorylation.	MUTAGEN	0
Q13976/G666A	PRKG1	-	1	G -> A (in dbSNP:rs750949508)	VARIANT	0
Q13976/I19A	PRKG1	-	1	I->A: Loss of binding to PPP1R12A.	MUTAGEN	0
Q13976/I249V	PRKG1	-	1	I -> V (in dbSNP:rs56082459)	VARIANT	0
Q13976/I33A	PRKG1	-	1	I->A: Loss of binding to PPP1R12A.	MUTAGEN	0
Q13976/L12A	PRKG1	-	1	L->A: Loss of binding to PPP1R12A.	MUTAGEN	0
Q13976/L26P	PRKG1	-	1	L->P: Loss of binding to PPP1R12A.	MUTAGEN	0
Q13976/L281A	PRKG1	-	1	L->A: Reduces cGMP binding affinity.	MUTAGEN	0
Q13976/L40A	PRKG1	-	1	L->A: Loss of binding to PPP1R12A.	MUTAGEN	0
Q13976/N267S	PRKG1	neutral	1	N -> S (in dbSNP:rs34997494)	VARIANT	2
Q13976/R282A	PRKG1	-	1	R->A: Reduces cGMP binding affinity.	MUTAGEN	0
Q13976/T302A	PRKG1	-	1	T->A: Reduces cGMP binding affinity.	MUTAGEN	0
Q13976/Y336A	PRKG1	-	1	Y->A: Reduces cGMP binding affinity.	MUTAGEN	0
Q13976/Y474F	PRKG1	-	1	Y -> F (in dbSNP:rs149710600)	VARIANT	0
Q14004/G714R	CDK13	-	1	G -> R (in CHDFIDD; dbSNP:rs1057519633)	VARIANT	0
Q14004/G717R	CDK13	-	1	G -> R (in CHDFIDD; dbSNP:rs1057519632)	VARIANT	0
Q14004/K734E	CDK13	-	1	K -> E (in CHDFIDD; dbSNP:rs1064795731)	VARIANT	0
Q14004/L403F	CDK13	neutral	0	L -> F (in dbSNP:rs3735137)	VARIANT	3
Q14004/N842D	CDK13	-	1	N -> D (in CHDFIDD; dbSNP:rs1554333853)	VARIANT	0
Q14004/N842S	CDK13	-	2	N -> S (in CHDFIDD; dbSNP:rs878853160)	VARIANT	0
Q14004/P356A	CDK13	-	0	P -> A (in dbSNP:rs17537669)	VARIANT	0
Q14004/Q103R	CDK13	-	0	Q -> R (in RNA edited version)	VARIANT	0
Q14004/R410Q	CDK13	-	0	R -> Q (in dbSNP:rs17496261)	VARIANT	0
Q14004/R700L	CDK13	-	2	R -> L (in dbSNP:rs1057000)	VARIANT	0
Q14004/R751Q	CDK13	-	1	R -> Q (in CHDFIDD; dbSNP:rs1057519634)	VARIANT	1
Q14004/S340F	CDK13	-	0	S -> F (in dbSNP:rs13622)	VARIANT	0
Q14004/S624G	CDK13	-	0	S -> G (in dbSNP:rs17496275)	VARIANT	0
Q14004/T494A	CDK13	-	1	T -> A (in dbSNP:rs34624759)	VARIANT	0
Q14004/T500A	CDK13	neutral	1	T -> A (in dbSNP:rs3735135)	VARIANT	0
Q14004/T670R	CDK13	neutral	1	T -> R (in dbSNP:rs34775357)	VARIANT	1
Q14004/V1062M	CDK13	-	0	V -> M (in dbSNP:rs17496712)	VARIANT	0
Q14004/V1170M	CDK13	neutral	2	V -> M (in dbSNP:rs3204309)	VARIANT	0
Q14012/E361K	CAMK1	neutral	1	E -> K (in dbSNP:rs56033923)	VARIANT	2
Q14012/K49A	CAMK1	loss	2	K->A: Catalytically inactive form; prevents CDK4 activation.	MUTAGEN	0
Q14012/P217S	CAMK1	-	1	P -> S (in a metastatic melanoma sample; somatic mutation; dbSNP:rs907102077)	VARIANT	1
Q14012/T177A	CAMK1	loss	1	T->A: Loss of activation by CaMKK1.	MUTAGEN	0
Q14012/T177D	CAMK1	increase	1	T->D: Partial activation in absence of CaMKK1.	MUTAGEN	0
Q14164/A371T	IKBKE	neutral	1	A -> T (in dbSNP:rs17021877)	VARIANT	0
Q14164/A602V	IKBKE	neutral	1	A -> V (in dbSNP:rs12059562)	VARIANT	3
Q14164/E128K	IKBKE	-	0	E -> K (in dbSNP:rs41296028)	VARIANT	0
Q14164/E168A	IKBKE	decrease	1	E->A: Slight decrease of kinase activity.	MUTAGEN	0
Q14164/E515D	IKBKE	neutral	0	E -> D (in dbSNP:rs41299015)	VARIANT	2
Q14164/G660E	IKBKE	-	1	G -> E (in dbSNP:rs55822317)	VARIANT	0
Q14164/I543M	IKBKE	neutral	0	I -> M (in dbSNP:rs41299037)	VARIANT	0
Q14164/K231R	IKBKE	-	1	K->R: Loss of sumoylation and loss of targeting to nuclear bodies.	MUTAGEN	0
Q14164/K30A	IKBKE	decrease	1	K->A: Loss of ubiquitination and decreased kinase activity. No effect on homodimerization.	MUTAGEN	0
Q14164/K30R	IKBKE	decrease	1	K->R: Loss of ubiquitination and decreased kinase activity. Decreases interaction with IKBKB, IKBKG and MYD88. No effect on homodimerization.	MUTAGEN	0
Q14164/K38A	IKBKE	loss	1	K->A: Loss of kinase activity and loss of nuclear import.	MUTAGEN	0
Q14164/K401A	IKBKE	decrease	1	K->A: Loss of ubiquitination and decreased kinase activity. No effect on homodimerization.	MUTAGEN	0
Q14164/K401R	IKBKE	decrease	1	K->R: Loss of ubiquitination and decreased kinase activity. Decreases interaction with IKBKB, IKBKG and MYD88. No effect on homodimerization.	MUTAGEN	0
Q14164/K416A	IKBKE	-	1	K->A: No effect on ubiquitination.	MUTAGEN	0
Q14164/K416R	IKBKE	-	1	K->R: No effect on ubiquitination.	MUTAGEN	0
Q14164/P713L	IKBKE	neutral	1	P -> L (in dbSNP:rs3748022)	VARIANT	8
Q14164/S172A	IKBKE	loss	1	S->A: Loss of autophosphorylation and of kinase activity.	MUTAGEN	0
Q14164/S172E	IKBKE	decrease	1	S->E: Decrease in kinase activity.	MUTAGEN	0
Q14164/T483M	IKBKE	neutral	1	T -> M (in dbSNP:rs52817862)	VARIANT	0
Q14289/E970K	PTK2B	-	1	E -> K (in dbSNP:rs56263944)	VARIANT	0
Q14289/K457A	PTK2B	loss	1	K->A: Abolishes kinase activity.	MUTAGEN	0
Q14289/K838T	PTK2B	neutral	2	K -> T (in dbSNP:rs751019)	VARIANT	0
Q14289/L808P	PTK2B	-	1	L -> P (in dbSNP:rs55747955)	VARIANT	0
Q14289/P859A	PTK2B	-	1	P->A: Loss of interaction with NPHP1.	MUTAGEN	0
Q14289/Q359E	PTK2B	neutral	1	Q -> E (in dbSNP:rs56175011)	VARIANT	1
Q14289/R698H	PTK2B	-	1	R -> H (in dbSNP:rs35174236)	VARIANT	0
Q14289/Y402F	PTK2B	loss	1	Y->F: Abolishes autophosphorylation. Abolishes interaction with SRC.	MUTAGEN	0
Q14289/Y881F	PTK2B	decrease	1	Y->F: Loss of phosphorylation site. Strongly reduced interaction with GRB2.	MUTAGEN	0
Q14296/A436V	FASTK	-	0	A -> V (in dbSNP:rs2288648)	VARIANT	0
Q14296/M35G	FASTK	-	1	M->G: Abolishes isoform 4 expression.	MUTAGEN	0
Q14296/V424L	FASTK	-	1	V -> L (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs758691941)	VARIANT	0
Q14680/C154A	MELK	-	1	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-168; A-169; A-204; A-286 and A-339.	MUTAGEN	0
Q14680/C168A	MELK	-	1	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-169; A-204; A-286 and A-339.	MUTAGEN	0
Q14680/C169A	MELK	-	1	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-204; A-286 and A-339.	MUTAGEN	0
Q14680/C204A	MELK	-	1	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-286 and A-339.	MUTAGEN	0
Q14680/C286A	MELK	-	1	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-204; and A-339.	MUTAGEN	0
Q14680/C29V	MELK	-	1	C->V: Abolishes dependence to reducing agents; when associated with V-70; A-89; A-154; A-168; A-169; A-204; A-286 and A-339.	MUTAGEN	0
Q14680/C339A	MELK	-	1	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-204 and A-286.	MUTAGEN	0
Q14680/C70V	MELK	-	1	C->V: Abolishes dependence to reducing agents; when associated with V-29; A-89; A-154; A-168; A-169; A-204; A-286 and A-339.	MUTAGEN	0
Q14680/C89A	MELK	-	1	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-154; A-168; A-169; A-204; A-286 and A-339.	MUTAGEN	0
Q14680/D150A	MELK	loss	3	D->A: Abolishes enzymatic activity.	MUTAGEN	0
Q14680/K219R	MELK	neutral	1	K -> R (in dbSNP:rs35142210)	VARIANT	0
Q14680/R333K	MELK	neutral	1	R -> K (in dbSNP:rs34655121)	VARIANT	0
Q14680/S171A	MELK	loss	1	S->A: Abolishes activation of serine/threonine-protein kinase activity and has only weak activity.	MUTAGEN	0
Q14680/S171D	MELK	loss	1	S->D: Inactive.	MUTAGEN	0
Q14680/T167A	MELK	loss	1	T->A: Abolishes activation of serine/threonine-protein kinase activity and has only weak activity.	MUTAGEN	0
Q14680/T167D	MELK	-	1	T->D,E: Phosphomimetic mutant that has similar kinase activity as wild-type.	MUTAGEN	0
Q14680/T167E	MELK	activating	1	T->D,E: Phosphomimetic mutant that has similar kinase activity as wild-type.	MUTAGEN	0
Q14680/T345A	MELK	-	1	T->A: No effect on interaction with PPP1R8.	MUTAGEN	0
Q14680/T348I	MELK	neutral	1	T -> I (in dbSNP:rs55845414)	VARIANT	0
Q14680/T387A	MELK	-	1	T->A: No effect on interaction with PPP1R8.	MUTAGEN	0
Q14680/T409A	MELK	-	1	T->A: No effect on interaction with PPP1R8.	MUTAGEN	0
Q14680/T415A	MELK	-	1	T->A: No effect on interaction with PPP1R8.	MUTAGEN	0
Q14680/T428A	MELK	-	1	T->A: No effect on interaction with PPP1R8.	MUTAGEN	1
Q14680/T446A	MELK	-	1	T->A: Inhibits interaction with PPP1R8.	MUTAGEN	0
Q14680/T460A	MELK	-	1	T->A: Inhibits interaction with PPP1R8.	MUTAGEN	0
Q14680/T460M	MELK	-	1	T -> M (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs144052967)	VARIANT	0
Q14680/T466A	MELK	-	1	T->A: Inhibits interaction with PPP1R8.	MUTAGEN	0
Q14680/T478A	MELK	-	1	T->A: Strongly inhibits interaction with PPP1R8. Enhances enzymatic activity.	MUTAGEN	0
Q14680/T518A	MELK	-	1	T->A: No effect on interaction with PPP1R8.	MUTAGEN	0
Q14680/T56M	MELK	-	1	T -> M (in dbSNP:rs35233455)	VARIANT	0
Q14680/Y163F	MELK	decrease	1	Y->F: Abolishes autophosphorylation on tyrosine but still active on exogenous substrates.	MUTAGEN	0
Q15059/A161T	BRD3	-	1	A -> T (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	0
Q15059/A172V	BRD3	neutral	1	A -> V (in dbSNP:rs34609592)	VARIANT	0
Q15059/K435Q	BRD3	neutral	1	K -> Q (in dbSNP:rs36093130)	VARIANT	0
Q15059/R441H	BRD3	-	1	R -> H (in dbSNP:rs56017928)	VARIANT	0
Q15059/S447P	BRD3	-	1	S -> P (in dbSNP:rs55754444)	VARIANT	0
Q15059/T36N	BRD3	-	1	T -> N (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	0
Q15118/A134T	PDK1	neutral	0	A -> T (in dbSNP:rs35661499)	VARIANT	0
Q15118/N412T	PDK1	-	1	N -> T (in dbSNP:rs34250425)	VARIANT	0
Q15119/G342R	PDK2	-	2	G -> R (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs17855787)	VARIANT	0
Q15120/D121N	PDK3	-	1	D->N: No effect on kinase activity; when associated with H-120.	MUTAGEN	0
Q15120/E219A	PDK3	-	1	E -> A (in a head & neck squamous cell carcinoma sample; somatic mutation)	VARIANT	0
Q15120/K114T	PDK3	-	1	K -> T (in dbSNP:rs146331370)	VARIANT	0
Q15120/N120H	PDK3	-	1	N->H: No effect on kinase activity; when associated with N-121.	MUTAGEN	0
Q15120/R158H	PDK3	activating	1	R -> H (in CMTX6; gain of function; results in a 5-fold increase in kinase activity, decreased sensitivity to pyruvate inhibition, reduced affinity for nucleotides and increased affinity for pyruvate dehydrogenase complex component E2 (PDC-E2), leading to PDC hyperphosphorylation and increased inactivation; dbSNP:rs397515323)	VARIANT	0
Q15120/Y334S	PDK3	-	1	Y -> S	VARIANT	0
Q15131/C358Y	CDK10	neutral	1	C -> Y (in dbSNP:rs56242003)	VARIANT	0
Q15131/N168S	CDK10	-	1	N -> S (in dbSNP:rs56340740)	VARIANT	0
Q15131/P96L	CDK10	neutral	1	P -> L (in dbSNP:rs55819627)	VARIANT	0
Q15131/R342H	CDK10	-	1	R -> H (in dbSNP:rs55757604)	VARIANT	0
Q15139/E857K	PRKD1	-	1	E -> K (in a colorectal cancer sample; somatic mutation)	VARIANT	0
Q15139/G592R	PRKD1	-	1	G -> R (in CHDED; dbSNP:rs1057519635)	VARIANT	0
Q15139/H152Y	PRKD1	-	1	H -> Y (in a colorectal cancer sample; somatic mutation; dbSNP:rs1383618278)	VARIANT	1
Q15139/H891R	PRKD1	neutral	1	H -> R (in dbSNP:rs45582934)	VARIANT	0
Q15139/K478Q	PRKD1	-	1	K -> Q (in dbSNP:rs55852813)	VARIANT	0
Q15139/K612W	PRKD1	loss	1	K->W: Loss of kinase activity.	MUTAGEN	0
Q15139/L299W	PRKD1	-	1	L -> W (in CHDED; dbSNP:rs1057519636)	VARIANT	0
Q15139/P157G	PRKD1	-	1	P->G: Increase in ability to bind phorbol ester, loss of ability to bind DAG.	MUTAGEN	0
Q15139/P281G	PRKD1	-	1	P->G: No effect on ability to bind phorbol ester, slight increase in ability to bind DAG.	MUTAGEN	0
Q15139/P585S	PRKD1	-	1	P -> S (in a metastatic melanoma sample; somatic mutation)	VARIANT	0
Q15139/P679L	PRKD1	-	1	P -> L (in dbSNP:rs34588699)	VARIANT	0
Q15139/R677M	PRKD1	-	1	R -> M (in a lung bronchoalveolar carcinoma sample; somatic mutation)	VARIANT	0
Q15139/R825K	PRKD1	-	0	R -> K (in dbSNP:rs11161065)	VARIANT	0
Q15139/S225P	PRKD1	-	1	S -> P	VARIANT	0
Q15139/Y432E	PRKD1	-	1	Y->E: Decreased phosphorylation level when coexpressed with SRC in HeLa cells. Unchanged phosphorylation level when coexpressed with ABL.	MUTAGEN	0
Q15139/Y432F	PRKD1	-	1	Y->F: Decreased phosphorylation level when coexpressed with SRC in HeLa cells. Unchanged phosphorylation level when coexpressed with ABL. Unaltered kinase activity. Decreased kinase activity; when associated with F-463 and F-502.	MUTAGEN	0
Q15139/Y463E	PRKD1	activating	1	Y->E: Constitutive activation and constitutive phosphorylation of S-738 and S-742.	MUTAGEN	0
Q15139/Y463F	PRKD1	decrease	1	Y->F: Decreased phosphorylation level when coexpressed with either SRC or ABL in HeLa cells. Decreased kinase activity.	MUTAGEN	0
Q15139/Y502E	PRKD1	loss	1	Y->E: Loss of activation.	MUTAGEN	0
Q15139/Y502F	PRKD1	-	1	Y->F: Decreased phosphorylation level when coexpressed with SRC in HeLa cells. Unchanged phosphorylation level when coexpressed with ABL. Unaltered kinase activity. Decreased kinase activity; when associated with F-432 and F-502.	MUTAGEN	0
Q15208/D145N	STK38	-	1	D -> N (in dbSNP:rs56005153)	VARIANT	0
Q15208/E18K	STK38	-	1	E -> K (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q15208/K118A	STK38	loss	2	K->A: Loss of autophosphorylation and kinase activity.	MUTAGEN	0
Q15208/K267R	STK38	-	1	K -> R (in dbSNP:rs56105564)	VARIANT	0
Q15208/S281A	STK38	loss	1	S->A: Loss of autophosphorylation and kinase activity.	MUTAGEN	0
Q15208/T444A	STK38	decrease	1	T->A: Decreases autophosphorylation and kinase activity.	MUTAGEN	0
Q15208/T74A	STK38	decrease	1	T->A: Decreases autophosphorylation and kinase activity. Reduced binding of S100B.	MUTAGEN	0
Q15303/A773S	ERBB4	-	1	A->S: No effect on kinase activity.	MUTAGEN	1
Q15303/D1000A	ERBB4	-	1	D->A: Abolishes APC/C-mediated degradation; when associated with A-992 and A-995.	MUTAGEN	0
Q15303/D843N	ERBB4	loss	1	D->N: Loss of kinase activity.	MUTAGEN	6
Q15303/D861Y	ERBB4	loss	1	D->Y: Loss of kinase activity.	MUTAGEN	0
Q15303/E810K	ERBB4	-	1	E->K: No effect on kinase activity.	MUTAGEN	1
Q15303/E872K	ERBB4	-	1	E->K: No effect on kinase activity.	MUTAGEN	5
Q15303/I947R	ERBB4	activating	1	I->R: Constitutively autophosphorylated.	MUTAGEN	0
Q15303/K751R	ERBB4	loss	3	K->R: Abolishes kinase activity. Abolishes phosphorylation, proteolytic processing and nuclear localization.	MUTAGEN	0
Q15303/L710N	ERBB4	decrease	1	L->N: Strongly reduced autophosphorylation.	MUTAGEN	0
Q15303/L864R	ERBB4	decrease	1	L->R: Strongly reduced autophosphorylation.	MUTAGEN	0
Q15303/L995A	ERBB4	-	1	L->A: Abolishes APC/C-mediated degradation; when associated with A-992 and A-1000.	MUTAGEN	0
Q15303/M766R	ERBB4	decrease	1	M->R: Strongly reduced autophosphorylation.	MUTAGEN	0
Q15303/P854Q	ERBB4	-	1	P->Q: No effect on kinase activity.	MUTAGEN	0
Q15303/R1275W	ERBB4	decrease	1	R -> W (in ALS19; reduces autophosphorylation upon NRG1 stimulation; dbSNP:rs397514263)	VARIANT	0
Q15303/R782Q	ERBB4	-	1	R->Q: No effect on kinase activity.	MUTAGEN	1
Q15303/R927Q	ERBB4	decrease	1	R -> Q (in ALS19; reduces autophosphorylation upon NRG1 stimulation; dbSNP:rs397514262)	VARIANT	1
Q15303/R992A	ERBB4	-	1	R->A: Abolishes APC/C-mediated degradation; when associated with A-995 and A-1000.	MUTAGEN	0
Q15303/S303Y	ERBB4	-	1	S -> Y (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	1
Q15303/T140I	ERBB4	-	1	T -> I (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q15303/T926M	ERBB4	-	1	T->M: No effect on kinase activity.	MUTAGEN	3
Q15303/V675A	ERBB4	-	2	V->A: Abolishes proteolytic processing and nuclear localization.	MUTAGEN	0
Q15303/V721I	ERBB4	-	1	V->I: No effect on kinase activity.	MUTAGEN	1
Q15303/Y1035A	ERBB4	-	1	Y->A: No effect on interaction with WWOX. Abolishes interaction with WWOX; when associated with A-1301.	MUTAGEN	0
Q15303/Y1056A	ERBB4	loss	1	Y->A: Abolishes interaction with NEDD4 and impairs ubiquitination. Promotes nuclear translocation of ERBB4 intracellular domain E4ICD1.	MUTAGEN	0
Q15303/Y1056F	ERBB4	-	1	Y->F: Abolishes interaction with WWP1; when associated with F-1301.	MUTAGEN	0
Q15303/Y1301A	ERBB4	-	3	Y->A: No effect on interaction with WWOX. Abolishes interaction with WWOX; when associated with A-1035. Loss of interaction with YAP1 and stimulation of transcription.	MUTAGEN	0
Q15303/Y1301F	ERBB4	-	3	Y->F: Abolishes interaction with WWP1; when associated with F-1056.	MUTAGEN	0
Q15349/E311K	RPS6KA2	-	1	E -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs267600891)	VARIANT	1
Q15375/E170K	EPHA7	-	1	E -> K (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q15375/G232R	EPHA7	-	1	G -> R (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q15375/I138V	EPHA7	neutral	2	I -> V (in dbSNP:rs2278107)	VARIANT	6
Q15375/P278S	EPHA7	neutral	1	P -> S (in dbSNP:rs2278106)	VARIANT	4
Q15375/P903S	EPHA7	-	1	P -> S (in a metastatic melanoma sample; somatic mutation)	VARIANT	2
Q15375/R371W	EPHA7	-	1	R -> W (in a colorectal cancer sample; somatic mutation; dbSNP:rs371089003)	VARIANT	2
Q15418/K335T	RPS6KA1	neutral	2	K -> T (in dbSNP:rs2229712)	VARIANT	4
Q15569/D175A	TESK1	-	1	D->A: Abolishes inhibition of SPRY4-mediated repression of cell spreading. No effect on interaction with SPRY4 or colocalization with SPRY4 at vesicular spots in the cytoplasm.	MUTAGEN	0
Q15569/G574S	TESK1	-	1	G -> S (in dbSNP:rs55673450)	VARIANT	0
Q15569/H539Y	TESK1	-	2	H -> Y (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation; dbSNP:rs1373248755)	VARIANT	2
Q15746/A128V	MYLK	neutral	1	A -> V (in dbSNP:rs143896146)	VARIANT	0
Q15746/A1491S	MYLK	decrease	1	A -> S (in AAT7; decreases kinase activity; dbSNP:rs1576422965)	VARIANT	0
Q15746/A1527V	MYLK	-	1	A -> V (in dbSNP:rs34982967)	VARIANT	0
Q15746/A1754T	MYLK	decrease	1	A -> T (in AAT7; 4-fold reduced affinity for calmodulin; decreased kinase activity compared to wild-type protein)	VARIANT	0
Q15746/A701T	MYLK	neutral	1	A -> T (in dbSNP:rs142835596)	VARIANT	0
Q15746/D914E	MYLK	neutral	0	D -> E (in dbSNP:rs3732487)	VARIANT	0
Q15746/E1399K	MYLK	-	1	E -> K (in dbSNP:rs181663420)	VARIANT	1
Q15746/K608A	MYLK	loss	1	K->A: Loss of acetylation and no kinase activity repression by NAA10/ARD1.	MUTAGEN	0
Q15746/L861P	MYLK	neutral	0	L -> P (in dbSNP:rs3732486)	VARIANT	0
Q15746/M405V	MYLK	-	1	M -> V (in dbSNP:rs35436690)	VARIANT	0
Q15746/P1588L	MYLK	-	1	P -> L (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs1576401641)	VARIANT	1
Q15746/P160R	MYLK	neutral	1	P -> R (in dbSNP:rs111256888)	VARIANT	0
Q15746/P21H	MYLK	neutral	0	P -> H (in dbSNP:rs28497577)	VARIANT	4
Q15746/P336L	MYLK	-	0	P -> L (in dbSNP:rs35912339)	VARIANT	0
Q15746/P443S	MYLK	-	1	P -> S (in dbSNP:rs35156360)	VARIANT	0
Q15746/P652A	MYLK	-	1	P -> A (in dbSNP:rs750686734)	VARIANT	0
Q15746/Q133H	MYLK	neutral	1	Q -> H (in dbSNP:rs140148380)	VARIANT	0
Q15746/R378H	MYLK	-	1	R -> H (in dbSNP:rs56378658)	VARIANT	0
Q15746/R607G	MYLK	-	1	R -> G	VARIANT	0
Q15746/R845C	MYLK	neutral	0	R -> C (in dbSNP:rs3732485)	VARIANT	0
Q15746/S1759P	MYLK	-	1	S -> P (in AAT7; 7-fold reduced affinity for calmodulin; 6-fold decreased Vmax; dbSNP:rs387906781)	VARIANT	0
Q15746/T1085A	MYLK	neutral	1	T -> A (in dbSNP:rs75370906)	VARIANT	0
Q15746/T276A	MYLK	-	1	T -> A (in dbSNP:rs55846245)	VARIANT	0
Q15746/T692M	MYLK	-	1	T -> M (in dbSNP:rs776858093)	VARIANT	0
Q15746/V1213M	MYLK	-	1	V -> M (in AAT7; unknown pathological significance; dbSNP:rs368390254)	VARIANT	3
Q15746/V261A	MYLK	neutral	1	V -> A (in dbSNP:rs3796164)	VARIANT	1
Q15746/V709M	MYLK	-	1	V -> M (in dbSNP:rs112537316)	VARIANT	0
Q15746/V877M	MYLK	-	0	V -> M (in dbSNP:rs34542174)	VARIANT	0
Q15746/W656C	MYLK	-	2	W -> C (in dbSNP:rs138172035)	VARIANT	0
Q15759/A221V	MAPK11	-	1	A -> V (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
Q15759/R275H	MAPK11	neutral	1	R -> H (in dbSNP:rs33932986)	VARIANT	0
Q15759/T180A	MAPK11	loss	1	T->A: Inactivation.	MUTAGEN	0
Q15759/Y182F	MAPK11	loss	1	Y->F: Inactivation.	MUTAGEN	0
Q15772/A1135V	SPEG	-	1	A -> V (in dbSNP:rs55670811)	VARIANT	0
Q15772/E1178D	SPEG	-	1	E -> D (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs757589345)	VARIANT	0
Q15772/P1103L	SPEG	-	1	P -> L (in dbSNP:rs56334571)	VARIANT	0
Q15772/R1234W	SPEG	-	1	R -> W (in dbSNP:rs55916864)	VARIANT	0
Q15772/R1340Q	SPEG	-	1	R -> Q (in dbSNP:rs34994343)	VARIANT	0
Q15772/R206H	SPEG	neutral	1	R -> H (in dbSNP:rs55821435)	VARIANT	0
Q15772/R934C	SPEG	-	1	R -> C (in dbSNP:rs34398769)	VARIANT	0
Q15772/R966Q	SPEG	-	1	R -> Q (in dbSNP:rs34861443)	VARIANT	0
Q15831/A205T	STK11	-	1	A -> T (in sporadic cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs730881981)	VARIANT	1
Q15831/D176N	STK11	loss	0	D -> N (in PJS; loss of kinase activity, leading to greatly reduced autophosphorylation; fails to phosphorylate 	VARIANT	0
Q15831/D176Y	STK11	loss	2	D -> Y (in sporadic cancer; somatic mutation; Loss of kinase activity)	VARIANT	0
Q15831/D194A	STK11	loss	3	D->A: Loss of kinase activity.	MUTAGEN	0
Q15831/D194N	STK11	-	1	D -> N (in PJS; dbSNP:rs121913315)	VARIANT	6
Q15831/D194V	STK11	-	1	D -> V (in lung cancer; somatic mutation; dbSNP:rs121913316)	VARIANT	3
Q15831/D194Y	STK11	-	1	D -> Y (in melanoma; sporadic malignant; somatic mutation; dbSNP:rs121913315)	VARIANT	12
Q15831/D208N	STK11	-	1	D -> N (in colorectal cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs1555738372)	VARIANT	0
Q15831/D277Y	STK11	-	1	D -> Y (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	0
Q15831/E14K	STK11	-	1	E -> K (in cervical cancer; somatic mutation)	VARIANT	0
Q15831/E16G	STK11	-	1	E -> G (in PJS)	VARIANT	0
Q15831/E199K	STK11	loss	1	E -> K (in colorectal cancer; somatic mutation; impaired kinase activity; dbSNP:rs121913317)	VARIANT	2
Q15831/E199Q	STK11	-	1	E -> Q (in sporadic cancer; somatic mutation; does not affect kinase activity)	VARIANT	0
Q15831/E223V	STK11	loss	1	E -> V (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	0
Q15831/F157S	STK11	-	1	F -> S (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	0
Q15831/F204A	STK11	-	1	F->A: No effect. Impaired formation of a heterotrimeric complex with STRADA and CAB39; when associated with A-74.	MUTAGEN	0
Q15831/F231L	STK11	-	1	F -> L (in cervical cancer; somatic mutation; dbSNP:rs929783669)	VARIANT	0
Q15831/F354L	STK11	-	1	F -> L (in colorectal cancer; somatic mutation; dbSNP:rs59912467)	VARIANT	55
Q15831/G135R	STK11	-	1	G -> R (in melanoma; sporadic malignant; somatic mutation; dbSNP:rs137853081)	VARIANT	0
Q15831/G163D	STK11	decrease	3	G -> D (in TGCT; a tumor with seminoma and teratoma components; associated with severely impaired but detectable kinase activity; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; predominantly nuclear localization; dbSNP:rs137853078)	VARIANT	1
Q15831/G171S	STK11	loss	2	G -> S (in colorectal cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs1599926499)	VARIANT	0
Q15831/G215D	STK11	-	1	G -> D (in colorectal cancer; somatic mutation; dbSNP:rs1057520038)	VARIANT	0
Q15831/H174R	STK11	loss	1	H -> R (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	3
Q15831/I177N	STK11	loss	1	I -> N (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs1057520041)	VARIANT	0
Q15831/K44R	STK11	-	1	K->R: No effect on kinase activity.	MUTAGEN	0
Q15831/K48Q	STK11	-	1	K->Q: No effect on basal nucleocytoplasmic localization, but fails to translocate to the cytoplasm when coexpressed with SIRT1.	MUTAGEN	0
Q15831/K48R	STK11	increase	1	K->R: Enhanced phosphorylation at Thr-336 and Ser-428, enhanced cytoplasmic localization and increased kinase activity.	MUTAGEN	0
Q15831/K78I	STK11	loss	2	K->I: Loss of kinase activity, leading to greatly reduced autophosphorylation.	MUTAGEN	0
Q15831/K78M	STK11	loss	2	K->M: Loss of kinase activity, leading to reduced autophosphorylation and acting as a dominant-negative mutant.	MUTAGEN	0
Q15831/K96R	STK11	-	1	K->R: No effect on kinase activity.	MUTAGEN	0
Q15831/K97R	STK11	-	1	K->R: No effect on kinase activity.	MUTAGEN	0
Q15831/L160P	STK11	-	1	L -> P (in cervical cancer; somatic mutation)	VARIANT	0
Q15831/L245R	STK11	-	1	L -> R (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	0
Q15831/L285Q	STK11	-	1	L -> Q (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	0
Q15831/L67P	STK11	loss	2	L -> P (in PJS; abolishes kinase activity, leading to loss of autophosphorylation; dbSNP:rs137853077)	VARIANT	0
Q15831/N181E	STK11	loss	1	N -> E (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; requires 2 nucleotide substitutions; dbSNP:rs1568707668)	VARIANT	0
Q15831/P281L	STK11	-	1	P -> L (in ovarian carcinoma; somatic mutation; dbSNP:rs121913322)	VARIANT	9
Q15831/P314H	STK11	-	1	P -> H (in colorectal cancer; no effect heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	0
Q15831/P315S	STK11	-	2	P -> S (in PJS; pathogenicity uncertain; no effect heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs786202431)	VARIANT	1
Q15831/P324L	STK11	-	1	P -> L (in gastric carcinoma; no effect heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs367807476)	VARIANT	2
Q15831/Q123R	STK11	-	1	Q -> R (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs764449808)	VARIANT	0
Q15831/Q170P	STK11	loss	1	Q -> P (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	1
Q15831/R297K	STK11	-	1	R -> K (in PJS; dbSNP:rs1568710381)	VARIANT	1
Q15831/R74A	STK11	-	1	R->A: Impaired formation of a heterotrimeric complex with STRADA and CAB39; when associated with A-204.	MUTAGEN	0
Q15831/R86G	STK11	-	1	R -> G (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs1057520039)	VARIANT	0
Q15831/R87K	STK11	-	1	R -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1568690463)	VARIANT	2
Q15831/S216F	STK11	loss	1	S -> F (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs1057520017)	VARIANT	11
Q15831/S232P	STK11	-	1	S -> P (in sporadic cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	0
Q15831/S428A	STK11	-	1	S->A,E: No effect on kinase activity.	MUTAGEN	0
Q15831/S428E	STK11	-	1	S->A,E: No effect on kinase activity.	MUTAGEN	0
Q15831/T189A	STK11	decrease	1	T->A: Reduced phosphorylation.	MUTAGEN	0
Q15831/T230P	STK11	-	1	T -> P (in sporadic cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	0
Q15831/T250P	STK11	-	1	T -> P (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	0
Q15831/T367M	STK11	-	1	T -> M (in colorectal cancer; somatic mutation; dbSNP:rs587782835)	VARIANT	0
Q15831/V66M	STK11	-	2	V -> M (in cervical carcinoma; somatic mutation; dbSNP:rs1599915144)	VARIANT	0
Q15831/W239C	STK11	-	1	W -> C (in PJS; late onset suggests reduced penetrance; dbSNP:rs137853082)	VARIANT	5
Q15831/W308C	STK11	loss	1	W -> C (in PJS; abolishes kinase activity, leading to loss of autophosphorylation; dbSNP:rs1057520042)	VARIANT	3
Q15831/Y272H	STK11	-	1	Y -> H (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39)	VARIANT	0
Q15831/Y49D	STK11	-	1	Y -> D (in melanoma; sporadic malignant; somatic mutation; dbSNP:rs137853080)	VARIANT	0
Q15835/C514S	GRK1	-	1	C -> S (in dbSNP:rs771561763)	VARIANT	0
Q15835/E136Q	GRK1	-	1	E -> Q (in dbSNP:rs542688076)	VARIANT	0
Q15835/K219A	GRK1	loss	1	K->A: Loss of autophosphorylation and RHO phosphorylation.	MUTAGEN	0
Q15835/M522T	GRK1	-	1	M -> T (in dbSNP:rs779749742)	VARIANT	0
Q15835/N330S	GRK1	-	1	N -> S (in dbSNP:rs375409897)	VARIANT	0
Q15835/P391H	GRK1	-	1	P -> H (in CSNBO2; dbSNP:rs570621429)	VARIANT	0
Q15835/R438H	GRK1	-	1	R -> H (in dbSNP:rs750619057)	VARIANT	2
Q15835/S21E	GRK1	-	1	S->E: Not phosphorylated by PKA.	MUTAGEN	0
Q15835/S536L	GRK1	-	1	S -> L (in dbSNP:rs553969577)	VARIANT	0
Q15835/T298M	GRK1	-	1	T -> M (in dbSNP:rs572803634)	VARIANT	1
Q15835/V380D	GRK1	-	1	V -> D (in CSNBO2; dbSNP:rs777094000)	VARIANT	0
Q16288/A664S	NTRK3	-	1	A -> S (in a lung carcinoma sample; somatic mutation)	VARIANT	0
Q16288/E781K	NTRK3	-	1	E -> K (in dbSNP:rs56393451)	VARIANT	0
Q16288/H677Y	NTRK3	-	2	H -> Y (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	0
Q16288/I533F	NTRK3	-	1	I -> F (probable disease-associated variant found in patients with CHD; associated with CHD susceptibility; no change in autophosphorylation; changed NTRK3 signaling with decreased apoptosis in absence of NTF3; dbSNP:rs869112057)	VARIANT	0
Q16288/I71V	NTRK3	-	1	I -> V (found in patients with CHD; unknown pathological significance; dbSNP:rs200923715)	VARIANT	0
Q16288/I817M	NTRK3	-	1	I -> M (probable disease-associated variant found in patients with CHD; associated with CHD susceptibility; no change in autophosphorylation; changed NTRK3 signaling with decreased apoptosis in absence of NTF3; dbSNP:rs869209165)	VARIANT	0
Q16288/K572N	NTRK3	loss	1	K->N: Loss of autophosphorylation and loss of NTRK3 signaling.	MUTAGEN	0
Q16288/K768R	NTRK3	-	1	K -> R (in dbSNP:rs55770052)	VARIANT	0
Q16288/L336Q	NTRK3	-	1	L -> Q (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q16288/N163I	NTRK3	-	1	N -> I (found in patients with CHD; unknown pathological significance; no change in autophosphorylation; no effect on NTRK3 signaling; dbSNP:rs547862658)	VARIANT	0
Q16288/R306C	NTRK3	-	1	R -> C (in dbSNP:rs56386352)	VARIANT	0
Q16288/R678Q	NTRK3	-	1	R -> Q (in dbSNP:rs55890138)	VARIANT	5
Q16288/R735F	NTRK3	-	0	R -> F (in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions)	VARIANT	0
Q16288/R745P	NTRK3	-	1	R -> P (in a lung carcinoma sample; somatic mutation)	VARIANT	0
Q16288/T149R	NTRK3	-	1	T -> R (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs368222977)	VARIANT	2
Q16288/T93M	NTRK3	decrease	1	T -> M (probable disease-associated variant found in patients with CHD; associated with CHD susceptibility; significantly reduced autophosphorylation; decreased NTRK3 signaling associated with decreased apoptosis in absence of NTF3; dbSNP:rs147992979)	VARIANT	1
Q16288/V21F	NTRK3	-	1	V -> F (in dbSNP:rs200822610)	VARIANT	1
Q16288/V307L	NTRK3	-	1	V -> L (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs1388363572)	VARIANT	1
Q16288/W736C	NTRK3	-	1	W -> C (in a lung carcinoma sample; somatic mutation)	VARIANT	0
Q16288/Y766F	NTRK3	-	1	Y -> F (in a lung carcinoma sample; somatic mutation)	VARIANT	0
Q16512/A197E	PKN1	-	1	A -> E (in dbSNP:rs1287763348)	VARIANT	0
Q16512/A921V	PKN1	-	1	A -> V (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q16512/D108A	PKN1	-	1	D->A: Abolishes cleavage by caspase-3 and formation of AF1 fragment.	MUTAGEN	0
Q16512/D451A	PKN1	loss	1	D->A: Abolishes cleavage by caspase-3 and formation of 70 kDa fragment.	MUTAGEN	0
Q16512/D454A	PKN1	loss	1	D->A: Abolishes cleavage by caspase-3 and formation of 70 kDa fragment.	MUTAGEN	0
Q16512/D558A	PKN1	loss	1	D->A: Abolishes cleavage by caspase-3 and formation of AF3 fragment.	MUTAGEN	0
Q16512/D560A	PKN1	loss	1	D->A: Abolishes cleavage by caspase-3 and formation of AF3 fragment.	MUTAGEN	0
Q16512/F873L	PKN1	-	1	F -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation)	VARIANT	2
Q16512/I718V	PKN1	-	2	I -> V (in dbSNP:rs2230539)	VARIANT	0
Q16512/K644E	PKN1	loss	2	K->E: Abolishes Serine/threonine-protein kinase activity.	MUTAGEN	0
Q16512/K644R	PKN1	decrease	2	K->R: Substantial reduction of autophosphorylation.	MUTAGEN	0
Q16512/L555I	PKN1	-	2	L -> I (in dbSNP:rs34309238)	VARIANT	0
Q16512/R181A	PKN1	-	1	R->A: Abolishes interaction with bacterial SspH1.	MUTAGEN	0
Q16512/R181K	PKN1	-	1	R->K: Decreases interaction with bacterial SspH1.	MUTAGEN	0
Q16512/R185A	PKN1	-	1	R->A: Abolishes interaction with bacterial SspH1.	MUTAGEN	0
Q16512/R185C	PKN1	-	1	R -> C (in a metastatic melanoma sample; somatic mutation; dbSNP:rs267605306)	VARIANT	1
Q16512/R436W	PKN1	neutral	1	R -> W (in dbSNP:rs35132656)	VARIANT	0
Q16512/R520Q	PKN1	-	1	R -> Q (in dbSNP:rs56273055)	VARIANT	0
Q16512/R635Q	PKN1	neutral	1	R -> Q (in dbSNP:rs35416389)	VARIANT	0
Q16512/V901I	PKN1	neutral	3	V -> I (in dbSNP:rs10846)	VARIANT	1
Q16513/A197E	PKN2	-	0	A -> E (in dbSNP:rs35207128)	VARIANT	0
Q16513/D117A	PKN2	-	2	D->A: Prevents proteolytic processing by caspase-3 during apoptosis. Diminishes pro-apoptotic function; when associated with E-700.	MUTAGEN	0
Q16513/D700E	PKN2	-	2	D->E: Prevents proteolytic processing by caspase-3 during apoptosis. Diminishes pro-apoptotic function; when associated with A-117.	MUTAGEN	0
Q16513/D978A	PKN2	-	2	D->A: Does not inhibit catalytic activity.	MUTAGEN	0
Q16513/D978S	PKN2	-	2	D->A,S: Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'.	MUTAGEN	0
Q16513/E94D	PKN2	-	0	E -> D (in dbSNP:rs12039846)	VARIANT	0
Q16513/F974A	PKN2	-	1	F->A: Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'.	MUTAGEN	0
Q16513/F977A	PKN2	decrease	2	F->A,L: Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'. Reduces catalytic activity by 90%.	MUTAGEN	0
Q16513/F977L	PKN2	decrease	2	F->A,L: Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'. Reduces catalytic activity by 90%.	MUTAGEN	0
Q16513/F977W	PKN2	decrease	2	F->W,Y: Reduces catalytic activity by 50%.	MUTAGEN	0
Q16513/F977Y	PKN2	decrease	2	F->W,Y: Reduces catalytic activity by 50%.	MUTAGEN	0
Q16513/K686R	PKN2	-	1	K->R: Does not inhibit interaction with PTPN13.	MUTAGEN	0
Q16513/Q655R	PKN2	neutral	0	Q -> R (in dbSNP:rs12085658)	VARIANT	0
Q16513/T121A	PKN2	-	1	T->A: Does not suppress ciliogenesis; when associated with A-124.	MUTAGEN	0
Q16513/T124A	PKN2	-	1	T->A: Does not suppress ciliogenesis; when associated with A-121.	MUTAGEN	0
Q16513/T816A	PKN2	decrease	1	T->A: Reduces catalytic activity.	MUTAGEN	0
Q16513/T958A	PKN2	loss	1	T->A: Abolishes catalytic activity.	MUTAGEN	0
Q16513/Y979A	PKN2	decrease	2	Y->A: Reduces catalytic activity by 50%.	MUTAGEN	0
Q16513/Y979F	PKN2	decrease	2	Y->F,L,W: Reduces catalytic activity by 25%.	MUTAGEN	0
Q16513/Y979L	PKN2	decrease	2	Y->F,L,W: Reduces catalytic activity by 25%.	MUTAGEN	0
Q16513/Y979W	PKN2	decrease	2	Y->F,L,W: Reduces catalytic activity by 25%.	MUTAGEN	0
Q16539/A320T	MAPK14	decrease	1	A->T: Lowered kinase activity.	MUTAGEN	0
Q16539/A34V	MAPK14	decrease	1	A->V: Lowered kinase activity.	MUTAGEN	0
Q16539/A51V	MAPK14	-	1	A -> V (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	3
Q16539/D168A	MAPK14	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
Q16539/D176A	MAPK14	increase	1	D->A: Emulation of the active state. Increase in activity; when associated with S-327 or L-327.	MUTAGEN	0
Q16539/D177A	MAPK14	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
Q16539/D343G	MAPK14	-	1	D -> G (in dbSNP:rs45496794)	VARIANT	0
Q16539/F327L	MAPK14	increase	1	F->L: Emulation of the active state. Increase in activity; when associated with A-176.	MUTAGEN	0
Q16539/F327S	MAPK14	increase	1	F->S: Emulation of the active state. Increase in activity; when associated with A-176.	MUTAGEN	0
Q16539/K53R	MAPK14	loss	1	K->R: Loss of kinase activity.	MUTAGEN	0
Q16539/K54R	MAPK14	decrease	1	K->R: Impairs MAP2K6/MKK6-dependent autophosphorylation.	MUTAGEN	0
Q16539/P322R	MAPK14	-	1	P -> R (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q16539/T175A	MAPK14	-	1	T->A: No effect on either the kinase activity or tyrosine phosphorylation.	MUTAGEN	0
Q16539/T180E	MAPK14	loss	1	T->E: Loss of kinase activity.	MUTAGEN	0
Q16539/W337R	MAPK14	loss	1	W->R: Loss of kinase activity.	MUTAGEN	0
Q16539/Y182F	MAPK14	loss	1	Y->F: Loss of kinase activity.	MUTAGEN	0
Q16539/Y69H	MAPK14	decrease	1	Y->H: Lowered kinase activity.	MUTAGEN	0
Q16566/D178N	CAMK4	-	1	D -> N (in dbSNP:rs35548075)	VARIANT	0
Q16566/E150G	CAMK4	-	1	E -> G (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q16566/I469M	CAMK4	-	1	I -> M (in a lung large cell carcinoma sample; somatic mutation; dbSNP:rs1239950009)	VARIANT	0
Q16566/K75E	CAMK4	loss	1	K->E: Loss of activity; dominant negative form.	MUTAGEN	0
Q16566/Q465R	CAMK4	neutral	1	Q -> R (in dbSNP:rs56360861)	VARIANT	0
Q16566/S12A	CAMK4	loss	1	S->A: Loss of activity.	MUTAGEN	0
Q16566/S13A	CAMK4	loss	1	S->A: Loss of activity.	MUTAGEN	0
Q16566/S189A	CAMK4	increase	1	S->A: Increases phosphorylation of CREB1 2-fold. Decreases total O-linked glycosylation 2-fold. Increases ATP-binding affinity.	MUTAGEN	0
Q16566/T200A	CAMK4	loss	1	T->A: Loss of activation by CaMKK1 or CaMKK2.	MUTAGEN	0
Q16584/A282G	MAP3K11	-	1	A -> G (in dbSNP:rs34594252)	VARIANT	0
Q16584/D151V	MAP3K11	-	1	D -> V (in dbSNP:rs34178129)	VARIANT	0
Q16584/E164A	MAP3K11	decrease	1	E->A: Greatly reduced autophosphorylation activity.	MUTAGEN	0
Q16584/K144A	MAP3K11	decrease	2	K->A: Greatly reduced autophosphorylation activity.	MUTAGEN	0
Q16584/K144R	MAP3K11	loss	2	K->R: Loss of kinase activity. Prevents activation of SAPK and MAPK14.	MUTAGEN	0
Q16584/P252H	MAP3K11	neutral	1	P -> H (in dbSNP:rs17855912)	VARIANT	0
Q16584/S281A	MAP3K11	decrease	1	S->A: Reduced autophosphorylation activity. Reduced activation of SAPK and MAPK14.	MUTAGEN	0
Q16584/S281E	MAP3K11	-	1	S->E: No effect on SAPK activation.	MUTAGEN	0
Q16584/T277A	MAP3K11	decrease	1	T->A: Severely reduced autophosphorylation activity. Prevents phosphorylation of SAPK and MAPK14.	MUTAGEN	0
Q16584/T277E	MAP3K11	-	1	T->E: No effect on SAPK activation.	MUTAGEN	0
Q16584/T278A	MAP3K11	-	1	T->A: No effect on autophosphorylation activity or activation of SAPK and MAPK14.	MUTAGEN	0
Q16620/G309R	NTRK2	-	0	G -> R	VARIANT	0
Q16620/G545V	NTRK2	-	0	G -> V (in dbSNP:rs1075108)	VARIANT	0
Q16620/L138F	NTRK2	-	1	L -> F (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	2
Q16620/M697I	NTRK2	-	1	M -> I (in a lung carcinoma sample; somatic mutation)	VARIANT	0
Q16620/N338Y	NTRK2	-	0	N -> Y (in dbSNP:rs1047856)	VARIANT	0
Q16620/R699G	NTRK2	-	1	R -> G (in a lung carcinoma sample; somatic mutation)	VARIANT	0
Q16620/R718C	NTRK2	-	1	R -> C (in a lung carcinoma sample; somatic mutation; dbSNP:rs1324578301)	VARIANT	0
Q16620/T704I	NTRK2	-	1	T -> I (in OBHD; unknown pathological significance; dbSNP:rs1554774973)	VARIANT	0
Q16620/Y434C	NTRK2	-	1	Y -> C (in DEE58; unknown pathological significance; dbSNP:rs886041091)	VARIANT	0
Q16620/Y706C	NTRK2	decrease	1	Y -> C (in OBHD; expressed normally on the cell surface; results in markedly impaired ligand-induced phosphorylation as well as impaired downstream MAPK1 phosphorylation; dbSNP:rs121434633)	VARIANT	0
Q16644/D276Y	MAPKAPK3	-	1	D -> Y (in dbSNP:rs56107897)	VARIANT	0
Q16644/E105A	MAPKAPK3	-	1	E -> A (in an ovarian endometrioid sample; somatic mutation)	VARIANT	1
Q16644/K73M	MAPKAPK3	loss	1	K->M: Higher affinity toward PCH2.	MUTAGEN	0
Q16644/L173P	MAPKAPK3	-	1	L -> P (in MDPT3; decreased localization to the nucleus; dbSNP:rs886037913)	VARIANT	0
Q16644/P28S	MAPKAPK3	-	1	P -> S (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs375412266)	VARIANT	1
Q16654/A17V	PDK4	-	1	A -> V (in dbSNP:rs56391840)	VARIANT	0
Q16654/D109G	PDK4	-	1	D -> G (in dbSNP:rs34898343)	VARIANT	0
Q16654/D394A	PDK4	-	1	D->A: Loss of activity; when associated with A-395.	MUTAGEN	0
Q16654/L19M	PDK4	-	1	L -> M (in dbSNP:rs55761955)	VARIANT	0
Q16654/R161A	PDK4	loss	1	R->A: Loss of activity.	MUTAGEN	0
Q16654/W395A	PDK4	-	1	W->A: Loss of activity; when associated with A-394.	MUTAGEN	0
Q16654/Y157F	PDK4	loss	1	Y->F: Loss of activity.	MUTAGEN	0
Q16659/L290V	MAPK6	-	2	L -> V (in dbSNP:rs35697691)	VARIANT	3
Q16671/D426G	AMHR2	-	1	D -> G (in PMDS2)	VARIANT	0
Q16671/D491H	AMHR2	-	1	D -> H (in PMDS2; dbSNP:rs780680518)	VARIANT	0
Q16671/G142V	AMHR2	-	1	G -> V (in PMDS2)	VARIANT	0
Q16671/H282Q	AMHR2	-	1	H -> Q (in PMDS2; dbSNP:rs539695176)	VARIANT	0
Q16671/R319H	AMHR2	-	0	R -> H (in dbSNP:rs144236183)	VARIANT	0
Q16671/R406Q	AMHR2	-	1	R -> Q (in PMDS2; dbSNP:rs137853104)	VARIANT	1
Q16671/R504C	AMHR2	-	1	R -> C (in PMDS2; dbSNP:rs772294564)	VARIANT	2
Q16671/R54C	AMHR2	-	1	R -> C (in PMDS2; dbSNP:rs534999427)	VARIANT	0
Q16671/V458A	AMHR2	-	1	V -> A (in PMDS2; dbSNP:rs775889926)	VARIANT	0
Q16816/R323C	PHKG1	-	1	R -> C (in dbSNP:rs149458708)	VARIANT	0
Q16816/V48M	PHKG1	-	1	V -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs368370244)	VARIANT	0
Q16832/E113K	DDR2	-	1	E -> K (in SEMD-SL; abolishes collagen binding; dbSNP:rs397514747)	VARIANT	0
Q16832/I726R	DDR2	-	2	I -> R (in SEMD-SL; causes retention in an intracellular compartment and thereby abolishes signaling in response collagen binding; dbSNP:rs121964864)	VARIANT	0
Q16832/K608A	DDR2	loss	1	K->A: Abolishes kinase activity.	MUTAGEN	0
Q16832/L610P	DDR2	increase	1	L -> P (in WRCN; increased autophosphorylation in patient fibroblasts)	VARIANT	0
Q16832/M441I	DDR2	neutral	1	M -> I (in dbSNP:rs34722354)	VARIANT	2
Q16832/R105S	DDR2	-	2	R -> S (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q16832/R124W	DDR2	-	1	R -> W (in SEMD-SL)	VARIANT	1
Q16832/R478C	DDR2	-	1	R -> C (in dbSNP:rs34869543)	VARIANT	0
Q16832/R752C	DDR2	-	2	R -> C (in SEMD-SL; causes retention in an intracellular compartment and thereby abolishes signaling in response collagen binding; dbSNP:rs121964863)	VARIANT	4
Q16832/T713I	DDR2	-	2	T -> I (in SEMD-SL; causes retention in an intracellular compartment and thereby abolishes signaling in response collagen binding; dbSNP:rs121964865)	VARIANT	0
Q16832/V543F	DDR2	-	1	V -> F (in dbSNP:rs55973200)	VARIANT	0
Q16832/W52A	DDR2	-	2	W->A: Abolishes collagen binding.	MUTAGEN	0
Q16832/Y736F	DDR2	decrease	1	Y->F: Reduces autophosphorylation. Abolishes phosphorylation by SRC; when associated with F-740 and F-741.	MUTAGEN	0
Q16832/Y740C	DDR2	increase	1	Y -> C (in WRCN; increased autophosphorylation in patient fibroblasts)	VARIANT	0
Q16832/Y740F	DDR2	increase	1	Y->F: Promotes autophosphorylation. Abolishes phosphorylation by SRC; when associated with F-736 and F-741.	MUTAGEN	0
Q16832/Y741F	DDR2	decrease	1	Y->F: Reduces autophosphorylation. Abolishes phosphorylation by SRC; when associated with F-736 and F-740.	MUTAGEN	0
Q2M2I8/D176A	AAK1	loss	2	D->A: Inhibits autophosphorylation and phosphorylation of AP2M1. Does not affect NUMB localization.	MUTAGEN	0
Q2M2I8/G835D	AAK1	-	1	G -> D	VARIANT	0
Q2M2I8/I59V	AAK1	-	1	I -> V (in dbSNP:rs34535244)	VARIANT	0
Q2M2I8/K509Q	AAK1	-	2	K -> Q (in dbSNP:rs6715776)	VARIANT	0
Q2M2I8/K74A	AAK1	loss	3	K->A: Inhibits autophosphorylation and phosphorylation of AP2M1. Does not affect NUMB localization. Does not interact with monoubiquitinated NOTCH1.	MUTAGEN	0
Q2M2I8/P725T	AAK1	-	1	P -> T (in dbSNP:rs35285785)	VARIANT	0
Q2M2I8/P771R	AAK1	neutral	1	P -> R (in dbSNP:rs34422616)	VARIANT	0
Q2M2I8/Q533H	AAK1	-	1	Q -> H (in dbSNP:rs1263928487)	VARIANT	3
Q2M2I8/T694M	AAK1	neutral	1	T -> M (in dbSNP:rs55889248)	VARIANT	0
Q2M2I8/V603A	AAK1	neutral	1	V -> A (in dbSNP:rs56038532)	VARIANT	0
Q32MK0/G390R	MYLK3	-	1	G -> R (in a colorectal cancer sample; somatic mutation; dbSNP:rs141602742)	VARIANT	0
Q32MK0/S70T	MYLK3	-	0	S -> T (in dbSNP:rs9923813)	VARIANT	0
Q32MK0/V180L	MYLK3	neutral	1	V -> L (in dbSNP:rs28407821)	VARIANT	2
Q38SD2/A1803T	LRRK1	-	1	A -> T	VARIANT	0
Q38SD2/D1927G	LRRK1	-	1	D -> G	VARIANT	0
Q38SD2/F1022C	LRRK1	loss	1	F->C: No effect on GTP-binding but loss of subsequent stimulation of kinase activity.	MUTAGEN	0
Q38SD2/I1412T	LRRK1	decrease	1	I->T: No effect on GTP-binding but reduction in subsequent stimulation of kinase activity.	MUTAGEN	0
Q38SD2/K1270W	LRRK1	loss	1	K->W: Loss of autophosphorylation.	MUTAGEN	0
Q38SD2/K651A	LRRK1	-	1	K->A: Loss of GTP/GDP-binding.	MUTAGEN	0
Q38SD2/K746G	LRRK1	decrease	1	K->G: No effect on GTP-binding but reduction in subsequent stimulation of kinase activity.	MUTAGEN	0
Q38SD2/L1824F	LRRK1	-	1	L -> F	VARIANT	0
Q38SD2/S1847N	LRRK1	-	1	S -> N	VARIANT	0
Q3MIX3/S17R	ADCK5	neutral	1	S -> R (in dbSNP:rs6599528)	VARIANT	0
Q52WX2/A261S	SBK1	-	1	A -> S	VARIANT	0
Q52WX2/K92E	SBK1	-	1	K -> E (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
Q52WX2/N250T	SBK1	-	1	N -> T (in dbSNP:rs56072383)	VARIANT	0
Q52WX2/R12H	SBK1	-	0	R -> H (in dbSNP:rs35448675)	VARIANT	0
Q56UN5/E676Q	MAP3K19	neutral	0	E -> Q (in dbSNP:rs1112542)	VARIANT	0
Q56UN5/E812G	MAP3K19	neutral	0	E -> G (in dbSNP:rs3905317)	VARIANT	0
Q56UN5/I500M	MAP3K19	-	1	I -> M (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	0
Q56UN5/T438I	MAP3K19	neutral	0	T -> I (in dbSNP:rs16831235)	VARIANT	0
Q58A45/F293A	PAN3	-	2	F->A: Reduces interaction with polyadenylate-binding protein.	MUTAGEN	0
Q58A45/Y203A	PAN3	-	1	Y->A: Reduces interaction with polyadenylate-binding protein.	MUTAGEN	0
Q58F21/A89V	BRDT	-	1	A -> V (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs781375003)	VARIANT	0
Q58F21/E357K	BRDT	-	1	E -> K (in dbSNP:rs34674879)	VARIANT	0
Q58F21/G928D	BRDT	-	1	G -> D (in SPGF21; no effect on protein expression; unknown pathological significance; dbSNP:rs754258809)	VARIANT	0
Q58F21/H288Y	BRDT	-	1	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
Q58F21/K238N	BRDT	neutral	2	K -> N (in dbSNP:rs1156281)	VARIANT	0
Q58F21/K336T	BRDT	-	0	K -> T (in dbSNP:rs1064567)	VARIANT	0
Q58F21/N410K	BRDT	neutral	2	N -> K (in dbSNP:rs3088232)	VARIANT	0
Q58F21/P542A	BRDT	-	1	P -> A (in dbSNP:rs55912588)	VARIANT	0
Q58F21/P696L	BRDT	neutral	3	P -> L (in dbSNP:rs10747493)	VARIANT	0
Q58F21/Q62K	BRDT	neutral	4	Q -> K (in dbSNP:rs10783071)	VARIANT	0
Q58F21/R605Q	BRDT	-	0	R -> Q (in dbSNP:rs35327986)	VARIANT	0
Q58F21/R6Q	BRDT	-	1	R -> Q (in dbSNP:rs56273490)	VARIANT	0
Q59H18/A785G	TNNI3K	-	0	A -> G (in dbSNP:rs45578635)	VARIANT	0
Q59H18/D151H	TNNI3K	-	1	D -> H (in dbSNP:rs34874695)	VARIANT	0
Q59H18/D833Y	TNNI3K	-	0	D -> Y (in dbSNP:rs45614933)	VARIANT	0
Q59H18/F309L	TNNI3K	-	1	F -> L	VARIANT	0
Q59H18/G526D	TNNI3K	decrease	1	G -> D (in CCDD; the mutation results in decreased protein solubility; causes abnormal aggregation; markedly reduced protein expression is observed in the sarcoplasm and nuclei of patient cardiomyocytes; dbSNP:rs606231469)	VARIANT	0
Q59H18/I686T	TNNI3K	neutral	1	I -> T (in dbSNP:rs3737564)	VARIANT	0
Q59H18/K490R	TNNI3K	loss	1	K->R: Loss of autophosphorylation activity.	MUTAGEN	0
Q59H18/M798I	TNNI3K	-	1	M -> I (in a head & Neck squamous cell carcinoma sample; somatic mutation; dbSNP:rs201613442)	VARIANT	0
Q59H18/P263L	TNNI3K	neutral	1	P -> L (in dbSNP:rs34521608)	VARIANT	0
Q59H18/R629G	TNNI3K	-	1	R -> G (in a colorectal cancer sample; somatic mutation)	VARIANT	0
Q59H18/S430L	TNNI3K	-	1	S -> L (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q59H18/T637M	TNNI3K	neutral	1	T -> M (in dbSNP:rs2274260)	VARIANT	0
Q59H18/V510L	TNNI3K	-	1	V -> L (in dbSNP:rs34335537)	VARIANT	0
Q5JZY3/A956T	EPHA10	-	1	A -> T	VARIANT	0
Q5JZY3/F281I	EPHA10	neutral	1	F -> I (in dbSNP:rs4653328)	VARIANT	0
Q5JZY3/G749E	EPHA10	neutral	0	G -> E (in dbSNP:rs6671088)	VARIANT	0
Q5JZY3/H775R	EPHA10	-	1	H -> R (in a breast infiltrating ductal carcinoma sample; somatic mutation)	VARIANT	0
Q5JZY3/L629P	EPHA10	neutral	0	L -> P (in dbSNP:rs17511304)	VARIANT	2
Q5JZY3/L630P	EPHA10	-	1	L -> P	VARIANT	0
Q5JZY3/R150H	EPHA10	-	1	R -> H (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs771803475)	VARIANT	6
Q5JZY3/R807Q	EPHA10	neutral	0	R -> Q (in dbSNP:rs6670599)	VARIANT	0
Q5JZY3/T220K	EPHA10	neutral	1	T -> K (in dbSNP:rs56276182)	VARIANT	0
Q5JZY3/V103L	EPHA10	-	0	V -> L (in dbSNP:rs34557762)	VARIANT	0
Q5JZY3/V645I	EPHA10	neutral	0	V -> I (in dbSNP:rs12405650)	VARIANT	3
Q5S007/A419V	LRRK2	-	1	A -> V (in dbSNP:rs34594498)	VARIANT	0
Q5S007/A716V	LRRK2	-	1	A -> V (in dbSNP:rs281865043)	VARIANT	0
Q5S007/C228S	LRRK2	-	1	C -> S (in dbSNP:rs56108242)	VARIANT	0
Q5S007/C727D	LRRK2	decrease	1	C->D: Decreased kinase activity. Loss of RAB29-mediated activation and autophosphorylation of S-910, S-935, S-955, S-973 and S-1292. Decreased membrane association; when associated with G-1441, C-1699 and S-2019.	MUTAGEN	0
Q5S007/D1375E	LRRK2	-	0	D -> E (in dbSNP:rs28365226)	VARIANT	0
Q5S007/D1994A	LRRK2	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
Q5S007/D1994N	LRRK2	loss	3	D->N: Loss of kinase activity. No loss of interaction with SEC16A and no loss of ability to recruit SEC16A to endoplasmic reticulum exit sites. Decreases proteosomal degradation of MAPT; when associated with A-1906 and A-2017.	MUTAGEN	0
Q5S007/D2017A	LRRK2	loss	4	D->A: Loss of kinase activity. Decreases proteosomal degradation of MAPT; when associated with A-1906 and N-1994. Loss of phosphorylation of RAB10; when associated with G-1441, C-1699, or S-2019.	MUTAGEN	0
Q5S007/D2175H	LRRK2	-	1	D -> H (in PARK8; shows decreased WD domain homodimerization; no effect on kinase activity; dbSNP:rs72547981)	VARIANT	0
Q5S007/D944Y	LRRK2	-	0	D -> Y (in dbSNP:rs17519916)	VARIANT	0
Q5S007/E2395K	LRRK2	-	1	E -> K (in dbSNP:rs78964014)	VARIANT	0
Q5S007/E2395R	LRRK2	-	1	E->R: Decreases WD domain homodimerization. No effect on kinase activity.	MUTAGEN	0
Q5S007/F2344A	LRRK2	-	1	F->A: Decreases WD domain homodimerization. No effect on kinase activity.	MUTAGEN	0
Q5S007/G2385R	LRRK2	-	7	G -> R (in PARK8; under conditions of oxidative stress the variant protein is more toxic and is associated with a higher rate of apoptosis; reduced binding to synaptic vesicles; no loss of interaction with SEC16A; shows an increase in activity in phosphorylation of RAB8A and RAB10; shows decreased WD domain homodimerization; reduced autophosphorylation at Ser-935; dbSNP:rs34778348)	VARIANT	2
Q5S007/H2391D	LRRK2	increase	1	H->D: Increases kinase activity.	MUTAGEN	0
Q5S007/I1122V	LRRK2	-	2	I -> V (in PARK8; dbSNP:rs34805604)	VARIANT	0
Q5S007/I1371V	LRRK2	-	2	I -> V (in PARK8; unknown pathological significance; dbSNP:rs17466213)	VARIANT	0
Q5S007/I2012T	LRRK2	-	1	I -> T (in PARK8; unknown pathological significance; dbSNP:rs34015634)	VARIANT	1
Q5S007/I2020T	LRRK2	increase	8	I -> T (in PARK8; significant increase in autophosphorylation of about 40% in comparison to wild-type protein in vitro; shows a progressive reduction in neurite length and branching; shows an increase in activity in phosphorylation of RAB8A and RAB10; dbSNP:rs35870237)	VARIANT	0
Q5S007/I723V	LRRK2	neutral	3	I -> V (in dbSNP:rs10878307)	VARIANT	0
Q5S007/K1347A	LRRK2	loss	1	K->A: GTPase-dead mutant. Loss of interaction with SEC16A and impaired ability to recruit SEC16A to endoplasmic reticulum exit sites.	MUTAGEN	0
Q5S007/K1359I	LRRK2	-	1	K -> I (found in a renal cell carcinoma sample; somatic mutation)	VARIANT	0
Q5S007/K1906A	LRRK2	loss	1	K->A: Loss of kinase activity. Decreases proteosomal degradation of MAPT; when associated with N-1994 and A-2017.	MUTAGEN	0
Q5S007/K1906M	LRRK2	-	2	K -> M (does not inhibit interaction with RAB29; shows a progressive increase in neurite length and branching)	VARIANT	0
Q5S007/K871E	LRRK2	-	1	K -> E (in dbSNP:rs281865044)	VARIANT	0
Q5S007/L119P	LRRK2	-	2	L -> P (in dbSNP:rs33995463)	VARIANT	0
Q5S007/L1870F	LRRK2	-	1	L -> F (in dbSNP:rs281865053)	VARIANT	0
Q5S007/L2343D	LRRK2	-	1	L->D: Decreases WD domain homodimerization. No effect on kinase activity.	MUTAGEN	0
Q5S007/L2439I	LRRK2	-	1	L -> I (in PARK8; shows decreased WD domain homodimerization; no effect on kinase activity; dbSNP:rs72547983)	VARIANT	0
Q5S007/L2466H	LRRK2	-	1	L -> H (in PARK8; dbSNP:rs281865057)	VARIANT	0
Q5S007/L728D	LRRK2	decrease	1	L->D: Decreased kinase activity. Loss of RAB29-mediated activation and autophosphorylation of S-910, S-935, S-955, S-973 and S-1292. Decreased membrane association; when associated with G-1441, C-1699 and S-2019.	MUTAGEN	0
Q5S007/L729D	LRRK2	decrease	1	L->D: Decreased kinase activity. Loss of RAB29-mediated activation and autophosphorylation of S-910, S-935, S-955, S-973 and S-1292. Decreased membrane association; when associated with G-1441, C-1699 and S-2019.	MUTAGEN	0
Q5S007/L760D	LRRK2	decrease	1	L->D: Decreased kinase activity and loss of RAB29-mediated activation.	MUTAGEN	0
Q5S007/L761D	LRRK2	decrease	1	L->D: Decreased kinase activity and loss of RAB29-mediated activation.	MUTAGEN	0
Q5S007/L762D	LRRK2	decrease	1	L->D: Decreased kinase activity and loss of RAB29-mediated activation.	MUTAGEN	0
Q5S007/L789D	LRRK2	-	1	L->D: No effect on kinase activity and RAB29-mediated activation.	MUTAGEN	0
Q5S007/L790D	LRRK2	-	1	L->D: No effect on kinase activity and RAB29-mediated activation.	MUTAGEN	0
Q5S007/L791D	LRRK2	-	1	L->D: No effect on kinase activity and RAB29-mediated activation.	MUTAGEN	0
Q5S007/M1646T	LRRK2	neutral	2	M -> T (in dbSNP:rs35303786)	VARIANT	0
Q5S007/M1869T	LRRK2	-	2	M -> T (in PARK8; unknown pathological significance; dbSNP:rs35602796)	VARIANT	0
Q5S007/M2397T	LRRK2	neutral	3	M -> T (in dbSNP:rs3761863)	VARIANT	1
Q5S007/M2408A	LRRK2	-	1	M->A,E: No effect on WD domain homodimerization. No effect on kinase activity.	MUTAGEN	0
Q5S007/M2408E	LRRK2	-	1	M->A,E: No effect on WD domain homodimerization. No effect on kinase activity.	MUTAGEN	0
Q5S007/M712V	LRRK2	-	1	M -> V (in PARK8; dbSNP:rs199566791)	VARIANT	0
Q5S007/N2081D	LRRK2	-	2	N -> D (in dbSNP:rs33995883)	VARIANT	0
Q5S007/N2261I	LRRK2	-	1	N -> I (in dbSNP:rs12581902)	VARIANT	0
Q5S007/N551K	LRRK2	neutral	4	N -> K (in dbSNP:rs7308720)	VARIANT	0
Q5S007/P1262A	LRRK2	neutral	1	P -> A (in dbSNP:rs4640000)	VARIANT	0
Q5S007/P1542S	LRRK2	-	3	P -> S (in PARK8; unknown pathological significance; dbSNP:rs33958906)	VARIANT	0
Q5S007/P2119L	LRRK2	-	1	P -> L (in dbSNP:rs12423862)	VARIANT	0
Q5S007/P755L	LRRK2	-	0	P -> L (in dbSNP:rs34410987)	VARIANT	1
Q5S007/Q930R	LRRK2	-	1	Q -> R (in PARK8; unknown pathological significance; dbSNP:rs281865045)	VARIANT	0
Q5S007/R1067Q	LRRK2	-	1	R -> Q (in PARK8; dbSNP:rs111341148)	VARIANT	0
Q5S007/R1398H	LRRK2	-	4	R -> H (in dbSNP:rs7133914)	VARIANT	3
Q5S007/R1398Q	LRRK2	-	1	R->Q: Decreased kinase activity; when associated with G-1343.	MUTAGEN	0
Q5S007/R1441C	LRRK2	increase	10	R -> C (in PARK8; shows an increase in activity in both autophosphorylation and phosphorylation of a generic substrate; loss of interaction with SEC16A; shows an increase in activity in phosphorylation of RAB10; decreases phosphorylation-dependent binding to YWHAG; dbSNP:rs33939927)	VARIANT	1
Q5S007/R1441G	LRRK2	increase	1	R->G: Decreased membrane association when associated with D-727, D-728, or D-729. Inhibits autophosphorylation and RAB10 phosphorylation when associated with N-1348 or A-2017.	VARIANT	0
Q5S007/R1441H	LRRK2	increase	4	R -> H (in PARK8; shows an increase in activity in phosphorylation of RAB8A and RAB10; decreases phosphorylation-dependent binding to YWHAG; dbSNP:rs34995376)	VARIANT	0
Q5S007/R1514Q	LRRK2	-	3	R -> Q (in PARK8; unknown pathological significance; dbSNP:rs35507033)	VARIANT	0
Q5S007/R1550Q	LRRK2	-	1	R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs200212150)	VARIANT	1
Q5S007/R1628P	LRRK2	-	3	R -> P (may be associated with Parkinson disease in some populations; dbSNP:rs33949390)	VARIANT	0
Q5S007/R1723P	LRRK2	-	1	R -> P (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
Q5S007/R1728H	LRRK2	increase	3	R -> H (in PARK8; shows an increase in activity in phosphorylation of RAB8A and RAB10; dbSNP:rs145364431)	VARIANT	2
Q5S007/R1728L	LRRK2	-	1	R -> L (in PARK8; dbSNP:rs145364431)	VARIANT	0
Q5S007/R1941H	LRRK2	-	1	R -> H (in PARK8; dbSNP:rs77428810)	VARIANT	0
Q5S007/R2143H	LRRK2	-	1	R -> H (in PARK8; dbSNP:rs201271001)	VARIANT	1
Q5S007/R2394E	LRRK2	-	1	R->E: Decreases WD domain homodimerization. Increases kinase activity and autophosphorylation at Ser-1292.	MUTAGEN	0
Q5S007/R50H	LRRK2	-	0	R -> H (in dbSNP:rs2256408)	VARIANT	0
Q5S007/R793M	LRRK2	-	3	R -> M (in PARK8; unknown pathological significance; dbSNP:rs35173587)	VARIANT	0
Q5S007/S1096C	LRRK2	-	0	S -> C (in PARK8; unknown pathological significance; dbSNP:rs76535406)	VARIANT	1
Q5S007/S1228T	LRRK2	-	1	S -> T (in PARK8; dbSNP:rs60185966)	VARIANT	0
Q5S007/S1647T	LRRK2	neutral	2	S -> T (in dbSNP:rs11564148)	VARIANT	2
Q5S007/S2345D	LRRK2	-	1	S->D: Decreases WD domain homodimerization. No effect on kinase activity.	MUTAGEN	0
Q5S007/S2409A	LRRK2	-	1	S->A: Decreases WD domain homodimerization.	MUTAGEN	0
Q5S007/T1343G	LRRK2	-	1	T->G: Decreased kinase activity; when associated with Q-1398.	MUTAGEN	0
Q5S007/T1348N	LRRK2	-	1	T->N: Loss of GTP binding. Inhibits autophosphorylation and RAB10 phosphorylation; when associated with G-1441, C-1699, or S-2019.	MUTAGEN	0
Q5S007/T2031S	LRRK2	increase	2	T -> S (in PARK8; shows an increase in activity in phosphorylation of RAB8A and RAB10; dbSNP:rs78029637)	VARIANT	0
Q5S007/T2141M	LRRK2	-	1	T -> M (in PARK8; dbSNP:rs111691891)	VARIANT	3
Q5S007/T2356I	LRRK2	-	2	T -> I (in PARK8; shows decreased WD domain homodimerization; no effect on kinase activity; dbSNP:rs113511708)	VARIANT	0
Q5S007/V1598E	LRRK2	-	1	V -> E (in PARK8; unknown pathological significance; dbSNP:rs721710)	VARIANT	0
Q5S007/V2390M	LRRK2	-	1	V -> M (in PARK8; shows decreased WD domain homodimerization; no effect on kinase activity; dbSNP:rs79546190)	VARIANT	2
Q5S007/Y1699C	LRRK2	-	1	Y->C: Decreased membrane association when associated with D-727, D-728, or D-729. Inhibits autophosphorylation and RAB10 phosphorylation when associated with N-1348 or A-2017.	VARIANT	0
Q5S007/Y2189C	LRRK2	-	1	Y -> C (in PARK8; no effect on WD domain homodimerization; no effect on kinase activity; dbSNP:rs35658131)	VARIANT	0
Q5S007/Y2346A	LRRK2	-	1	Y->A: Decreases WD domain homodimerization. No effect on kinase activity.	MUTAGEN	0
Q5TCX8/C784G	MAP3K21	-	1	C -> G (in dbSNP:rs963981)	VARIANT	0
Q5TCX8/D420N	MAP3K21	-	1	D -> N (in dbSNP:rs35465006)	VARIANT	0
Q5TCX8/E563D	MAP3K21	-	1	E -> D (in dbSNP:rs35758282)	VARIANT	0
Q5TCX8/E741D	MAP3K21	-	1	E -> D (in dbSNP:rs3795374)	VARIANT	0
Q5TCX8/P982L	MAP3K21	-	1	P -> L (in dbSNP:rs34794284)	VARIANT	0
Q5TCX8/R892W	MAP3K21	-	1	R -> W (in dbSNP:rs55681416)	VARIANT	0
Q5TCX8/R977C	MAP3K21	-	1	R -> C (in dbSNP:rs56065162)	VARIANT	0
Q5TCX8/S597F	MAP3K21	-	1	S -> F (in dbSNP:rs34984140)	VARIANT	0
Q5TCX8/T900I	MAP3K21	-	1	T -> I (in dbSNP:rs34499091)	VARIANT	0
Q5TCX8/V728I	MAP3K21	-	1	V -> I (in dbSNP:rs3795375)	VARIANT	0
Q5TCY1/D741E	TTBK1	-	1	D -> E (in dbSNP:rs56377340)	VARIANT	0
Q5TCY1/E744D	TTBK1	-	1	E -> D (in dbSNP:rs3800295)	VARIANT	0
Q5TCY1/G623A	TTBK1	-	1	G -> A (in dbSNP:rs3800294)	VARIANT	8
Q5TCY1/K1145R	TTBK1	neutral	1	K -> R (in dbSNP:rs3800297)	VARIANT	1
Q5TCY1/L1184S	TTBK1	neutral	1	L -> S (in dbSNP:rs3800298)	VARIANT	0
Q5TCY1/P613L	TTBK1	neutral	1	P -> L (in dbSNP:rs34993661)	VARIANT	0
Q5TCY1/P649R	TTBK1	neutral	1	P -> R (in dbSNP:rs35175743)	VARIANT	3
Q5TCY1/P855S	TTBK1	-	1	P -> S (in a metastatic melanoma sample; somatic mutation; dbSNP:rs267601046)	VARIANT	1
Q5TCY1/S806F	TTBK1	-	1	S -> F (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q5VST9/A1086S	OBSCN	neutral	1	A -> S (in dbSNP:rs117147433)	VARIANT	0
Q5VST9/A1090T	OBSCN	-	1	A -> T (in dbSNP:rs752906025)	VARIANT	0
Q5VST9/A1101P	OBSCN	-	1	A -> P (in dbSNP:rs780907202)	VARIANT	0
Q5VST9/A1136V	OBSCN	-	2	A -> V (in a colorectal cancer sample; somatic mutation; dbSNP:rs950055015)	VARIANT	0
Q5VST9/A51T	OBSCN	neutral	1	A -> T (in dbSNP:rs1771487)	VARIANT	0
Q5VST9/A908T	OBSCN	neutral	0	A -> T (in dbSNP:rs1757153)	VARIANT	0
Q5VST9/G1121R	OBSCN	-	1	G -> R	VARIANT	0
Q5VST9/G804S	OBSCN	-	1	G -> S (in dbSNP:rs55950009)	VARIANT	0
Q5VST9/H1156Q	OBSCN	-	1	H -> Q	VARIANT	0
Q5VST9/K1027R	OBSCN	neutral	1	K -> R (in dbSNP:rs55760713)	VARIANT	0
Q5VST9/L1133V	OBSCN	-	1	L -> V (in dbSNP:rs777214598)	VARIANT	0
Q5VST9/Q1248H	OBSCN	neutral	1	Q -> H (in dbSNP:rs199523598)	VARIANT	0
Q5VST9/Q502R	OBSCN	neutral	2	Q -> R (in dbSNP:rs1771487)	VARIANT	0
Q5VST9/S1091T	OBSCN	-	1	S -> T (in dbSNP:rs965007403)	VARIANT	0
Q5VT25/A1148T	CDC42BPA	-	1	A -> T (in dbSNP:rs56219089)	VARIANT	0
Q5VT25/A1469V	CDC42BPA	-	1	A -> V (in dbSNP:rs55687355)	VARIANT	0
Q5VT25/A1699V	CDC42BPA	neutral	0	A -> V (in dbSNP:rs2802269)	VARIANT	0
Q5VT25/A1712V	CDC42BPA	neutral	2	A -> V (in dbSNP:rs2802269)	VARIANT	0
Q5VT25/D478A	CDC42BPA	loss	1	D->A: Prevents cleavage by CASP3, impairs the increase of its kinase activity and impairs extrusion apical actin ring assembly.	MUTAGEN	0
Q5VT25/D984A	CDC42BPA	-	1	D->A: Prevents cleavage by CASP3.	MUTAGEN	0
Q5VT25/E50K	CDC42BPA	-	1	E -> K (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
Q5VT25/H1579A	CDC42BPA	-	1	H->A: Loss of CDC42 binding; when associated with A-1582.	MUTAGEN	0
Q5VT25/H1582A	CDC42BPA	-	1	H->A: Loss of CDC42 binding; when associated with A-1579.	MUTAGEN	0
Q5VT25/I1418K	CDC42BPA	-	1	I -> K	VARIANT	0
Q5VT25/I537T	CDC42BPA	-	1	I -> T (in dbSNP:rs56364976)	VARIANT	0
Q5VT25/K106A	CDC42BPA	loss	1	K->A: Loss of kinase activity.	MUTAGEN	0
Q5VT25/R1211H	CDC42BPA	neutral	1	R -> H (in dbSNP:rs961490)	VARIANT	0
Q5VT25/S222L	CDC42BPA	-	1	S->L: Increase in autophosphorylation but not kinase activity.	MUTAGEN	0
Q5VT25/S234A	CDC42BPA	loss	1	S->A: Loss of autophosphorylation and kinase activity.	MUTAGEN	0
Q5VT25/T1618A	CDC42BPA	neutral	1	T -> A (in dbSNP:rs2297417)	VARIANT	1
Q5VT25/T231M	CDC42BPA	-	1	T -> M (in dbSNP:rs34614709)	VARIANT	1
Q5VT25/T240A	CDC42BPA	loss	1	T->A: Loss of autophosphorylation and kinase activity.	MUTAGEN	0
Q5VT25/T403A	CDC42BPA	loss	1	T->A: Loss of autophosphorylation and kinase activity.	MUTAGEN	0
Q5VT25/T780M	CDC42BPA	-	1	T -> M (in dbSNP:rs56119119)	VARIANT	1
Q5VT25/V1317I	CDC42BPA	neutral	2	V -> I (in dbSNP:rs1929860)	VARIANT	4
Q5VT25/Y790C	CDC42BPA	-	1	Y -> C (in dbSNP:rs34943764)	VARIANT	0
Q6DT37/A537D	CDC42BPG	neutral	1	A -> D (in dbSNP:rs34241745)	VARIANT	0
Q6DT37/P168L	CDC42BPG	neutral	1	P -> L (in dbSNP:rs34454471)	VARIANT	0
Q6DT37/Q1135R	CDC42BPG	neutral	0	Q -> R (in dbSNP:rs3741395)	VARIANT	1
Q6DT37/S280F	CDC42BPG	-	1	S -> F (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs770462360)	VARIANT	0
Q6DT37/T362P	CDC42BPG	-	1	T -> P (in dbSNP:rs55688429)	VARIANT	0
Q6IQ55/A184E	TTBK2	loss	1	A->E,G: Impaired serine/threonine-protein kinase activity.	MUTAGEN	0
Q6IQ55/A184G	TTBK2	loss	1	A->E,G: Impaired serine/threonine-protein kinase activity.	MUTAGEN	0
Q6IQ55/D163A	TTBK2	loss	1	D->A: Abolishes serine/threonine-protein kinase activity.	MUTAGEN	0
Q6IQ55/D635G	TTBK2	-	1	D -> G (in a lung small cell carcinoma sample; somatic mutation)	VARIANT	0
Q6IQ55/E842G	TTBK2	-	1	E -> G (found in a patient with SCA11; unknown pathological significance; dbSNP:rs202004988)	VARIANT	0
Q6IQ55/G724E	TTBK2	-	1	G -> E (in dbSNP:rs201524659)	VARIANT	0
Q6IQ55/K1241T	TTBK2	-	1	K -> T (in dbSNP:rs36104367)	VARIANT	0
Q6IQ55/K143A	TTBK2	loss	1	K->E,A: Leads to inactivation/destabilization of the protein.	MUTAGEN	0
Q6IQ55/K143E	TTBK2	loss	1	K->E,A: Leads to inactivation/destabilization of the protein.	MUTAGEN	0
Q6IQ55/K367I	TTBK2	-	1	K -> I (in dbSNP:rs764753481)	VARIANT	0
Q6IQ55/K50A	TTBK2	loss	1	K->E,A: Leads to inactivation/destabilization of the protein.	MUTAGEN	0
Q6IQ55/K50E	TTBK2	loss	1	K->E,A: Leads to inactivation/destabilization of the protein.	MUTAGEN	0
Q6IQ55/L8P	TTBK2	neutral	3	L -> P (in dbSNP:rs6493068)	VARIANT	5
Q6IQ55/P1122R	TTBK2	-	1	P -> R (in dbSNP:rs56142516)	VARIANT	0
Q6IQ55/R1110H	TTBK2	-	1	R -> H (found in a patient with SCA11; unknown pathological significance; dbSNP:rs146279300)	VARIANT	2
Q6IQ55/R120Q	TTBK2	-	1	R -> Q (in dbSNP:rs35328266)	VARIANT	0
Q6IQ55/R181A	TTBK2	loss	1	R->E,A: Impaired serine/threonine-protein kinase activity.	MUTAGEN	0
Q6IQ55/R181E	TTBK2	loss	1	R->E,A: Impaired serine/threonine-protein kinase activity.	MUTAGEN	0
Q6IQ55/R500P	TTBK2	-	1	R -> P (in dbSNP:rs56039839)	VARIANT	0
Q6IQ55/T1062I	TTBK2	neutral	1	T -> I (in dbSNP:rs55833708)	VARIANT	0
Q6IQ55/T1084M	TTBK2	neutral	1	T -> M (in dbSNP:rs34348991)	VARIANT	3
Q6IQ55/T313A	TTBK2	neutral	1	T -> A (in dbSNP:rs56017612)	VARIANT	0
Q6IQ55/V1097A	TTBK2	-	1	V -> A (in dbSNP:rs55796513)	VARIANT	0
Q6IQ55/V440M	TTBK2	-	1	V -> M (in dbSNP:rs56311523)	VARIANT	0
Q6J9G0/L237S	STYK1	-	1	L -> S (in dbSNP:rs55877878)	VARIANT	0
Q6J9G0/R210W	STYK1	-	1	R -> W (in dbSNP:rs34981955)	VARIANT	0
Q6J9G0/R379H	STYK1	-	1	R -> H (in dbSNP:rs34638573)	VARIANT	0
Q6J9G0/R71G	STYK1	neutral	0	R -> G (in dbSNP:rs6650202)	VARIANT	0
Q6J9G0/S204G	STYK1	neutral	5	S -> G (in dbSNP:rs3759259)	VARIANT	1
Q6J9G0/V395I	STYK1	-	1	V -> I (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
Q6J9G0/V400L	STYK1	-	1	V -> L (in dbSNP:rs55766125)	VARIANT	0
Q6P0Q8/A1463T	MAST2	neutral	1	A -> T (in dbSNP:rs3737738)	VARIANT	0
Q6P0Q8/D1221E	MAST2	-	1	D -> E (in dbSNP:rs56060730)	VARIANT	0
Q6P0Q8/D1551G	MAST2	neutral	3	D -> G (in dbSNP:rs1052610)	VARIANT	0
Q6P0Q8/D388E	MAST2	neutral	2	D -> E (in dbSNP:rs11211247)	VARIANT	1
Q6P0Q8/G1468A	MAST2	-	1	G -> A (in dbSNP:rs3737737)	VARIANT	3
Q6P0Q8/G1703E	MAST2	-	1	G -> E	VARIANT	0
Q6P0Q8/G655A	MAST2	-	1	G -> A (in a breast mucinous carcinoma sample; somatic mutation)	VARIANT	1
Q6P0Q8/I659M	MAST2	neutral	4	I -> M (in dbSNP:rs1707336)	VARIANT	2
Q6P0Q8/K1197R	MAST2	neutral	1	K -> R (in dbSNP:rs1052607)	VARIANT	2
Q6P0Q8/K1673R	MAST2	neutral	1	K -> R (in dbSNP:rs34070850)	VARIANT	0
Q6P0Q8/K275E	MAST2	-	1	K -> E (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
Q6P0Q8/L69F	MAST2	-	1	L -> F (in dbSNP:rs55914403)	VARIANT	0
Q6P0Q8/R1246L	MAST2	-	1	R -> L (in dbSNP:rs56309943)	VARIANT	0
Q6P0Q8/R991L	MAST2	neutral	1	R -> L (in dbSNP:rs56114653)	VARIANT	0
Q6P0Q8/T1608I	MAST2	-	0	T -> I (in dbSNP:rs35474583)	VARIANT	0
Q6P0Q8/V1304M	MAST2	neutral	1	V -> M (in dbSNP:rs33931638)	VARIANT	1
Q6P2M8/Q262H	PNCK	-	1	Q -> H (in dbSNP:rs56060609)	VARIANT	0
Q6P3R8/C531R	NEK5	-	1	C -> R	VARIANT	0
Q6P3R8/K255Q	NEK5	neutral	0	K -> Q (in dbSNP:rs34756139)	VARIANT	1
Q6P3R8/R290H	NEK5	-	1	R -> H	VARIANT	0
Q6P3W7/P357L	SCYL2	neutral	2	P -> L (in dbSNP:rs33968174)	VARIANT	0
Q6P3W7/Q863H	SCYL2	-	1	Q -> H (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	2
Q6P3W7/T720S	SCYL2	-	1	T -> S (in dbSNP:rs763873645)	VARIANT	1
Q6P5Z2/A180E	PKN3	-	1	A -> E (in dbSNP:rs56251280)	VARIANT	0
Q6P5Z2/K588E	PKN3	loss	2	K->E: Abolishes autophosphorylation and catalytic activity.	MUTAGEN	0
Q6P5Z2/K588R	PKN3	loss	2	K->R: Abolishes catalytic activity.	MUTAGEN	0
Q6P5Z2/T718A	PKN3	loss	1	T->A: Abolishes phosphorylation.	MUTAGEN	0
Q6P5Z2/V404L	PKN3	-	0	V -> L (in dbSNP:rs12932)	VARIANT	0
Q6PHR2/K139R	ULK3	loss	2	K->R: Loss of kinase activity. Does not promote GLI1 nuclear localization.	MUTAGEN	0
Q6PHR2/K445R	ULK3	-	0	K -> R (in dbSNP:rs12898397)	VARIANT	1
Q6PHR2/K44R	ULK3	decrease	1	K->R: Decreased kinase activity.	MUTAGEN	0
Q6PHR2/R101H	ULK3	neutral	0	R -> H (in dbSNP:rs34945944)	VARIANT	0
Q6SA08/H33Y	TSSK4	-	1	H -> Y (in dbSNP:rs36036137)	VARIANT	0
Q6SA08/K54M	TSSK4	loss	1	K->M: Loss of kinase activity.	MUTAGEN	0
Q6SA08/Q196R	TSSK4	neutral	1	Q -> R (in dbSNP:rs1270764)	VARIANT	0
Q6SA08/V145M	TSSK4	-	1	V -> M (in dbSNP:rs35468205)	VARIANT	0
Q6SA08/Y89C	TSSK4	-	1	Y -> C (in dbSNP:rs34083933)	VARIANT	0
Q6VAB6/A879L	KSR2	-	1	A->L: Impairs MAP2K1 binding.	MUTAGEN	0
Q6VAB6/D786A	KSR2	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
Q6VAB6/R676S	KSR2	-	1	R -> S (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	0
Q6VAB6/R718H	KSR2	-	1	R->H: Impairs formation of heterotetramers with MAP2K1, but not the formation of heterodimers.	MUTAGEN	0
Q6XUX3/D200G	DSTYK	-	1	D -> G (in CAKUT1)	VARIANT	0
Q6XUX3/K681Q	DSTYK	-	1	K->Q: No change.	MUTAGEN	0
Q6XUX3/L432V	DSTYK	neutral	0	L -> V (in dbSNP:rs35845538)	VARIANT	4
Q6XUX3/R29Q	DSTYK	-	1	R -> Q (in CAKUT1; unknown pathological significance; dbSNP:rs200780796)	VARIANT	0
Q6XUX3/S843L	DSTYK	-	1	S -> L (in CAKUT1; dbSNP:rs778586547)	VARIANT	0
Q6ZMQ8/A1332T	AATK	neutral	1	A -> T (in dbSNP:rs55713566)	VARIANT	4
Q6ZMQ8/E1160K	AATK	-	1	E -> K (in dbSNP:rs55793641)	VARIANT	0
Q6ZMQ8/F1266S	AATK	neutral	2	F -> S (in dbSNP:rs36000545)	VARIANT	0
Q6ZMQ8/G703C	AATK	-	3	G -> C (in dbSNP:rs7503604)	VARIANT	0
Q6ZMQ8/L97V	AATK	-	1	L -> V (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q6ZMQ8/M104V	AATK	-	1	M -> V (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs1337040042)	VARIANT	0
Q6ZMQ8/P1192S	AATK	neutral	1	P -> S (in dbSNP:rs55856613)	VARIANT	0
Q6ZMQ8/S815R	AATK	-	1	S -> R (in dbSNP:rs56032966)	VARIANT	0
Q6ZMQ8/S81F	AATK	-	1	S -> F (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
Q6ZMQ8/S923L	AATK	-	1	S -> L (in dbSNP:rs56313973)	VARIANT	0
Q6ZMQ8/T118M	AATK	neutral	0	T -> M (in dbSNP:rs8082016)	VARIANT	0
Q6ZN16/A192T	MAP3K15	neutral	1	A -> T (in dbSNP:rs5909299)	VARIANT	1
Q6ZN16/D226H	MAP3K15	-	1	D -> H (in dbSNP:rs56338727)	VARIANT	0
Q6ZN16/G838S	MAP3K15	neutral	1	G -> S (in dbSNP:rs56381411)	VARIANT	0
Q6ZN16/N1029H	MAP3K15	-	1	N -> H (in dbSNP:rs55787622)	VARIANT	1
Q6ZN16/Q1251E	MAP3K15	neutral	1	Q -> E (in dbSNP:rs15943)	VARIANT	0
Q6ZN16/R255S	MAP3K15	-	1	R -> S (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
Q6ZN16/R494C	MAP3K15	-	1	R -> C (in dbSNP:rs41305349)	VARIANT	0
Q6ZN16/R677Q	MAP3K15	-	1	R -> Q (in a metastatic melanoma sample; somatic mutation)	VARIANT	2
Q6ZN16/S199N	MAP3K15	neutral	1	S -> N (in dbSNP:rs55916006)	VARIANT	0
Q6ZN16/S456G	MAP3K15	neutral	1	S -> G (in dbSNP:rs56212339)	VARIANT	0
Q6ZN16/S562L	MAP3K15	-	1	S -> L (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q6ZN16/S993L	MAP3K15	neutral	1	S -> L (in dbSNP:rs56233219)	VARIANT	0
Q6ZN16/W1247R	MAP3K15	-	1	W -> R (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q6ZWH5/A66V	NEK10	-	1	A -> V (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs201821707)	VARIANT	0
Q6ZWH5/E379K	NEK10	-	1	E -> K (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q6ZWH5/F50L	NEK10	-	1	F -> L (in dbSNP:rs56125830)	VARIANT	1
Q6ZWH5/G67S	NEK10	neutral	1	G -> S (in dbSNP:rs55958314)	VARIANT	0
Q6ZWH5/K548R	NEK10	decrease	2	K->R: Catalytically inactive. Impaired mucociliary transport.	MUTAGEN	0
Q6ZWH5/L513S	NEK10	neutral	2	L -> S (in dbSNP:rs10510592)	VARIANT	5
Q6ZWH5/L701V	NEK10	neutral	1	L -> V (in dbSNP:rs34313679)	VARIANT	0
Q6ZWH5/N659S	NEK10	neutral	1	N -> S (in dbSNP:rs55833401)	VARIANT	0
Q6ZWH5/P748L	NEK10	-	1	P -> L (in CILD44; unknown pathological significance; dbSNP:rs1575215909)	VARIANT	0
Q6ZWH5/R773C	NEK10	-	1	R -> C (in CILD44; unknown pathological significance; dbSNP:rs766982731)	VARIANT	0
Q6ZWH5/S684D	NEK10	-	1	S->D: Increased mucociliary transport.	MUTAGEN	0
Q76MJ5/A318T	ERN2	-	1	A -> T (in dbSNP:rs56191901)	VARIANT	0
Q76MJ5/H858Y	ERN2	-	1	H -> Y (in dbSNP:rs56137182)	VARIANT	0
Q76MJ5/K548A	ERN2	loss	1	K->A: Loss of autophosphorylation, of induction of apoptosis and of 28S rRNA cleavage, attenuation of repression of protein synthesis.	MUTAGEN	0
Q76MJ5/L410F	ERN2	-	1	L -> F (in dbSNP:rs55687638)	VARIANT	1
Q76MJ5/L504F	ERN2	-	1	L -> F (in dbSNP:rs56001432)	VARIANT	0
Q76MJ5/R118C	ERN2	-	1	R -> C (in dbSNP:rs56117885)	VARIANT	0
Q76MJ5/R184C	ERN2	-	1	R -> C (in dbSNP:rs34683474)	VARIANT	0
Q76MJ5/R271Q	ERN2	-	2	R -> Q (in dbSNP:rs55772851)	VARIANT	0
Q76MJ5/R537Q	ERN2	-	1	R -> Q (in dbSNP:rs56176960)	VARIANT	0
Q76MJ5/S487T	ERN2	neutral	2	S -> T (in dbSNP:rs26764)	VARIANT	0
Q76MJ5/V69I	ERN2	neutral	1	V -> I (in dbSNP:rs9932495)	VARIANT	0
Q7KZI7/T208A	MARK2	loss	1	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
Q7KZI7/T596A	MARK2	-	2	T->A: Loss of membrane dissociation and binding to YWHAZ.	MUTAGEN	0
Q7L7X3/A855T	TAOK1	-	1	A -> T (in dbSNP:rs34151057)	VARIANT	0
Q7L7X3/D169A	TAOK1	loss	1	D->A: Loss of serine/threonine-protein kinase activity.	MUTAGEN	0
Q7L7X3/D305A	TAOK1	-	1	D -> A (in DDIB)	VARIANT	0
Q7L7X3/D376N	TAOK1	-	1	D->N: Does not abolish cleavage by caspase-3 (CASP3).	MUTAGEN	0
Q7L7X3/E17G	TAOK1	-	1	E -> G (in DDIB)	VARIANT	0
Q7L7X3/K298E	TAOK1	-	1	K -> E (in DDIB)	VARIANT	0
Q7L7X3/K57A	TAOK1	loss	1	K->A: Abolishes kinase activity, ability to activate the MAPK8/JNK cascade and cleavage by caspase-3 (CASP3).	MUTAGEN	0
Q7L7X3/L167R	TAOK1	-	1	L -> R (in DDIB; affects neuron maturation and migration)	VARIANT	0
Q7L7X3/L315F	TAOK1	-	1	L -> F (in DDIB; unknown pathological significance)	VARIANT	0
Q7L7X3/L548P	TAOK1	-	1	L -> P (in DDIB; affects neuron maturation and migration)	VARIANT	0
Q7L7X3/M231V	TAOK1	-	1	M -> V (in DDIB; unknown pathological significance)	VARIANT	0
Q7L7X3/R150I	TAOK1	-	1	R -> I (in DDIB)	VARIANT	0
Q7L7X3/S111F	TAOK1	-	1	S -> F (in DDIB; dbSNP:rs2030976698)	VARIANT	0
Q7L7X3/S990A	TAOK1	-	1	S->A: Abolishes phosphorylation by ATM; when associated with A-643 and A-785.	MUTAGEN	0
Q7L7X3/T643A	TAOK1	-	1	T->A: Abolishes phosphorylation by ATM; when associated with A-785 and A-990.	MUTAGEN	0
Q7L7X3/T785A	TAOK1	-	1	T->A: Abolishes phosphorylation by ATM; when associated with A-643 and A-990.	MUTAGEN	0
Q7RTN6/F233A	STRADA	-	1	F->A: Inhibits interaction with STK11/LKB1; when associated with A-.	MUTAGEN	0
Q7RTN6/H231A	STRADA	-	1	H->A: Inhibits interaction with STK11/LKB1; when associated with A-.	MUTAGEN	0
Q7RTN6/L241A	STRADA	-	1	L->A: Inhibits interaction with STK11/LKB1.	MUTAGEN	0
Q7RTN6/P64S	STRADA	-	1	P -> S (in dbSNP:rs55695051)	VARIANT	0
Q7RTN6/Q251A	STRADA	-	1	Q->A: Inhibits interaction with STK11/LKB1.	MUTAGEN	0
Q7RTN6/R13W	STRADA	-	1	R -> W (in dbSNP:rs35808156)	VARIANT	3
Q7RTN6/S60I	STRADA	-	1	S -> I (in dbSNP:rs56271007)	VARIANT	0
Q7RTN6/T329A	STRADA	loss	1	T->A: Loss of STK11/LKB1-mediated phosphorylation.	MUTAGEN	0
Q7RTN6/T419A	STRADA	loss	1	T->A: Loss of STK11/LKB1-mediated phosphorylation.	MUTAGEN	0
Q7RTN6/Y185F	STRADA	-	1	Y->F: Suppresses STK11/LKB1 activation without affecting complex assembly.	MUTAGEN	0
Q7Z2Y5/A1121P	NRK	-	1	A -> P (in dbSNP:rs35720774)	VARIANT	0
Q7Z2Y5/A993E	NRK	-	0	A -> E (in dbSNP:rs16984889)	VARIANT	0
Q7Z2Y5/D971G	NRK	-	1	D -> G (in dbSNP:rs35334892)	VARIANT	0
Q7Z2Y5/E579G	NRK	-	1	E -> G (in dbSNP:rs56350428)	VARIANT	0
Q7Z2Y5/E679G	NRK	-	1	E -> G (in dbSNP:rs35115195)	VARIANT	0
Q7Z2Y5/G1471A	NRK	-	1	G -> A (in dbSNP:rs34232354)	VARIANT	0
Q7Z2Y5/H1276L	NRK	-	1	H -> L (in dbSNP:rs35942881)	VARIANT	1
Q7Z2Y5/I880L	NRK	-	1	I -> L (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs764355898)	VARIANT	0
Q7Z2Y5/M1472L	NRK	-	1	M -> L (in dbSNP:rs35609510)	VARIANT	0
Q7Z2Y5/P1106S	NRK	-	1	P -> S (in dbSNP:rs35393519)	VARIANT	0
Q7Z2Y5/P426A	NRK	-	1	P -> A (in dbSNP:rs55635933)	VARIANT	0
Q7Z2Y5/Q355H	NRK	-	1	Q -> H (in dbSNP:rs55862725)	VARIANT	0
Q7Z2Y5/R727H	NRK	neutral	0	R -> H (in dbSNP:rs33936206)	VARIANT	1
Q7Z2Y5/S424C	NRK	-	1	S -> C (in a breast infiltrating ductal carcinoma sample; somatic mutation)	VARIANT	2
Q7Z2Y5/V358M	NRK	-	1	V -> M (in dbSNP:rs209373)	VARIANT	3
Q7Z695/P622L	ADCK2	neutral	1	P -> L (in dbSNP:rs1046515)	VARIANT	0
Q7Z695/S307P	ADCK2	neutral	1	S -> P (in dbSNP:rs1140034)	VARIANT	1
Q7Z695/S66G	ADCK2	neutral	0	S -> G (in dbSNP:rs2968558)	VARIANT	1
Q7Z695/V418L	ADCK2	neutral	1	V -> L (in dbSNP:rs3748092)	VARIANT	0
Q7Z695/V418M	ADCK2	neutral	0	V -> M (in dbSNP:rs3748092)	VARIANT	0
Q7Z7A4/A525V	PXK	neutral	0	A -> V (in dbSNP:rs34579268)	VARIANT	0
Q7Z7A4/A535V	PXK	neutral	0	A -> V (in dbSNP:rs34579268)	VARIANT	0
Q7Z7A4/I426V	PXK	-	1	I -> V (in dbSNP:rs55973253)	VARIANT	0
Q7Z7A4/K481R	PXK	neutral	2	K -> R (in dbSNP:rs56384862)	VARIANT	0
Q7Z7A4/R54Q	PXK	-	1	R->Q: No effect on subcellular location.	MUTAGEN	0
Q7Z7A4/R92L	PXK	-	1	R->L: Results in redistribution of protein from cytoplasm throughout entire cell.	MUTAGEN	0
Q7Z7A4/Y56A	PXK	-	1	Y->A: Results in redistribution of protein from cytoplasm throughout entire cell.	MUTAGEN	0
Q86SG6/A497P	NEK8	-	1	A -> P (in NPHP9; a full-length mouse NEK8 construct containing the mutation shows a defect in ciliary localization with no apparent effect on ciliation, mitosis or centriole number; dbSNP:rs146326420)	VARIANT	0
Q86SG6/H425Y	NEK8	-	1	H -> Y (in NPHP9; a full-length mouse NEK8 construct containing the mutation shows a defect in ciliary localization with no apparent effect on ciliation, mitosis or centriole number; dbSNP:rs118204032)	VARIANT	0
Q86SG6/L330F	NEK8	-	1	L -> F (in NPHP9; a full-length mouse NEK8 construct containing the mutation shows a defect in ciliary localization with no apparent effect on ciliation, mitosis or centriole number; dbSNP:rs199962228)	VARIANT	0
Q86TB3/A1551S	ALPK2	-	2	A -> S (in dbSNP:rs3809983)	VARIANT	0
Q86TB3/A1919T	ALPK2	-	1	A -> T (in dbSNP:rs374271622)	VARIANT	0
Q86TB3/A1978T	ALPK2	-	1	A -> T (in dbSNP:rs146618330)	VARIANT	0
Q86TB3/A202T	ALPK2	neutral	1	A -> T (in dbSNP:rs115979836)	VARIANT	0
Q86TB3/A29V	ALPK2	-	1	A -> V (in dbSNP:rs138405027)	VARIANT	0
Q86TB3/A457V	ALPK2	-	1	A -> V (in dbSNP:rs199872766)	VARIANT	0
Q86TB3/A969T	ALPK2	-	1	A -> T (in dbSNP:rs371835741)	VARIANT	0
Q86TB3/E1969K	ALPK2	-	0	E -> K (in dbSNP:rs1313881443)	VARIANT	0
Q86TB3/E942K	ALPK2	-	1	E -> K (in an ovarian undifferentiated carcinoma sample; somatic mutation)	VARIANT	0
Q86TB3/G1063V	ALPK2	neutral	0	G -> V (in dbSNP:rs34347938)	VARIANT	0
Q86TB3/G810S	ALPK2	neutral	4	G -> S (in dbSNP:rs3809970)	VARIANT	0
Q86TB3/H1174P	ALPK2	neutral	4	H -> P (in dbSNP:rs3809977)	VARIANT	0
Q86TB3/H1767Y	ALPK2	-	1	H -> Y (in dbSNP:rs7234999)	VARIANT	0
Q86TB3/H719Q	ALPK2	neutral	4	H -> Q (in dbSNP:rs12103986)	VARIANT	0
Q86TB3/I2157V	ALPK2	neutral	3	I -> V (in dbSNP:rs7240666)	VARIANT	0
Q86TB3/K1134N	ALPK2	-	0	K -> N (in dbSNP:rs35791514)	VARIANT	0
Q86TB3/K1476T	ALPK2	-	1	K -> T (in a melanoma metastatic sample; somatic mutation)	VARIANT	0
Q86TB3/K1729E	ALPK2	-	0	K -> E (in dbSNP:rs34409558)	VARIANT	0
Q86TB3/K1730E	ALPK2	neutral	1	K -> E (in dbSNP:rs17065127)	VARIANT	0
Q86TB3/K1745N	ALPK2	-	1	K -> N (in dbSNP:rs56206581)	VARIANT	0
Q86TB3/K829N	ALPK2	neutral	1	K -> N (in dbSNP:rs3809973)	VARIANT	0
Q86TB3/L1057V	ALPK2	neutral	4	L -> V (in dbSNP:rs3809976)	VARIANT	0
Q86TB3/L1288S	ALPK2	-	1	L -> S (in dbSNP:rs35882005)	VARIANT	0
Q86TB3/L1296V	ALPK2	neutral	0	L -> V (in dbSNP:rs3809976)	VARIANT	0
Q86TB3/N916K	ALPK2	neutral	4	N -> K (in dbSNP:rs4940404)	VARIANT	0
Q86TB3/P1449S	ALPK2	neutral	4	P -> S (in dbSNP:rs3809982)	VARIANT	0
Q86TB3/Q1579R	ALPK2	neutral	1	Q -> R (in dbSNP:rs33910491)	VARIANT	0
Q86TB3/Q1853E	ALPK2	-	1	Q -> E (rare variant found in East Asian patients; decreases luminal apoptosis, cell aggregation and basolateral membrane localization in colorectal cancer cells; dbSNP:rs55674018)	VARIANT	0
Q86TB3/R136S	ALPK2	neutral	1	R -> S (in dbSNP:rs9944810)	VARIANT	0
Q86TB3/R1884C	ALPK2	neutral	1	R -> C (in dbSNP:rs33969768)	VARIANT	0
Q86TB3/R825T	ALPK2	neutral	4	R -> T (in dbSNP:rs3809972)	VARIANT	0
Q86TB3/S388L	ALPK2	-	1	S -> L (in dbSNP:rs147887741)	VARIANT	0
Q86TB3/S884L	ALPK2	neutral	1	S -> L (in dbSNP:rs3809974)	VARIANT	0
Q86TB3/S977T	ALPK2	-	1	S -> T (in dbSNP:rs3809975)	VARIANT	0
Q86TB3/T397I	ALPK2	neutral	1	T -> I (in dbSNP:rs79863383)	VARIANT	0
Q86TB3/T875P	ALPK2	neutral	1	T -> P (in dbSNP:rs34109891)	VARIANT	0
Q86TB3/T891I	ALPK2	neutral	4	T -> I (in dbSNP:rs3826593)	VARIANT	0
Q86TW2/A164G	ADCK1	-	1	A->G: No effect on role in maintaining mitochondrial structure and function.	MUTAGEN	0
Q86TW2/D315A	ADCK1	-	1	D->A: No effect on role in maintaining mitochondrial structure and function.	MUTAGEN	0
Q86TW2/K183I	ADCK1	-	1	K->I: No effect on role in maintaining mitochondrial structure and function.	MUTAGEN	0
Q86UE8/A108G	TLK2	-	1	A -> G	VARIANT	0
Q86UE8/A95G	TLK2	-	1	A -> G (in dbSNP:rs2598147)	VARIANT	0
Q86UE8/D551G	TLK2	decrease	1	D -> G (in MRD57; unknown pathological significance; exhibits abnormal perinuclear localization instead of diffuse nuclear localization; mildly impairs kinase activity; reduced phosphorylation of ASF1A; dbSNP:rs2082811958)	VARIANT	0
Q86UE8/D592V	TLK2	loss	2	D->V: Loss of kinase activity. No impact on interaction with ASF1A.	MUTAGEN	0
Q86UE8/D613A	TLK2	loss	3	D->A: Loss of kinase activity.	MUTAGEN	0
Q86UE8/D629N	TLK2	decrease	2	D -> N (in MRD57; reduced phosphorylation of ASF1A; dbSNP:rs1568006217)	VARIANT	0
Q86UE8/E447K	TLK2	-	1	E -> K (in MRD57; unknown pathological significance; dbSNP:rs1567959483)	VARIANT	0
Q86UE8/E54D	TLK2	-	1	E -> D	VARIANT	0
Q86UE8/F173L	TLK2	-	1	F -> L (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1331331651)	VARIANT	0
Q86UE8/G297D	TLK2	-	1	G -> D (in MRD57; unknown pathological significance; dbSNP:rs1555639254)	VARIANT	0
Q86UE8/H493R	TLK2	decrease	2	H -> R (in MRD57; reduced kinase activity; dbSNP:rs1567974030)	VARIANT	0
Q86UE8/H518N	TLK2	decrease	1	H->N: Reduced kinase activity.	MUTAGEN	2
Q86UE8/H518R	TLK2	decrease	2	H -> R (in MRD57; severely reduced kinase activity; dbSNP:rs1567995650)	VARIANT	0
Q86UE8/H6R	TLK2	-	2	H -> R (in dbSNP:rs45550140)	VARIANT	0
Q86UE8/P680R	TLK2	-	1	P -> R (in MRD57; dbSNP:rs1568018905)	VARIANT	0
Q86UE8/R109L	TLK2	-	1	R -> L (in dbSNP:rs1555617262)	VARIANT	2
Q86UE8/R262Q	TLK2	-	1	R -> Q (in dbSNP:rs762409144)	VARIANT	7
Q86UE8/R339Q	TLK2	-	1	R -> Q (in MRD57; unknown pathological significance; dbSNP:rs1567948287)	VARIANT	0
Q86UE8/R339W	TLK2	-	1	R -> W (in MRD57; unknown pathological significance; dbSNP:rs1567948262)	VARIANT	0
Q86UE8/R568W	TLK2	-	1	R -> W (in MRD57; dbSNP:rs1283838287)	VARIANT	1
Q86UE8/R720A	TLK2	decrease	1	R->A: Reduced phosphorylation of ASF1A.	MUTAGEN	0
Q86UE8/S617A	TLK2	increase	1	S->A: Increase in autophosphorylation.	MUTAGEN	0
Q86UE8/S617D	TLK2	loss	1	S->D: Loss of kinase activity.	MUTAGEN	0
Q86UE8/S617L	TLK2	decrease	2	S -> L (in MRD57; exhibits abnormal perinuclear localization instead of diffuse nuclear localization; impairs kinase activity; reduced phosphorylation of ASF1A; dbSNP:rs2082914686)	VARIANT	3
Q86UE8/S659A	TLK2	decrease	1	S->A: Reduced kinase activity.	MUTAGEN	0
Q86UE8/S686A	TLK2	decrease	1	S->A: Reduced kinase activity.	MUTAGEN	0
Q86UE8/S686D	TLK2	decrease	1	S->D: Reduced kinase activity.	MUTAGEN	0
Q86UE8/T695A	TLK2	decrease	1	T->A: Reduced kinase activity.	MUTAGEN	1
Q86UX6/A454T	STK32C	-	1	A -> T (in dbSNP:rs56109103)	VARIANT	1
Q86UX6/E467K	STK32C	neutral	1	E -> K (in dbSNP:rs55812591)	VARIANT	2
Q86UX6/R376H	STK32C	-	1	R -> H (in a colorectal cancer sample; somatic mutation; dbSNP:rs764558009)	VARIANT	0
Q86UX6/T334A	STK32C	-	1	T -> A (in dbSNP:rs17854384)	VARIANT	0
Q86UX6/V151L	STK32C	-	1	V -> L (found in a patient with global developmental delay; unknown pathological significance)	VARIANT	0
Q86Y07/I157M	VRK2	-	1	I -> M (in dbSNP:rs35966666)	VARIANT	0
Q86Y07/I167V	VRK2	neutral	4	I -> V (in dbSNP:rs1051061)	VARIANT	1
Q86Y07/N211S	VRK2	-	0	N -> S (in dbSNP:rs36081172)	VARIANT	0
Q86Y07/N50D	VRK2	-	1	N -> D (in dbSNP:rs34130684)	VARIANT	0
Q86YV5/A1113T	PRAG1	-	2	A -> T (in dbSNP:rs12549973)	VARIANT	3
Q86YV5/F1271A	PRAG1	-	1	F->A: Decreases homodimerization. Decreases interaction with PEAK1.	MUTAGEN	0
Q86YV5/F1366A	PRAG1	-	1	F->A: Decreases homodimerization. Abolished interaction with PEAK1. Decreases cell migration.	MUTAGEN	0
Q86YV5/H851R	PRAG1	-	1	H -> R (in dbSNP:rs56215812)	VARIANT	2
Q86YV5/I1243A	PRAG1	-	1	I->A: No effect on homodimerization. Decreases oligomerization. Decreases interaction with PEAK1.	MUTAGEN	0
Q86YV5/L122I	PRAG1	-	1	L -> I (in dbSNP:rs55764617)	VARIANT	0
Q86YV5/L955A	PRAG1	-	1	L->A: Decreases homodimerization. Abolished interaction with PEAK1. No effect on cell migration.	MUTAGEN	0
Q86YV5/L966A	PRAG1	-	1	L->A: Decreases homodimerization. Abolished interaction with PEAK1. Decreases cell migration.	MUTAGEN	0
Q86YV5/P569L	PRAG1	-	1	P -> L (in dbSNP:rs4840955)	VARIANT	2
Q86YV5/P595A	PRAG1	-	1	P -> A (in dbSNP:rs55994745)	VARIANT	0
Q86YV5/P662T	PRAG1	-	1	P -> T (in dbSNP:rs56351643)	VARIANT	0
Q86YV5/P814L	PRAG1	-	1	P -> L (in dbSNP:rs56207906)	VARIANT	0
Q86YV5/R1278A	PRAG1	-	1	R->A: Decreases homodimerization.	MUTAGEN	0
Q86YV5/R1315H	PRAG1	-	1	R -> H (in dbSNP:rs1314830862)	VARIANT	0
Q86YV5/R137G	PRAG1	-	1	R -> G (in dbSNP:rs56290960)	VARIANT	0
Q86YV5/R404Q	PRAG1	-	1	R -> Q (in dbSNP:rs3896980)	VARIANT	1
Q86YV5/S1003L	PRAG1	-	1	S -> L (in dbSNP:rs56289289)	VARIANT	0
Q86YV5/S578C	PRAG1	-	1	S -> C (in dbSNP:rs4840953)	VARIANT	1
Q86YV5/V1041M	PRAG1	-	1	V -> M (in dbSNP:rs28533138)	VARIANT	0
Q86YV5/V139I	PRAG1	-	1	V -> I (in dbSNP:rs34346032)	VARIANT	0
Q86YV5/W1382A	PRAG1	-	1	W->A: Decreases homodimerization. Abolished interaction with PEAK1. Decreases cell migration.	MUTAGEN	0
Q86YV5/Y1282A	PRAG1	-	1	Y->A: No effect on homodimerization. Decreases oligomerization. Decreases interaction with PEAK1. No effect on cell migration.	MUTAGEN	0
Q86Z02/D315N	HIPK1	loss	1	D->N: Loss of kinase activity and impaired MAP3K5-JNK inactivation.	MUTAGEN	0
Q86Z02/G310C	HIPK1	-	1	G -> C (in dbSNP:rs34335651)	VARIANT	0
Q86Z02/K1203R	HIPK1	-	1	K->R: Nuclear subcellular location. Impaired sumoylation and cytoplasmic subcellular location; when associated with R-25; R-317; R-440 and R-556.	MUTAGEN	0
Q86Z02/K219A	HIPK1	loss	1	K->A: Loss of kinase activity.	MUTAGEN	0
Q86Z02/K25R	HIPK1	-	1	K->R: Reduced sumoylation and cytoplasmic subcellular location. Impaired sumoylation and cytoplasmic subcellular location; when associated with R-317; R-440; R-556 and R-1203.	MUTAGEN	0
Q86Z02/K317R	HIPK1	-	1	K->R: Nuclear subcellular location. Impaired sumoylation and cytoplasmic subcellular location; when associated with R-25; R-440; R-556 and R-1203.	MUTAGEN	0
Q86Z02/K440R	HIPK1	-	1	K->R: Nuclear subcellular location. Impaired sumoylation and cytoplasmic subcellular location; when associated with R-25; R-317; R-556 and R-1203.	MUTAGEN	0
Q86Z02/K556R	HIPK1	-	1	K->R: Nuclear subcellular location. Impaired sumoylation and cytoplasmic subcellular location; when associated with R-25; R-317; R-440 and R-1203.	MUTAGEN	0
Q86Z02/L1165V	HIPK1	-	1	L -> V	VARIANT	0
Q86Z02/Q6R	HIPK1	-	0	Q -> R (in dbSNP:rs35324789)	VARIANT	0
Q8IU85/I66M	CAMK1D	neutral	1	I -> M (in dbSNP:rs34194224)	VARIANT	0
Q8IU85/K52A	CAMK1D	loss	1	K->A: Catalytically inactive form.	MUTAGEN	0
Q8IU85/T180A	CAMK1D	loss	2	T->A: Loss of ionomycin-induced activation.	MUTAGEN	0
Q8IV63/C288Y	VRK3	neutral	1	C -> Y (in dbSNP:rs10409482)	VARIANT	0
Q8IV63/F171L	VRK3	neutral	1	F -> L (in dbSNP:rs11547883)	VARIANT	0
Q8IV63/H304L	VRK3	-	0	H -> L (in dbSNP:rs35261919)	VARIANT	0
Q8IV63/P105T	VRK3	neutral	1	P -> T (in dbSNP:rs11547882)	VARIANT	0
Q8IV63/R370C	VRK3	-	1	R -> C (in dbSNP:rs35331034)	VARIANT	0
Q8IV63/S170P	VRK3	-	0	S -> P (in dbSNP:rs11547881)	VARIANT	0
Q8IV63/S268L	VRK3	neutral	1	S -> L (in dbSNP:rs10410075)	VARIANT	0
Q8IV63/S371G	VRK3	neutral	1	S -> G (in dbSNP:rs56407496)	VARIANT	0
Q8IV63/S59F	VRK3	neutral	1	S -> F (in dbSNP:rs2033262)	VARIANT	0
Q8IV63/T188A	VRK3	neutral	0	T -> A (in dbSNP:rs11879620)	VARIANT	0
Q8IVH8/H424Q	MAP4K3	-	1	H -> Q (in dbSNP:rs56317466)	VARIANT	0
Q8IVH8/K45E	MAP4K3	loss	1	K->E: Loss of kinase activity and ability to activate JNK family.	MUTAGEN	0
Q8IVH8/T669S	MAP4K3	-	1	T -> S (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
Q8IVH8/V200L	MAP4K3	-	1	V -> L (in dbSNP:rs35957290)	VARIANT	0
Q8IVT5/A637F	KSR1	-	1	A->F: No effect on MAP2K1 or MAP2K2 mediated-BRAF-KSR1 dimerization and BRAF activation.	MUTAGEN	0
Q8IVT5/C62D	KSR1	-	1	C->D: Reduces interaction with BRAF and MAP2K1 and thus phosphorylation of MAP2K1.	MUTAGEN	0
Q8IVT5/E72K	KSR1	decrease	1	E->K: Loss of interaction with BRAF and MAP2K1 and severe decrease in MAP2K1 phosphorylation levels.	MUTAGEN	0
Q8IVT5/L47D	KSR1	-	1	L->D: Reduces interaction with BRAF and MAP2K1 and thus phosphorylation of MAP2K1.	MUTAGEN	0
Q8IVT5/Q663H	KSR1	-	1	Q -> H	VARIANT	0
Q8IVT5/R639M	KSR1	-	1	R->M: No effect on MAP2K1 mediated-BRAF-KSR1 dimerization and BRAF activation.	MUTAGEN	0
Q8IVT5/R665H	KSR1	-	1	R->H: Loss of MAP2K1 mediated-BRAF-KSR1 dimerization.	MUTAGEN	0
Q8IVT5/S227P	KSR1	-	1	S -> P	VARIANT	0
Q8IVT5/V359A	KSR1	-	1	V -> A	VARIANT	0
Q8IVT5/W831R	KSR1	-	1	W->R: Loss of the interaction with MAP2K1 resulting in loss of BRAF-KSR1 dimerization and BRAF activation. No effect on ATP binding or interaction with HSP90AA1, 14-3-3 and CDC37.	MUTAGEN	0
Q8IVW4/M394T	CDKL3	-	1	M -> T (in dbSNP:rs35687772)	VARIANT	0
Q8IW41/K51M	MAPKAPK5	loss	1	K->M: Kinase defective mutant, abolishes activity.	MUTAGEN	0
Q8IW41/L337G	MAPKAPK5	activating	1	L->G: Induces constitutive protein kinase activity.	MUTAGEN	0
Q8IW41/M67I	MAPKAPK5	-	1	M -> I (in dbSNP:rs34132040)	VARIANT	0
Q8IW41/R282K	MAPKAPK5	-	1	R -> K (in dbSNP:rs34843470)	VARIANT	0
Q8IW41/S212D	MAPKAPK5	increase	1	S->D: Mimicks phosphorylation state and displays a slightly higher protein kinase activity.	MUTAGEN	0
Q8IW41/T182A	MAPKAPK5	-	3	T->A: No p38-beta/MAPK11-induced activation.	MUTAGEN	0
Q8IW41/T182D	MAPKAPK5	activating	3	T->D: Mimicks phosphorylation state and induces constitutive protein kinase activity.	MUTAGEN	0
Q8IWB6/D88G	TEX14	-	1	D -> G (in dbSNP:rs56292204)	VARIANT	0
Q8IWB6/I559M	TEX14	-	1	I -> M	VARIANT	0
Q8IWB6/K321E	TEX14	-	1	K -> E (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	0
Q8IWB6/S443C	TEX14	-	1	S -> C	VARIANT	0
Q8IWQ3/G310A	BRSK2	decrease	1	G->A: Decreased activation of kinase activity.	MUTAGEN	0
Q8IWQ3/K48M	BRSK2	loss	2	K->M: Loss of catalytic activity. Causes disintegration of actin stress fibers.	MUTAGEN	0
Q8IWQ3/T174A	BRSK2	loss	3	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
Q8IWQ3/T174E	BRSK2	activating	3	T->E: Constitutively activated.	MUTAGEN	0
Q8IWQ3/T260A	BRSK2	decrease	2	T->A: Decreased phosphorylation. Nearly abolishes stimulation of insulin secretion.	MUTAGEN	0
Q8IWQ3/T443A	BRSK2	activating	1	T->A: Constitutively activated. Promotes formation of actin stress fibers.	MUTAGEN	0
Q8IWU2/A1341G	LMTK2	neutral	1	A -> G (in dbSNP:rs56343792)	VARIANT	0
Q8IWU2/A862T	LMTK2	neutral	1	A -> T (in dbSNP:rs34005293)	VARIANT	0
Q8IWU2/D1061N	LMTK2	-	1	D -> N (in dbSNP:rs3801295)	VARIANT	1
Q8IWU2/D1220N	LMTK2	-	1	D -> N (in dbSNP:rs35912712)	VARIANT	0
Q8IWU2/D484H	LMTK2	-	1	D -> H (in a lung large cell carcinoma sample; somatic mutation; dbSNP:rs147940573)	VARIANT	0
Q8IWU2/I693T	LMTK2	neutral	1	I -> T (in dbSNP:rs56204700)	VARIANT	1
Q8IWU2/L780M	LMTK2	-	2	L -> M (in dbSNP:rs11765552)	VARIANT	4
Q8IWU2/P30A	LMTK2	neutral	0	P -> A (in dbSNP:rs3735252)	VARIANT	0
Q8IWU2/S1401N	LMTK2	neutral	1	S -> N (in dbSNP:rs45488394)	VARIANT	0
Q8IWU2/S916R	LMTK2	-	1	S -> R (in dbSNP:rs55867257)	VARIANT	0
Q8IWU2/V595I	LMTK2	-	1	V -> I (in dbSNP:rs34461195)	VARIANT	0
Q8IWU2/V624M	LMTK2	-	1	V -> M (in dbSNP:rs34628253)	VARIANT	0
Q8IWU2/V849F	LMTK2	-	1	V -> F (in dbSNP:rs56196840)	VARIANT	0
Q8IY84/E64Q	NIM1K	-	1	E -> Q (in dbSNP:rs55663207)	VARIANT	0
Q8IY84/L260I	NIM1K	-	1	L -> I (in dbSNP:rs35659008)	VARIANT	0
Q8IY84/M320I	NIM1K	-	1	M -> I (in dbSNP:rs55770078)	VARIANT	1
Q8IY84/P333S	NIM1K	-	1	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs866026698)	VARIANT	0
Q8IY84/P411T	NIM1K	-	1	P -> T (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q8IY84/R21W	NIM1K	-	1	R -> W (in dbSNP:rs55664335)	VARIANT	1
Q8IY84/T229A	NIM1K	loss	1	T->A: Loss of autophosphorylation and kinase activity.	MUTAGEN	0
Q8IY84/T229E	NIM1K	activating	1	T->E: Constitutively active.	MUTAGEN	0
Q8IYT8/A662V	ULK2	-	1	A -> V (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q8IYT8/D842E	ULK2	-	1	D -> E (in dbSNP:rs35107651)	VARIANT	0
Q8IYT8/G627E	ULK2	-	1	G -> E (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q8IYT8/G752R	ULK2	-	1	G -> R (in dbSNP:rs55730189)	VARIANT	0
Q8IYT8/K39R	ULK2	decrease	1	K->R: Decreased kinase activity and decreased autophosphorylation.	MUTAGEN	0
Q8IYT8/P242S	ULK2	neutral	1	P -> S (in dbSNP:rs34670978)	VARIANT	0
Q8IYT8/T533I	ULK2	-	0	T -> I (in dbSNP:rs4462660)	VARIANT	0
Q8IYT8/V370M	ULK2	neutral	2	V -> M (in dbSNP:rs150122)	VARIANT	0
Q8IZE3/G597A	SCYL3	neutral	1	G -> A (in dbSNP:rs12143301)	VARIANT	0
Q8IZE3/Q621R	SCYL3	neutral	2	Q -> R (in dbSNP:rs4656197)	VARIANT	0
Q8IZL9/A137T	CDK20	-	0	A -> T (in dbSNP:rs28364955)	VARIANT	0
Q8IZL9/K281R	CDK20	-	0	K -> R (in dbSNP:rs28364963)	VARIANT	0
Q8IZL9/S106N	CDK20	-	1	S -> N (in dbSNP:rs41286029)	VARIANT	0
Q8IZL9/S86L	CDK20	-	0	S -> L (in dbSNP:rs28364953)	VARIANT	0
Q8IZL9/T161A	CDK20	decrease	1	T->A: Impairs CDK2 T-160 phosphorylation and activity.	MUTAGEN	0
Q8IZX4/A1540T	TAF1L	-	1	A -> T (in dbSNP:rs55782058)	VARIANT	0
Q8IZX4/E794D	TAF1L	-	1	E -> D (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	0
Q8IZX4/G256A	TAF1L	neutral	1	G -> A (in dbSNP:rs55991718)	VARIANT	0
Q8IZX4/G47A	TAF1L	-	1	G -> A (in a lung small cell carcinoma sample; somatic mutation)	VARIANT	0
Q8IZX4/H1549Y	TAF1L	-	1	H -> Y (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs1587670372)	VARIANT	0
Q8IZX4/H1824Q	TAF1L	-	1	H -> Q (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	0
Q8IZX4/I1411V	TAF1L	-	1	I -> V (in dbSNP:rs34500740)	VARIANT	0
Q8IZX4/I1805V	TAF1L	neutral	0	I -> V (in dbSNP:rs16918393)	VARIANT	0
Q8IZX4/I532N	TAF1L	-	1	I -> N (in dbSNP:rs56128445)	VARIANT	0
Q8IZX4/K1038N	TAF1L	-	1	K -> N (in dbSNP:rs55767137)	VARIANT	0
Q8IZX4/K1731N	TAF1L	neutral	1	K -> N (in dbSNP:rs34241003)	VARIANT	0
Q8IZX4/L750F	TAF1L	-	1	L -> F (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	0
Q8IZX4/L762I	TAF1L	-	1	L -> I (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	0
Q8IZX4/M371V	TAF1L	neutral	1	M -> V (in dbSNP:rs17219559)	VARIANT	0
Q8IZX4/P1389S	TAF1L	-	1	P -> S (in dbSNP:rs56393725)	VARIANT	0
Q8IZX4/P1810L	TAF1L	-	1	P -> L (in dbSNP:rs56342342)	VARIANT	0
Q8IZX4/P637S	TAF1L	-	1	P -> S (in dbSNP:rs56157814)	VARIANT	0
Q8IZX4/Q171E	TAF1L	-	1	Q -> E (in dbSNP:rs56352331)	VARIANT	0
Q8IZX4/R1016C	TAF1L	neutral	1	R -> C (in dbSNP:rs35905429)	VARIANT	0
Q8IZX4/R1356C	TAF1L	-	1	R -> C (in dbSNP:rs56107531)	VARIANT	0
Q8IZX4/R845Q	TAF1L	-	1	R -> Q (in dbSNP:rs34787787)	VARIANT	0
Q8IZX4/T1169I	TAF1L	neutral	1	T -> I (in dbSNP:rs55976674)	VARIANT	0
Q8IZX4/V1312L	TAF1L	-	1	V -> L (in dbSNP:rs55824107)	VARIANT	0
Q8N2I9/A10V	STK40	-	1	A -> V (in dbSNP:rs56314546)	VARIANT	0
Q8N2I9/A395T	STK40	neutral	3	A -> T (in dbSNP:rs3795498)	VARIANT	4
Q8N2I9/M133T	STK40	-	1	M -> T (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs755089893)	VARIANT	0
Q8N2I9/R211Q	STK40	-	1	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs539738963)	VARIANT	0
Q8N4C8/A514T	MINK1	-	1	A -> T (in dbSNP:rs56131206)	VARIANT	0
Q8N4C8/E1010V	MINK1	-	1	E -> V (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	1
Q8N4C8/I1200V	MINK1	-	1	I -> V	VARIANT	0
Q8N4C8/P775L	MINK1	neutral	8	P -> L (in dbSNP:rs11556635)	VARIANT	2
Q8N4C8/V771A	MINK1	-	2	V -> A (in dbSNP:rs11556634)	VARIANT	2
Q8N4C8/V863I	MINK1	neutral	1	V -> I (in dbSNP:rs2302319)	VARIANT	1
Q8N568/G119C	DCLK2	-	1	G -> C (in dbSNP:rs56327537)	VARIANT	0
Q8N568/I583V	DCLK2	-	1	I -> V (in dbSNP:rs35745104)	VARIANT	0
Q8N568/R372H	DCLK2	-	1	R -> H (in dbSNP:rs34386880)	VARIANT	0
Q8N568/V212M	DCLK2	-	1	V -> M (found in a patient with hereditary motor and sensory neuropathy; unknown pathological significance; dbSNP:rs759398144)	VARIANT	0
Q8N5S9/E375G	CAMKK1	-	2	E -> G (in dbSNP:rs7214723)	VARIANT	1
Q8N752/A257T	CSNK1A1L	-	1	A -> T (in dbSNP:rs55895045)	VARIANT	0
Q8N752/D42E	CSNK1A1L	neutral	1	D -> E (in dbSNP:rs9576175)	VARIANT	6
Q8N752/E177K	CSNK1A1L	neutral	1	E -> K (in dbSNP:rs17054882)	VARIANT	0
Q8N752/K230N	CSNK1A1L	neutral	1	K -> N (in dbSNP:rs56252523)	VARIANT	0
Q8N752/P220L	CSNK1A1L	-	1	P -> L (in dbSNP:rs56252856)	VARIANT	0
Q8N752/R170S	CSNK1A1L	neutral	1	R -> S (in dbSNP:rs17773251)	VARIANT	0
Q8N752/R21Q	CSNK1A1L	-	1	R -> Q (in a colorectal cancer sample; somatic mutation; dbSNP:rs373362769)	VARIANT	0
Q8N752/R21W	CSNK1A1L	neutral	1	R -> W (in dbSNP:rs56158728)	VARIANT	2
Q8N752/S5G	CSNK1A1L	-	1	S -> G (in dbSNP:rs56224973)	VARIANT	0
Q8NB16/C86S	MLKL	-	1	C->S: Abolishes binding to necrosulfonamide inhibitor.	MUTAGEN	0
Q8NB16/D100E	MLKL	neutral	1	D -> E (in dbSNP:rs33987771)	VARIANT	0
Q8NB16/E351K	MLKL	increase	1	E->K: Binds ATP with an enhanced affinity.	MUTAGEN	0
Q8NB16/F398I	MLKL	-	1	F -> I (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	2
Q8NB16/I76G	MLKL	-	1	I->G: Does not affect formation of homotrimers, while translocation to the plasma membrane on necroptosis induction is impaired; when associated with G-58.	MUTAGEN	0
Q8NB16/K230M	MLKL	loss	1	K->M: Abolishes ATP-binding.	MUTAGEN	0
Q8NB16/K331N	MLKL	loss	1	K->N: Impairs ATP-binding.	MUTAGEN	0
Q8NB16/L162G	MLKL	-	1	L->G: Impairs formation of homotrimers and translocation to the plasma membrane on necroptosis induction; when associated with G-165.	MUTAGEN	0
Q8NB16/L165G	MLKL	-	1	L->G: Impairs formation of homotrimers and translocation to the plasma membrane on necroptosis induction; when associated with G-162.	MUTAGEN	0
Q8NB16/L291P	MLKL	-	1	L -> P (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1313508921)	VARIANT	1
Q8NB16/L58G	MLKL	-	1	L->G: Does not affect formation of homotrimers, while translocation to the plasma membrane on necroptosis induction is impaired; when associated with G-76.	MUTAGEN	0
Q8NB16/M169L	MLKL	neutral	1	M -> L (in dbSNP:rs55929310)	VARIANT	0
Q8NB16/R146Q	MLKL	neutral	1	R -> Q (in dbSNP:rs34515646)	VARIANT	0
Q8NB16/R421H	MLKL	-	1	R -> H (in dbSNP:rs55987292)	VARIANT	0
Q8NB16/S132P	MLKL	neutral	1	S -> P (in dbSNP:rs35589326)	VARIANT	0
Q8NB16/S358A	MLKL	-	1	S->A: No effect. Abolishes ability to mediate necroptosis; when associated with A-357.	MUTAGEN	0
Q8NB16/S52T	MLKL	neutral	1	S -> T (in dbSNP:rs34251827)	VARIANT	0
Q8NB16/T357A	MLKL	-	1	T->A: No effect. Abolishes ability to mediate necroptosis; when associated with A-358.	MUTAGEN	0
Q8NB16/T364M	MLKL	-	1	T -> M (in dbSNP:rs34389205)	VARIANT	0
Q8NCB2/E279D	CAMKV	-	1	E -> D (in dbSNP:rs56071455)	VARIANT	0
Q8NCB2/G60S	CAMKV	-	1	G -> S (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	2
Q8NCB2/P472L	CAMKV	-	1	P -> L (in dbSNP:rs56307047)	VARIANT	0
Q8NCB2/R274W	CAMKV	-	1	R -> W (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q8NCB2/R40W	CAMKV	-	1	R -> W (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs1407808379)	VARIANT	0
Q8NCB2/Y491C	CAMKV	-	1	Y -> C (in dbSNP:rs17849325)	VARIANT	0
Q8NE28/E473K	STKLD1	-	0	E -> K (in dbSNP:rs3124747)	VARIANT	0
Q8NE28/G139D	STKLD1	-	1	G -> D (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
Q8NE28/R568Q	STKLD1	-	0	R -> Q (in dbSNP:rs17150554)	VARIANT	0
Q8NE63/A106T	HIPK4	-	1	A -> T (in dbSNP:rs34434715)	VARIANT	1
Q8NE63/A386T	HIPK4	neutral	1	A -> T (in dbSNP:rs56365273)	VARIANT	0
Q8NE63/G421S	HIPK4	neutral	1	G -> S (in dbSNP:rs56117722)	VARIANT	0
Q8NE63/R302Q	HIPK4	neutral	0	R -> Q (in dbSNP:rs11670988)	VARIANT	4
Q8NE63/R481C	HIPK4	-	1	R -> C (in dbSNP:rs55801979)	VARIANT	0
Q8NE63/S406R	HIPK4	neutral	1	S -> R (in dbSNP:rs56094851)	VARIANT	0
Q8NE63/T381M	HIPK4	neutral	1	T -> M (in dbSNP:rs55760165)	VARIANT	0
Q8NE63/V171M	HIPK4	-	1	V -> M (in dbSNP:rs55964225)	VARIANT	0
Q8NER5/G216R	ACVR1C	-	1	G -> R (in dbSNP:rs34742924)	VARIANT	0
Q8NER5/I195T	ACVR1C	-	1	I -> T (in dbSNP:rs56188432)	VARIANT	1
Q8NER5/I355V	ACVR1C	-	1	I -> V (in dbSNP:rs35500979)	VARIANT	0
Q8NER5/I482V	ACVR1C	neutral	1	I -> V (in dbSNP:rs7594480)	VARIANT	5
Q8NER5/K222R	ACVR1C	loss	2	K->R: Loss of response to NODAL and SMAD2 phosphorylation.	MUTAGEN	0
Q8NER5/T194D	ACVR1C	-	1	T->D: Pro-apoptotic.	MUTAGEN	0
Q8NER5/W267R	ACVR1C	-	1	W -> R (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
Q8NEV4/A1032T	MYO3A	neutral	1	A -> T (in dbSNP:rs34918608)	VARIANT	0
Q8NEV4/A833S	MYO3A	neutral	1	A -> S (in dbSNP:rs33947968)	VARIANT	0
Q8NEV4/D1347H	MYO3A	-	1	D -> H (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	0
Q8NEV4/D204N	MYO3A	-	0	D -> N (in dbSNP:rs3737274)	VARIANT	0
Q8NEV4/I348V	MYO3A	neutral	1	I -> V (in dbSNP:rs3824699)	VARIANT	0
Q8NEV4/K1488E	MYO3A	neutral	1	K -> E (in dbSNP:rs34204285)	VARIANT	0
Q8NEV4/N525K	MYO3A	-	1	N -> K (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs1423134583)	VARIANT	0
Q8NEV4/P1287T	MYO3A	neutral	1	P -> T (in dbSNP:rs35575696)	VARIANT	0
Q8NEV4/R1313S	MYO3A	neutral	3	R -> S (in dbSNP:rs1999240)	VARIANT	0
Q8NEV4/R319H	MYO3A	-	1	R -> H (in dbSNP:rs3824700)	VARIANT	0
Q8NEV4/S956N	MYO3A	neutral	1	S -> N (in dbSNP:rs3758449)	VARIANT	0
Q8NEV4/S956R	MYO3A	-	1	S -> R (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
Q8NEV4/T1284S	MYO3A	neutral	1	T -> S (in dbSNP:rs3740231)	VARIANT	0
Q8NEV4/T1417I	MYO3A	neutral	1	T -> I (in dbSNP:rs34151474)	VARIANT	0
Q8NEV4/T178I	MYO3A	neutral	1	T -> I (in dbSNP:rs33968748)	VARIANT	0
Q8NEV4/V1045M	MYO3A	neutral	1	V -> M (in dbSNP:rs35447806)	VARIANT	0
Q8NEV4/V1137M	MYO3A	-	1	V -> M (in dbSNP:rs35449183)	VARIANT	0
Q8NEV4/V1195A	MYO3A	-	1	V -> A (in dbSNP:rs35675577)	VARIANT	0
Q8NEV4/V369I	MYO3A	neutral	1	V -> I (in dbSNP:rs3817420)	VARIANT	0
Q8NFD2/A239T	ANKK1	neutral	1	A -> T (in dbSNP:rs7118900)	VARIANT	2
Q8NFD2/D4Y	ANKK1	-	1	D -> Y (in dbSNP:rs35657708)	VARIANT	0
Q8NFD2/E376K	ANKK1	-	1	E -> K (in dbSNP:rs56299709)	VARIANT	0
Q8NFD2/E426K	ANKK1	-	1	E -> K (in dbSNP:rs55699907)	VARIANT	0
Q8NFD2/E713K	ANKK1	neutral	2	E -> K (in dbSNP:rs1800497)	VARIANT	1
Q8NFD2/G318R	ANKK1	-	1	G -> R (in dbSNP:rs11604671)	VARIANT	0
Q8NFD2/G442R	ANKK1	neutral	1	G -> R (in dbSNP:rs4938016)	VARIANT	1
Q8NFD2/G451R	ANKK1	-	1	G -> R (in dbSNP:rs34983219)	VARIANT	0
Q8NFD2/H367Q	ANKK1	neutral	1	H -> Q (in dbSNP:rs34298987)	VARIANT	0
Q8NFD2/H490R	ANKK1	neutral	1	H -> R (in dbSNP:rs2734849)	VARIANT	0
Q8NFD2/K347T	ANKK1	-	1	K -> T (in a breast infiltrating ductal carcinoma sample; somatic mutation)	VARIANT	1
Q8NFD2/L366F	ANKK1	-	1	L -> F (in dbSNP:rs56339158)	VARIANT	0
Q8NFD2/N653S	ANKK1	-	1	N -> S (in dbSNP:rs55849504)	VARIANT	0
Q8NFD2/P276L	ANKK1	neutral	1	P -> L (in dbSNP:rs35488601)	VARIANT	0
Q8NFD2/P596L	ANKK1	-	1	P -> L (in dbSNP:rs7104979)	VARIANT	0
Q8NFD2/Q717L	ANKK1	-	1	Q -> L (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q8NFD2/R122H	ANKK1	-	1	R -> H (in dbSNP:rs35877321)	VARIANT	0
Q8NFD2/R736L	ANKK1	-	1	R -> L (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
Q8NFD2/S670G	ANKK1	neutral	1	S -> G (in dbSNP:rs56006094)	VARIANT	0
Q8NFD2/T595I	ANKK1	-	1	T -> I (in dbSNP:rs55787008)	VARIANT	0
Q8NG66/D617N	NEK11	-	1	D -> N (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs765563230)	VARIANT	0
Q8NG66/E451K	NEK11	neutral	1	E -> K (in dbSNP:rs35409692)	VARIANT	0
Q8NG66/E488V	NEK11	neutral	4	E -> V (in dbSNP:rs3738000)	VARIANT	2
Q8NG66/E492K	NEK11	-	1	E -> K (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs140599545)	VARIANT	0
Q8NG66/E606K	NEK11	-	1	E -> K (in dbSNP:rs55944737)	VARIANT	0
Q8NG66/I263V	NEK11	-	1	I -> V (in dbSNP:rs35567155)	VARIANT	0
Q8NG66/K61R	NEK11	loss	1	K->R: Loss of kinase activity.	MUTAGEN	0
Q8NG66/M548T	NEK11	-	1	M -> T (in dbSNP:rs55813244)	VARIANT	0
Q8NG66/S213L	NEK11	-	1	S -> L (in dbSNP:rs55920129)	VARIANT	1
Q8NG66/T108M	NEK11	-	1	T -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs200709914)	VARIANT	0
Q8NG66/V562A	NEK11	neutral	1	V -> A (in dbSNP:rs16836266)	VARIANT	1
Q8NG66/Y123C	NEK11	neutral	1	Y -> C (in dbSNP:rs55806123)	VARIANT	0
Q8NI60/A215G	COQ8A	-	1	A->I,L,G: Does not impair homodimerization.	MUTAGEN	0
Q8NI60/A215I	COQ8A	-	1	A->I,L,G: Does not impair homodimerization.	MUTAGEN	0
Q8NI60/A215L	COQ8A	-	1	A->I,L,G: Does not impair homodimerization.	MUTAGEN	0
Q8NI60/A221L	COQ8A	-	1	A->L: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/A228F	COQ8A	-	1	A->I,L,F: Does not impair homodimerization.	MUTAGEN	0
Q8NI60/A228I	COQ8A	-	1	A->I,L,F: Does not impair homodimerization.	MUTAGEN	0
Q8NI60/A228L	COQ8A	-	1	A->I,L,F: Does not impair homodimerization.	MUTAGEN	0
Q8NI60/A230I	COQ8A	-	1	A->I: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/A304T	COQ8A	-	1	A -> T (in COQ10D4; dbSNP:rs778798354)	VARIANT	0
Q8NI60/A304V	COQ8A	-	1	A -> V (in COQ10D4; dbSNP:rs748118737)	VARIANT	0
Q8NI60/A339G	COQ8A	-	1	A->G: Enables autophosphorylation but inhibits coenzyme Q biosynthesis in vivo.	MUTAGEN	0
Q8NI60/D488N	COQ8A	-	1	D->N: Impaired binding ADP or ATP.	MUTAGEN	0
Q8NI60/D507N	COQ8A	-	2	D->N: Strongly impairs binding ADP or ATP. Impaired multi-subunit COQ enzyme complex.	MUTAGEN	0
Q8NI60/E405A	COQ8A	-	1	E->A,Q: Slightly affects selectivity for binding ADP or ATP.	MUTAGEN	0
Q8NI60/E405Q	COQ8A	-	1	E->A,Q: Slightly affects selectivity for binding ADP or ATP.	MUTAGEN	0
Q8NI60/E411Q	COQ8A	-	1	E->Q: Impaired binding ADP or ATP.	MUTAGEN	0
Q8NI60/E551K	COQ8A	-	3	E -> K (in COQ10D4; decreased stability; dbSNP:rs119468004)	VARIANT	0
Q8NI60/F217A	COQ8A	-	1	F->A: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/F226A	COQ8A	-	1	F->A: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/F578V	COQ8A	-	1	F -> V (in COQ10D4; unknown pathological significance)	VARIANT	0
Q8NI60/G218F	COQ8A	-	1	G->I,L,F: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/G218I	COQ8A	-	1	G->I,L,F: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/G218L	COQ8A	-	1	G->I,L,F: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/G219A	COQ8A	-	1	G->A,F: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/G219F	COQ8A	-	1	G->A,F: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/G219I	COQ8A	-	1	G->I: Strongly impairs homodimerization.	MUTAGEN	0
Q8NI60/G223A	COQ8A	-	1	G->A,I,L,F: Strongly impairs homodimerization.	MUTAGEN	0
Q8NI60/G223F	COQ8A	-	1	G->A,I,L,F: Strongly impairs homodimerization.	MUTAGEN	0
Q8NI60/G223I	COQ8A	-	1	G->A,I,L,F: Strongly impairs homodimerization.	MUTAGEN	0
Q8NI60/G223L	COQ8A	-	1	G->A,I,L,F: Strongly impairs homodimerization.	MUTAGEN	0
Q8NI60/G225L	COQ8A	-	1	G->L: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/G227F	COQ8A	-	1	G->V,F,L,I: Strongly impairs homodimerization.	MUTAGEN	0
Q8NI60/G227I	COQ8A	-	1	G->V,F,L,I: Strongly impairs homodimerization.	MUTAGEN	0
Q8NI60/G227L	COQ8A	-	1	G->V,F,L,I: Strongly impairs homodimerization.	MUTAGEN	0
Q8NI60/G227V	COQ8A	-	1	G->V,F,L,I: Strongly impairs homodimerization.	MUTAGEN	0
Q8NI60/G272D	COQ8A	-	2	G -> D (in COQ10D4; dbSNP:rs119468006)	VARIANT	0
Q8NI60/G272V	COQ8A	-	2	G -> V (in COQ10D4; dbSNP:rs119468006)	VARIANT	0
Q8NI60/G549S	COQ8A	-	3	G -> S (in COQ10D4; decreased stability; dbSNP:rs119468009)	VARIANT	0
Q8NI60/H85Q	COQ8A	-	0	H -> Q (in dbSNP:rs2297411)	VARIANT	0
Q8NI60/I341T	COQ8A	-	1	I -> T (in dbSNP:rs55798516)	VARIANT	0
Q8NI60/K276H	COQ8A	-	2	K->R,H: Does not affect selectivity for binding ADP or ATP. Impaired multi-subunit COQ enzyme complex.	MUTAGEN	0
Q8NI60/K276R	COQ8A	-	2	K->R,H: Does not affect selectivity for binding ADP or ATP. Impaired multi-subunit COQ enzyme complex.	MUTAGEN	0
Q8NI60/K358R	COQ8A	-	1	K->R: Abolishes binding ADP or ATP.	MUTAGEN	0
Q8NI60/L214A	COQ8A	-	1	L->A,I,L,F: Strongly impairs homodimerization.	MUTAGEN	0
Q8NI60/L214F	COQ8A	-	1	L->I,F,G,V: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/L214G	COQ8A	-	1	L->I,F,G,V: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/L214I	COQ8A	-	1	L->I,F,G,V: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/L214V	COQ8A	-	1	L->I,F,G,V: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/L220G	COQ8A	-	1	L->G: Impaired homodimerization.	MUTAGEN	0
Q8NI60/L224V	COQ8A	-	1	L->V: Impaired homodimerization.	MUTAGEN	0
Q8NI60/L229A	COQ8A	-	1	L->A: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/N216A	COQ8A	-	1	N->A,L,F,M: Does not impair homodimerization.	MUTAGEN	0
Q8NI60/N216F	COQ8A	-	1	N->A,L,F,M: Does not impair homodimerization.	MUTAGEN	0
Q8NI60/N216L	COQ8A	-	1	N->A,L,F,M: Does not impair homodimerization.	MUTAGEN	0
Q8NI60/N216M	COQ8A	-	1	N->A,L,F,M: Does not impair homodimerization.	MUTAGEN	0
Q8NI60/N493A	COQ8A	-	1	N->A: Impaired binding ADP or ATP.	MUTAGEN	0
Q8NI60/P602R	COQ8A	-	1	P -> R (in COQ10D4; dbSNP:rs61995958)	VARIANT	0
Q8NI60/Q279H	COQ8A	-	1	Q->R,H: Does not affect selectivity for binding ADP or ATP.	MUTAGEN	0
Q8NI60/Q279R	COQ8A	-	1	Q->R,H: Does not affect selectivity for binding ADP or ATP.	MUTAGEN	0
Q8NI60/R213W	COQ8A	-	2	R -> W (in COQ10D4; dbSNP:rs119468005)	VARIANT	0
Q8NI60/R271C	COQ8A	-	1	R -> C (in COQ10D4; dbSNP:rs145034527)	VARIANT	0
Q8NI60/R299W	COQ8A	-	3	R -> W (in COQ10D4; decreased stability; dbSNP:rs201908721)	VARIANT	0
Q8NI60/R611A	COQ8A	-	1	R->A,Q: Does not affect selectivity for binding ADP or ATP.	MUTAGEN	0
Q8NI60/R611Q	COQ8A	-	1	R->A,Q: Does not affect selectivity for binding ADP or ATP.	MUTAGEN	0
Q8NI60/V222A	COQ8A	-	1	V->A: Slightly impaired homodimerization.	MUTAGEN	0
Q8NI60/Y429C	COQ8A	-	2	Y -> C (in COQ10D4; decreased stability; dbSNP:rs144147839)	VARIANT	0
Q8NI60/Y514C	COQ8A	-	1	Y -> C (in COQ10D4; dbSNP:rs119468008)	VARIANT	0
Q8TAS1/K54A	UHMK1	loss	1	K->A: Loss of kinase activity.	MUTAGEN	0
Q8TAS1/L159V	UHMK1	-	1	L -> V (in dbSNP:rs34466082)	VARIANT	0
Q8TAS1/Y197D	UHMK1	-	1	Y -> D (in dbSNP:rs56201055)	VARIANT	0
Q8TD08/D155A	MAPK15	loss	3	D->A: Unable to induce the formation of autophagosomal structures. Is able to bind to MAP1LC3B and to colocalize with this protein to autophagosomal structures. Does not induce phosphorylation by methyl methanesulfonate. Loas of phosphorylation. Dominant negative mutant. Not phosphorylated at Thr-175 and Tyr-177.	MUTAGEN	0
Q8TD08/K42A	MAPK15	-	1	K->A: Not phosphorylated at Thr-175 and Tyr-177.	MUTAGEN	0
Q8TD08/K42R	MAPK15	loss	3	K->R: Loss of autophosphorylation and activity. Does not increase dopamine transporter activity. Impairs kinase activity. Does not rescue cilium assembly in MAPK15-depleted cells.	MUTAGEN	0
Q8TD08/P390A	MAPK15	-	1	P->A: Impairs chromatin binding; when associated with A-398. Increases kinase activity; when associated with A-398.	MUTAGEN	0
Q8TD08/P398A	MAPK15	-	1	P->A: Impairs chromatin binding; when associated with A-390. Increases kinase activity; when associated with A-390.	MUTAGEN	0
Q8TD08/Q300A	MAPK15	-	1	Q->A: Impairs interaction with PCNA. Associates with chromatin.	MUTAGEN	0
Q8TD08/R59Q	MAPK15	loss	1	R->Q: Does not increase dopamine transporter activity. Impairs kinase activity.	MUTAGEN	0
Q8TD08/S505P	MAPK15	neutral	0	S -> P (in dbSNP:rs56038219)	VARIANT	0
Q8TD08/T175A	MAPK15	loss	3	T->A: Loss of autophosphorylation and activity. Still heavily phosphorylated at Tyr-177. Does not rescues inhibition of O-glycosylation in MAPK15-depleted cells; when associated with F-177.	MUTAGEN	0
Q8TD08/T221K	MAPK15	neutral	0	T -> K (in dbSNP:rs60732298)	VARIANT	3
Q8TD08/Y177A	MAPK15	loss	2	Y->A: Loss of autophosphorylation and activity. Heavily phosphorylated at Thr-175.	MUTAGEN	0
Q8TD08/Y177F	MAPK15	-	1	Y->F: Does not rescue inhibition of O-glycosylation in MAPK15-depleted cells; when associated with A-175.	MUTAGEN	0
Q8TD19/I167T	NEK9	increase	1	I -> T (in NC; increased autophosphorylation at T-210; dbSNP:rs879253775)	VARIANT	1
Q8TD19/I573T	NEK9	increase	1	I -> T (in NC; increased autophosphorylation at T-210; dbSNP:rs1555352529)	VARIANT	0
Q8TD19/K81M	NEK9	loss	1	K->M: Loss of activity and autophosphorylation.	MUTAGEN	0
Q8TD19/P828T	NEK9	neutral	1	P -> T (in dbSNP:rs36014869)	VARIANT	2
Q8TD19/P870S	NEK9	-	1	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
Q8TD19/R429H	NEK9	neutral	3	R -> H (in dbSNP:rs10146482)	VARIANT	0
Q8TD19/R681H	NEK9	-	1	R -> H (in APUG; dbSNP:rs142859694)	VARIANT	0
Q8TD19/T210A	NEK9	decrease	1	T->A: Significant reduction of autophosphorylation.	MUTAGEN	0
Q8TD19/T214A	NEK9	-	1	T->A: No effect on autophosphorylation.	MUTAGEN	0
Q8TDC3/G327A	BRSK1	loss	1	G->A: Abolishes activation of kinase activity.	MUTAGEN	1
Q8TDC3/G391E	BRSK1	-	1	G -> E (in a metastatic melanoma sample; somatic mutation)	VARIANT	2
Q8TDC3/G749S	BRSK1	-	1	G -> S (in dbSNP:rs12978445)	VARIANT	1
Q8TDC3/K59A	BRSK1	loss	1	K->A: Loss of kinase activity.	MUTAGEN	0
Q8TDC3/P764A	BRSK1	neutral	1	P -> A (in dbSNP:rs55796422)	VARIANT	0
Q8TDC3/R303W	BRSK1	-	1	R -> W (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs144130246)	VARIANT	3
Q8TDC3/T189A	BRSK1	loss	1	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
Q8TDC3/T531N	BRSK1	-	1	T -> N (in dbSNP:rs55892637)	VARIANT	0
Q8TDC3/V319I	BRSK1	-	1	V -> I (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q8TDR2/K231M	STK35	loss	1	K->M: No autophosphorylation.	MUTAGEN	0
Q8TDX7/D261A	NEK7	-	1	D->A: Does not affect interaction with NEK9.	MUTAGEN	0
Q8TDX7/D290R	NEK7	-	1	D->R: Does not affect interaction with NLRP3.	MUTAGEN	0
Q8TDX7/E280R	NEK7	-	1	E->V,R: Does not affect interaction with NLRP3.	MUTAGEN	0
Q8TDX7/E280V	NEK7	-	1	E->V,R: Does not affect interaction with NLRP3.	MUTAGEN	0
Q8TDX7/H125A	NEK7	-	1	H->A: Does not affect interaction with NEK9.	MUTAGEN	0
Q8TDX7/H262A	NEK7	-	1	H->A: Does not affect interaction with NEK9.	MUTAGEN	0
Q8TDX7/I169F	NEK7	-	1	I->F: Does not affect interaction with NEK9.	MUTAGEN	0
Q8TDX7/I275M	NEK7	-	1	I -> M (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
Q8TDX7/K128E	NEK7	-	1	K->E: Does not affect interaction with NLRP3.	MUTAGEN	0
Q8TDX7/K130A	NEK7	-	1	K->A,E: Does not affect interaction with NEK9.	MUTAGEN	0
Q8TDX7/K130E	NEK7	-	1	K->A,E: Does not affect interaction with NEK9.	MUTAGEN	0
Q8TDX7/K96E	NEK7	increase	1	K->E: Strongly increased protein kinase activity.	MUTAGEN	0
Q8TDX7/L132D	NEK7	loss	1	L->D: Abolished interaction with NEK9 and subsequent activation of NEK7 kinase activity.	MUTAGEN	0
Q8TDX7/L132W	NEK7	-	1	L->W: Does not affect interaction with NEK9.	MUTAGEN	0
Q8TDX7/L31A	NEK7	decrease	1	L->A: Significant decrease in catalytic activity; when associated with A-28.	MUTAGEN	0
Q8TDX7/M122A	NEK7	decrease	1	M->A,R: Decreased interaction with NEK9 and subsequent activation of NEK7 kinase activity.	MUTAGEN	0
Q8TDX7/M122R	NEK7	decrease	1	M->A,R: Decreased interaction with NEK9 and subsequent activation of NEK7 kinase activity.	MUTAGEN	0
Q8TDX7/N33D	NEK7	decrease	1	N->D: Significant decrease in catalytic activity.	MUTAGEN	0
Q8TDX7/N90A	NEK7	decrease	1	N->A: Reduced protein kinase activity.	MUTAGEN	0
Q8TDX7/N90K	NEK7	decrease	1	N->R,K: Strongly reduced protein kinase activity.	MUTAGEN	0
Q8TDX7/N90R	NEK7	decrease	1	N->R,K: Strongly reduced protein kinase activity.	MUTAGEN	0
Q8TDX7/Q129R	NEK7	-	1	Q->R: Decreased interaction with NLRP3.	MUTAGEN	0
Q8TDX7/R131A	NEK7	loss	1	R->A,D: Abolished interaction with NEK9 and subsequent activation of NEK7 kinase activity.	MUTAGEN	0
Q8TDX7/R131D	NEK7	loss	1	R->A,D: Abolished interaction with NEK9 and subsequent activation of NEK7 kinase activity.	MUTAGEN	0
Q8TDX7/R131E	NEK7	-	1	R->E: Decreased interaction with NLRP3.	MUTAGEN	0
Q8TDX7/R136E	NEK7	-	1	R->E: Decreased interaction with NLRP3.	MUTAGEN	0
Q8TDX7/R155E	NEK7	decrease	1	R->E: Strongly reduced protein kinase activity.	MUTAGEN	0
Q8TDX7/R294E	NEK7	-	1	R->E: Does not affect interaction with NLRP3.	MUTAGEN	0
Q8TDX7/R35G	NEK7	neutral	1	R -> G (in dbSNP:rs55833332)	VARIANT	0
Q8TDX7/S195A	NEK7	loss	1	S->A: Abolished phosphorylation with NEK9 and protein kinase activity.	MUTAGEN	0
Q8TDX7/T172A	NEK7	-	1	T->A: Does not affect interaction with NEK9.	MUTAGEN	0
Q8TDX7/Y28A	NEK7	decrease	1	Y->A: Significant decrease in catalytic activity; when associated with A-31.	MUTAGEN	0
Q8TDX7/Y97A	NEK7	increase	2	Y->A: 5-fold increase in catalytic activity.	MUTAGEN	0
Q8TDX7/Y97F	NEK7	increase	1	Y->F,L: Moderate increase in catalytic activity.	MUTAGEN	0
Q8TDX7/Y97L	NEK7	increase	1	Y->F,L: Moderate increase in catalytic activity.	MUTAGEN	0
Q8TEA7/D265N	TBCK	-	1	D -> N (in dbSNP:rs34770077)	VARIANT	0
Q8TEA7/I151M	TBCK	-	1	I -> M (in dbSNP:rs35835241)	VARIANT	0
Q8TEA7/I806V	TBCK	-	1	I -> V (in a head & Neck squamous cell carcinoma sample; somatic mutation)	VARIANT	0
Q8TEA7/K489N	TBCK	-	1	K -> N (in dbSNP:rs2305685)	VARIANT	0
Q8TEA7/L551P	TBCK	-	1	L -> P (in IHPRF3)	VARIANT	0
Q8TEA7/M471I	TBCK	neutral	1	M -> I (in dbSNP:rs34961213)	VARIANT	2
Q8TEA7/Q266E	TBCK	neutral	3	Q -> E (in dbSNP:rs3775091)	VARIANT	0
Q8TEA7/R503I	TBCK	-	1	R -> I (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q8TEA7/R511H	TBCK	-	1	R -> H (in IHPRF3; dbSNP:rs869320711)	VARIANT	0
Q8TEA7/R66L	TBCK	-	1	R -> L (in dbSNP:rs35784409)	VARIANT	0
Q8TEA7/R692C	TBCK	-	1	R -> C (in dbSNP:rs35790205)	VARIANT	0
Q8TEA7/T425M	TBCK	neutral	1	T -> M (in dbSNP:rs34307452)	VARIANT	0
Q8TF76/D707L	HASPIN	decrease	1	D->L: Markedly reduced affinity for histone H3 and reduced histone H3 phosphorylation.	MUTAGEN	0
Q8TF76/D709N	HASPIN	decrease	1	D->N: Markedly reduced affinity for histone H3 and reduced histone H3 phosphorylation.	MUTAGEN	0
Q8TF76/D716L	HASPIN	decrease	1	D->L: Markedly reduced histone H3 phosphorylation.	MUTAGEN	0
Q8TF76/E492A	HASPIN	decrease	1	E->A: Markedly reduced affinity for histone H3 and reduced histone H3 phosphorylation.	MUTAGEN	0
Q8TF76/G204D	HASPIN	-	3	G -> D (in dbSNP:rs220462)	VARIANT	2
Q8TF76/G283S	HASPIN	-	1	G -> S (in dbSNP:rs56224301)	VARIANT	0
Q8TF76/G713F	HASPIN	decrease	1	G->F: Markedly reduced affinity for histone H3 and reduced histone H3 phosphorylation.	MUTAGEN	0
Q8TF76/H651A	HASPIN	decrease	2	H->A: Strongly reduced enzyme activity, markedly reduced affinity for histone H3.	MUTAGEN	0
Q8TF76/I328T	HASPIN	-	3	I -> T (in dbSNP:rs220461)	VARIANT	1
Q8TF76/K511A	HASPIN	decrease	1	K->A: Strongly reduced enzyme activity.	MUTAGEN	0
Q8TF76/M706V	HASPIN	-	1	M -> V (in dbSNP:rs56134695)	VARIANT	0
Q8TF76/N422D	HASPIN	-	0	N -> D (in dbSNP:rs7223226)	VARIANT	0
Q8TF76/Q301L	HASPIN	-	1	Q -> L (in dbSNP:rs55649477)	VARIANT	0
Q8TF76/R145H	HASPIN	-	1	R -> H (in dbSNP:rs55991903)	VARIANT	0
Q8TF76/R82C	HASPIN	-	4	R -> C (in dbSNP:rs9907144)	VARIANT	7
Q8TF76/V378A	HASPIN	-	3	V -> A (in dbSNP:rs3809806)	VARIANT	2
Q8TF76/V76E	HASPIN	-	1	V -> E (in dbSNP:rs11653889)	VARIANT	1
Q8WTQ7/C113W	GRK7	-	1	C -> W (in dbSNP:rs56070798)	VARIANT	0
Q8WTQ7/E309Q	GRK7	neutral	1	E -> Q (in dbSNP:rs55824414)	VARIANT	0
Q8WTQ7/E443G	GRK7	-	1	E -> G (in dbSNP:rs36009541)	VARIANT	0
Q8WTQ7/P460T	GRK7	-	1	P -> T (in dbSNP:rs33928105)	VARIANT	0
Q8WTQ7/R226W	GRK7	-	1	R -> W (in dbSNP:rs35566288)	VARIANT	1
Q8WTQ7/R461C	GRK7	-	0	R -> C (in dbSNP:rs36004830)	VARIANT	1
Q8WTQ7/R81H	GRK7	-	1	R -> H (in dbSNP:rs34429284)	VARIANT	1
Q8WTQ7/S115C	GRK7	neutral	1	S -> C (in dbSNP:rs34769632)	VARIANT	1
Q8WTQ7/S127T	GRK7	-	1	S -> T (in dbSNP:rs35318124)	VARIANT	0
Q8WTQ7/S23A	GRK7	-	1	S->A: No effect on kinase activity. Increase kinase activity; when associated with A-36.	MUTAGEN	0
Q8WTQ7/S253F	GRK7	-	1	S -> F (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q8WTQ7/S36A	GRK7	-	1	S->A: No effect on kinase activity. Increase kinase activity; when associated with A-23.	MUTAGEN	0
Q8WTQ7/V196G	GRK7	-	1	V -> G (in dbSNP:rs55707760)	VARIANT	0
Q8WTQ7/V196M	GRK7	-	1	V -> M (in dbSNP:rs56019094)	VARIANT	0
Q8WTQ7/V313I	GRK7	-	1	V -> I (in dbSNP:rs56076641)	VARIANT	0
Q8WU08/K58M	STK32A	neutral	1	K -> M (in dbSNP:rs35852718)	VARIANT	0
Q8WU08/M316I	STK32A	-	1	M -> I (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
Q8WU08/S89F	STK32A	-	1	S -> F (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q8WXR4/A406T	MYO3B	neutral	1	A -> T (in dbSNP:rs10168181)	VARIANT	0
Q8WXR4/E352Q	MYO3B	-	1	E -> Q (in dbSNP:rs56179904)	VARIANT	0
Q8WXR4/E773G	MYO3B	neutral	2	E -> G (in dbSNP:rs33962844)	VARIANT	1
Q8WXR4/E798K	MYO3B	-	0	E -> K (in dbSNP:rs11892763)	VARIANT	0
Q8WXR4/H316L	MYO3B	-	1	H -> L (in dbSNP:rs55633190)	VARIANT	0
Q8WXR4/I1092V	MYO3B	-	1	I -> V (in dbSNP:rs34219776)	VARIANT	0
Q8WXR4/I275V	MYO3B	neutral	1	I -> V (in dbSNP:rs10209102)	VARIANT	0
Q8WXR4/K309E	MYO3B	neutral	2	K -> E (in dbSNP:rs4668246)	VARIANT	2
Q8WXR4/N267S	MYO3B	-	1	N -> S (in dbSNP:rs34509373)	VARIANT	0
Q8WXR4/N388S	MYO3B	-	1	N -> S (in dbSNP:rs34273653)	VARIANT	0
Q8WXR4/P21S	MYO3B	-	1	P -> S (in dbSNP:rs35391761)	VARIANT	0
Q8WXR4/Q638P	MYO3B	-	1	Q -> P (in dbSNP:rs55911627)	VARIANT	0
Q8WXR4/R1082K	MYO3B	neutral	2	R -> K (in dbSNP:rs10185178)	VARIANT	0
Q8WXR4/R1165C	MYO3B	neutral	1	R -> C (in dbSNP:rs56052422)	VARIANT	0
Q8WXR4/R185H	MYO3B	neutral	1	R -> H (in dbSNP:rs55911154)	VARIANT	1
Q8WXR4/R918Q	MYO3B	-	1	R -> Q (in dbSNP:rs55769829)	VARIANT	0
Q8WXR4/R990C	MYO3B	-	1	R -> C (in dbSNP:rs34236931)	VARIANT	0
Q8WXR4/S969C	MYO3B	-	1	S -> C (in dbSNP:rs35857918)	VARIANT	0
Q8WXR4/V1137I	MYO3B	neutral	1	V -> I (in dbSNP:rs34546065)	VARIANT	0
Q8WXR4/V770I	MYO3B	neutral	2	V -> I (in dbSNP:rs6736609)	VARIANT	1
Q8WZ42/A1081T	TTN	-	1	A -> T (in dbSNP:rs55914517)	VARIANT	0
Q8WZ42/A1347T	TTN	-	1	A -> T (in a metastatic melanoma sample; somatic mutation; dbSNP:rs267599092)	VARIANT	0
Q8WZ42/A743V	TTN	-	1	A -> V (in CMD1G; affects interaction with TCAP/telethonin; dbSNP:rs267607157)	VARIANT	0
Q8WZ42/D60Y	TTN	-	1	D -> Y (in dbSNP:rs35683768)	VARIANT	0
Q8WZ42/E937D	TTN	-	1	E -> D (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	0
Q8WZ42/G1137R	TTN	-	1	G -> R (in dbSNP:rs72647870)	VARIANT	0
Q8WZ42/G1345D	TTN	neutral	1	G -> D (in dbSNP:rs36021856)	VARIANT	0
Q8WZ42/I1393V	TTN	neutral	1	I -> V (in dbSNP:rs16866531)	VARIANT	0
Q8WZ42/K1201E	TTN	neutral	2	K -> E (in dbSNP:rs10497520)	VARIANT	0
Q8WZ42/R1350H	TTN	-	1	R -> H (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs539470256)	VARIANT	0
Q8WZ42/R279W	TTN	-	1	R -> W (in MFM9; disrupts NBR1-binding; dbSNP:rs138060032)	VARIANT	0
Q8WZ42/R328C	TTN	neutral	2	R -> C (in dbSNP:rs16866538)	VARIANT	0
Q8WZ42/R360T	TTN	neutral	1	R -> T (in dbSNP:rs56128843)	VARIANT	0
Q8WZ42/R740L	TTN	-	1	R -> L (in CMH9; dbSNP:rs28933405)	VARIANT	0
Q8WZ42/R922H	TTN	-	1	R -> H (in dbSNP:rs56046320)	VARIANT	0
Q8WZ42/S1249L	TTN	neutral	0	S -> L (in dbSNP:rs1552280)	VARIANT	0
Q8WZ42/S1295L	TTN	neutral	3	S -> L (in dbSNP:rs1552280)	VARIANT	0
Q8WZ42/T799M	TTN	-	1	T -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs149061352)	VARIANT	0
Q8WZ42/T811I	TTN	neutral	1	T -> I (in dbSNP:rs35813871)	VARIANT	0
Q8WZ42/V115M	TTN	-	1	V -> M (in a metastatic melanoma sample; somatic mutation; dbSNP:rs564777385)	VARIANT	0
Q8WZ42/V1202A	TTN	-	1	V -> A (in dbSNP:rs150667217)	VARIANT	0
Q8WZ42/V1353L	TTN	-	1	V -> L (in dbSNP:rs36062108)	VARIANT	0
Q8WZ42/V498I	TTN	neutral	2	V -> I (in dbSNP:rs72647851)	VARIANT	0
Q8WZ42/V54M	TTN	-	1	V -> M (in CMD1G; affects interaction with TCAP/telethonin; dbSNP:rs139517732)	VARIANT	0
Q8WZ42/W976R	TTN	-	1	W -> R (in CMD1G; dbSNP:rs267607155)	VARIANT	0
Q92519/H4R	TRIB2	neutral	1	H -> R (in dbSNP:rs55813198)	VARIANT	0
Q92630/F455Y	DYRK2	-	1	F -> Y (in dbSNP:rs55774594)	VARIANT	0
Q92630/H245N	DYRK2	neutral	1	H -> N (in dbSNP:rs34166200)	VARIANT	0
Q92630/K251R	DYRK2	loss	1	K->R: Abolishes protein serine/threonine kinase activity.	MUTAGEN	0
Q92630/N295S	DYRK2	-	1	N -> S (in dbSNP:rs56293072)	VARIANT	0
Q92630/P198L	DYRK2	-	1	P -> L (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs1384093596)	VARIANT	1
Q92630/R451Q	DYRK2	-	1	R -> Q (in dbSNP:rs35688869)	VARIANT	1
Q92630/S442A	DYRK2	-	1	S->A: Impaired ATM-mediated phosphorylation, reduced affinity with MDM2 and altered MDM2-triggered ubiquitination.	MUTAGEN	0
Q92630/S98G	DYRK2	-	1	S -> G (in dbSNP:rs35139851)	VARIANT	0
Q92630/T106A	DYRK2	-	1	T->A: Impaired ATM-mediated phosphorylation, reduced affinity with MDM2 and altered MDM2-triggered ubiquitination.	MUTAGEN	0
Q92772/A411V	CDKL2	-	1	A -> V (in dbSNP:rs56231363)	VARIANT	0
Q92772/I132T	CDKL2	-	0	I -> T (in dbSNP:rs17000707)	VARIANT	0
Q92772/L98I	CDKL2	-	1	L -> I (in an ovarian papillary serous adenocarcinoma sample; somatic mutation)	VARIANT	0
Q92772/M197T	CDKL2	-	1	M -> T (in dbSNP:rs56343717)	VARIANT	0
Q92772/R149Q	CDKL2	-	1	R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs755711267)	VARIANT	3
Q92772/Y77S	CDKL2	-	0	Y -> S (in dbSNP:rs35921414)	VARIANT	0
Q92918/N811S	MAP4K1	-	0	N -> S (in dbSNP:rs12975825)	VARIANT	0
Q92918/P312T	MAP4K1	-	1	P -> T (in dbSNP:rs55924696)	VARIANT	0
Q92918/P351S	MAP4K1	neutral	1	P -> S (in dbSNP:rs34591617)	VARIANT	0
Q92918/P361L	MAP4K1	-	1	P -> L (in dbSNP:rs56060067)	VARIANT	0
Q92918/S737F	MAP4K1	-	1	S -> F (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1238066548)	VARIANT	1
Q92918/T355A	MAP4K1	activating	1	T->A: Retains kinase activity. Not degraded by the Cul7-RING ubiquitin-protein ligase complex containing FBXW8.	MUTAGEN	0
Q96BR1/A92V	SGK3	-	1	A -> V (in a breast cancer sample; somatic mutation)	VARIANT	1
Q96BR1/K191M	SGK3	loss	1	K->M: Abolishes activity.	MUTAGEN	0
Q96BR1/L355P	SGK3	-	1	L -> P (in dbSNP:rs750700898)	VARIANT	0
Q96BR1/R90A	SGK3	-	1	R->A: Partially localized to the membrane.	MUTAGEN	0
Q96BR1/S486D	SGK3	increase	1	S->D: Increased activation.	MUTAGEN	0
Q96C45/A1261V	ULK4	neutral	0	A -> V (in dbSNP:rs6769117)	VARIANT	0
Q96C45/A542T	ULK4	neutral	0	A -> T (in dbSNP:rs1052501)	VARIANT	0
Q96C45/A715T	ULK4	neutral	0	A -> T (in dbSNP:rs17215589)	VARIANT	1
Q96C45/I224V	ULK4	neutral	0	I -> V (in dbSNP:rs1716975)	VARIANT	1
Q96C45/K39R	ULK4	neutral	1	K -> R (in dbSNP:rs2272007)	VARIANT	3
Q96C45/K569R	ULK4	neutral	0	K -> R (in dbSNP:rs3774372)	VARIANT	1
Q96C45/L603S	ULK4	neutral	0	L -> S (in dbSNP:rs17063572)	VARIANT	0
Q96C45/N139K	ULK4	neutral	1	N -> K (in dbSNP:rs35833603)	VARIANT	3
Q96C45/S1260N	ULK4	neutral	0	S -> N (in dbSNP:rs12488691)	VARIANT	0
Q96C45/S223N	ULK4	-	1	S -> N (in dbSNP:rs55840267)	VARIANT	0
Q96C45/S348G	ULK4	-	2	S -> G (in dbSNP:rs35263917)	VARIANT	0
Q96C45/S417P	ULK4	neutral	1	S -> P (in dbSNP:rs75907560)	VARIANT	2
Q96C45/S640A	ULK4	neutral	0	S -> A (in dbSNP:rs4973986)	VARIANT	2
Q96C45/T415M	ULK4	-	1	T -> M (in dbSNP:rs371185820)	VARIANT	0
Q96C45/V18A	ULK4	-	1	V -> A (in dbSNP:rs34538622)	VARIANT	0
Q96D53/A498E	COQ8B	-	1	A -> E (in NPHS9)	VARIANT	0
Q96D53/D286G	COQ8B	-	1	D -> G (in NPHS9; dbSNP:rs398122979)	VARIANT	0
Q96D53/H174R	COQ8B	-	1	H -> R (in dbSNP:rs3865452)	VARIANT	0
Q96D53/L98R	COQ8B	-	1	L -> R (in NPHS9)	VARIANT	0
Q96D53/P310L	COQ8B	-	1	P -> L (in NPHS9)	VARIANT	0
Q96D53/R178W	COQ8B	-	2	R -> W (in NPHS9; dbSNP:rs398122978)	VARIANT	0
Q96D53/R320W	COQ8B	-	1	R -> W (in NPHS9; dbSNP:rs369573693)	VARIANT	0
Q96D53/R343W	COQ8B	-	1	R -> W (in NPHS9; dbSNP:rs398122981)	VARIANT	0
Q96D53/R477Q	COQ8B	-	1	R -> Q (in NPHS9; dbSNP:rs1057519347)	VARIANT	0
Q96D53/R78C	COQ8B	-	1	R -> C (in dbSNP:rs11538384)	VARIANT	0
Q96D53/T318M	COQ8B	-	1	T -> M (in dbSNP:rs55899516)	VARIANT	0
Q96D53/T352R	COQ8B	-	1	T -> R (in dbSNP:rs36012476)	VARIANT	0
Q96D53/T462M	COQ8B	-	1	T -> M (in dbSNP:rs56083906)	VARIANT	0
Q96GD4/A52V	AURKB	neutral	1	A -> V (in dbSNP:rs55878091)	VARIANT	0
Q96GD4/H100Q	AURKB	-	0	H -> Q (in dbSNP:rs3027254)	VARIANT	0
Q96GD4/K106R	AURKB	loss	4	K->R: Leads to loss of kinase activity and severely impairs mitotic progression.	MUTAGEN	0
Q96GD4/K215Q	AURKB	activating	1	K->Q: Mimics acetylation, promoting accurate chromosome segregation.	MUTAGEN	0
Q96GD4/K215R	AURKB	loss	1	K->R: Abolished acetylation by KAT5, leading to impaired chromosome segregation.	MUTAGEN	0
Q96GD4/M298T	AURKB	neutral	6	M -> T (in dbSNP:rs1059476)	VARIANT	3
Q96GD4/T179M	AURKB	-	1	T -> M (in dbSNP:rs55871613)	VARIANT	0
Q96GX5/D606Y	MASTL	-	0	D -> Y (in dbSNP:rs35413630)	VARIANT	0
Q96GX5/E167D	MASTL	-	2	E -> D (found in a large family with autosomal dominant thrombocytopenia; unknown pathological significance; no effect on nuclear localization; dbSNP:rs28941470)	VARIANT	0
Q96GX5/K72M	MASTL	activating	1	K->M: Hyperactive form.	MUTAGEN	0
Q96GX5/P620A	MASTL	-	1	P -> A (in dbSNP:rs3802526)	VARIANT	4
Q96GX5/T337K	MASTL	neutral	1	T -> K (in dbSNP:rs36121140)	VARIANT	1
Q96GX5/V610I	MASTL	neutral	1	V -> I (in dbSNP:rs35571315)	VARIANT	2
Q96J92/A601S	WNK4	neutral	0	A -> S (in dbSNP:rs55781437)	VARIANT	0
Q96J92/D564A	WNK4	-	2	D -> A (in PHA2B; impaired interaction with KLHL3; dbSNP:rs137853094)	VARIANT	0
Q96J92/E434D	WNK4	-	1	E -> D (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
Q96J92/E562K	WNK4	-	3	E -> K (in PHA2B; impaired interaction with KLHL3; dbSNP:rs137853093)	VARIANT	0
Q96J92/L1013P	WNK4	-	1	L -> P	VARIANT	0
Q96J92/P813L	WNK4	-	1	P -> L	VARIANT	0
Q96J92/P961S	WNK4	neutral	0	P -> S (in dbSNP:rs2290041)	VARIANT	0
Q96J92/P992S	WNK4	-	1	P -> S (in a metastatic melanoma sample; somatic mutation)	VARIANT	0
Q96J92/Q565E	WNK4	-	3	Q -> E (in PHA2B; impaired interaction with KLHL3; dbSNP:rs137853092)	VARIANT	0
Q96J92/R1185C	WNK4	-	1	R -> C (in PHA2B; dbSNP:rs137853095)	VARIANT	1
Q96J92/R677W	WNK4	neutral	0	R -> W (in dbSNP:rs9896991)	VARIANT	0
Q96KB5/E220D	PBK	neutral	0	E -> D (in dbSNP:rs17057901)	VARIANT	0
Q96KB5/M241L	PBK	-	1	M -> L (in dbSNP:rs36086402)	VARIANT	0
Q96KB5/N107S	PBK	neutral	4	N -> S (in dbSNP:rs3779620)	VARIANT	0
Q96KB5/T320A	PBK	-	1	T->A: Decrease in the binding to DLG1.	MUTAGEN	0
Q96KB5/T9E	PBK	-	1	T->E: TP53-binding.	MUTAGEN	0
Q96KG9/H495Y	SCYL1	-	1	H -> Y (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q96KG9/P479L	SCYL1	-	1	P -> L (in dbSNP:rs55977709)	VARIANT	0
Q96KG9/Q663H	SCYL1	neutral	1	Q -> H (in dbSNP:rs56076708)	VARIANT	0
Q96KG9/W755S	SCYL1	-	1	W -> S (in dbSNP:rs56077405)	VARIANT	0
Q96L34/R377Q	MARK4	-	1	R -> Q (in dbSNP:rs35070611)	VARIANT	1
Q96L34/R418C	MARK4	-	1	R -> C (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs780763668)	VARIANT	0
Q96L34/T214A	MARK4	loss	1	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
Q96L34/T214E	MARK4	increase	2	T->E: Mimicks phosphorylation state, leading to increased activity. Decreases mTORC1 activity.	MUTAGEN	0
Q96L96/A1137G	ALPK3	-	0	A -> G (in dbSNP:rs34173528)	VARIANT	0
Q96L96/A1557D	ALPK3	neutral	1	A -> D (in dbSNP:rs34775428)	VARIANT	0
Q96L96/A1873V	ALPK3	neutral	0	A -> V (in dbSNP:rs36002219)	VARIANT	0
Q96L96/E1013K	ALPK3	neutral	0	E -> K (in dbSNP:rs35633849)	VARIANT	0
Q96L96/E929D	ALPK3	-	1	E -> D (in dbSNP:rs56191073)	VARIANT	0
Q96L96/G1364E	ALPK3	-	1	G -> E (in a metastatic melanoma sample; somatic mutation)	VARIANT	0
Q96L96/G579E	ALPK3	neutral	1	G -> E (in dbSNP:rs3803405)	VARIANT	0
Q96L96/G663D	ALPK3	neutral	1	G -> D (in dbSNP:rs34409363)	VARIANT	0
Q96L96/L1622P	ALPK3	neutral	1	L -> P (in dbSNP:rs187316)	VARIANT	0
Q96L96/P1299L	ALPK3	neutral	3	P -> L (in dbSNP:rs306197)	VARIANT	0
Q96L96/Q433E	ALPK3	-	1	Q -> E (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q96L96/Q602R	ALPK3	neutral	1	Q -> R (in dbSNP:rs55702300)	VARIANT	0
Q96L96/R1412W	ALPK3	neutral	1	R -> W (in dbSNP:rs55752937)	VARIANT	0
Q96L96/R336H	ALPK3	neutral	1	R -> H (in dbSNP:rs34407151)	VARIANT	0
Q96L96/R836L	ALPK3	-	1	R -> L (in dbSNP:rs34906636)	VARIANT	0
Q96L96/T338I	ALPK3	-	1	T -> I (in dbSNP:rs56015306)	VARIANT	0
Q96L96/T414S	ALPK3	neutral	1	T -> S (in dbSNP:rs3803403)	VARIANT	0
Q96L96/T761M	ALPK3	neutral	1	T -> M (in dbSNP:rs16974569)	VARIANT	0
Q96NX5/A443T	CAMK1G	-	1	A -> T (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1228276529)	VARIANT	1
Q96NX5/E259Q	CAMK1G	-	1	E -> Q (in dbSNP:rs35561962)	VARIANT	0
Q96NX5/V329I	CAMK1G	neutral	2	V -> I (in dbSNP:rs11119315)	VARIANT	6
Q96PF2/C245S	TSSK2	-	0	C -> S (in dbSNP:rs8140743)	VARIANT	0
Q96PF2/E244K	TSSK2	-	0	E -> K (in dbSNP:rs35048893)	VARIANT	0
Q96PF2/K27R	TSSK2	-	2	K -> R (may be associated with infertility; dbSNP:rs3747052)	VARIANT	0
Q96PF2/M61V	TSSK2	-	1	M -> V (in dbSNP:rs35532431)	VARIANT	0
Q96PF2/T280M	TSSK2	neutral	1	T -> M (in dbSNP:rs1052763)	VARIANT	0
Q96PF2/Y197C	TSSK2	neutral	1	Y -> C (in dbSNP:rs56279111)	VARIANT	0
Q96PN8/A140T	TSSK3	-	1	A -> T (in dbSNP:rs55786268)	VARIANT	0
Q96PN8/I71V	TSSK3	neutral	0	I -> V (in dbSNP:rs35508255)	VARIANT	0
Q96PN8/S235L	TSSK3	-	1	S -> L (in dbSNP:rs35457991)	VARIANT	0
Q96PY6/A294P	NEK1	-	1	A -> P (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q96PY6/A463V	NEK1	neutral	1	A -> V (in dbSNP:rs34540355)	VARIANT	0
Q96PY6/A598T	NEK1	neutral	1	A -> T (in dbSNP:rs33933790)	VARIANT	0
Q96PY6/D1180N	NEK1	-	1	D -> N (in dbSNP:rs35503975)	VARIANT	0
Q96PY6/E25K	NEK1	-	1	E -> K (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q96PY6/E724G	NEK1	neutral	2	E -> G (in dbSNP:rs34099167)	VARIANT	0
Q96PY6/G145R	NEK1	-	1	G -> R (in SRTD6; dbSNP:rs431905508)	VARIANT	0
Q96PY6/I10F	NEK1	-	1	I -> F (in dbSNP:rs34214559)	VARIANT	0
Q96PY6/K745N	NEK1	-	1	K -> N	VARIANT	0
Q96PY6/L253S	NEK1	-	1	L -> S (in SRTD6)	VARIANT	0
Q96PY6/L76V	NEK1	-	1	L -> V (in dbSNP:rs35093214)	VARIANT	0
Q96PY6/N717K	NEK1	neutral	0	N -> K (in dbSNP:rs34324114)	VARIANT	0
Q96PY6/Q883E	NEK1	neutral	1	Q -> E (in dbSNP:rs6828134)	VARIANT	0
Q96PY6/R261H	NEK1	-	1	R -> H (in ALS24; associated with disease susceptibility; dbSNP:rs200161705)	VARIANT	0
Q96PY6/R355G	NEK1	-	1	R -> G (in dbSNP:rs35763578)	VARIANT	0
Q96Q04/L929V	LMTK3	neutral	0	L -> V (in dbSNP:rs1643478)	VARIANT	0
Q96Q04/V900L	LMTK3	neutral	0	V -> L (in dbSNP:rs1643478)	VARIANT	0
Q96Q15/A167V	SMG1	-	1	A -> V (in dbSNP:rs1382468496)	VARIANT	0
Q96Q15/A35T	SMG1	neutral	1	A -> T (in dbSNP:rs12051350)	VARIANT	0
Q96Q15/A588S	SMG1	-	1	A -> S (in dbSNP:rs750840136)	VARIANT	0
Q96Q15/A952G	SMG1	-	1	A -> G (in dbSNP:rs555078480)	VARIANT	0
Q96Q15/D160N	SMG1	-	1	D -> N	VARIANT	0
Q96Q15/D320G	SMG1	-	1	D -> G	VARIANT	0
Q96Q15/F1016L	SMG1	-	1	F -> L (in dbSNP:rs1394431566)	VARIANT	0
Q96Q15/G465S	SMG1	-	1	G -> S (in dbSNP:rs200419100)	VARIANT	0
Q96Q15/H546R	SMG1	-	1	H -> R (in dbSNP:rs376234691)	VARIANT	0
Q96Q15/I1332V	SMG1	-	1	I -> V (in dbSNP:rs949474935)	VARIANT	0
Q96Q15/I612K	SMG1	-	2	I -> K (in dbSNP:rs17842615)	VARIANT	0
Q96Q15/N1103H	SMG1	-	1	N -> H (in dbSNP:rs563883658)	VARIANT	0
Q96Q15/N151Y	SMG1	-	1	N -> Y (in dbSNP:rs750788715)	VARIANT	0
Q96Q15/N832D	SMG1	-	1	N -> D (in dbSNP:rs80176913)	VARIANT	0
Q96Q15/N969S	SMG1	-	1	N -> S (in dbSNP:rs1412788971)	VARIANT	0
Q96Q15/P1275R	SMG1	-	1	P -> R	VARIANT	0
Q96Q15/Q1292P	SMG1	-	1	Q -> P (in dbSNP:rs375411122)	VARIANT	0
Q96Q15/R1029Q	SMG1	-	1	R -> Q	VARIANT	0
Q96Q15/R126C	SMG1	-	1	R -> C (in dbSNP:rs752796432)	VARIANT	0
Q96Q15/R812C	SMG1	-	1	R -> C (in dbSNP:rs1233400465)	VARIANT	0
Q96Q15/S1358P	SMG1	-	1	S -> P	VARIANT	0
Q96Q15/S144C	SMG1	-	2	S -> C (in dbSNP:rs766737607)	VARIANT	0
Q96Q15/S753C	SMG1	-	1	S -> C (in dbSNP:rs569679854)	VARIANT	0
Q96Q15/S809C	SMG1	-	1	S -> C (in dbSNP:rs919788709)	VARIANT	0
Q96Q15/T1072S	SMG1	-	1	T -> S (in dbSNP:rs45516593)	VARIANT	0
Q96Q15/V829I	SMG1	-	1	V -> I	VARIANT	0
Q96Q40/E276D	CDK15	-	1	E -> D (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1490814436)	VARIANT	1
Q96Q40/K93E	CDK15	-	1	K -> E (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	0
Q96Q40/Q127R	CDK15	-	1	Q -> R (in dbSNP:rs56135556)	VARIANT	0
Q96Q40/R64G	CDK15	-	1	R -> G (in dbSNP:rs34776344)	VARIANT	0
Q96Q40/T255I	CDK15	neutral	1	T -> I (in dbSNP:rs34851370)	VARIANT	0
Q96QP1/A1160G	ALPK1	-	1	A -> G (in dbSNP:rs55696324)	VARIANT	0
Q96QP1/D231A	ALPK1	-	1	D->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity; when associated with A-67.	MUTAGEN	0
Q96QP1/E910D	ALPK1	neutral	1	E -> D (in dbSNP:rs35308602)	VARIANT	0
Q96QP1/F295K	ALPK1	-	1	F->K: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity; when associated with E-237.	MUTAGEN	0
Q96QP1/G565D	ALPK1	neutral	4	G -> D (in dbSNP:rs2074388)	VARIANT	0
Q96QP1/G681D	ALPK1	neutral	2	G -> D (in dbSNP:rs35519493)	VARIANT	0
Q96QP1/G870S	ALPK1	-	1	G -> S (in dbSNP:rs2074380)	VARIANT	0
Q96QP1/H1008P	ALPK1	-	0	H -> P (in dbSNP:rs34079946)	VARIANT	0
Q96QP1/H642R	ALPK1	neutral	4	H -> R (in dbSNP:rs13148353)	VARIANT	0
Q96QP1/K1067M	ALPK1	loss	1	K->M: Abolishes the serine/threonine-protein kinase and ability to initiate the innate immune response.	MUTAGEN	0
Q96QP1/K233A	ALPK1	-	1	K->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity.	MUTAGEN	0
Q96QP1/K339E	ALPK1	-	1	K -> E (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
Q96QP1/K383E	ALPK1	neutral	1	K -> E (in dbSNP:rs147641444)	VARIANT	0
Q96QP1/L1117P	ALPK1	-	1	L -> P (in dbSNP:rs35756863)	VARIANT	0
Q96QP1/L320M	ALPK1	-	1	L -> M (in dbSNP:rs757602009)	VARIANT	0
Q96QP1/M732I	ALPK1	neutral	4	M -> I (in dbSNP:rs2074379)	VARIANT	0
Q96QP1/M861T	ALPK1	neutral	4	M -> T (in dbSNP:rs11726117)	VARIANT	0
Q96QP1/N175D	ALPK1	neutral	1	N -> D (in dbSNP:rs6533616)	VARIANT	0
Q96QP1/N916D	ALPK1	neutral	1	N -> D (in dbSNP:rs2074381)	VARIANT	0
Q96QP1/P660L	ALPK1	neutral	1	P -> L (in dbSNP:rs35389530)	VARIANT	0
Q96QP1/P935L	ALPK1	-	1	P -> L (in dbSNP:rs34780600)	VARIANT	0
Q96QP1/Q67A	ALPK1	-	1	Q->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity; when associated with A-231.	MUTAGEN	0
Q96QP1/Q67R	ALPK1	neutral	1	Q -> R (in dbSNP:rs33943680)	VARIANT	0
Q96QP1/R1084Q	ALPK1	neutral	1	R -> Q (in dbSNP:rs34677416)	VARIANT	0
Q96QP1/R116A	ALPK1	-	1	R->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity.	MUTAGEN	0
Q96QP1/R150A	ALPK1	-	1	R->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity.	MUTAGEN	0
Q96QP1/R153A	ALPK1	-	1	R->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity.	MUTAGEN	0
Q96QP1/R873I	ALPK1	neutral	1	R -> I (in dbSNP:rs34946272)	VARIANT	0
Q96QP1/T237E	ALPK1	-	1	T->E: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity; when associated with K-295.	MUTAGEN	0
Q96QP1/T237M	ALPK1	-	2	T -> M (in ROSAH)	VARIANT	0
Q96QP1/T292M	ALPK1	-	1	T -> M (in dbSNP:rs34120296)	VARIANT	0
Q96QS6/A176S	PSKH2	neutral	1	A -> S (in dbSNP:rs6998760)	VARIANT	4
Q96QS6/G211R	PSKH2	neutral	1	G -> R (in dbSNP:rs36074412)	VARIANT	0
Q96QS6/G72D	PSKH2	-	1	G -> D (in dbSNP:rs56407605)	VARIANT	0
Q96QS6/I336V	PSKH2	neutral	1	I -> V (in dbSNP:rs16876805)	VARIANT	0
Q96QS6/K212I	PSKH2	-	1	K -> I (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs778066815)	VARIANT	1
Q96QS6/Q132R	PSKH2	neutral	1	Q -> R (in dbSNP:rs16879427)	VARIANT	0
Q96QS6/R114Q	PSKH2	-	1	R -> Q (in dbSNP:rs35915498)	VARIANT	2
Q96QS6/R148Q	PSKH2	-	1	R -> Q (in dbSNP:rs56356246)	VARIANT	0
Q96QS6/R79K	PSKH2	neutral	1	R -> K (in dbSNP:rs35315725)	VARIANT	0
Q96QS6/S116I	PSKH2	-	1	S -> I (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q96QS6/S266R	PSKH2	neutral	1	S -> R (in dbSNP:rs34037815)	VARIANT	0
Q96QS6/T225A	PSKH2	neutral	1	T -> A (in dbSNP:rs34457516)	VARIANT	0
Q96QT4/A1033G	TRPM7	-	0	A -> G (in dbSNP:rs34530969)	VARIANT	0
Q96QT4/A1254V	TRPM7	-	1	A -> V (in dbSNP:rs56288221)	VARIANT	0
Q96QT4/D1306E	TRPM7	-	1	D -> E (in dbSNP:rs55970334)	VARIANT	0
Q96QT4/F949Y	TRPM7	-	1	F -> Y (in dbSNP:rs55681028)	VARIANT	0
Q96QT4/G1046D	TRPM7	-	1	G -> D (probable disease-associated variant found in a patient with hypomagnesemia and secondary hypocalcemia; de novo variant; causes severely reduced Mg(2+) uptake in transfected cells; dbSNP:rs2059709974)	VARIANT	0
Q96QT4/G1799D	TRPM7	loss	1	G->D: Loss of kinase activity.	MUTAGEN	0
Q96QT4/G68V	TRPM7	-	1	G -> V (in dbSNP:rs56064201)	VARIANT	0
Q96QT4/I1145V	TRPM7	-	0	I -> V (in dbSNP:rs34711809)	VARIANT	0
Q96QT4/I1211T	TRPM7	-	1	I -> T (in dbSNP:rs56090496)	VARIANT	0
Q96QT4/I459T	TRPM7	-	1	I -> T (in dbSNP:rs55924090)	VARIANT	0
Q96QT4/K1648R	TRPM7	loss	1	K->R: Loss of kinase activity.	MUTAGEN	0
Q96QT4/K574N	TRPM7	-	1	K -> N (in dbSNP:rs56040619)	VARIANT	0
Q96QT4/M830V	TRPM7	-	1	M -> V (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	0
Q96QT4/Q1064R	TRPM7	-	1	Q -> R (in dbSNP:rs56298128)	VARIANT	0
Q96QT4/R1444K	TRPM7	-	1	R -> K (in dbSNP:rs55840070)	VARIANT	0
Q96QT4/S406C	TRPM7	-	1	S -> C (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
Q96QT4/T1482I	TRPM7	-	3	T -> I (mutant channels are functional but show increased susceptibility to inhibition by intracellular magnesium concentrations compared to wild-type channels; dbSNP:rs8042919)	VARIANT	0
Q96QT4/T720S	TRPM7	-	1	T -> S (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1040254222)	VARIANT	0
Q96RG2/A1151K	PASK	decrease	1	A->K: Induces lower protein kinase activity and ability to autophosphorylate.	MUTAGEN	0
Q96RG2/E11K	PASK	-	1	E -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1277219458)	VARIANT	1
Q96RG2/E796K	PASK	neutral	1	E -> K (in dbSNP:rs35129131)	VARIANT	0
Q96RG2/F1266C	PASK	-	3	F -> C (in dbSNP:rs1131293)	VARIANT	1
Q96RG2/G725D	PASK	neutral	1	G -> D (in dbSNP:rs2005771)	VARIANT	0
Q96RG2/K1028R	PASK	loss	2	K->R: Loss of autophosphorylating activity.	MUTAGEN	0
Q96RG2/L514S	PASK	neutral	1	L -> S (in dbSNP:rs2240543)	VARIANT	0
Q96RG2/P1301S	PASK	-	1	P -> S	VARIANT	0
Q96RG2/P684R	PASK	-	1	P -> R (in dbSNP:rs56372985)	VARIANT	0
Q96RG2/P844Q	PASK	neutral	1	P -> Q (in dbSNP:rs36082918)	VARIANT	0
Q96RG2/Q426R	PASK	-	1	Q -> R (in dbSNP:rs35187712)	VARIANT	0
Q96RG2/R1058A	PASK	decrease	1	R->A: Induces lower protein kinase activity.	MUTAGEN	0
Q96RG2/R1058K	PASK	-	1	R->K: Does not affect protein kinase activity.	MUTAGEN	0
Q96RG2/R937H	PASK	neutral	1	R -> H (in dbSNP:rs56139954)	VARIANT	0
Q96RG2/T1161A	PASK	loss	5	T->A: Loss of catalytic activity (PubMed:11459942). According to another report, does not affect the protein kinase activity (PubMed:20943661). Does not affect protein translation.	MUTAGEN	0
Q96RG2/T1165A	PASK	loss	2	T->A: Loss of catalytic activity. Does not affect protein translation.	MUTAGEN	0
Q96RG2/T512A	PASK	-	1	T -> A (in dbSNP:rs56033464)	VARIANT	0
Q96RG2/V1210M	PASK	neutral	1	V -> M (in dbSNP:rs10167000)	VARIANT	0
Q96RG2/V250I	PASK	neutral	2	V -> I (in dbSNP:rs1470414)	VARIANT	5
Q96RG2/V694M	PASK	neutral	1	V -> M (in dbSNP:rs6727226)	VARIANT	0
Q96RG2/Y1152F	PASK	decrease	1	Y->F: Induces lower protein kinase activity.	MUTAGEN	0
Q96RR4/A182T	CAMKK2	-	1	A -> T (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs1207121718)	VARIANT	0
Q96RR4/C123Y	CAMKK2	neutral	1	C -> Y (in dbSNP:rs35403710)	VARIANT	0
Q96RR4/P127L	CAMKK2	-	1	P -> L (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
Q96RR4/R363C	CAMKK2	neutral	0	R -> C (in dbSNP:rs1132780)	VARIANT	1
Q96RR4/R492H	CAMKK2	-	1	R -> H (in dbSNP:rs34129994)	VARIANT	0
Q96RR4/S10N	CAMKK2	neutral	1	S -> N (in dbSNP:rs28360477)	VARIANT	0
Q96RR4/T85S	CAMKK2	neutral	4	T -> S (in dbSNP:rs3817190)	VARIANT	1
Q96RU7/E347K	TRIB3	-	1	E -> K (in dbSNP:rs56342286)	VARIANT	0
Q96RU7/Q84R	TRIB3	-	2	Q -> R (in dbSNP:rs2295490)	VARIANT	0
Q96RU7/R153H	TRIB3	neutral	1	R -> H (in dbSNP:rs35051116)	VARIANT	0
Q96RU7/R274H	TRIB3	-	1	R -> H (in dbSNP:rs56291463)	VARIANT	0
Q96RU7/T60I	TRIB3	-	1	T -> I (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs757496714)	VARIANT	0
Q96RU8/D355A	TRIB1	-	1	D->A: Decreased interaction with COP1.	MUTAGEN	0
Q96RU8/E360A	TRIB1	-	1	E->A: Decreased interaction with COP1.	VARIANT	0
Q96RU8/E360D	TRIB1	neutral	1	E -> D (in dbSNP:rs16900603)	VARIANT	0
Q96RU8/I357A	TRIB1	-	1	I->A: Decreased interaction with COP1.	MUTAGEN	0
Q96RU8/P359A	TRIB1	-	1	P->A: Strongly decreased interaction with COP1.	MUTAGEN	0
Q96RU8/Q356A	TRIB1	-	1	Q->A: Decreased interaction with COP1.	MUTAGEN	0
Q96RU8/R298C	TRIB1	-	1	R -> C (in dbSNP:rs55953723)	VARIANT	0
Q96RU8/S173R	TRIB1	-	1	S -> R (in dbSNP:rs56285697)	VARIANT	0
Q96RU8/T215M	TRIB1	-	1	T -> M (in dbSNP:rs34349706)	VARIANT	0
Q96RU8/V267I	TRIB1	-	1	V -> I (in dbSNP:rs56056430)	VARIANT	0
Q96RU8/V358A	TRIB1	-	1	V->I,A: Loss of interaction with COP1.	MUTAGEN	0
Q96RU8/V358I	TRIB1	-	1	V->I,A: Loss of interaction with COP1.	MUTAGEN	0
Q96RU8/Y361A	TRIB1	-	1	Y->A: No effect on interaction with COP1.	MUTAGEN	0
Q96S38/A546P	RPS6KC1	neutral	1	A -> P (in dbSNP:rs35281247)	VARIANT	0
Q96S38/C1003Y	RPS6KC1	-	1	C -> Y (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q96S38/E1022K	RPS6KC1	-	1	E -> K (in a breast infiltrating ductal carcinoma sample; somatic mutation)	VARIANT	1
Q96S38/E96K	RPS6KC1	-	1	E -> K (in dbSNP:rs56032860)	VARIANT	0
Q96S38/G663A	RPS6KC1	-	1	G -> A (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
Q96S38/L554I	RPS6KC1	-	1	L -> I (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
Q96S38/L853F	RPS6KC1	neutral	1	L -> F (in dbSNP:rs34080597)	VARIANT	0
Q96S38/N575S	RPS6KC1	neutral	1	N -> S (in dbSNP:rs56060894)	VARIANT	0
Q96S38/P319L	RPS6KC1	neutral	1	P -> L (in dbSNP:rs56369827)	VARIANT	0
Q96S38/P424L	RPS6KC1	neutral	1	P -> L (in dbSNP:rs56183862)	VARIANT	0
Q96S38/P42T	RPS6KC1	-	1	P -> T (in dbSNP:rs56087470)	VARIANT	0
Q96S38/P561R	RPS6KC1	-	0	P -> R (in dbSNP:rs17020314)	VARIANT	0
Q96S44/A25T	TP53RK	-	0	A -> T	VARIANT	0
Q96S44/G42D	TP53RK	-	1	G -> D (in GAMOS4; dbSNP:rs773814837)	VARIANT	0
Q96S44/R123Q	TP53RK	neutral	1	R -> Q (in dbSNP:rs34983477)	VARIANT	0
Q96S44/R243L	TP53RK	-	1	R -> L (in GAMOS4; dbSNP:rs776588426)	VARIANT	0
Q96S44/T129A	TP53RK	neutral	1	T -> A (in dbSNP:rs11550540)	VARIANT	0
Q96S44/T145A	TP53RK	-	1	T -> A (in dbSNP:rs56008408)	VARIANT	0
Q96S44/T81R	TP53RK	-	1	T -> R (in GAMOS4; abolished interaction with TPRKB; dbSNP:rs1432218739)	VARIANT	0
Q96S53/G11A	TESK2	-	1	G -> A (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1428512439)	VARIANT	2
Q96SB4/I72T	SRPK1	-	0	I -> T (in dbSNP:rs35519113)	VARIANT	0
Q96SB4/S222A	SRPK1	-	1	S->A: No effect on protein phosphorylation.	MUTAGEN	0
Q96SB4/S311G	SRPK1	-	1	S->G: No effect on protein phosphorylation.	MUTAGEN	0
Q96SB4/S37A	SRPK1	-	1	S->A: No effect on protein phosphorylation.	MUTAGEN	0
Q96SB4/S436G	SRPK1	-	1	S->G: No effect on protein phosphorylation.	MUTAGEN	0
Q96SB4/S51A	SRPK1	decrease	1	S->A: Protein phosphorylation impaired at this position.	MUTAGEN	0
Q96SB4/S555A	SRPK1	decrease	1	S->A: Protein phosphorylation impaired at this position.	MUTAGEN	0
Q96SB4/S619A	SRPK1	-	1	S->A: No effect on protein phosphorylation.	MUTAGEN	0
Q99558/G514K	MAP3K14	-	1	G -> K (in a lung neuroendocrine carcinoma sample; somatic mutation; requires 2 nucleotide substitutions)	VARIANT	0
Q99558/H674Y	MAP3K14	-	0	H -> Y (in dbSNP:rs11867907)	VARIANT	0
Q99558/P928H	MAP3K14	-	1	P -> H (in dbSNP:rs56036201)	VARIANT	0
Q99558/S140N	MAP3K14	-	1	S -> N (in dbSNP:rs11574819)	VARIANT	0
Q99558/T255M	MAP3K14	-	0	T -> M (in dbSNP:rs11574820)	VARIANT	0
Q99558/T559A	MAP3K14	-	1	T->A: Abolishes 'Lys-63'-linked ubiquitination.	MUTAGEN	0
Q99558/T764A	MAP3K14	-	1	T -> A (in dbSNP:rs56302559)	VARIANT	0
Q99558/T852I	MAP3K14	-	1	T -> I (in an ovarian mucinous carcinoma sample; somatic mutation)	VARIANT	0
Q99570/D393N	PIK3R4	-	1	D -> N (in dbSNP:rs34633532)	VARIANT	0
Q99570/F273L	PIK3R4	-	1	F -> L (in dbSNP:rs55951445)	VARIANT	1
Q99570/G1043V	PIK3R4	-	1	G -> V (in dbSNP:rs56160735)	VARIANT	0
Q99570/L699V	PIK3R4	neutral	1	L -> V (in dbSNP:rs56369596)	VARIANT	0
Q99570/R342H	PIK3R4	-	1	R -> H (in dbSNP:rs56295394)	VARIANT	0
Q99570/R347W	PIK3R4	-	1	R -> W (in dbSNP:rs34797184)	VARIANT	0
Q99570/R936Q	PIK3R4	-	1	R -> Q (in a breast cancer sample; somatic mutation; dbSNP:rs181132426)	VARIANT	1
Q99570/T388I	PIK3R4	-	1	T -> I (in dbSNP:rs34663155)	VARIANT	0
Q99640/D251A	PKMYT1	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
Q99640/E103Q	PKMYT1	-	1	E -> Q (in dbSNP:rs55834293)	VARIANT	0
Q99640/E351K	PKMYT1	-	1	E -> K (in dbSNP:rs56382954)	VARIANT	0
Q99640/N238A	PKMYT1	loss	1	N->A: Loss of kinase activity.	MUTAGEN	0
Q99640/P417R	PKMYT1	-	0	P -> R (in dbSNP:rs4149800)	VARIANT	0
Q99640/R140C	PKMYT1	-	1	R -> C (in dbSNP:rs4149796)	VARIANT	0
Q99640/R246H	PKMYT1	-	1	R -> H (in dbSNP:rs35192104)	VARIANT	0
Q99640/V445A	PKMYT1	-	0	V -> A (in dbSNP:rs10546)	VARIANT	0
Q99683/D1315N	MAP3K5	neutral	1	D -> N (in dbSNP:rs41288957)	VARIANT	0
Q99683/G1006R	MAP3K5	-	1	G -> R (in dbSNP:rs45626535)	VARIANT	0
Q99683/I1214T	MAP3K5	-	1	I -> T (in dbSNP:rs56379668)	VARIANT	0
Q99683/I1250V	MAP3K5	neutral	1	I -> V (in dbSNP:rs35551087)	VARIANT	3
Q99683/K709M	MAP3K5	loss	3	K->M: Loss of kinase activity. Inhibits activation of JNK and apoptosis mediated by TNFRSF6 and DAXX. Does not affect interaction with TRIM48.	MUTAGEN	0
Q99683/K709R	MAP3K5	loss	3	K->R: Loss of kinase activity. Abolishes DAXX-mediated apoptosis. Loss of RC3H2-mediated ubiquitination.	MUTAGEN	0
Q99683/R32K	MAP3K5	-	1	R->K: No effect on methylation by PRMT1.	MUTAGEN	0
Q99683/R78K	MAP3K5	-	1	R->K: Reduced methylation by PRMT1. Abolishes methylation by PRMT1 and PRMT1-mediated inhibition of MAPK35 activation; when associated with K-80.	MUTAGEN	0
Q99683/R80K	MAP3K5	-	1	R->K: Reduced methylation by PRMT1. Abolishes methylation by PRMT1 and PRMT1-mediated inhibition of MAPK35 activation; when associated with K-78.	MUTAGEN	0
Q99683/S1033A	MAP3K5	increase	1	S->A: Enhanced induction of apoptosis and increased kinase activity.	MUTAGEN	0
Q99683/S966A	MAP3K5	increase	2	S->A: Enhanced induction of apoptosis, increased kinase activity, and loss of YWHAG binding.	MUTAGEN	0
Q99683/T1314I	MAP3K5	neutral	1	T -> I (in dbSNP:rs45599539)	VARIANT	0
Q99683/T838A	MAP3K5	-	1	T->A: Does not affect interaction with TRIM48.	MUTAGEN	0
Q99759/A325G	MAP3K3	-	0	A -> G (in dbSNP:rs34042309)	VARIANT	0
Q99759/A435G	MAP3K3	-	0	A -> G (in dbSNP:rs9910858)	VARIANT	0
Q99759/V281M	MAP3K3	neutral	1	V -> M (in dbSNP:rs36109904)	VARIANT	2
Q99986/K179A	VRK1	-	1	K->A: Does not affect phosphorylation at S-342.	MUTAGEN	0
Q99986/S125A	VRK1	-	1	S->A: Does not abolish autophosphorylation.	MUTAGEN	0
Q99986/S14A	VRK1	-	1	S->A: Does not abolish autophosphorylation.	MUTAGEN	0
Q99986/S150A	VRK1	-	1	S->A: Does not abolish autophosphorylation.	MUTAGEN	0
Q99986/S158A	VRK1	-	1	S->A: Does not abolish autophosphorylation.	MUTAGEN	0
Q99986/S239A	VRK1	-	1	S->A: Does not abolish autophosphorylation.	MUTAGEN	0
Q99986/S342A	VRK1	decrease	2	S->A: Abolishes phosphorylation by PLK3 and induction of Golgi fragmentation during mitosis. Strongly reduced autophosphorylation.	MUTAGEN	0
Q99986/T102A	VRK1	-	1	T->A: Does not abolish autophosphorylation.	MUTAGEN	0
Q99986/T305A	VRK1	-	1	T->A: Does not abolish autophosphorylation.	MUTAGEN	0
Q99986/T312A	VRK1	-	1	T->A: Does not abolish autophosphorylation.	MUTAGEN	0
Q99986/T353A	VRK1	decrease	1	T->A: Strongly reduced autophosphorylation.	MUTAGEN	0
Q99986/T355A	VRK1	-	1	T->A: Does not abolish autophosphorylation.	MUTAGEN	0
Q99986/T390A	VRK1	-	1	T->A: Does not abolish autophosphorylation.	MUTAGEN	0
Q9BQI3/F292L	EIF2AK1	-	1	F -> L (in dbSNP:rs55982710)	VARIANT	0
Q9BQI3/G202S	EIF2AK1	-	1	G -> S (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs1216460058)	VARIANT	1
Q9BQI3/I448V	EIF2AK1	decrease	1	I -> V (in LEMSPAD; unknown pathological significance; mildly reduced phosphorylation of eukaryotic translation initiation factor 2-alpha; dbSNP:rs1583476115)	VARIANT	0
Q9BQI3/K132T	EIF2AK1	-	1	K -> T (in dbSNP:rs34851195)	VARIANT	0
Q9BQI3/K558R	EIF2AK1	neutral	3	K -> R (in dbSNP:rs2640)	VARIANT	2
Q9BQI3/L319H	EIF2AK1	neutral	1	L -> H (in dbSNP:rs34909691)	VARIANT	0
Q9BQI3/P139S	EIF2AK1	-	1	P -> S (in dbSNP:rs55963745)	VARIANT	0
Q9BQI3/R117T	EIF2AK1	-	1	R -> T (in dbSNP:rs34889754)	VARIANT	0
Q9BQI3/R134K	EIF2AK1	neutral	1	R -> K (in dbSNP:rs55744865)	VARIANT	0
Q9BQI3/R145H	EIF2AK1	-	1	R -> H (in dbSNP:rs55971369)	VARIANT	0
Q9BRS2/D324A	RIOK1	loss	1	D->A: Abolishes autophosphorylation activity; enhances association with pre-40S ribosomal subunits; inhibits processing of 18S-E pre-rRNA to the mature 18S rRNA.	MUTAGEN	0
Q9BRS2/V375I	RIOK1	-	0	V -> I (in dbSNP:rs56067778)	VARIANT	0
Q9BUB5/D232A	MKNK1	-	1	D->A: Loss of kinase activity; when associated with K-78.	MUTAGEN	0
Q9BUB5/D308N	MKNK1	neutral	1	D -> N (in dbSNP:rs55791614)	VARIANT	0
Q9BUB5/K49Q	MKNK1	-	1	K -> Q (in dbSNP:rs56351860)	VARIANT	0
Q9BUB5/K78M	MKNK1	-	1	K->M: Loss of kinase activity; when associated with D-232.	MUTAGEN	0
Q9BUB5/L158V	MKNK1	-	1	L -> V (in dbSNP:rs56408722)	VARIANT	0
Q9BUB5/R446Q	MKNK1	neutral	1	R -> Q (in dbSNP:rs34881418)	VARIANT	0
Q9BUB5/T250A	MKNK1	-	1	T->A: Loss of kinase activity; when associated with T-255.	MUTAGEN	0
Q9BUB5/T255A	MKNK1	-	1	T->A: Loss of kinase activity; when associated with T-250.	MUTAGEN	0
Q9BUB5/T385D	MKNK1	activating	1	T->D: Constitutively active.	MUTAGEN	0
Q9BVS4/D246A	RIOK2	loss	1	D->A: Abolishes autophosphorylation; impairs release of pre-40S trans-acting factors and rRNA processing; when associated with A-123.	MUTAGEN	0
Q9BVS4/E409D	RIOK2	-	1	E -> D (in dbSNP:rs35829000)	VARIANT	0
Q9BVS4/G349R	RIOK2	neutral	2	G -> R (in dbSNP:rs160632)	VARIANT	0
Q9BVS4/H144R	RIOK2	neutral	1	H -> R (in dbSNP:rs35165987)	VARIANT	0
Q9BVS4/H144Y	RIOK2	-	1	H -> Y (in dbSNP:rs17849382)	VARIANT	0
Q9BVS4/I216T	RIOK2	-	1	I -> T (in a renal clear cell carcinoma sample; somatic mutation; dbSNP:rs147608663)	VARIANT	0
Q9BVS4/I403A	RIOK2	-	1	I->A: Nuclear relocalization; when associated with A-400.	MUTAGEN	0
Q9BVS4/K123A	RIOK2	loss	1	K->A: Abolishes autophosphorylation; impairs release of pre-40S trans-acting factors and rRNA processing; when associated with A-246.	MUTAGEN	0
Q9BVS4/L400A	RIOK2	-	1	L->A: Nuclear relocalization; when associated with A-403.	MUTAGEN	0
Q9BVS4/M244V	RIOK2	neutral	1	M -> V (in dbSNP:rs33996030)	VARIANT	0
Q9BVS4/N397S	RIOK2	neutral	1	N -> S (in dbSNP:rs12188395)	VARIANT	0
Q9BVS4/R155H	RIOK2	-	1	R -> H (in dbSNP:rs34916955)	VARIANT	0
Q9BVS4/R507H	RIOK2	neutral	1	R -> H (in dbSNP:rs34555783)	VARIANT	0
Q9BVS4/S335A	RIOK2	-	1	S->A: Does not affect autophosphorylation activity; when associated with A-380 and A-548. Does not affect the timing of metaphase-anaphase transition; when associated with A-380 and A-548.	MUTAGEN	0
Q9BVS4/S335D	RIOK2	-	1	S->D: Increases time spent in metaphase; when associated with D-380 and D-548.	MUTAGEN	0
Q9BVS4/S380A	RIOK2	-	1	S->A: Does not affect autophosphorylation activity; when associated with A-335 and A-548. Does not affect the timing of metaphase-anaphase transition; when associated with A-335 and A-548.	MUTAGEN	0
Q9BVS4/S380D	RIOK2	-	1	S->D: Increases time spent in metaphase; when associated with D-335 and D-548.	MUTAGEN	0
Q9BVS4/S548A	RIOK2	-	1	S->A: Does not affect autophosphorylation activity; when associated with A-335 and A-380. Does not affect the timing of metaphase-anaphase transition; when associated with A-335 and A-380.	MUTAGEN	0
Q9BVS4/S548D	RIOK2	-	1	S->D: Increases time spent in metaphase; when associated with D-335 and D-380.	MUTAGEN	0
Q9BVS4/S96C	RIOK2	-	1	S -> C (in dbSNP:rs2544773)	VARIANT	0
Q9BVS4/V175I	RIOK2	neutral	1	V -> I (in dbSNP:rs35713904)	VARIANT	0
Q9BWU1/F197L	CDK19	-	1	F -> L (in DEE87; dbSNP:rs1779473436)	VARIANT	0
Q9BWU1/G28A	CDK19	-	1	G -> A (in DEE87; dbSNP:rs1783518890)	VARIANT	0
Q9BWU1/G28R	CDK19	decrease	1	G -> R (in DEE87; decreased protein kinase activity)	VARIANT	0
Q9BWU1/R200W	CDK19	-	1	R -> W (in DEE87; dbSNP:rs1779472995)	VARIANT	2
Q9BWU1/T196A	CDK19	-	1	T -> A (in DEE87; fails to rescue neurologic phenotypes in a Drosophila model system; dbSNP:rs1779473650)	VARIANT	0
Q9BWU1/W198C	CDK19	-	1	W -> C (in DEE87; dbSNP:rs1779473213)	VARIANT	0
Q9BWU1/Y32C	CDK19	-	1	Y -> C (in DEE87; dbSNP:rs1783517622)	VARIANT	0
Q9BWU1/Y32H	CDK19	increase	3	Y -> H (in DEE87; fails to rescue neurologic phenotypes in a Drosophila model system; increased protein kinase activity; dbSNP:rs1236246272)	VARIANT	0
Q9BX84/E872G	TRPM6	loss	1	E -> G (in HOMG1; loss of function; no effect on cell membrane localization)	VARIANT	0
Q9BX84/F948L	TRPM6	-	0	F -> L (in dbSNP:rs13290391)	VARIANT	0
Q9BX84/G75V	TRPM6	-	1	G -> V (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs1193127627)	VARIANT	0
Q9BX84/H1243R	TRPM6	-	1	H -> R (in dbSNP:rs55694430)	VARIANT	0
Q9BX84/K1584E	TRPM6	neutral	1	K -> E (in dbSNP:rs2274924)	VARIANT	0
Q9BX84/K1804R	TRPM6	loss	1	K->R: Abolishes kinase activity but does not affect expression levels or binding to RACK1.	MUTAGEN	0
Q9BX84/L1143P	TRPM6	loss	1	L -> P (in HOMG1; loss of function; no effect on cell membrane localization)	VARIANT	0
Q9BX84/L1673S	TRPM6	-	1	L -> S (in dbSNP:rs56254742)	VARIANT	0
Q9BX84/L708P	TRPM6	loss	1	L -> P (in HOMG1; loss of function; no effect on cell membrane localization)	VARIANT	0
Q9BX84/M338I	TRPM6	neutral	1	M -> I (in dbSNP:rs56155062)	VARIANT	0
Q9BX84/N1071D	TRPM6	-	0	N -> D (in dbSNP:rs2274922)	VARIANT	0
Q9BX84/Q1274R	TRPM6	neutral	1	Q -> R (in dbSNP:rs34608911)	VARIANT	0
Q9BX84/Q1663R	TRPM6	neutral	2	Q -> R (no effect on function or cell membrane localization; dbSNP:rs55679040)	VARIANT	0
Q9BX84/S141L	TRPM6	decrease	2	S -> L (in HOMG1; impairs heterodimer formation resulting in intracellular retention; dbSNP:rs121912625)	VARIANT	0
Q9BX84/S1754N	TRPM6	loss	1	S -> N (in HOMG1; loss of function; no effect on cell membrane localization)	VARIANT	0
Q9BX84/T1724I	TRPM6	-	1	T -> I (in dbSNP:rs56290308)	VARIANT	0
Q9BX84/T1851A	TRPM6	decrease	1	T->A: Significantly decreases autophosphorylation. Does not alter binding to RACK1 but prevents inhibition by RACK1.	MUTAGEN	0
Q9BX84/T1851D	TRPM6	loss	1	T->D: Significantly decreases autophosphorylation. Does not alter binding to RACK1 or inhibition by RACK1.	MUTAGEN	0
Q9BX84/V1393I	TRPM6	neutral	1	V -> I (in dbSNP:rs3750425)	VARIANT	0
Q9BX84/W1007C	TRPM6	-	1	W -> C (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q9BX84/Y1053C	TRPM6	loss	1	Y -> C (in HOMG1; loss of function; no effect on cell membrane localization)	VARIANT	0
Q9BXA6/D135N	TSSK6	loss	2	D->N: Loss of kinase activity. No effect of binding to TSACC.	MUTAGEN	0
Q9BXA6/K41M	TSSK6	loss	2	K->M: Loss of kinase activity. Loss of binding to TSACC.	MUTAGEN	0
Q9BXA7/A50T	TSSK1B	-	1	A -> T (in dbSNP:rs747955728)	VARIANT	3
Q9BXA7/G288W	TSSK1B	neutral	1	G -> W (in dbSNP:rs34696815)	VARIANT	0
Q9BXA7/G293E	TSSK1B	neutral	1	G -> E (in dbSNP:rs11953478)	VARIANT	0
Q9BXA7/H83Y	TSSK1B	-	1	H -> Y (in dbSNP:rs55930004)	VARIANT	0
Q9BXA7/R237C	TSSK1B	-	1	R -> C (in dbSNP:rs55738530)	VARIANT	1
Q9BXA7/T174A	TSSK1B	loss	1	T->A: Loss of kinase activity.	MUTAGEN	0
Q9BXA7/T174E	TSSK1B	activating	1	T->E: Constitutively active.	MUTAGEN	0
Q9BXA7/V233L	TSSK1B	-	1	V -> L (in dbSNP:rs55940513)	VARIANT	0
Q9BXM7/A124V	PINK1	-	1	A -> V (in dbSNP:rs1274588239)	VARIANT	0
Q9BXM7/A168P	PINK1	-	4	A -> P (in PARK6; no effect on autophosphorylation; localizes to the mitochondria and immunogold experiments reveal that both wild-type and mutant proteins face the mitochondrial intermembrane space; dbSNP:rs768091663)	VARIANT	0
Q9BXM7/A217D	PINK1	-	1	A -> D (in PARK6; dbSNP:rs74315360)	VARIANT	0
Q9BXM7/A280T	PINK1	-	1	A -> T (in PARK6; early-onset; dbSNP:rs772510148)	VARIANT	0
Q9BXM7/A339T	PINK1	-	4	A -> T (in dbSNP:rs55831733)	VARIANT	1
Q9BXM7/A340T	PINK1	neutral	7	A -> T (in dbSNP:rs3738136)	VARIANT	0
Q9BXM7/A383T	PINK1	-	2	A -> T (in dbSNP:rs45515602)	VARIANT	0
Q9BXM7/A537T	PINK1	-	1	A -> T (in dbSNP:rs771032673)	VARIANT	0
Q9BXM7/C125G	PINK1	-	1	C -> G (in PARK6)	VARIANT	0
Q9BXM7/C377F	PINK1	-	1	C -> F (in dbSNP:rs34203620)	VARIANT	0
Q9BXM7/C388R	PINK1	-	1	C -> R (in PARK6; dbSNP:rs1553146806)	VARIANT	0
Q9BXM7/C575R	PINK1	-	1	C -> R (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions; dbSNP:rs1553147052)	VARIANT	0
Q9BXM7/C92F	PINK1	-	1	C -> F (in PARK6; dbSNP:rs1553145550)	VARIANT	0
Q9BXM7/D362A	PINK1	-	3	D->A: Abolishes MFN2 phosphorylation and interaction with PRKN; when associated with A-219 and A-384. Loss of enzyme activity and impaired localization of PRKN to mitochondria; when associated with M-219 and A-384.	MUTAGEN	0
Q9BXM7/D362H	PINK1	-	1	D -> H	VARIANT	0
Q9BXM7/D384A	PINK1	-	3	D->A: Abolishes MFN2 phosphorylation and interaction with PRKN; when associated with A-219 and A-362. Loss of enzyme activity and impaired localization of PRKN to mitochondria; when associated with M-219 and A-362.	MUTAGEN	0
Q9BXM7/D384N	PINK1	loss	1	D->N: Loss of activity. Abolishes Drp1 phosphorylation. No effect on localization to mitochondria.	MUTAGEN	0
Q9BXM7/D525N	PINK1	-	2	D -> N (in dbSNP:rs531477772)	VARIANT	0
Q9BXM7/E231G	PINK1	-	1	E -> G (in dbSNP:rs1303935100)	VARIANT	0
Q9BXM7/E240K	PINK1	-	2	E -> K (in PARK6; dbSNP:rs573931674)	VARIANT	0
Q9BXM7/E417G	PINK1	-	1	E -> G (in PARK6; dbSNP:rs1553146822)	VARIANT	0
Q9BXM7/E476K	PINK1	neutral	5	E -> K (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions; dbSNP:rs115477764)	VARIANT	0
Q9BXM7/G309D	PINK1	decrease	5	G -> D (in PARK6; fails to maintain mitochondrial membrane potential; full-length mutant has no effect on autophosphorylation; strongly reduces interaction with PRKN; decreases PRKN and SNCAIP ubiquitination and degradation; decreases Drp1 phosphorylation; dbSNP:rs74315355)	VARIANT	0
Q9BXM7/G386A	PINK1	loss	2	G -> A (in PARK6; abolishes kinase activity)	VARIANT	0
Q9BXM7/G395V	PINK1	-	1	G -> V (in dbSNP:rs1035071310)	VARIANT	0
Q9BXM7/G409V	PINK1	-	1	G -> V (in PARK6; dbSNP:rs1553146818)	VARIANT	0
Q9BXM7/G411S	PINK1	neutral	1	G -> S (in dbSNP:rs45478900)	VARIANT	0
Q9BXM7/H271Q	PINK1	-	1	H -> Q (in PARK6; dbSNP:rs28940284)	VARIANT	0
Q9BXM7/I111S	PINK1	-	1	I -> S (in dbSNP:rs1553145560)	VARIANT	0
Q9BXM7/I442T	PINK1	-	2	I -> T (in dbSNP:rs1553146877)	VARIANT	0
Q9BXM7/K186N	PINK1	-	1	K -> N (in dbSNP:rs143204084)	VARIANT	0
Q9BXM7/K219A	PINK1	-	1	K->A: Abolishes MFN2 phosphorylation and interaction with PRKN; when associated with Ala-362 and Ala-384.	MUTAGEN	0
Q9BXM7/K219M	PINK1	-	2	K->M: Loss of enzyme activity and impaired localization of PRKN to mitochondria; when associated with A-362 and A-384.	MUTAGEN	0
Q9BXM7/L148W	PINK1	-	1	L -> W (in dbSNP:rs56297806)	VARIANT	0
Q9BXM7/L268V	PINK1	-	2	L -> V (in PARK6; dbSNP:rs372280083)	VARIANT	0
Q9BXM7/L347P	PINK1	decrease	5	L -> P (in PARK6; strongly reduces interaction with PRKN; reduced ubiquitination of MIRO1; dbSNP:rs28940285)	VARIANT	0
Q9BXM7/L369P	PINK1	-	1	L -> P (in PARK6; dbSNP:rs1195888869)	VARIANT	0
Q9BXM7/L461S	PINK1	-	1	L -> S	VARIANT	0
Q9BXM7/L489P	PINK1	-	1	L -> P (in PARK6; dbSNP:rs1553146903)	VARIANT	0
Q9BXM7/L67F	PINK1	-	1	L -> F (in dbSNP:rs763142730)	VARIANT	0
Q9BXM7/M318L	PINK1	-	1	M -> L (in dbSNP:rs139226733)	VARIANT	0
Q9BXM7/M341I	PINK1	-	1	M -> I (in dbSNP:rs35813094)	VARIANT	0
Q9BXM7/N235I	PINK1	-	1	N -> I (in dbSNP:rs1557562082)	VARIANT	0
Q9BXM7/N451S	PINK1	-	1	N -> S (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions; dbSNP:rs747400197)	VARIANT	0
Q9BXM7/N521T	PINK1	neutral	7	N -> T (in dbSNP:rs1043424)	VARIANT	0
Q9BXM7/P196L	PINK1	-	1	P -> L (in PARK6; dbSNP:rs138302371)	VARIANT	0
Q9BXM7/P196S	PINK1	-	1	P -> S (in dbSNP:rs35802484)	VARIANT	1
Q9BXM7/P209L	PINK1	-	1	P -> L (in dbSNP:rs34677717)	VARIANT	0
Q9BXM7/P215L	PINK1	-	1	P -> L (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs371854396)	VARIANT	1
Q9BXM7/P296L	PINK1	-	2	P -> L (in dbSNP:rs779060308)	VARIANT	0
Q9BXM7/P305L	PINK1	-	0	P -> L (in dbSNP:rs7349186)	VARIANT	0
Q9BXM7/P322L	PINK1	-	1	P -> L (in dbSNP:rs768019187)	VARIANT	0
Q9BXM7/P399L	PINK1	decrease	2	P -> L (probable disease-associated variant found in early-onset Parkinson disease with digenic inheritance; found in a patient also carrying mutation S-39 in PARK7; decreases PRKN and SNCAIP ubiquitination and degradation; dbSNP:rs119451946)	VARIANT	0
Q9BXM7/P425S	PINK1	-	1	P -> S (in dbSNP:rs554114655)	VARIANT	0
Q9BXM7/Q115L	PINK1	neutral	2	Q -> L (in dbSNP:rs148871409)	VARIANT	0
Q9BXM7/Q126P	PINK1	-	2	Q -> P (in PARK6; strongly reduces interaction with PRKN; dbSNP:rs775809722)	VARIANT	0
Q9BXM7/R147H	PINK1	-	1	R -> H (in PARK6; unknown pathological significance; dbSNP:rs138050841)	VARIANT	1
Q9BXM7/R263G	PINK1	-	1	R -> G (in dbSNP:rs1553146419)	VARIANT	0
Q9BXM7/R276Q	PINK1	-	1	R -> Q (in dbSNP:rs548506734)	VARIANT	0
Q9BXM7/R279H	PINK1	-	1	R -> H (in PARK6; dbSNP:rs74315358)	VARIANT	0
Q9BXM7/R407Q	PINK1	-	1	R -> Q (in PARK6; early-onset; dbSNP:rs556540177)	VARIANT	0
Q9BXM7/R464H	PINK1	-	1	R -> H (in PARK6; dbSNP:rs764328076)	VARIANT	0
Q9BXM7/R501P	PINK1	-	1	R -> P (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions; dbSNP:rs61744200)	VARIANT	0
Q9BXM7/R68P	PINK1	-	1	R -> P (in dbSNP:rs1385309950)	VARIANT	0
Q9BXM7/R98W	PINK1	-	1	R -> W (in dbSNP:rs575668171)	VARIANT	0
Q9BXM7/S477T	PINK1	-	1	S -> T (in dbSNP:rs34416410)	VARIANT	0
Q9BXM7/T145M	PINK1	-	1	T -> M (in dbSNP:rs45604240)	VARIANT	0
Q9BXM7/T257I	PINK1	-	0	T -> I (in dbSNP:rs370906995)	VARIANT	0
Q9BXM7/T313M	PINK1	decrease	4	T -> M (in PARK6; decreases PRKN and SNCAIP ubiquitination and degradation; slightly decreases Drp1 phosphorylation; dbSNP:rs74315359)	VARIANT	0
Q9BXM7/V170G	PINK1	-	1	V -> G (in PARK6; dbSNP:rs1553145929)	VARIANT	0
Q9BXM7/V317I	PINK1	-	2	V -> I (in dbSNP:rs200949139)	VARIANT	0
Q9BXM7/Y431H	PINK1	-	1	Y -> H (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions; dbSNP:rs74315361)	VARIANT	0
Q9BXU1/A393T	STK31	-	1	A -> T (in dbSNP:rs56244148)	VARIANT	0
Q9BXU1/A489P	STK31	-	1	A -> P (in dbSNP:rs34414354)	VARIANT	0
Q9BXU1/A600T	STK31	neutral	1	A -> T (in dbSNP:rs55796076)	VARIANT	0
Q9BXU1/E261K	STK31	neutral	1	E -> K (in dbSNP:rs10264952)	VARIANT	0
Q9BXU1/E709K	STK31	-	1	E -> K (in dbSNP:rs56181834)	VARIANT	0
Q9BXU1/G410E	STK31	neutral	1	G -> E (in dbSNP:rs4722266)	VARIANT	0
Q9BXU1/H684R	STK31	-	1	H -> R (in dbSNP:rs41273999)	VARIANT	0
Q9BXU1/H684Y	STK31	-	1	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
Q9BXU1/I277K	STK31	-	1	I -> K (in dbSNP:rs55950645)	VARIANT	0
Q9BXU1/K1009T	STK31	neutral	0	K -> T (in dbSNP:rs33998018)	VARIANT	0
Q9BXU1/K268N	STK31	neutral	1	K -> N (in dbSNP:rs10264967)	VARIANT	0
Q9BXU1/N621K	STK31	neutral	1	N -> K (in dbSNP:rs10263079)	VARIANT	0
Q9BXU1/Q71H	STK31	-	2	Q -> H (in dbSNP:rs6945306)	VARIANT	0
Q9BXU1/R385C	STK31	neutral	0	R -> C (in dbSNP:rs35995607)	VARIANT	0
Q9BXU1/S125F	STK31	-	1	S -> F (in dbSNP:rs56268851)	VARIANT	0
Q9BXU1/S623I	STK31	neutral	1	S -> I (in dbSNP:rs10247878)	VARIANT	0
Q9BXU1/T1000M	STK31	-	1	T -> M (in dbSNP:rs55794023)	VARIANT	0
Q9BXU1/T1010S	STK31	-	1	T -> S (in dbSNP:rs56391043)	VARIANT	0
Q9BXU1/T362P	STK31	-	0	T -> P (in dbSNP:rs35545265)	VARIANT	0
Q9BXU1/V860L	STK31	-	1	V -> L (in a lung small cell carcinoma sample; somatic mutation)	VARIANT	0
Q9BYP7/A998T	WNK3	-	1	A -> T (in dbSNP:rs56404148)	VARIANT	0
Q9BYP7/D294A	WNK3	loss	2	D->A: Catalytically inactive form. Inhibits sodium-coupled chloride cotransporters and activates potassium-coupled chloride cotransporters.	MUTAGEN	0
Q9BYP7/K1169E	WNK3	-	1	K -> E (in dbSNP:rs55903619)	VARIANT	0
Q9BYP7/L1533F	WNK3	-	1	L -> F (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q9BYP7/Q704H	WNK3	neutral	1	Q -> H (in dbSNP:rs56077971)	VARIANT	0
Q9BYP7/S1634P	WNK3	-	1	S -> P (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	0
Q9BYP7/S854C	WNK3	-	1	S -> C (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
Q9BYP7/T1375I	WNK3	-	1	T -> I (in dbSNP:rs55879434)	VARIANT	0
Q9BYT3/A437T	STK33	neutral	1	A -> T (in dbSNP:rs3751095)	VARIANT	4
Q9BYT3/A458E	STK33	neutral	1	A -> E (in dbSNP:rs35296353)	VARIANT	0
Q9BYT3/D436E	STK33	neutral	1	D -> E (in dbSNP:rs3751096)	VARIANT	4
Q9BYT3/E98D	STK33	neutral	1	E -> D (in dbSNP:rs34525052)	VARIANT	1
Q9BYT3/K60E	STK33	-	0	K -> E (in dbSNP:rs60786172)	VARIANT	0
Q9BYT3/L160V	STK33	-	1	L -> V (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q9BZL6/A496V	PRKD2	-	1	A -> V (in dbSNP:rs55716765)	VARIANT	0
Q9BZL6/A835V	PRKD2	-	0	A -> V (in dbSNP:rs314665)	VARIANT	0
Q9BZL6/D695A	PRKD2	loss	1	D->A: Loss of kinase activity.	MUTAGEN	0
Q9BZL6/G848E	PRKD2	-	1	G -> E (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q9BZL6/G870E	PRKD2	-	1	G -> E (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	2
Q9BZL6/P275G	PRKD2	-	1	P->G: Increase in ability to bind phorbol ester, slight increase in ability to bind DAG.	MUTAGEN	0
Q9BZL6/S244E	PRKD2	-	1	S->E: Constitutive kinase activity; when associated with E-706 and E-710.	MUTAGEN	0
Q9BZL6/S604G	PRKD2	-	1	S -> G (in dbSNP:rs34325043)	VARIANT	0
Q9BZL6/S706A	PRKD2	-	1	S->A: Abolishes phosphorylation. Loss of Tyr-717 phosphorylation and any other tyrosine phosphorylation, and increases NF-kappa-B activation in response to oxidative stress; when associated with A-710.	MUTAGEN	0
Q9BZL6/S706E	PRKD2	-	2	S->E: Constitutive kinase activity; when associated with E-710 or with E-244 and E-710. Increases Tyr-717 phosphorylation; when associated with E-710 or with E-710 and D-438.	MUTAGEN	0
Q9BZL6/S710A	PRKD2	-	1	S->A: Abolishes phosphorylation. Loss of Tyr-717 phosphorylation and any other tyrosine phosphorylation, and increases NF-kappa-B activation in response to oxidative stress; when associated with A-706.	MUTAGEN	0
Q9BZL6/S710E	PRKD2	-	2	S->E: Constitutive kinase activity; when associated with E-706 or with E-244 and E-706. when associated with E-710 or with E-244 and E-710. Increases Tyr-717 phosphorylation; when associated with E-710 or with E-710 and D-438.	MUTAGEN	0
Q9BZL6/V324M	PRKD2	-	1	V -> M (in dbSNP:rs45455991)	VARIANT	1
Q9BZL6/W773R	PRKD2	-	1	W -> R (in dbSNP:rs55933311)	VARIANT	0
Q9BZL6/Y438D	PRKD2	increase	1	Y->D: Slight increase in Tyr-717 phosphorylation. No effect on Ser-706 or/and Ser-710 phosphorylation. Increase in Tyr-717 phosphorylation; when associated with E-706 and E-710.	MUTAGEN	0
Q9BZL6/Y438F	PRKD2	decrease	2	Y->F: Loss of phosphorylation. No effect on phosphorylation of Tyr-717 and on Ser-706 or/and Ser-710 phosphorylation.	MUTAGEN	0
Q9BZL6/Y717F	PRKD2	loss	1	Y->F: Abolishes phosphorylation. Decreases substrate affinity and increases catalytic efficiency. Increases Ser-706 or/and Ser-710 phosphorylation. Increases NF-kappa-B activation in response to oxidative stress.	MUTAGEN	0
Q9BZL6/Y87F	PRKD2	-	1	Y->F: Loss of phosphorylation. No effect on the interaction with PRKCD. No effect on Ser-706 or/and Ser-710 phosphorylation.	MUTAGEN	0
Q9C098/E422K	DCLK3	-	1	E -> K (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs373605259)	VARIANT	5
Q9C098/E633D	DCLK3	neutral	1	E -> D (in dbSNP:rs35704209)	VARIANT	0
Q9C098/G570R	DCLK3	-	1	G -> R (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	0
Q9C098/P108L	DCLK3	-	1	P -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation)	VARIANT	1
Q9C098/R24Q	DCLK3	neutral	1	R -> Q (in dbSNP:rs56070233)	VARIANT	2
Q9C098/R554C	DCLK3	-	1	R -> C (in a lung squamous cell carcinoma sample; somatic mutation; dbSNP:rs374711533)	VARIANT	2
Q9C098/S472N	DCLK3	-	1	S -> N (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q9C098/V596A	DCLK3	-	1	V -> A (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	0
Q9C0K7/G155E	STRADB	-	1	G -> E (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q9C0K7/P386L	STRADB	-	1	P -> L (in dbSNP:rs35636836)	VARIANT	0
Q9H093/A516V	NUAK2	neutral	1	A -> V (in dbSNP:rs35070935)	VARIANT	0
Q9H093/G541E	NUAK2	-	1	G -> E (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	0
Q9H093/K503R	NUAK2	-	1	K -> R (in an ovarian Endometrioid carcinoma sample; somatic mutation; dbSNP:rs1271546767)	VARIANT	0
Q9H093/K81R	NUAK2	loss	1	K->R: Loss of autophosphorylation, kinase activity and of anti-apoptotic activity.	MUTAGEN	0
Q9H093/R341L	NUAK2	-	1	R -> L (in dbSNP:rs35208615)	VARIANT	0
Q9H093/T208A	NUAK2	loss	1	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
Q9H093/T309S	NUAK2	-	1	T -> S (in dbSNP:rs55745939)	VARIANT	0
Q9H0K1/P825L	SIK2	-	1	P -> L (in dbSNP:rs55889697)	VARIANT	0
Q9H0K1/P828L	SIK2	-	0	P -> L (in dbSNP:rs45520245)	VARIANT	0
Q9H0K1/P829S	SIK2	-	0	P -> S (in dbSNP:rs45586732)	VARIANT	0
Q9H0K1/R809Q	SIK2	-	1	R -> Q (in dbSNP:rs34223841)	VARIANT	2
Q9H0K1/T175A	SIK2	loss	1	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
Q9H0K1/T175E	SIK2	activating	1	T->E: Constitutively active.	MUTAGEN	0
Q9H0K1/T458I	SIK2	-	1	T -> I (in dbSNP:rs35789057)	VARIANT	0
Q9H1R3/A117V	MYLK2	-	1	A -> V (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs1229709568)	VARIANT	0
Q9H1R3/A87V	MYLK2	-	1	A -> V (in CMH; dbSNP:rs121908107)	VARIANT	1
Q9H1R3/A95E	MYLK2	-	1	A -> E (in CMH; dbSNP:rs121908108)	VARIANT	0
Q9H1R3/G142V	MYLK2	-	1	G -> V (in dbSNP:rs56385445)	VARIANT	0
Q9H1R3/K324N	MYLK2	-	1	K -> N (in dbSNP:rs34146416)	VARIANT	0
Q9H1R3/P144A	MYLK2	-	1	P -> A (in dbSNP:rs34396614)	VARIANT	0
Q9H2G2/A658G	SLK	neutral	1	A -> G (in dbSNP:rs56400929)	VARIANT	0
Q9H2G2/C552Y	SLK	neutral	1	C -> Y (in dbSNP:rs805657)	VARIANT	0
Q9H2G2/E604Q	SLK	-	1	E -> Q (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs190220654)	VARIANT	0
Q9H2G2/G666E	SLK	neutral	0	G -> E (in dbSNP:rs7071400)	VARIANT	0
Q9H2G2/I679T	SLK	neutral	1	I -> T (in dbSNP:rs34326537)	VARIANT	0
Q9H2G2/K63R	SLK	loss	1	K->R: Loss of activity.	MUTAGEN	0
Q9H2G2/K683N	SLK	-	1	K -> N (in dbSNP:rs35389916)	VARIANT	0
Q9H2G2/Q405K	SLK	-	1	Q -> K (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	0
Q9H2G2/T697I	SLK	neutral	1	T -> I (in dbSNP:rs3740469)	VARIANT	0
Q9H2K8/C727Y	TAOK3	-	1	C -> Y (in dbSNP:rs55857273)	VARIANT	0
Q9H2K8/D165A	TAOK3	loss	1	D->A: Loss of serine/threonine-protein kinase activity.	MUTAGEN	0
Q9H2K8/P20T	TAOK3	-	1	P -> T (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	0
Q9H2K8/S324A	TAOK3	-	1	S->A: Inhibits activation of the p38/MAPK14 stress-activated MAPK cascade in response to DNA damage.	MUTAGEN	0
Q9H2K8/S392Y	TAOK3	-	1	S -> Y (in a lung small cell carcinoma sample; somatic mutation)	VARIANT	0
Q9H2K8/S47N	TAOK3	neutral	2	S -> N (in dbSNP:rs428073)	VARIANT	0
Q9H2K8/T181A	TAOK3	-	1	T->A: No autophosphorylation and no kinase activity; when associated with F-183.	MUTAGEN	0
Q9H2K8/Y183F	TAOK3	-	1	Y->F: No autophosphorylation and no kinase activity; when associated with A-181.	MUTAGEN	0
Q9H2X6/K228A	HIPK2	loss	10	K->A: Locates in the nucleoplasm, no effect on interaction with RANBP9, but loss of kinase activity toward PML, RUNX1, EP300 and DAZAP2.	MUTAGEN	0
Q9H2X6/K228R	HIPK2	loss	9	K->R: Abolishes enzymatic activity, no effect on interaction with TP53 and TP73 or on BMP-induced transcriptional activation. Enhances BMP-induced transcriptional activation; when associated with 359-AAF-361.	MUTAGEN	0
Q9H2X6/K803A	HIPK2	-	1	K->A: Impaired nuclear localization; when associated with A-805.	MUTAGEN	0
Q9H2X6/K805A	HIPK2	-	1	K->A: Impaired nuclear localization; when associated with A-803.	MUTAGEN	0
Q9H2X6/K835E	HIPK2	-	1	K->E: Impaired nuclear localization.	MUTAGEN	0
Q9H2X6/R1027Q	HIPK2	-	1	R -> Q (in dbSNP:rs35255718)	VARIANT	1
Q9H2X6/R792Q	HIPK2	-	1	R -> Q (in dbSNP:rs56132157)	VARIANT	0
Q9H2X6/R833A	HIPK2	-	1	R->A: Impaired nuclear localization.	MUTAGEN	0
Q9H3Y6/A397V	SRMS	neutral	1	A -> V (in dbSNP:rs6011889)	VARIANT	0
Q9H3Y6/A453T	SRMS	neutral	1	A -> T (in dbSNP:rs310655)	VARIANT	0
Q9H3Y6/D377E	SRMS	-	1	D -> E (in dbSNP:rs55838540)	VARIANT	0
Q9H3Y6/G75R	SRMS	-	1	G -> R (in dbSNP:rs55863722)	VARIANT	1
Q9H3Y6/I88V	SRMS	neutral	1	I -> V (in dbSNP:rs35558836)	VARIANT	0
Q9H3Y6/K258M	SRMS	loss	2	K->M: Loss of kinase activity. Exhibits a diffused cytoplasmic localization. No effect on interaction with KHDRBS1 or VIM but abolishes tyrosine phosphorylation of both substrates.	MUTAGEN	0
Q9H3Y6/P218L	SRMS	neutral	0	P -> L (in dbSNP:rs378483)	VARIANT	0
Q9H3Y6/P325L	SRMS	-	0	P -> L (in dbSNP:rs8122355)	VARIANT	0
Q9H3Y6/P452L	SRMS	-	1	P -> L (in dbSNP:rs8120713)	VARIANT	0
Q9H3Y6/R73C	SRMS	-	1	R -> C (in dbSNP:rs56053583)	VARIANT	0
Q9H3Y6/S465T	SRMS	neutral	1	S -> T (in dbSNP:rs33933649)	VARIANT	0
Q9H3Y6/V255M	SRMS	neutral	0	V -> M (in dbSNP:rs34969822)	VARIANT	0
Q9H3Y6/V301L	SRMS	-	1	V -> L (in dbSNP:rs310657)	VARIANT	0
Q9H3Y6/V457L	SRMS	-	1	V -> L (in dbSNP:rs310654)	VARIANT	0
Q9H3Y6/W223A	SRMS	loss	1	W->A: Loss of kinase activity.	MUTAGEN	0
Q9H3Y6/Y380F	SRMS	decrease	1	Y->F: Significant reduction in phosphorylation.	MUTAGEN	0
Q9H422/C191R	HIPK3	-	1	C -> R (in dbSNP:rs35689361)	VARIANT	0
Q9H422/G170E	HIPK3	neutral	1	G -> E (in dbSNP:rs34698015)	VARIANT	0
Q9H422/K226R	HIPK3	loss	1	K->R: Loss of kinase activity and impaired activation of SF1.	MUTAGEN	0
Q9H422/P729L	HIPK3	-	1	P -> L (in dbSNP:rs55807239)	VARIANT	0
Q9H422/Q142R	HIPK3	-	1	Q -> R (in dbSNP:rs34193811)	VARIANT	0
Q9H422/S500N	HIPK3	neutral	1	S -> N (in dbSNP:rs11032229)	VARIANT	0
Q9H422/V474I	HIPK3	neutral	0	V -> I (in dbSNP:rs266472)	VARIANT	0
Q9H4A3/A141T	WNK1	neutral	1	A -> T (in dbSNP:rs11554421)	VARIANT	0
Q9H4A3/A149V	WNK1	neutral	1	A -> V (in dbSNP:rs34880640)	VARIANT	0
Q9H4A3/A1546V	WNK1	-	1	A -> V (in dbSNP:rs56351358)	VARIANT	0
Q9H4A3/C1506S	WNK1	neutral	2	C -> S (in dbSNP:rs7955371)	VARIANT	0
Q9H4A3/D527G	WNK1	-	1	D -> G (in dbSNP:rs34408667)	VARIANT	0
Q9H4A3/E1199G	WNK1	-	1	E -> G (in a colorectal cancer sample; somatic mutation)	VARIANT	0
Q9H4A3/E419Q	WNK1	-	1	E -> Q (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	1
Q9H4A3/F2362L	WNK1	-	1	F -> L (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q9H4A3/H823R	WNK1	-	1	H -> R (in dbSNP:rs56015776)	VARIANT	0
Q9H4A3/I509T	WNK1	neutral	1	I -> T (in dbSNP:rs34728563)	VARIANT	0
Q9H4A3/M1808I	WNK1	neutral	2	M -> I (in dbSNP:rs12828016)	VARIANT	1
Q9H4A3/P1823L	WNK1	neutral	1	P -> L (in dbSNP:rs17755373)	VARIANT	0
Q9H4A3/Q1799E	WNK1	-	2	Q -> E (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	VARIANT	0
Q9H4A3/R1957H	WNK1	-	1	R -> H (in dbSNP:rs36083875)	VARIANT	1
Q9H4A3/R2380W	WNK1	-	1	R -> W (in dbSNP:rs56262445)	VARIANT	0
Q9H4A3/S2190C	WNK1	-	1	S -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	1
Q9H4A3/T1056P	WNK1	neutral	2	T -> P (in dbSNP:rs956868)	VARIANT	0
Q9H4A3/T665I	WNK1	neutral	1	T -> I (in dbSNP:rs2286007)	VARIANT	13
Q9H4A3/T674A	WNK1	neutral	1	T -> A (in dbSNP:rs11833299)	VARIANT	0
Q9H4B4/D203A	PLK3	loss	1	D->A: Kinase defective mutant, abolishes activity.	MUTAGEN	0
Q9H4B4/D491N	PLK3	-	1	D -> N (in dbSNP:rs17855444)	VARIANT	0
Q9H4B4/K91R	PLK3	loss	7	K->R: Kinase defective mutant, abolishes activity.	MUTAGEN	0
Q9H4B4/L283F	PLK3	-	0	L -> F (in dbSNP:rs17880471)	VARIANT	0
Q9H4B4/L68F	PLK3	-	0	L -> F (in dbSNP:rs17884316)	VARIANT	0
Q9H4B4/R483C	PLK3	-	0	R -> C (in dbSNP:rs17884653)	VARIANT	1
Q9H4B4/S498L	PLK3	-	0	S -> L (in dbSNP:rs17880829)	VARIANT	0
Q9H4B4/S618P	PLK3	-	0	S -> P (in dbSNP:rs17881786)	VARIANT	0
Q9H4B4/T219E	PLK3	loss	1	T->E: Kinase-defective mutant.	MUTAGEN	0
Q9H4B4/T61S	PLK3	-	0	T -> S (in dbSNP:rs17884581)	VARIANT	0
Q9H5K3/L137R	POMK	loss	2	L -> R (in MDDGA12; loss of kinase activity; dbSNP:rs397509385)	VARIANT	0
Q9H5K3/M301T	POMK	-	1	M -> T (in dbSNP:rs33920561)	VARIANT	0
Q9H5K3/M342I	POMK	-	1	M -> I (in a lung small cell carcinoma sample; somatic mutation)	VARIANT	0
Q9H5K3/Q258R	POMK	-	1	Q -> R (in MDDGA12; dbSNP:rs397509386)	VARIANT	0
Q9H5K3/S48P	POMK	-	1	S -> P (in dbSNP:rs34466747)	VARIANT	0
Q9H5K3/V254M	POMK	-	1	V -> M (in dbSNP:rs34715198)	VARIANT	0
Q9H5K3/V302D	POMK	-	1	V -> D (in MDDGA12; dbSNP:rs199756983)	VARIANT	0
Q9H5K3/Y140F	POMK	-	1	Y -> F (in dbSNP:rs34750053)	VARIANT	0
Q9H792/A1707D	PEAK1	-	1	A->D: Disrupts homodimerization.	MUTAGEN	0
Q9H792/D836E	PEAK1	-	1	D -> E (in dbSNP:rs56388121)	VARIANT	0
Q9H792/F1609A	PEAK1	-	1	F->A: No effect on interaction with PRAG1.	MUTAGEN	0
Q9H792/G213R	PEAK1	-	1	G -> R (in dbSNP:rs35459975)	VARIANT	0
Q9H792/H611Q	PEAK1	-	1	H -> Q (in a bladder carcinoma NOS sample; somatic mutation)	VARIANT	0
Q9H792/P1145L	PEAK1	-	1	P -> L (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q9H792/P1408Q	PEAK1	neutral	1	P -> Q (in dbSNP:rs56079860)	VARIANT	0
Q9H792/R1071K	PEAK1	neutral	1	R -> K (in dbSNP:rs12909704)	VARIANT	1
Q9H792/R1699G	PEAK1	-	1	R -> G (in dbSNP:rs34004337)	VARIANT	0
Q9H792/S1035F	PEAK1	-	1	S -> F (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q9H792/S1542T	PEAK1	neutral	1	S -> T (in dbSNP:rs1867780)	VARIANT	0
Q9H792/S440P	PEAK1	neutral	1	S -> P (in dbSNP:rs35335169)	VARIANT	0
Q9H792/S792I	PEAK1	-	1	S -> I (in dbSNP:rs34885462)	VARIANT	0
Q9H792/T1077P	PEAK1	neutral	1	T -> P (in dbSNP:rs56133554)	VARIANT	0
Q9H792/V240I	PEAK1	-	1	V -> I (in dbSNP:rs56129428)	VARIANT	0
Q9H792/Y1188F	PEAK1	-	2	Y->F: Fails to bind SHC1. Reduced recruitment of SHC1 to focal adhesions. Slightly reduces interaction with GRB2. Does not affect interaction with RASAL2. Does not affect association with integrin ITGB1.	MUTAGEN	0
Q9H792/Y635E	PEAK1	-	0	Y->E: 50% reduction in interaction with GRB2. No effect on interaction with SHC1.	MUTAGEN	0
Q9H792/Y635F	PEAK1	-	1	Y->F: Impairs interaction with tensin TNS3 and association with integrin ITGB1. 50% reduction in interaction with GRB2. No effect on interaction with unphosphorylated SHC1 but reduces interaction with tyrosine-phosphorylated SHC1. Reduces focal adhesion localization. Reduces cell migration.	MUTAGEN	0
Q9H792/Y665E	PEAK1	-	1	Y->E: No effect on localization with actin. Decreases localization in focal adhesion. Fails to regulate focal adhesion dynamics. Decreases cell migration.	MUTAGEN	0
Q9H792/Y665F	PEAK1	-	1	Y->F: No effect on focal adhesion subcellular localization. Does not affect colocalization with F-actin.	MUTAGEN	0
Q9HAZ1/I363V	CLK4	-	1	I -> V (in dbSNP:rs55746655)	VARIANT	0
Q9HAZ1/K189R	CLK4	loss	1	K->R: Loss of function.	MUTAGEN	0
Q9HAZ1/L352F	CLK4	neutral	1	L -> F (in dbSNP:rs35272416)	VARIANT	0
Q9HBH9/D228G	MKNK2	decrease	1	D->G: Reduced phosphorylation.	MUTAGEN	0
Q9HBH9/D73N	MKNK2	-	1	D -> N (in dbSNP:rs56158214)	VARIANT	0
Q9HBH9/Q10K	MKNK2	neutral	0	Q -> K (in dbSNP:rs3746101)	VARIANT	0
Q9HBH9/R428Q	MKNK2	neutral	0	R -> Q (in dbSNP:rs34475638)	VARIANT	0
Q9HBH9/T244A	MKNK2	-	1	T->A: Loss of kinase activity; when associated with T-249.	MUTAGEN	0
Q9HBH9/T249A	MKNK2	-	1	T->A: Loss of kinase activity; when associated with T-244.	MUTAGEN	0
Q9HBH9/T379D	MKNK2	activating	1	T->D: Constitutively active.	MUTAGEN	0
Q9HBY8/E199K	SGK2	-	1	E -> K (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q9HBY8/H289Y	SGK2	-	1	H -> Y (in dbSNP:rs35793869)	VARIANT	0
Q9HBY8/S356D	SGK2	increase	1	S->D: Increased activation.	MUTAGEN	0
Q9HC98/K74M	NEK6	-	2	K->M: Loss of autophosphorylation and of kinase activity and induction of apoptosis; when associated with M-75.	MUTAGEN	0
Q9HC98/K75M	NEK6	-	2	K->M: Loss of autophosphorylation and of kinase activity and induction of apoptosis; when associated with M-74.	MUTAGEN	0
Q9HC98/Y108A	NEK6	increase	1	Y->A: Increase in catalytic activity.	MUTAGEN	0
Q9HCP0/N169A	CSNK1G1	loss	1	N->A: Loss of kinase activity.	MUTAGEN	0
Q9HCP0/R206K	CSNK1G1	-	1	R -> K (in dbSNP:rs55799101)	VARIANT	0
Q9HCP0/R230W	CSNK1G1	-	1	R -> W (probable disease-associated variant found in a patient with non-syndromic early-onset epilepsy associated with severe developmental delay and microcephaly; dbSNP:rs587777544)	VARIANT	2
Q9HCP0/V329I	CSNK1G1	neutral	1	V -> I (in dbSNP:rs55699712)	VARIANT	2
Q9NQU5/A376V	PAK6	-	1	A -> V (in dbSNP:rs55806501)	VARIANT	0
Q9NQU5/E184K	PAK6	-	1	E -> K (in dbSNP:rs56349744)	VARIANT	0
Q9NQU5/E475K	PAK6	-	0	E -> K (in dbSNP:rs34445577)	VARIANT	2
Q9NQU5/G205E	PAK6	-	1	G -> E (in dbSNP:rs55920845)	VARIANT	0
Q9NQU5/H215R	PAK6	neutral	1	H -> R (in dbSNP:rs3743135)	VARIANT	0
Q9NQU5/L514R	PAK6	-	1	L -> R (in a lung small cell carcinoma sample; somatic mutation)	VARIANT	0
Q9NQU5/M76V	PAK6	neutral	1	M -> V (in dbSNP:rs2412504)	VARIANT	0
Q9NQU5/P208T	PAK6	-	1	P -> T (in dbSNP:rs35501648)	VARIANT	0
Q9NQU5/P337L	PAK6	neutral	1	P -> L (in dbSNP:rs3743137)	VARIANT	0
Q9NQU5/R103C	PAK6	-	0	R -> C (in dbSNP:rs36081263)	VARIANT	0
Q9NQU5/R3H	PAK6	-	1	R -> H (in a colorectal cancer sample; somatic mutation; dbSNP:rs201346085)	VARIANT	0
Q9NQU5/S165A	PAK6	-	1	S->A: Almost complete loss of PAK6 activation by MAP2K6/MAPKK6; when associated with F-566.	MUTAGEN	0
Q9NQU5/S560A	PAK6	-	1	S->A: Complete loss of PAK6 activation by MAP2K6/MAPKK6; when associated with A-165.	MUTAGEN	0
Q9NQU5/T151I	PAK6	-	0	T -> I (in dbSNP:rs35593179)	VARIANT	0
Q9NQU5/T210M	PAK6	-	1	T -> M (in dbSNP:rs34869667)	VARIANT	1
Q9NQU5/Y566F	PAK6	-	1	Y->F: Complete loss of PAK6 activation by MAP2K6/MAPKK6; when associated with A-165.	MUTAGEN	0
Q9NR20/A61T	DYRK4	-	0	A -> T (in dbSNP:rs12306130)	VARIANT	0
Q9NR20/A70S	DYRK4	-	1	A -> S	VARIANT	0
Q9NR20/D454V	DYRK4	neutral	0	D -> V (in dbSNP:rs1801016)	VARIANT	0
Q9NR20/K133R	DYRK4	loss	1	K->R: Loss of kinase activity.	MUTAGEN	0
Q9NR20/N189S	DYRK4	neutral	1	N -> S (in dbSNP:rs3741927)	VARIANT	0
Q9NR20/V95I	DYRK4	-	1	V -> I (in dbSNP:rs746486416)	VARIANT	0
Q9NR20/Y264F	DYRK4	loss	1	Y->F: Abolishes kinase activity.	MUTAGEN	0
Q9NRH2/G611S	SNRK	-	1	G -> S (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs368877591)	VARIANT	0
Q9NRH2/L260S	SNRK	-	1	L -> S (in dbSNP:rs35624204)	VARIANT	0
Q9NRH2/P391S	SNRK	neutral	1	P -> S (in dbSNP:rs56104180)	VARIANT	0
Q9NRH2/P748L	SNRK	-	1	P -> L (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
Q9NRH2/T173A	SNRK	loss	1	T->A,E: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
Q9NRH2/T173E	SNRK	loss	1	T->A,E: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
Q9NRL2/D344E	BAZ1A	-	0	D -> E (in dbSNP:rs1133285)	VARIANT	0
Q9NRL2/N1366K	BAZ1A	neutral	2	N -> K (in dbSNP:rs1044140)	VARIANT	0
Q9NRM7/A1014G	LATS2	neutral	1	A -> G (in dbSNP:rs45523141)	VARIANT	0
Q9NRM7/A324V	LATS2	-	1	A -> V (in dbSNP:rs558614)	VARIANT	3
Q9NRM7/G363S	LATS2	neutral	0	G -> S (in dbSNP:rs2770928)	VARIANT	2
Q9NRM7/G40E	LATS2	-	1	G -> E (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q9NRM7/I799V	LATS2	-	1	I -> V (in dbSNP:rs35368391)	VARIANT	0
Q9NRM7/K697A	LATS2	loss	2	K->A: Loss of kinase activity, autophosphorylation and tumor suppressor activity.	MUTAGEN	0
Q9NRM7/L1025P	LATS2	-	1	L -> P (in dbSNP:rs56116059)	VARIANT	0
Q9NRM7/S83C	LATS2	-	1	S->C: Fails to localize at the centromere during interphase.	MUTAGEN	0
Q9NRM7/S83E	LATS2	-	1	S->E: Fails to localize at the centromere during interphase.	MUTAGEN	0
Q9NRM7/S872A	LATS2	loss	1	S->A: Loss of tumor suppressor activity.	MUTAGEN	0
Q9NRM7/S91L	LATS2	-	1	S -> L (in dbSNP:rs55842804)	VARIANT	2
Q9NRP7/D329N	STK36	neutral	1	D -> N (in dbSNP:rs34027859)	VARIANT	0
Q9NRP7/F476S	STK36	-	1	F -> S (in dbSNP:rs34128793)	VARIANT	0
Q9NRP7/G1003D	STK36	neutral	2	G -> D (in dbSNP:rs1863704)	VARIANT	9
Q9NRP7/H1313P	STK36	-	1	H -> P	VARIANT	0
Q9NRP7/I90M	STK36	-	1	I -> M (in dbSNP:rs55706732)	VARIANT	0
Q9NRP7/K295R	STK36	neutral	1	K -> R (in dbSNP:rs1863703)	VARIANT	0
Q9NRP7/K33R	STK36	-	1	K->R: No effect on nuclear localization of GLI1 or GLI2 or on GLI-mediated transcription.	MUTAGEN	0
Q9NRP7/K463N	STK36	-	1	K -> N (in dbSNP:rs17856747)	VARIANT	0
Q9NRP7/L462V	STK36	neutral	1	L -> V (in dbSNP:rs45586733)	VARIANT	0
Q9NRP7/L672P	STK36	-	1	L -> P (in dbSNP:rs35448374)	VARIANT	0
Q9NRP7/L840V	STK36	neutral	1	L -> V (in dbSNP:rs36099639)	VARIANT	0
Q9NRP7/P1185S	STK36	-	1	P -> S (in an ovarian endometrioid sample; somatic mutation)	VARIANT	1
Q9NRP7/Q1138K	STK36	-	1	Q -> K (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
Q9NRP7/Q638P	STK36	-	0	Q -> P (in dbSNP:rs6709303)	VARIANT	0
Q9NRP7/R1112Q	STK36	neutral	1	R -> Q (in dbSNP:rs12993599)	VARIANT	0
Q9NRP7/R240W	STK36	-	1	R -> W (in dbSNP:rs35038757)	VARIANT	3
Q9NRP7/R477W	STK36	neutral	1	R -> W (in dbSNP:rs16859180)	VARIANT	0
Q9NRP7/R583Q	STK36	neutral	1	R -> Q (in dbSNP:rs1344642)	VARIANT	2
Q9NRP7/R839Q	STK36	-	1	R -> Q (in dbSNP:rs13023540)	VARIANT	0
Q9NRP7/S660C	STK36	-	1	S -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation; dbSNP:rs1244829273)	VARIANT	1
Q9NRP7/S767T	STK36	-	1	S -> T (in dbSNP:rs17856748)	VARIANT	0
Q9NRP7/S767Y	STK36	-	1	S -> Y (in an ovarian papillary serous adenocarcinoma sample; somatic mutation)	VARIANT	0
Q9NRP7/T816A	STK36	-	1	T -> A (in dbSNP:rs34271431)	VARIANT	0
Q9NRP7/V1004I	STK36	neutral	0	V -> I (in dbSNP:rs55633575)	VARIANT	0
Q9NRP7/Y1111C	STK36	-	1	Y -> C (in dbSNP:rs56278660)	VARIANT	1
Q9NSY1/D212V	BMP2K	-	1	D -> V (in dbSNP:rs56143363)	VARIANT	0
Q9NSY1/G405S	BMP2K	neutral	1	G -> S (in dbSNP:rs2288255)	VARIANT	3
Q9NSY1/Q486H	BMP2K	neutral	0	Q -> H (in dbSNP:rs2114202)	VARIANT	2
Q9NSY1/R288H	BMP2K	-	1	R -> H (in dbSNP:rs55782848)	VARIANT	0
Q9NSY1/T1002S	BMP2K	neutral	0	T -> S (in dbSNP:rs12507099)	VARIANT	0
Q9NSY1/V68M	BMP2K	-	1	V -> M (in a lung squamous cell carcinoma sample; somatic mutation; dbSNP:rs770167074)	VARIANT	0
Q9NWZ3/A428T	IRAK4	neutral	1	A -> T (in dbSNP:rs4251545)	VARIANT	0
Q9NWZ3/G298D	IRAK4	decrease	3	G -> D (in IMD67; decreases inhibition of NF-kappa-B complex activation; impairs neutrophil migration and phagocytosis; dbSNP:rs568782766)	VARIANT	0
Q9NWZ3/H390R	IRAK4	-	0	H -> R (in dbSNP:rs4251583)	VARIANT	0
Q9NWZ3/I26T	IRAK4	-	1	I -> T (no effect on inhibition of NF-kappa-B activation; no effect on interaction with MYD88; dbSNP:rs138116867)	VARIANT	0
Q9NWZ3/I39V	IRAK4	-	1	I -> V (no effect on inhibition of NF-kappa-B activation; no effect on interaction with MYD88; dbSNP:rs113588409)	VARIANT	0
Q9NWZ3/I5V	IRAK4	-	2	I -> V (no effect on inhibition of NF-kappa-B activation; no effect on interaction with MYD88; dbSNP:rs56312115)	VARIANT	0
Q9NWZ3/K213A	IRAK4	loss	1	K->A: Loss of kinase activity.	MUTAGEN	0
Q9NWZ3/M355V	IRAK4	-	1	M -> V (in dbSNP:rs142376871)	VARIANT	1
Q9NWZ3/R12C	IRAK4	-	2	R -> C (in IMD67; no effect on inhibition of NF-kappa-B complex activation; loss of interaction with MYD88; decreases protein stability; dbSNP:rs377584435)	VARIANT	2
Q9NWZ3/R20W	IRAK4	-	1	R -> W (increases inhibition of NF-kappa-B complex activation; decreases interaction with MYD88; decreases protein stability; dbSNP:rs143625818)	VARIANT	0
Q9NWZ3/R391H	IRAK4	neutral	2	R -> H (in dbSNP:rs55944915)	VARIANT	0
Q9NWZ3/S98R	IRAK4	-	1	S -> R (no effect on inhibition of NF-kappa-B activation; no effect on interaction with MYD88; dbSNP:rs4251469)	VARIANT	0
Q9NY57/D310V	STK32B	-	1	D -> V (in dbSNP:rs56259884)	VARIANT	0
Q9NY57/G35E	STK32B	-	1	G -> E (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q9NY57/K342T	STK32B	-	1	K -> T (in dbSNP:rs55961955)	VARIANT	0
Q9NY57/R198G	STK32B	neutral	2	R -> G (in dbSNP:rs3733182)	VARIANT	4
Q9NY57/R244H	STK32B	-	1	R -> H (in dbSNP:rs35207488)	VARIANT	0
Q9NYL2/A281T	MAP3K20	-	1	A -> T (in an ovarian endometrioid sample; somatic mutation)	VARIANT	1
Q9NYL2/A281V	MAP3K20	-	1	A -> V (in dbSNP:rs34683477)	VARIANT	0
Q9NYL2/A505S	MAP3K20	-	1	A -> S (in SFMMP; mild destabilization of the protein)	VARIANT	0
Q9NYL2/F368C	MAP3K20	-	1	F -> C (in SFMMP; produces protein aggregation; dbSNP:rs863225437)	VARIANT	0
Q9NYL2/K45M	MAP3K20	loss	3	K->M: Loss of kinase activity. Does not affect ability to activate EIF2AK4/GCN2 in response to mild ribosome collision.	MUTAGEN	0
Q9NYL2/K784T	MAP3K20	-	1	K -> T (in dbSNP:rs55830025)	VARIANT	0
Q9NYL2/P740T	MAP3K20	-	1	P -> T (in dbSNP:rs56202258)	VARIANT	0
Q9NYL2/R250W	MAP3K20	-	1	R -> W (in CNM6; unknown pathological significance; dbSNP:rs763481300)	VARIANT	0
Q9NYL2/R580W	MAP3K20	-	1	R -> W (in dbSNP:rs7593622)	VARIANT	0
Q9NYL2/S165A	MAP3K20	loss	1	S->A: Loss of autophosphorylation activity.	MUTAGEN	0
Q9NYL2/S531L	MAP3K20	-	4	S -> L (in dbSNP:rs3769148)	VARIANT	0
Q9NYL2/S657A	MAP3K20	-	1	S->A: Abolished association with BTRC without affecting protein stability.	MUTAGEN	0
Q9NYL2/T161A	MAP3K20	loss	1	T->A: Loss of autophosphorylation activity.	MUTAGEN	0
Q9NYL2/T162A	MAP3K20	decrease	1	T->A: Slight loss of autophosphorylation activity.	MUTAGEN	0
Q9NYL2/T267M	MAP3K20	-	1	T -> M (in dbSNP:rs6758025)	VARIANT	0
Q9NYL2/Y773H	MAP3K20	-	1	Y -> H (in dbSNP:rs35608243)	VARIANT	0
Q9NYV4/D877N	CDK12	loss	1	D->N: Abolishes kinase activity.	MUTAGEN	0
Q9NYV4/L1189Q	CDK12	neutral	1	L -> Q (in dbSNP:rs56362165)	VARIANT	0
Q9NYV4/P1275L	CDK12	neutral	1	P -> L (in dbSNP:rs34070318)	VARIANT	12
Q9NYV4/P530A	CDK12	-	1	P -> A (in dbSNP:rs56121596)	VARIANT	0
Q9NYV4/R912H	CDK12	-	1	R -> H (in a colorectal adenocarcinoma sample; somatic mutation)	VARIANT	1
Q9NYY3/E436K	PLK2	-	1	E -> K (in dbSNP:rs55768901)	VARIANT	0
Q9NYY3/G92S	PLK2	-	1	G -> S (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q9NYY3/H629A	PLK2	-	1	H->A: Impairs localization to the centrosome and centriole duplication; when associated with F-503 and M-631.	MUTAGEN	0
Q9NYY3/K631M	PLK2	-	1	K->M: Impairs localization to the centrosome and centriole duplication; when associated with F-503 and A-631.	MUTAGEN	0
Q9NYY3/N210A	PLK2	loss	1	N->A: Loss of kinase activity.	MUTAGEN	0
Q9NYY3/P487L	PLK2	-	1	P -> L (in dbSNP:rs55645589)	VARIANT	1
Q9NYY3/S14T	PLK2	-	1	S -> T (in an ovarian Endometrioid carcinoma sample; somatic mutation; dbSNP:rs1404394734)	VARIANT	1
Q9NYY3/W503F	PLK2	-	1	W->F: Impairs localization to the centrosome and centriole duplication; when associated with A-629 and M-631.	MUTAGEN	0
Q9NZJ5/A704S	EIF2AK3	-	3	A -> S (in dbSNP:rs1805165)	VARIANT	0
Q9NZJ5/D566V	EIF2AK3	-	1	D -> V (in dbSNP:rs55791823)	VARIANT	0
Q9NZJ5/P716L	EIF2AK3	-	1	P -> L (in dbSNP:rs55861585)	VARIANT	1
Q9NZJ5/Q166R	EIF2AK3	neutral	3	Q -> R (in dbSNP:rs13045)	VARIANT	0
Q9NZJ5/R588Q	EIF2AK3	-	1	R -> Q (in WRS; dbSNP:rs121908569)	VARIANT	1
Q9NZJ5/S136C	EIF2AK3	neutral	2	S -> C (in dbSNP:rs867529)	VARIANT	11
Q9P0L2/E691G	MARK1	-	1	E -> G (in dbSNP:rs55688276)	VARIANT	0
Q9P0L2/N355T	MARK1	-	1	N -> T (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
Q9P0L2/P578L	MARK1	-	1	P -> L (in dbSNP:rs55691439)	VARIANT	0
Q9P0L2/R645G	MARK1	-	0	R -> G (in dbSNP:rs12123778)	VARIANT	0
Q9P0L2/R698S	MARK1	-	1	R->S: Impairs phospholipid-binding, targeting to membrane and vesicle-binding; when associated with S-701.	MUTAGEN	0
Q9P0L2/R701S	MARK1	-	1	R->S: Impairs phospholipid-binding, targeting to membrane and vesicle-binding; when associated with S-698.	MUTAGEN	0
Q9P0L2/T215A	MARK1	loss	1	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
Q9P0L2/T215E	MARK1	activating	1	T->E: Constitutively active.	MUTAGEN	0
Q9P0L2/V530M	MARK1	-	1	V -> M (in dbSNP:rs56212551)	VARIANT	0
Q9P0L2/Y233C	MARK1	-	1	Y -> C (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	2
Q9P1W9/G138D	PIM2	-	1	G -> D (in dbSNP:rs35044770)	VARIANT	0
Q9P1W9/I280V	PIM2	-	1	I -> V (in dbSNP:rs35208542)	VARIANT	0
Q9P286/A555S	PAK5	-	1	A -> S (in dbSNP:rs34102290)	VARIANT	0
Q9P286/G118D	PAK5	-	1	G -> D (in dbSNP:rs55923311)	VARIANT	0
Q9P286/G704S	PAK5	-	1	G -> S (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1484691555)	VARIANT	2
Q9P286/P187A	PAK5	-	1	P -> A (in dbSNP:rs34280805)	VARIANT	0
Q9P286/R335P	PAK5	-	1	R -> P (in dbSNP:rs11700112)	VARIANT	5
Q9P286/S312P	PAK5	-	1	S -> P (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs952665081)	VARIANT	0
Q9P286/S511N	PAK5	-	2	S -> N (in dbSNP:rs2297345)	VARIANT	3
Q9P286/T538N	PAK5	-	1	T -> N (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q9P286/V604I	PAK5	-	1	V -> I (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q9P289/G36W	STK26	-	1	G -> W (in a gastric adenocarcinoma sample; somatic mutation)	VARIANT	2
Q9P289/K53E	STK26	loss	1	K->E: Abolished serine/threonine-protein kinase activity.	MUTAGEN	0
Q9P289/Q9R	STK26	-	1	Q -> R (in dbSNP:rs56035648)	VARIANT	0
Q9P289/R45C	STK26	-	1	R -> C (in dbSNP:rs56044451)	VARIANT	1
Q9P2K8/D872V	EIF2AK4	-	1	D -> V (in dbSNP:rs34665481)	VARIANT	0
Q9P2K8/G1306C	EIF2AK4	neutral	2	G -> C (in dbSNP:rs35602605)	VARIANT	0
Q9P2K8/H137R	EIF2AK4	-	1	H -> R (in dbSNP:rs35509999)	VARIANT	0
Q9P2K8/H939Y	EIF2AK4	-	1	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation)	VARIANT	0
Q9P2K8/I441L	EIF2AK4	neutral	2	I -> L (in dbSNP:rs2291627)	VARIANT	2
Q9P2K8/K1336R	EIF2AK4	neutral	1	K -> R (in dbSNP:rs35480871)	VARIANT	0
Q9P2K8/L643R	EIF2AK4	-	1	L -> R (in PVOD2; dbSNP:rs757852728)	VARIANT	0
Q9P2K8/Q1406H	EIF2AK4	-	1	Q -> H (in dbSNP:rs55721315)	VARIANT	0
Q9P2K8/R166W	EIF2AK4	-	1	R -> W (in dbSNP:rs34439704)	VARIANT	0
Q9P2K8/R585Q	EIF2AK4	-	1	R -> Q (in PVOD2; dbSNP:rs587777106)	VARIANT	0
Q9P2K8/T1060R	EIF2AK4	-	1	T -> R (in dbSNP:rs55781333)	VARIANT	0
Q9UBE8/A343T	NLK	-	1	A -> T (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	1
Q9UBE8/K167N	NLK	loss	1	K->N: Abrogates kinase activity.	MUTAGEN	0
Q9UBE8/V177A	NLK	-	0	V -> A (in dbSNP:rs11871287)	VARIANT	0
Q9UBS0/A420V	RPS6KB2	neutral	6	A -> V (in dbSNP:rs13859)	VARIANT	2
Q9UBS0/P267L	RPS6KB2	-	1	P -> L (in dbSNP:rs55987642)	VARIANT	3
Q9UBS0/T443M	RPS6KB2	-	1	T -> M (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs374535834)	VARIANT	0
Q9UBS0/V368M	RPS6KB2	-	1	V -> M (in dbSNP:rs55642995)	VARIANT	0
Q9UEE5/E126D	STK17A	neutral	1	E -> D (in dbSNP:rs56286238)	VARIANT	0
Q9UEE5/E286Q	STK17A	neutral	1	E -> Q (in dbSNP:rs3779062)	VARIANT	0
Q9UEE5/K362E	STK17A	neutral	4	K -> E (in dbSNP:rs1044141)	VARIANT	0
Q9UEE5/K90A	STK17A	loss	1	K->A: Loss of activity and of apoptotic function.	MUTAGEN	0
Q9UEE5/M167T	STK17A	-	1	M -> T (in dbSNP:rs35940029)	VARIANT	0
Q9UF33/A711V	EPHA6	neutral	0	A -> V (in dbSNP:rs4857276)	VARIANT	0
Q9UF33/F704S	EPHA6	-	1	F -> S	VARIANT	0
Q9UHD2/A533T	TBK1	-	1	A -> T (no effect on IFNB induction)	VARIANT	0
Q9UHD2/A571V	TBK1	-	1	A -> V (in FTDALS4; dbSNP:rs765035140)	VARIANT	0
Q9UHD2/D135N	TBK1	loss	4	D->N: Loss of kinase activity.	MUTAGEN	0
Q9UHD2/D296H	TBK1	-	1	D -> H (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	1
Q9UHD2/D33A	TBK1	decrease	1	D->A: Decreases phosphorylation and kinase activity.	MUTAGEN	0
Q9UHD2/D50A	TBK1	-	1	D -> A (in IIAE8; decreased expression levels; dbSNP:rs1010930015)	VARIANT	0
Q9UHD2/E355R	TBK1	-	2	E->R: Decreases phosphorylation and kinase activity. Abolishes dimerization; when associated with A-357 or R-448.	MUTAGEN	0
Q9UHD2/E448R	TBK1	-	1	E->R: Decreases phosphorylation and kinase activity. Abolishes dimerization; when associated with R-355.	MUTAGEN	0
Q9UHD2/E580A	TBK1	decrease	1	E->A: Decreases kinase activity.	MUTAGEN	0
Q9UHD2/E653Q	TBK1	-	1	E -> Q (no effect on IFNB induction)	VARIANT	0
Q9UHD2/E696K	TBK1	loss	2	E -> K (in FTDALS4; loss of kinase activity; impairs binding to OPTN; dbSNP:rs748112833)	VARIANT	1
Q9UHD2/F24S	TBK1	-	1	F -> S (loss of IFNB induction)	VARIANT	0
Q9UHD2/F470E	TBK1	-	1	F->E: Abolishes dimerization and decreases kinase activity but no effect on phosphorylation; when associated with E-459 and E-466.	MUTAGEN	0
Q9UHD2/G159A	TBK1	loss	2	G -> A (in IIAE8; loss of kinase activity; loss of autophosphorylation at S-172; loss of IFNB induction; dbSNP:rs1555202947)	VARIANT	0
Q9UHD2/G410R	TBK1	-	1	G -> R (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs1262765773)	VARIANT	0
Q9UHD2/H459E	TBK1	-	1	H->E: Abolishes dimerization and decreases kinase activity but no effect on phosphorylation; when associated with E-466 and E-470.	MUTAGEN	0
Q9UHD2/I207V	TBK1	-	1	I -> V (in IIAE8; unknown pathological significance; dbSNP:rs1555203557)	VARIANT	0
Q9UHD2/I305T	TBK1	-	1	I -> T (in FTDALS4; dbSNP:rs770942184)	VARIANT	0
Q9UHD2/I397T	TBK1	-	1	I -> T (no effect on IFNB induction)	VARIANT	0
Q9UHD2/I466E	TBK1	-	1	I->E: Abolishes dimerization and decreases kinase activity but no effect on phosphorylation; when associated with E-459 and E-470.	MUTAGEN	0
Q9UHD2/I522M	TBK1	-	1	I -> M (no effect on IFNB induction)	VARIANT	0
Q9UHD2/I582A	TBK1	decrease	1	I->A: Decreases kinase activity.	MUTAGEN	0
Q9UHD2/K291E	TBK1	-	1	K -> E (in dbSNP:rs34774243)	VARIANT	0
Q9UHD2/K30R	TBK1	-	1	K->R: Decreases ubiquitination. Abolishes ubiquitination, phosphorylation and kinase activity; when associated with R-401.	MUTAGEN	0
Q9UHD2/K38A	TBK1	loss	5	K->A: Loss of kinase activity.	MUTAGEN	0
Q9UHD2/K401E	TBK1	-	1	K -> E (in FTDALS4; dbSNP:rs756751089)	VARIANT	0
Q9UHD2/K401R	TBK1	-	1	K->R: Decreases ubiquitination. Abolishes ubiquitination, phosphorylation and kinase activity; when associated with R-30.	MUTAGEN	0
Q9UHD2/K570Q	TBK1	-	1	K -> Q (in dbSNP:rs17853341)	VARIANT	0
Q9UHD2/K589D	TBK1	decrease	1	K->D: Decreases phosphorylation and kinase activity.	MUTAGEN	0
Q9UHD2/K694E	TBK1	-	1	K->E: Strongly decreases interaction with TANK and TBKBP1. No effect on phosphorylation.	MUTAGEN	0
Q9UHD2/L306I	TBK1	-	2	L -> I (in FTDALS4; unknown pathological significance; dbSNP:rs201970436)	VARIANT	0
Q9UHD2/L316E	TBK1	decrease	1	L->E: Decreases kinase activity. No effect on phosphorylation.	MUTAGEN	0
Q9UHD2/L508I	TBK1	-	1	L -> I (no effect on IFNB induction)	VARIANT	0
Q9UHD2/L693A	TBK1	-	1	L->A: Almost abolishes interaction with TANK.	MUTAGEN	0
Q9UHD2/L704A	TBK1	-	1	L->A: Strongly decreases interaction with AZI2, TANK and TBKBP1. No effect on phosphorylation.	MUTAGEN	0
Q9UHD2/L711A	TBK1	-	1	L->A: Almost abolishes interaction with TANK.	MUTAGEN	0
Q9UHD2/M559R	TBK1	loss	1	M -> R (in FTDALS4; loss of kinase activity)	VARIANT	0
Q9UHD2/M598V	TBK1	-	1	M -> V (in FTDALS4; dbSNP:rs899858451)	VARIANT	0
Q9UHD2/M690A	TBK1	-	1	M->A: Decreases interaction with TANK.	MUTAGEN	0
Q9UHD2/N388D	TBK1	-	1	N -> D (in dbSNP:rs17857028)	VARIANT	0
Q9UHD2/N388S	TBK1	-	1	N -> S (no effect on IFNB induction)	VARIANT	0
Q9UHD2/N578A	TBK1	decrease	1	N->A: Reduced phosphorylation of STING1.	MUTAGEN	0
Q9UHD2/N708A	TBK1	-	1	N->A: Decreases interaction with TANK.	MUTAGEN	0
Q9UHD2/P659S	TBK1	-	1	P -> S (no effect on IFNB induction)	VARIANT	0
Q9UHD2/Q581A	TBK1	decrease	1	Q->A: Reduced phosphorylation of STING1.	MUTAGEN	0
Q9UHD2/R271Q	TBK1	-	1	R -> Q (in dbSNP:rs56196591)	VARIANT	0
Q9UHD2/R308Q	TBK1	decrease	1	R -> Q (in FTDALS4; reduced kinase activity)	VARIANT	0
Q9UHD2/R357A	TBK1	-	1	R->A: Decreases phosphorylation and kinase activity. Abolishes dimerization; when associated with R-355.	MUTAGEN	0
Q9UHD2/R357Q	TBK1	decrease	1	R -> Q (in FTDALS4; reduced kinase activity; dbSNP:rs758357594)	VARIANT	0
Q9UHD2/R384Q	TBK1	-	1	R -> Q (no effect on IFNB induction)	VARIANT	0
Q9UHD2/R47H	TBK1	loss	1	R -> H (in FTDALS4; loss of kinase activity)	VARIANT	0
Q9UHD2/R547D	TBK1	decrease	1	R->D: Decreases phosphorylation and kinase activity. Abolishes dimerization.	MUTAGEN	0
Q9UHD2/S151F	TBK1	-	1	S -> F (in dbSNP:rs55824172)	VARIANT	0
Q9UHD2/S172A	TBK1	loss	3	S->A: Loss of kinase activity. No effect on dimerization. Loss of localization to cytoplasmic spherical structures.	MUTAGEN	0
Q9UHD2/S172E	TBK1	decrease	2	S->E: Decreased kinase activity.	MUTAGEN	0
Q9UHD2/V152L	TBK1	-	1	V -> L (no effect on IFNB induction)	VARIANT	0
Q9UHD2/V464A	TBK1	neutral	2	V -> A (in dbSNP:rs35635889)	VARIANT	0
Q9UHD2/Y105C	TBK1	-	1	Y -> C (in FTDALS4; dbSNP:rs1366668789)	VARIANT	0
Q9UHD2/Y179A	TBK1	-	1	Y->A: Loss of localization to cytoplasmic spherical structures.	MUTAGEN	0
Q9UHD2/Y325E	TBK1	loss	1	Y->E: Abolishes phosphorylation and kinase activity.	MUTAGEN	0
Q9UHD2/Y577A	TBK1	decrease	2	Y->A: Decreases kinase activity. Reduced phosphorylation of STING1.	MUTAGEN	0
Q9UHY1/H460R	NRBP1	-	1	H -> R (in dbSNP:rs34260196)	VARIANT	0
Q9UHY1/P432L	NRBP1	-	1	P -> L (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs753734841)	VARIANT	0
Q9UHY1/V365I	NRBP1	neutral	1	V -> I (in dbSNP:rs56004639)	VARIANT	0
Q9UIG0/C338A	BAZ1B	loss	1	C->A: Loss of tyrosine-protein kinase activity.	MUTAGEN	0
Q9UIK4/K52A	DAPK2	loss	3	K->A: Loss of activity, apoptotic function and of autophosphorylation.	MUTAGEN	0
Q9UIK4/R271W	DAPK2	-	1	R -> W (in dbSNP:rs34270163)	VARIANT	0
Q9UIK4/R60W	DAPK2	-	1	R -> W (in dbSNP:rs56047843)	VARIANT	0
Q9UIK4/S299A	DAPK2	-	1	S->A: No effect on Ca(2+)-calmodulin independent phosphorylation or apoptotic activity.	MUTAGEN	0
Q9UIK4/S318A	DAPK2	activating	1	S->A: Loss of Ca(2+)-calmodulin independent phosphorylation, increase in apoptotic activity.	MUTAGEN	0
Q9UIK4/S318D	DAPK2	-	1	S->D: Abolishes apoptotic activity.	MUTAGEN	0
Q9UIK4/S320A	DAPK2	-	1	S->A: No effect on Ca(2+)-calmodulin independent phosphorylation or apoptotic activity.	MUTAGEN	0
Q9UIK4/S323A	DAPK2	-	1	S->A: No effect on Ca(2+)-calmodulin independent phosphorylation or apoptotic activity.	MUTAGEN	0
Q9UIK4/S367A	DAPK2	-	1	S->A: No effect on interaction with YWHAE.	MUTAGEN	0
Q9UIK4/S368A	DAPK2	-	1	S->A: No effect on interaction with YWHAE.	MUTAGEN	0
Q9UIK4/T329A	DAPK2	-	1	T->A: No effect on Ca(2+)-calmodulin independent phosphorylation or apoptotic activity.	MUTAGEN	0
Q9UK32/D692N	RPS6KA6	neutral	1	D -> N (in dbSNP:rs6616890)	VARIANT	2
Q9UK32/S258T	RPS6KA6	-	1	S -> T (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q9UK32/S372A	RPS6KA6	-	1	S->A: No effect on activity.	MUTAGEN	0
Q9UK32/S389A	RPS6KA6	decrease	1	S->A: Strongly decreases activity.	MUTAGEN	0
Q9UK32/T581A	RPS6KA6	-	1	T->A: No effect on activity.	MUTAGEN	0
Q9UK32/Y140C	RPS6KA6	-	1	Y -> C (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	1
Q9UKE5/A999T	TNIK	neutral	1	A -> T (in dbSNP:rs17857452)	VARIANT	0
Q9UKE5/G910E	TNIK	-	1	G -> E (in dbSNP:rs35090763)	VARIANT	0
Q9UKE5/K54A	TNIK	loss	2	K->A: Kinase dead. Loss of autophosphorylation and loss of function in cytoskeleton regulation.	MUTAGEN	0
Q9UKE5/K778E	TNIK	-	1	K -> E (in dbSNP:rs55778284)	VARIANT	0
Q9UKI8/D607A	TLK1	loss	2	D->A: Loss of kinase activity.	MUTAGEN	0
Q9UKI8/R121C	TLK1	-	1	R -> C	VARIANT	0
Q9UKI8/S743A	TLK1	loss	1	S->A: Loss of kinase inhibition in response to DNA damage.	MUTAGEN	0
Q9UKI8/S743D	TLK1	loss	1	S->D: Loss of kinase inhibition in response to DNA damage.	MUTAGEN	0
Q9UKI8/S743E	TLK1	loss	1	S->E: Loss of kinase inhibition in response to DNA damage.	MUTAGEN	0
Q9UL54/D169A	TAOK2	loss	1	D->A: Loss of kinase activity; No effect on MAP3K7-mediated activation of NF-kappa-B.	MUTAGEN	0
Q9UL54/D919N	TAOK2	-	1	D->N: No effect on kinase activity, nor on JNK activation, but severe reduction in nuclear localization and apoptotic membrane blebbing.	MUTAGEN	0
Q9UL54/K57A	TAOK2	loss	4	K->A: Loss of kinase activity. In isoform 1, excluded from the nucleus. No effect on microtubule-binding.	MUTAGEN	0
Q9UM73/A1234T	ALK	-	1	A -> T (in NBLST3; somatic mutation)	VARIANT	1
Q9UM73/A1274T	ALK	-	1	A -> T (in dbSNP:rs45502292)	VARIANT	1
Q9UM73/A704T	ALK	-	1	A -> T (in dbSNP:rs34829159)	VARIANT	1
Q9UM73/A877S	ALK	-	1	A -> S (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs746442213)	VARIANT	0
Q9UM73/D1091N	ALK	-	1	D -> N (in NBLST3; somatic mutation; dbSNP:rs864309584)	VARIANT	0
Q9UM73/D1529E	ALK	neutral	3	D -> E (in dbSNP:rs1881421)	VARIANT	10
Q9UM73/E1419K	ALK	-	1	E -> K (in dbSNP:rs56181542)	VARIANT	5
Q9UM73/E296Q	ALK	-	1	E -> Q (in dbSNP:rs56077855)	VARIANT	0
Q9UM73/E859A	ALK	-	1	E->A: Slightly decreased autophosphorylation. Decreased autophosphorylation and subsequent activation; when associated with A-974.	MUTAGEN	0
Q9UM73/E974A	ALK	-	1	E->A: Slightly decreased autophosphorylation. Decreased autophosphorylation and subsequent activation; when associated with A-859.	MUTAGEN	0
Q9UM73/E994A	ALK	-	1	E->A: SlStrongly reduced autophosphorylation and subsequent activation; when associated with A-966.	MUTAGEN	0
Q9UM73/F1174C	ALK	-	1	F -> C (in NBLST3; dbSNP:rs1057519697)	VARIANT	15
Q9UM73/F1174I	ALK	-	1	F -> I (in NBLST3; somatic mutation; dbSNP:rs281864719)	VARIANT	6
Q9UM73/F1174L	ALK	activating,resistance	3	F -> L (in NBLST3; somatic mutation; constitutively activated; retained in the endoplasmic reticulum and Golgi compartments; dbSNP:rs863225281)	VARIANT	137
Q9UM73/F1174V	ALK	activating,resistance	2	F -> V (in NBLST3; somatic mutation; constitutively activated; retained in the endoplasmic reticulum and Golgi compartments; dbSNP:rs281864719)	VARIANT	6
Q9UM73/F1245C	ALK	-	2	F -> C (in NBLST3; somatic mutation; dbSNP:rs863225283)	VARIANT	10
Q9UM73/F1245V	ALK	-	0	F -> V (in NBLST3; somatic mutation; dbSNP:rs281864720)	VARIANT	13
Q9UM73/F1376S	ALK	-	0	F -> S (in dbSNP:rs17694720)	VARIANT	0
Q9UM73/G1121D	ALK	-	1	G -> D (in dbSNP:rs55760835)	VARIANT	2
Q9UM73/G1128A	ALK	-	1	G -> A (in NBLST3; dbSNP:rs113994088)	VARIANT	0
Q9UM73/I1171N	ALK	resistance	1	I -> N (in NBLST3; somatic mutation; dbSNP:rs1057519698)	VARIANT	11
Q9UM73/I1250T	ALK	-	1	I -> T (in NBLST3; somatic mutation; dbSNP:rs113994092)	VARIANT	0
Q9UM73/I1461V	ALK	neutral	4	I -> V (in dbSNP:rs1670283)	VARIANT	0
Q9UM73/K1416N	ALK	-	1	K -> N (in dbSNP:rs55782189)	VARIANT	0
Q9UM73/K1491R	ALK	neutral	3	K -> R (in dbSNP:rs1881420)	VARIANT	19
Q9UM73/L560F	ALK	-	1	L -> F (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	VARIANT	1
Q9UM73/L868Q	ALK	-	0	L -> Q (in dbSNP:rs55941323)	VARIANT	0
Q9UM73/M1166R	ALK	-	1	M -> R (in NBLST3; somatic mutation; dbSNP:rs1057520019)	VARIANT	2
Q9UM73/M1328L	ALK	-	1	M -> L (in dbSNP:rs56160491)	VARIANT	0
Q9UM73/P1599H	ALK	-	0	P -> H (in dbSNP:rs1881423)	VARIANT	0
Q9UM73/Q1429R	ALK	-	1	Q -> R (in dbSNP:rs55906201)	VARIANT	0
Q9UM73/R1192P	ALK	-	2	R -> P (in NBLST3; dbSNP:rs113994089)	VARIANT	0
Q9UM73/R1275L	ALK	-	1	R -> L (observed in neuroblastoma; dbSNP:rs113994087)	VARIANT	8
Q9UM73/R1275Q	ALK	activating	5	R -> Q (in NBLST3; constitutively activated; retained in the endoplasmic reticulum and Golgi compartments; dbSNP:rs113994087)	VARIANT	101
Q9UM73/S90L	ALK	-	1	S -> L (in dbSNP:rs34617074)	VARIANT	0
Q9UM73/T1012M	ALK	-	1	T -> M (in dbSNP:rs35073634)	VARIANT	0
Q9UM73/T1151M	ALK	-	1	T -> M (in NBLST3; dbSNP:rs113994091)	VARIANT	4
Q9UM73/T680I	ALK	-	1	T -> I (in dbSNP:rs35228363)	VARIANT	19
Q9UM73/V163L	ALK	-	1	V -> L (in dbSNP:rs55697431)	VARIANT	0
Q9UM73/V476A	ALK	neutral	1	V -> A (in dbSNP:rs35093491)	VARIANT	28
Q9UM73/Y1278S	ALK	-	1	Y -> S (in NBLST3; somatic mutation; dbSNP:rs863225285)	VARIANT	6
Q9UM73/Y1507F	ALK	-	1	Y->F: Impairs interaction with SHC1.	MUTAGEN	0
Q9UM73/Y966A	ALK	-	1	Y->A: Slightly decreased autophosphorylation. Strongly reduced autophosphorylation and subsequent activation; when associated with A-994.	MUTAGEN	0
Q9UPE1/E233K	SRPK3	-	1	E -> K (in dbSNP:rs34497419)	VARIANT	0
Q9UPE1/G114E	SRPK3	-	1	G -> E (in dbSNP:rs35865042)	VARIANT	0
Q9UPE1/R101C	SRPK3	-	1	R -> C (in dbSNP:rs55910507)	VARIANT	0
Q9UPN9/C125A	TRIM33	-	1	C->A: Abolishes E3 activity but does not affect interaction with SMAD4; when associated with A-128.	MUTAGEN	0
Q9UPN9/C128A	TRIM33	-	1	C->A: Abolishes E3 activity but does not affect interaction with SMAD4; when associated with A-125.	MUTAGEN	0
Q9UPN9/E811K	TRIM33	-	1	E -> K (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	0
Q9UPN9/I840T	TRIM33	neutral	4	I -> T (in dbSNP:rs6537825)	VARIANT	0
Q9UPN9/L696S	TRIM33	-	1	L -> S (in dbSNP:rs56151583)	VARIANT	0
Q9UPN9/M580I	TRIM33	-	1	M -> I (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	0
Q9UPN9/P1090T	TRIM33	-	1	P -> T (in dbSNP:rs55784699)	VARIANT	0
Q9UPN9/P885S	TRIM33	-	1	P -> S (in a glioblastoma multiforme sample; somatic mutation)	VARIANT	0
Q9UPN9/V67A	TRIM33	neutral	0	V -> A (in dbSNP:rs6691166)	VARIANT	0
Q9UPN9/V961M	TRIM33	-	1	V -> M (in dbSNP:rs55688622)	VARIANT	0
Q9UPZ9/A615T	CILK1	-	2	A -> T (in EJM10; unknown pathological significance; impairs mitosis, cell-cycle exit and radial neuroblast migration, while promoting apoptosis, when tested in a heterologous system; dbSNP:rs55932059)	VARIANT	0
Q9UPZ9/F115Y	CILK1	-	1	F -> Y (in a renal clear cell carcinoma sample; somatic mutation)	VARIANT	0
Q9UPZ9/I102L	CILK1	-	1	I -> L (in EJM10; unknown pathological significance; dbSNP:rs748539319)	VARIANT	0
Q9UPZ9/K220E	CILK1	-	1	K -> E (in EJM10; impairs mitosis, cell-cycle exit and radial neuroblast migration, while promoting apoptosis, when tested in a heterologous system)	VARIANT	0
Q9UPZ9/K305T	CILK1	-	1	K -> T (in EJM10; impairs mitosis, cell-cycle exit and radial neuroblast migration, while promoting apoptosis, when tested in a heterologous system; dbSNP:rs765078446)	VARIANT	0
Q9UPZ9/K33R	CILK1	-	1	K->R: Loss of activity and autophosphorylation; when associated with R-34; R-36 and R-38.	MUTAGEN	0
Q9UPZ9/K34R	CILK1	-	1	K->R: Loss of activity and autophosphorylation; when associated with R-33; R-36 and R-38.	MUTAGEN	0
Q9UPZ9/K36R	CILK1	-	1	K->R: Loss of activity and autophosphorylation; when associated with R-33; R-34 and R-38.	MUTAGEN	0
Q9UPZ9/K38R	CILK1	-	1	K->R: Loss of activity and autophosphorylation; when associated with R-33; R-34 and R-36.	MUTAGEN	0
Q9UPZ9/P98L	CILK1	-	0	P -> L (in dbSNP:rs1493105)	VARIANT	0
Q9UPZ9/R272Q	CILK1	decrease	4	R -> Q (in ECO; significantly impairs kinase activity; decreased localization at the ciliary tips; impaired ciliogenesis; results in abnormally elongated cilia; impairs mitosis, cell-cycle exit and radial neuroblast migration, while promoting apoptosis, when tested in a heterologous system; loss of nuclear localization; dbSNP:rs118203918)	VARIANT	0
Q9UPZ9/R476Q	CILK1	-	1	R -> Q (in dbSNP:rs55895113)	VARIANT	0
Q9UPZ9/T157A	CILK1	decrease	1	T->A: Reduction of activity and loss of autophosphorylation. Loss of activity and autophosphorylation; when associated with F-159.	MUTAGEN	0
Q9UPZ9/T471K	CILK1	-	1	T -> K (in dbSNP:rs56164633)	VARIANT	0
Q9UPZ9/V320I	CILK1	-	2	V -> I (in dbSNP:rs33936662)	VARIANT	0
Q9UPZ9/Y159F	CILK1	decrease	1	Y->F: Reduction of activity and loss of autophosphorylation. Loss of activity and autophosphorylation; when associated with A-157.	MUTAGEN	0
Q9UQ07/D86N	MOK	neutral	1	D -> N (in dbSNP:rs34084056)	VARIANT	0
Q9UQ07/E272D	MOK	-	1	E -> D (in a breast pleomorphic lobular carcinoma sample; somatic mutation; dbSNP:rs1567133856)	VARIANT	1
Q9UQ07/K230R	MOK	neutral	1	K -> R (in dbSNP:rs34965156)	VARIANT	0
Q9UQ07/P248S	MOK	neutral	1	P -> S (in dbSNP:rs34299975)	VARIANT	0
Q9UQ07/Q398R	MOK	neutral	1	Q -> R (in dbSNP:rs2236493)	VARIANT	0
Q9UQ07/R38H	MOK	neutral	1	R -> H (in dbSNP:rs34114580)	VARIANT	0
Q9UQ07/V217I	MOK	-	1	V -> I (in dbSNP:rs148360666)	VARIANT	0
Q9UQB9/D166Y	AURKC	decrease	1	D->Y: Impairs kinase activity, and keeps AURKC with the chromosomes until the end of mitosis.	MUTAGEN	0
Q9UQB9/E148Q	AURKC	-	1	E -> Q (in a lung squamous cell carcinoma sample; somatic mutation)	VARIANT	0
Q9UQB9/G52E	AURKC	-	1	G -> E (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q9UQB9/H244Q	AURKC	-	1	H -> Q (in a lung adenocarcinoma sample; somatic mutation)	VARIANT	1
Q9UQB9/K72R	AURKC	decrease	2	K->R: Impairs kinase activity.	MUTAGEN	0
Q9UQB9/T198A	AURKC	decrease	2	T->A: Impairs kinase activity.	MUTAGEN	0
Q9UQM7/A112V	CAMK2A	-	1	A -> V (in MRD53; unknown pathological significance)	VARIANT	0
Q9UQM7/E109D	CAMK2A	increase	1	E -> D (in MRD53; no effect on protein abundance; increased autophosphorylation; decreased neuronal migration)	VARIANT	0
Q9UQM7/E183V	CAMK2A	decrease	2	E -> V (in MRD53; increased ubiquitin-mediated proteasomal degradation with a dominant negative effect on wild-type protein; decreased localization to dendritic spines; no effect on holoenzyme assembly; loss of interaction with SHANK3; loss of interaction with GRIN2B; loss of interaction with CACNB2; loss of interaction with LRRC7; loss of interaction with GRM5; decreased protein serine/threonine kinase activity with a dominant negative effect on wild-type protein; decreased autophosphorylation; changed dendritic spine development; decreased neuronal migration; dbSNP:rs1554122129)	VARIANT	0
Q9UQM7/F98S	CAMK2A	decrease	1	F -> S (in MRD53; no effect on protein abundance; decreased autophosphorylation; decreased neuronal migration; dbSNP:rs1554122526)	VARIANT	0
Q9UQM7/H282R	CAMK2A	increase	1	H -> R (in MRD53; decreased protein abundance; increased autophosphorylation; decreased neuronal migration; dbSNP:rs1554121875)	VARIANT	0
Q9UQM7/H466Y	CAMK2A	-	1	H -> Y (in MRT63; decreased oligomerization; dbSNP:rs1554119274)	VARIANT	0
Q9UQM7/K42R	CAMK2A	-	1	K->R: No effect on protein stability or degradation. No effect on neuronal migration; when associated with P-286.	MUTAGEN	0
Q9UQM7/P138A	CAMK2A	-	2	P -> A (in MRD53; unknown pathological significance; no effect on protein abundance; no effect on autophosphorylation; no effect on neuronal migration)	VARIANT	0
Q9UQM7/P212L	CAMK2A	-	1	P -> L (in MRD53; unknown pathological significance; no effect on protein abundance; no effect on autophosphorylation; no effect on neuronal migration; dbSNP:rs926027867)	VARIANT	0
Q9UQM7/P212Q	CAMK2A	increase	1	P -> Q (in MRD53; increased basal autophosphorylation)	VARIANT	1
Q9UQM7/P235L	CAMK2A	-	2	P -> L (in MRD53; unknown pathological significance; no effect on protein abundance; no effect on autophosphorylation; no effect on neuronal migration; dbSNP:rs864309606)	VARIANT	0
Q9UQM7/T286A	CAMK2A	-	1	T->A: No effect on neuronal migration.	MUTAGEN	0
Q9UQM7/T286D	CAMK2A	-	1	T->D: Loss of neuronal migration.	MUTAGEN	0
Q9UQM7/T286P	CAMK2A	-	1	T->P: No effect on neuronal migration; when associated with R-42.	VARIANT	0
Q9Y243/E17K	AKT3	activating	3	E -> K (in MPPH2 and melanoma; results in activation of AKT; dbSNP:rs397514606)	VARIANT	9
Q9Y243/G171R	AKT3	-	1	G -> R (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs1402272180)	VARIANT	1
Q9Y243/N229S	AKT3	-	2	N -> S (in MPPH2; dbSNP:rs397514605)	VARIANT	0
Q9Y243/R465W	AKT3	-	1	R -> W (in MPPH2; disease phenotype overlaps with megalencephaly-capillary malformation syndrome; dbSNP:rs587776935)	VARIANT	1
Q9Y243/S472A	AKT3	decrease	1	S->A: 67% decrease of activity after pervanadate treatment.	MUTAGEN	0
Q9Y243/S472D	AKT3	increase	1	S->D: 1.4-fold increase of phosphorylation steady state level, 50% decrease of activity after pervanadate treatment.	MUTAGEN	0
Q9Y243/T305A	AKT3	-	1	T->A: No activation after pervanadate treatment.	MUTAGEN	0
Q9Y243/T305D	AKT3	increase	1	T->D: 2-fold increase of phosphorylation steady state level, no activation after pervanadate treatment.	MUTAGEN	0
Q9Y243/T447A	AKT3	-	1	T->A: No effect.	MUTAGEN	0
Q9Y243/T447D	AKT3	-	1	T->D: No effect.	MUTAGEN	0
Q9Y2H1/G99A	STK38L	-	1	G -> A (in a aLLTEL/AML1+ sample; somatic mutation)	VARIANT	1
Q9Y2H1/K119A	STK38L	loss	1	K->A: Loss of autophosphorylation and kinase activity.	MUTAGEN	0
Q9Y2H1/S282A	STK38L	loss	1	S->A: Loss of autophosphorylation and kinase activity.	MUTAGEN	0
Q9Y2H1/T442A	STK38L	decrease	1	T->A: Decreased kinase activity.	MUTAGEN	0
Q9Y2H1/T75A	STK38L	decrease	1	T->A: Decreased kinase activity. Reduced binding of S100B.	MUTAGEN	0
Q9Y2H9/A1048S	MAST1	-	0	A -> S (in dbSNP:rs35052801)	VARIANT	0
Q9Y2H9/A269T	MAST1	-	1	A -> T (in a metastatic melanoma sample; somatic mutation)	VARIANT	3
Q9Y2H9/A915T	MAST1	-	1	A -> T (in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance)	VARIANT	1
Q9Y2H9/G517S	MAST1	-	1	G -> S (in MCCCHCM; dbSNP:rs1568413207)	VARIANT	1
Q9Y2H9/G98V	MAST1	-	1	G -> V (in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance)	VARIANT	0
Q9Y2H9/H1240Y	MAST1	-	1	H -> Y (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs1411105125)	VARIANT	1
Q9Y2H9/P1177R	MAST1	-	1	P -> R (in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance)	VARIANT	0
Q9Y2H9/P1292S	MAST1	-	1	P -> S (in dbSNP:rs35071862)	VARIANT	0
Q9Y2H9/S93L	MAST1	-	1	S -> L (in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance; dbSNP:rs878853165)	VARIANT	0
Q9Y2K2/A1161V	SIK3	-	1	A -> V (in a breast cancer sample; somatic mutation)	VARIANT	1
Q9Y2K2/D1098E	SIK3	neutral	0	D -> E (in dbSNP:rs11216163)	VARIANT	0
Q9Y2K2/H389L	SIK3	-	1	H -> L (in a breast cancer sample; somatic mutation; dbSNP:rs376144593)	VARIANT	2
Q9Y2K2/P1136R	SIK3	-	0	P -> R (in dbSNP:rs12225230)	VARIANT	1
Q9Y2K2/R187C	SIK3	decrease	1	R -> C (in SEMDK; decreased protein expression; decreased kinase activity; no effect on the interaction with DEPTOR, MLST8/GbetaL, RICTOR and RPTOR; dbSNP:rs1565460853)	VARIANT	0
Q9Y2K2/S551A	SIK3	loss	1	S->A: Loss of interaction with 14-3-3 proteins in response to cAMP signaling; inhibits cAMP signaling.	MUTAGEN	0
Q9Y2K2/S551E	SIK3	loss	1	S->E: Loss of interaction with 14-3-3 proteins in response to cAMP signaling; inhibits cAMP signaling.	MUTAGEN	0
Q9Y2K2/S626A	SIK3	-	1	S->A: No effect on interaction with 14-3-3 proteins, nor on cAMP signaling.	MUTAGEN	0
Q9Y2K2/S626E	SIK3	-	1	S->E: No effect on cAMP signaling.	MUTAGEN	0
Q9Y2K2/T221A	SIK3	loss	1	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	MUTAGEN	0
Q9Y2K2/T469A	SIK3	loss	1	T->A: Loss of interaction with 14-3-3 proteins in response to cAMP signaling; inhibits cAMP signaling.	MUTAGEN	0
Q9Y2K2/T469E	SIK3	loss	1	T->E: Loss of interaction with 14-3-3 proteins in response to cAMP signaling; inhibits cAMP signaling.	MUTAGEN	0
Q9Y2U5/D140G	MAP3K2	-	1	D -> G (in dbSNP:rs56307783)	VARIANT	0
Q9Y2U5/I110V	MAP3K2	-	1	I -> V (in dbSNP:rs55767983)	VARIANT	0
Q9Y2U5/M112I	MAP3K2	-	1	M -> I (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q9Y3S1/R974L	WNK2	-	0	R -> L (in dbSNP:rs10114908)	VARIANT	0
Q9Y3S1/V828M	WNK2	neutral	0	V -> M (in dbSNP:rs10761203)	VARIANT	6
Q9Y463/D239A	DYRK1B	loss	1	D->A: Abolishes kinase activity.	MUTAGEN	0
Q9Y463/H90P	DYRK1B	increase	1	H -> P (in AOMS3; expression of glucose-6-phosphatase is significantly higher than wild-type; dbSNP:rs587777380)	VARIANT	0
Q9Y463/K140R	DYRK1B	-	1	K->R: Abolishes kinase activity.	MUTAGEN	0
Q9Y463/L28P	DYRK1B	neutral	1	L -> P (in dbSNP:rs34587974)	VARIANT	0
Q9Y463/Q275R	DYRK1B	-	1	Q -> R (in a metastatic melanoma sample; somatic mutation)	VARIANT	1
Q9Y463/R102C	DYRK1B	decrease	1	R -> C (in AOMS3; accumulation of intracellular lipid is significantly greater than with wild-type protein; cells expressing the variant are able to transform into mature adipocytes without requiring adipogenic medium; expression levels of CEBPA, PPARG forms 1 and 2 and PPARGC1A are higher and those of GLI1 and CDKN1B are lower in cells transfected with the mutant protein compared to wild-type; WNT1 signaling activity is lower in mutant cells compared to wild-type; dbSNP:rs367643250)	VARIANT	0
Q9Y463/R102H	DYRK1B	-	1	R -> H (in dbSNP:rs55687541)	VARIANT	0
Q9Y463/S234G	DYRK1B	-	1	S -> G (in dbSNP:rs35858874)	VARIANT	0
Q9Y463/Y271F	DYRK1B	-	1	Y->F: Abolishes kinase activity; when associated with F-273.	MUTAGEN	0
Q9Y463/Y273F	DYRK1B	-	1	Y->F: Abolishes kinase activity; when associated with F-271.	MUTAGEN	0
Q9Y4A5/A1043T	TRRAP	-	1	A -> T (in DEDDFA; dbSNP:rs1562945106)	VARIANT	0
Q9Y4A5/D394N	TRRAP	-	1	D -> N (in DFNA75; unknown pathological significance; dbSNP:rs1554407965)	VARIANT	0
Q9Y4A5/E1104G	TRRAP	-	1	E -> G (in DEDDFA; dbSNP:rs1790257064)	VARIANT	0
Q9Y4A5/E1106K	TRRAP	-	1	E -> K (in DEDDFA; dbSNP:rs1584324956)	VARIANT	0
Q9Y4A5/F860L	TRRAP	-	1	F -> L (in DEDDFA; unknown pathological significance)	VARIANT	0
Q9Y4A5/G1111W	TRRAP	-	1	G -> W (in DEDDFA; unknown pathological significance)	VARIANT	0
Q9Y4A5/G1159R	TRRAP	-	1	G -> R (in DEDDFA; dbSNP:rs1790288810)	VARIANT	0
Q9Y4A5/I1031M	TRRAP	-	1	I -> M (in DEDDFA)	VARIANT	0
Q9Y4A5/L805F	TRRAP	-	1	L -> F (in DEDDFA; unknown pathological significance; dbSNP:rs1562940289)	VARIANT	0
Q9Y4A5/R1035Q	TRRAP	-	1	R -> Q (in DEDDFA; unknown pathological significance)	VARIANT	0
Q9Y4A5/R171C	TRRAP	-	1	R -> C (in DFNA75; unknown pathological significance; dbSNP:rs200157211)	VARIANT	0
Q9Y4A5/R878L	TRRAP	-	0	R -> L (in dbSNP:rs17161510)	VARIANT	0
Q9Y4A5/R893C	TRRAP	-	1	R -> C (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
Q9Y4A5/R893L	TRRAP	-	1	R -> L (in DEDDFA; unknown pathological significance)	VARIANT	0
Q9Y4A5/S1037R	TRRAP	-	1	S -> R (in DEDDFA; unknown pathological significance)	VARIANT	0
Q9Y4A5/S1070G	TRRAP	-	1	S -> G (in dbSNP:rs55920979)	VARIANT	0
Q9Y4A5/S722F	TRRAP	-	1	S -> F (found in a cutaneous malignant melanoma sample; somatic mutation; induces cell transformation and confers resistance to apoptosis; dbSNP:rs147405090)	VARIANT	0
Q9Y4K4/A334T	MAP4K5	neutral	1	A -> T (in dbSNP:rs12881869)	VARIANT	0
Q9Y4K4/H41Y	MAP4K5	-	0	H -> Y (in dbSNP:rs34726242)	VARIANT	0
Q9Y4K4/I446V	MAP4K5	-	1	I -> V (in dbSNP:rs55815015)	VARIANT	1
Q9Y4K4/K473N	MAP4K5	neutral	1	K -> N (in dbSNP:rs35768475)	VARIANT	0
Q9Y4K4/K49R	MAP4K5	loss	1	K->R: Loss of kinase activity and ability to activate JNK family.	MUTAGEN	0
Q9Y4K4/P407L	MAP4K5	neutral	1	P -> L (in dbSNP:rs34818002)	VARIANT	0
Q9Y4K4/R552Q	MAP4K5	-	1	R -> Q (in dbSNP:rs55997280)	VARIANT	0
Q9Y4K4/T633M	MAP4K5	neutral	1	T -> M (in dbSNP:rs17780143)	VARIANT	1
Q9Y572/D142N	RIPK3	loss	1	D->N: Abolishes kinase activity and ability to mediate necroptosis.	MUTAGEN	0
Q9Y572/E260V	RIPK3	-	0	E -> V (in dbSNP:rs7153640)	VARIANT	0
Q9Y572/K363R	RIPK3	-	1	K->R: Loss of PELI1-mediated ubiquitination. No loss of interaction with PELI1.	MUTAGEN	0
Q9Y572/K50A	RIPK3	loss	4	K->A: Abolishes kinase activity. Loss of PGAM5- and MLKL-binding. No effect on RIPK1-binding. Loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of STUB1-mediated ubiquitination.	MUTAGEN	0
Q9Y572/K50D	RIPK3	loss	3	K->D: Abolishes kinase activity.	MUTAGEN	0
Q9Y572/P492Q	RIPK3	neutral	1	P -> Q (in dbSNP:rs3212254)	VARIANT	31
Q9Y572/S227A	RIPK3	decrease	2	S->A: Abolishes ability to mediate necroptosis. Partial loss of kinase activity. No loss of PELI1-mediated degradation.	MUTAGEN	0
Q9Y572/S227D	RIPK3	-	1	S->D: No loss of PELI1-mediated degradation.	MUTAGEN	0
Q9Y572/T182A	RIPK3	loss	1	T->A: Abolishes kinase activity. Loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of interaction with STUB1 and STUB1-mediated ubiquitination. No loss of interaction with RIPK1. Loss of ability to mediate TNF-induced necroptosis. Loss of autophosphorylation at Ser-227.	MUTAGEN	0
Q9Y572/T182S	RIPK3	-	1	T->S: No loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of interaction with RIPK1 and MLKL.	MUTAGEN	0
Q9Y572/T300M	RIPK3	-	1	T -> M (in dbSNP:rs34106261)	VARIANT	12
Q9Y572/Y185A	RIPK3	-	1	Y->A,F: Loss of interaction with PELI1 and PELI1-mediated ubiquitination.	MUTAGEN	0
Q9Y572/Y185F	RIPK3	-	1	Y->A,F: Loss of interaction with PELI1 and PELI1-mediated ubiquitination.	MUTAGEN	0
Q9Y5P4/D324A	CERT1	-	0	D->A: Impairs the endoplasmic reticulum-to-Golgi ceramide trafficking and abolishes the interaction with 	MUTAGEN	0
Q9Y5P4/E472A	CERT1	-	1	E->A: Reduces ceramide transfer.	MUTAGEN	0
Q9Y5P4/G243R	CERT1	-	1	G -> R (in MRD34; associated with authism and epilepsy)	VARIANT	0
Q9Y5P4/K599R	CERT1	-	0	K -> R (in dbSNP:rs55882089)	VARIANT	0
Q9Y5P4/N530A	CERT1	-	1	N->A: Reduces ceramide transfer.	MUTAGEN	0
Q9Y5P4/Q493A	CERT1	-	1	Q->A: No effect on ceramide transfer activity.	MUTAGEN	0
Q9Y5P4/S132A	CERT1	loss	1	S->A: Abolishes the phosphorylation. Strongly reduces the interaction with phosphatidylinositol 4-phosphate. Increases the ceramide transfer activity.	MUTAGEN	0
Q9Y5P4/S132L	CERT1	-	1	S -> L (in MRD34; dbSNP:rs1064794019)	VARIANT	0
Q9Y5P4/S138C	CERT1	-	1	S -> C (found in a patient with intellectual disability)	VARIANT	0
Q9Y5P4/W499A	CERT1	-	1	W->A: Reduces affinity for membranes. Abolishes ceramide transfer; when associated with A-588.	MUTAGEN	0
Q9Y5P4/W588A	CERT1	-	0	W->A: Abolishes ceramide transfer; when associated with A-499.	MUTAGEN	0
Q9Y5S2/A142T	CDC42BPB	-	1	A -> T (in CHOCNS; unknown pathological significance)	VARIANT	0
Q9Y5S2/D175Y	CDC42BPB	-	1	D -> Y (in CHOCNS; unknown pathological significance)	VARIANT	0
Q9Y5S2/E1315K	CDC42BPB	-	1	E -> K (in a lung large cell carcinoma sample; somatic mutation)	VARIANT	0
Q9Y5S2/I1077V	CDC42BPB	-	0	I -> V (in dbSNP:rs34822377)	VARIANT	0
Q9Y5S2/I293M	CDC42BPB	-	1	I -> M (in CHOCNS; unknown pathological significance)	VARIANT	0
Q9Y5S2/K500E	CDC42BPB	-	1	K -> E (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1158962067)	VARIANT	1
Q9Y5S2/L871P	CDC42BPB	-	1	L -> P (in CHOCNS; unknown pathological significance)	VARIANT	0
Q9Y5S2/R1203K	CDC42BPB	-	2	R -> K (in dbSNP:rs146298297)	VARIANT	3
Q9Y5S2/R1299Q	CDC42BPB	-	1	R -> Q (in CHOCNS; unknown pathological significance)	VARIANT	0
Q9Y5S2/R1350P	CDC42BPB	-	1	R -> P (in CHOCNS; unknown pathological significance)	VARIANT	0
Q9Y5S2/R555Q	CDC42BPB	neutral	1	R -> Q (in dbSNP:rs36001612)	VARIANT	0
Q9Y5S2/R671Q	CDC42BPB	-	1	R -> Q (in dbSNP:rs55948035)	VARIANT	0
Q9Y5S2/R867C	CDC42BPB	-	1	R -> C (in CHOCNS)	VARIANT	0
Q9Y5S2/R876P	CDC42BPB	-	1	R -> P (in CHOCNS)	VARIANT	0
Q9Y5S2/R876W	CDC42BPB	-	2	R -> W (in a colorectal adenocarcinoma sample and CHOCNS; somatic mutation; dbSNP:rs1595472741)	VARIANT	0
Q9Y5S2/S1633Y	CDC42BPB	-	1	S -> Y (in dbSNP:rs56412851)	VARIANT	0
Q9Y616/D482N	IRAK3	-	1	D -> N (in dbSNP:rs35756811)	VARIANT	0
Q9Y616/E214L	IRAK3	-	1	E->L: Enhances dimerization.	MUTAGEN	0
Q9Y616/G269S	IRAK3	-	0	G -> S (in dbSNP:rs35823766)	VARIANT	1
Q9Y616/G84S	IRAK3	-	1	G -> S (in dbSNP:rs34443407)	VARIANT	1
Q9Y616/H57R	IRAK3	-	1	H -> R (in dbSNP:rs35239505)	VARIANT	0
Q9Y616/I147V	IRAK3	-	4	I -> V (in dbSNP:rs1152888)	VARIANT	1
Q9Y616/I171V	IRAK3	-	1	I -> V (in dbSNP:rs34682166)	VARIANT	0
Q9Y616/I270V	IRAK3	-	0	I -> V (in dbSNP:rs11465972)	VARIANT	0
Q9Y616/L210E	IRAK3	-	1	L->E: Abolishes dimerization.	MUTAGEN	0
Q9Y616/L400V	IRAK3	-	1	L -> V (may be associated with ASRT5; dbSNP:rs146120640)	VARIANT	0
Q9Y616/M391T	IRAK3	-	1	M -> T (in dbSNP:rs35737689)	VARIANT	0
Q9Y616/P111A	IRAK3	-	2	P -> A (may be associated with ASRT5; abolishes phosphorylation of Ser-110; abolishes interaction with PIN1; no effect on cytoplasmic localization; reduces protein stability; dbSNP:rs373806603)	VARIANT	0
Q9Y616/P22L	IRAK3	-	1	P -> L (may be associated with ASRT5; dbSNP:rs536546109)	VARIANT	0
Q9Y616/R384Q	IRAK3	-	1	R -> Q (in dbSNP:rs34272472)	VARIANT	1
Q9Y616/R429Q	IRAK3	-	1	R -> Q (may be associated with ASRT5; dbSNP:rs140671957)	VARIANT	0
Q9Y616/S110A	IRAK3	-	1	S->A: Abolishes phosphorylation. Abolishes interaction with PIN1. Reduces protein stability.	MUTAGEN	0
Q9Y616/S110E	IRAK3	-	1	S->E: Phosphomimic. Slight decrease in the interaction with PIN1. Weak interaction with PIN1 in absence of IL33-mediated dendritic cell stimulation. Increases resistant to degradation. Localizes to the nucleus in absence of stimulus. Does not affect isomerization of Pro-111 peptide bond.	MUTAGEN	0
Q9Y616/S288L	IRAK3	-	1	S -> L (in dbSNP:rs35574245)	VARIANT	0
Q9Y616/S467A	IRAK3	-	1	S->A: No effect on the interaction with PIN1.	MUTAGEN	0
Q9Y616/V134M	IRAK3	-	1	V -> M (may be associated with ASRT5; dbSNP:rs138559915)	VARIANT	0
Q9Y6E0/A414V	STK24	-	2	A -> V (in dbSNP:rs55953606)	VARIANT	1
Q9Y6E0/D321N	STK24	-	1	D->N: Loss of proteolytic cleavage by caspases.	MUTAGEN	0
Q9Y6E0/K65A	STK24	loss	1	K->A: Loss of activity and autophosphorylation.	MUTAGEN	0
Q9Y6E0/L426I	STK24	-	1	L -> I (in dbSNP:rs55897869)	VARIANT	0
Q9Y6E0/T18A	STK24	loss	1	T->A: Loss of phosphorylation by PKA.	MUTAGEN	0
Q9Y6E0/T190A	STK24	loss	1	T->A: Loss of activity and autophosphorylation.	MUTAGEN	0
Q9Y6R4/A1492V	MAP3K4	-	1	A -> V (in dbSNP:rs41267837)	VARIANT	0
Q9Y6R4/E1413Q	MAP3K4	-	1	E -> Q (in an ovarian serous carcinoma sample; somatic mutation)	VARIANT	0
Q9Y6R4/H906P	MAP3K4	neutral	1	H -> P (in dbSNP:rs35533223)	VARIANT	0
Q9Y6R4/I294T	MAP3K4	-	1	I -> T (in dbSNP:rs35842248)	VARIANT	0
Q9Y6R4/K1372R	MAP3K4	loss	2	K->R: Loss of activity.	MUTAGEN	0
Q9Y6R4/Q584H	MAP3K4	-	1	Q -> H (in dbSNP:rs34018542)	VARIANT	0
Q9Y6R4/R157H	MAP3K4	neutral	1	R -> H (in dbSNP:rs4559074)	VARIANT	0
Q9Y6R4/R566H	MAP3K4	-	1	R -> H (in dbSNP:rs55765351)	VARIANT	0
Q9Y6R4/V335I	MAP3K4	-	1	V -> I (in dbSNP:rs35730939)	VARIANT	0
Q9Y6S9/P121L	RPS6KL1	neutral	1	P -> L (in dbSNP:rs2286913)	VARIANT	0
Q9Y6S9/R21Q	RPS6KL1	neutral	1	R -> Q (in dbSNP:rs7156590)	VARIANT	0
Q9Y6S9/R332W	RPS6KL1	-	1	R -> W (in dbSNP:rs55871101)	VARIANT	0
P10721/D816V	KIT	constitutively-active	63			1691
P31749/E17K	AKT1	constitutively-active	14			925
Q04771/R206H	ACVR1	constitutively-active	10			16
Q06187/E41K	BTK	constitutively-active	9			0
Q04771/Q207D	HACVR1	constitutively-active	4			0
P23458/V658F	JAK1	constitutively-active	4			9
P06239/Y505F	LCK	constitutively-active	4			0
P00533/G719S	EGFR	constitutively-active	4			120
P00533/L858R	EGFR	constitutively-active	4			6730
O60674/R683G	JAK2	constitutively-active	4			66
Q15303/Q646C	ERBB4	constitutively-active	3			0
P36897/T204D	TGFBR1	constitutively-active	3			0
P29597/V678F	TYK2	constitutively-active	3			0
P11362/K656E	FGFR1	constitutively-active	3			21
O96013/S474E	PAK4	constitutively-active	3			0
Q13418/S343D	ILK	constitutively-active	2			0
Q02750/K57E	MAP2K1	constitutively-active	2			11
Q02750/Q56P	MAP2K1	constitutively-active	2			21
P53350/T210D	PLK1	constitutively-active	2			0
P22607/G382D	FGFR3	constitutively-active	2			0
P22607/G375C	FGFR3	constitutively-active	2			0
P07948/Y508F	LYN	constitutively-active	2			0
P04626/V659E	ERBB2	constitutively-active	2			1
O00141/S429D	SGK1	constitutively-active	2			0
P31749/S473D	AKT1	constitutively-active	2			0
Q8TDC3/T189E	BRSK1	constitutively-active	1			0
Q04771/Q207E	ACVR1	constitutively-active	1			1
P31749/T308D	AKT1	constitutively-active	1			0
P23458/S646F	JAK1	constitutively-active	1			1
P16234/V536E	PDGFRA	constitutively-active	1			3
P16234/I537D	PDGFRA	constitutively-active	1			0
P15056/V600F	BRAF	constitutively-active	1			0
P12931/Y530F	SRC	constitutively-active	1			0
P08631/Y515*	HCK	constitutively-active	1			0
P06493/Y15F	CDK1	constitutively-active	1			0
P06241/Y531F	FYN	constitutively-active	1			0
P04626/Q646C	ERBB2	constitutively-active	1			0
P00533/G652R	EGFR	constitutively-active	1			0
O60674/K539A	JAK2	constitutively-active	1			0
O60674/H574R	JAK2	constitutively-active	1			0
O60674/H345L	JAK2	constitutively-active	1			0
Q5S007/G2019S	LRRK2	constitutively-active	14			1
P52333/A572V	JAK3	constitutively-active	4			31
P17612/L206R	PRKACA	constitutively-active	4			0
P10721/N822K	KIT	constitutively-active	4			247
P10721/L576P	KIT	constitutively-active	3			258
Q13976/R177Q	PRKG1	constitutively-active	2			0
P22607/A391E	FGFR3	constitutively-active	2			2
P21802/C342Y	FGFR2	constitutively-active	2			0
P12931/E527K	SRC	constitutively-active	2			1
Q16566/K303fs	CAMK4	constitutively-active	1			0
Q13555/R292P	CAMK2G	constitutively-active	1			0
P09619/N666H	PDGFRB	constitutively-active	1			0
P07949/Y606C	RET	constitutively-active	1			0
O60674/S523L	JAK2	constitutively-active	1			2
P15056/V600K	BRAF	constitutively-active	2			1182
P11802/R24C	CDK4	constitutively-active	1			4
O60674/R867Q	JAK2	constitutively-active	1			4
P08581/N1100Y	MET	constitutively-acttive	1			0
Q15139/R603H	PRKD1	constitutively-active	1			0
